Catalyst Calendar
4575 total events · 3710 upcoming · 957 companies
Next Catalyst
207-2754Ph2 Data
Samsung Biologics·GBM
Phase 1/2Large Cap$40B
Mar 16
today
0d away
Legend:EnrollmentTrial Start / ConferenceData ReadoutFDA / Regulatory
Market Cap
Drug Phase
Event Type
Mar 2026
77 events this monthSun
Mon
Tue
Wed
Thu
Fri
Sat
13
TNG-3308
Transgene
21
Mirinesiran
Boundless Bio
34
Terarelsin
AbbVie
42
Olpatenlimab
Absci
53
GIL-2259
Gilead Sciences
63
VEC-8813
Vectura (PMI)
71
JNJ-2735
Johnson & Johnson
83
Kemarelsin
Livzon Pharma
93
Ivomavacamten
Cerevel (AbbVie)
103
Zanuderotide
Johnson & Johnson
111
MYO-9608
Myokardia (BMS)
12
132
Sotocapivasertib
Avrobio
141
Motazasiran
Gelesis
151
ELA-3520
Elanco
167
+1
207-2754
Samsung Biologics
174
GSK-4334
GSK
183
Gelisacituzumab
Genkyotex (Calliditas)
194
Elrarapivir
Regeneron
204
ILM-4317
Illumina
215
BII-5240
Biogen
222
Motanaritide
Intellia
236
NTL-2576
Intellia
244
Olpavorutinib
Replimune
253
EOR-IIT-902
EORTC
26
273
Semamavacamten
Ideaya Bio
281
Sovalemzoparlimab
Seer
29
30
31
Upcoming Events (3710)
| Date | When | Type | Drug | Company | Phase | Tier | Indication |
|---|---|---|---|---|---|---|---|
| 2026-03-16 | today | Ph2 Data | 207-2754 | Phase 1/2 | Large | GBM | |
| 2026-03-16 | today | Interim | 460-4909 | Preclinical | Small | PAH | |
| 2026-03-16 | today | Ph3 Readout | Sovabrutinib | NDA/BLA | Micro | CSU | |
| 2026-03-16 | today | Ph3 Readout | RIC-5834 | Phase 2/3 | Private | Alzheimer's | |
| 2026-03-16 | today | Ph2 Data | SEV-IIT-824 | Phase 2 | Private | SCD | |
| 2026-03-16 | today | AdCom | PBL-710 | Approved | Micro | Alzheimer's | |
| 2026-03-16 | today | PDUFA | CGE-1983 | Phase 2/3 | Micro | NMOSD | |
| 2026-03-17 | tomorrow | Interim | GSK-4334 | Preclinical | Large | LN | |
| 2026-03-17 | tomorrow | Ph3 Readout | GIL-2037 | Approved | Large | LN | |
| 2026-03-17 | tomorrow | Interim | VRT-1891 | Phase 1 | Large | Heart Failure | |
| 2026-03-17 | tomorrow | Ph3 Readout | RXR-1394 | Phase 3 | Mid | Meso | |
| 2026-03-18 | 2d away | Ph2 Data | Gelisacituzumab | Phase 2 | Private | RSV | |
| 2026-03-18 | 2d away | Ph3 Readout | Miriratamab | Phase 2/3 | Large | HNSCC | |
| 2026-03-18 | 2d away | Ph3 Readout | DIV-3233 | Phase 2/3 | Large | NSCLC | |
| 2026-03-19 | 3d away | Interim | Elrarapivir | Phase 1 | Large | HS | |
| 2026-03-19 | 3d away | Interim | Suramavacamten | Phase 1 | Micro | Dravet | |
| 2026-03-19 | 3d away | Ph3 Readout | Surasacituzumab | Phase 3 | Private | SCD | |
| 2026-03-19 | 3d away | PDUFA | TEM-8322 | Preclinical | Mid | Asthma | |
| 2026-03-20 | 4d away | Ph3 Readout | ILM-4317 | NDA/BLA | Large | SCD | |
| 2026-03-20 | 4d away | Ph3 Readout | Olpafutibatinib | Phase 3 | Private | PBC | |
| 2026-03-20 | 4d away | Ph2 Data | TES-1600 | Phase 1/2 | Private | CKD | |
| 2026-03-20 | 4d away | Enrollment Complete | DAN-IIT-515 | Preclinical | Private | AML | |
| 2026-03-21 | 5d away | Ph3 Readout | BII-5240 | Phase 2/3 | Large | PNH | |
| 2026-03-21 | 5d away | Interim | MD-IIT-494 | Phase 1 | Private | RCC | |
| 2026-03-21 | 5d away | Ph2 Data | Cevimavacamten | Phase 1/2 | Mid | SCD | |
| 2026-03-21 | 5d away | Interim | HYP-6536 | Preclinical | Mid | MCC | |
| 2026-03-21 | 5d away | AdCom | 299-6118 | Phase 1/2 | Micro | Melanoma | |
| 2026-03-22 | 6d away | Ph3 Readout | Motanaritide | Approved | Mid | PV | |
| 2026-03-22 | 6d away | Orphan Drug | Datocapivasertib | Phase 2/3 | Private | HNSCC | |
| 2026-03-23 | 1w away | Ph3 Readout | NTL-2576 | NDA/BLA | Mid | Pancreatic Ca | |
| 2026-03-23 | 1w away | Ph3 Readout | PRM-116 | NDA/BLA | Small | EoE | |
| 2026-03-23 | 1w away | Ph3 Readout | Olpatinib | NDA/BLA | Small | Dravet | |
| 2026-03-23 | 1w away | Ph3 Readout | FLA-9061 | NDA/BLA | Private | SCD | |
| 2026-03-23 | 1w away | Ph3 Readout | Gelizasiran | Phase 3 | Private | Migraine | |
| 2026-03-23 | 1w away | Ph3 Readout | FRE-IIT-984 | Approved | Private | Breast Ca | |
| 2026-03-24 | 1w away | Ph2 Data | Olpavorutinib | Phase 2 | Small | Pancreatic Ca | |
| 2026-03-24 | 1w away | Ph3 Readout | COR-7645 | NDA/BLA | Private | BCC | |
| 2026-03-24 | 1w away | AdCom | Ceviglumide | Phase 3 | Large | Pompe | |
| 2026-03-24 | 1w away | Fast Track | BLC-6641 | Phase 3 | Mid | NASH | |
| 2026-03-25 | 1w away | Ph3 Readout | EOR-IIT-902 | NDA/BLA | Private | Bladder Ca | |
| 2026-03-25 | 1w away | Ph3 Readout | MNO-1564 | Phase 3 | Micro | Hemophilia A | |
| 2026-03-25 | 1w away | Interim | MOM-9396 | Phase 1 | Private | Huntington's | |
| 2026-03-27 | 2w away | Ph2 Data | Semamavacamten | Phase 1/2 | Mid | Fabry | |
| 2026-03-27 | 2w away | Ph3 Readout | GLY-5612 | Phase 3 | Micro | MS | |
| 2026-03-27 | 2w away | Ph3 Readout | Kemalucimab | Phase 2/3 | Private | Celiac | |
| 2026-03-28 | 2w away | Ph3 Readout | Sovalemzoparlimab | Phase 3 | Small | MCL | |
| 2026-04-01 | 2w away | Ph2 Data | Terafutibatinib | Phase 1/2 | Large | Gastric Ca | |
| 2026-04-01 | 2w away | Ph3 Readout | AZN-1715 | Phase 3 | Large | Psoriasis | |
| 2026-04-01 | 2w away | Ph3 Readout | Rimacilimab | Phase 3 | Private | Pompe | |
| 2026-04-01 | 2w away | PDUFA | DAN-IIT-482 | Phase 2 | Private | UC | |
| 2026-04-02 | 2w away | Ph2 Data | VRT-9481 | Phase 1/2 | Large | ADPKD | |
| 2026-04-02 | 2w away | Interim | LEG-9870 | Phase 1 | Large | WM | |
| 2026-04-02 | 2w away | Ph3 Readout | Capilucimab | Phase 3 | Private | Bladder Ca | |
| 2026-04-02 | 2w away | Fast Track | Lisonaritide | Phase 1/2 | Mid | AS | |
| 2026-04-02 | 2w away | Ph1 Dose Esc | UTH-9370 | NDA/BLA | Large | PsA | |
| 2026-04-03 | 3w away | Ph3 Readout | FLA-5216 | Approved | Private | CML | |
| 2026-04-03 | 3w away | Ph2 Data | MYG-2072 | Phase 2 | Mid | Meso | |
| 2026-04-03 | 3w away | Ph3 Readout | A-1206 | Phase 2/3 | Large | RSV | |
| 2026-04-05 | 3w away | Ph3 Readout | Teratenlimab | Approved | Micro | MCL | |
| 2026-04-05 | 3w away | Ph2 Data | ROY-IIT-943 | Phase 1/2 | Private | Atopic Derm | |
| 2026-04-05 | 3w away | Ph3 Readout | Motanaritide | Approved | Small | CML | |
| 2026-04-06 | 3w away | Interim | Motazasiran | Preclinical | Micro | ACC | |
| 2026-04-08 | 3w away | Ph3 Readout | MRK-3812 | Phase 3 | Micro | WM | |
| 2026-04-08 | 3w away | Interim | 993-1656 | Preclinical | Micro | RA | |
| 2026-04-08 | 3w away | Ph3 Readout | Polatapinarof | Approved | Mid | MG | |
| 2026-04-08 | 3w away | Enrollment Complete | Kemalemzoparlimab | Phase 2 | Micro | Pompe | |
| 2026-04-09 | 3w away | Ph3 Readout | XEN-577 | Phase 2/3 | Mid | Myelofibrosis | |
| 2026-04-09 | 3w away | Ph2 Data | 452-7432 | Phase 2 | Large | Gastric Ca | |
| 2026-04-09 | 3w away | Ph3 Readout | Pexaosocimab | Phase 2/3 | Large | RCC | |
| 2026-04-10 | 4w away | Ph2 Data | TLX-9288 | Phase 2 | Mid | Meso | |
| 2026-04-10 | 4w away | Fast Track | ORC-2834 | Phase 2/3 | Private | Obesity | |
| 2026-04-11 | 4w away | Ph2 Data | BMR-8526 | Phase 1/2 | Large | AS | |
| 2026-04-11 | 4w away | Ph3 Readout | 369-789 | Phase 3 | Large | MS | |
| 2026-04-11 | 4w away | Ph3 Readout | Rimavorutinib | Phase 3 | Private | ACC | |
| 2026-04-12 | 4w away | Ph3 Readout | EVO-4804 | Approved | Private | NB | |
| 2026-04-12 | 4w away | Ph3 Readout | BWA-1517 | Approved | Micro | MCL | |
| 2026-04-12 | 4w away | Ph3 Readout | Miriosocimab | Approved | Large | Pompe | |
| 2026-04-12 | 4w away | Ph3 Readout | YB-6541 | Phase 3 | Private | HNSCC | |
| 2026-04-13 | 4w away | EMA Filing | Doxarelsin | Phase 1/2 | Private | ACC | |
| 2026-04-14 | 4w away | Interim | Rilurelsin | Phase 1 | Small | Crohn's | |
| 2026-04-15 | 1mo away | Interim | QUA-617 | Phase 1 | Private | ACC | |
| 2026-04-15 | 1mo away | Ph3 Readout | Polacilimab | NDA/BLA | Small | CF | |
| 2026-04-16 | 1mo away | Ph3 Readout | ALK-3993 | Phase 3 | Mid | LGS | |
| 2026-04-16 | 1mo away | Orphan Drug | Sotovorutinib | Phase 1/2 | Large | Melanoma | |
| 2026-04-17 | 1mo away | Ph2 Data | RLA-8772 | Phase 2 | Mid | PAH | |
| 2026-04-17 | 1mo away | Ph3 Readout | EYE-3796 | Phase 3 | Micro | LGS | |
| 2026-04-17 | 1mo away | AdCom | LLY-9749 | Phase 3 | Large | ADHD | |
| 2026-04-18 | 1mo away | Ph3 Readout | DSN-791 | NDA/BLA | Large | Asthma | |
| 2026-04-18 | 1mo away | Ph3 Readout | PRO-7290 | Phase 2/3 | Private | Ovarian Ca | |
| 2026-04-18 | 1mo away | Interim | SLN-2895 | Preclinical | Small | Pancreatic Ca | |
| 2026-04-19 | 1mo away | Ph2 Data | Miricilimab | Phase 2 | Small | Narcolepsy | |
| 2026-04-19 | 1mo away | Interim | Zoritapinarof | Phase 1 | Private | Atopic Derm | |
| 2026-04-19 | 1mo away | Orphan Drug | AII-IIT-879 | Preclinical | Private | HS | |
| 2026-04-20 | 1mo away | Ph3 Readout | Cevirasimod | Phase 2/3 | Small | RA | |
| 2026-04-21 | 1mo away | Interim | Zorimavacamten | Preclinical | Large | SMA | |
| 2026-04-21 | 1mo away | Ph3 Readout | RGN-9803 | NDA/BLA | Small | SCD | |
| 2026-04-21 | 1mo away | PDUFA | LLY-8903 | Preclinical | Large | Asthma | |
| 2026-04-22 | 1mo away | Ph3 Readout | Mirimavacamten | Approved | Micro | Angelman | |
| 2026-04-22 | 1mo away | Ph3 Readout | TRI-2954 | Approved | Private | Crohn's | |
| 2026-04-22 | 1mo away | Ph3 Readout | Kemaderotide | Approved | Micro | Endometrial Ca | |
| 2026-04-23 | 1mo away | Ph3 Readout | Nirasertib | Phase 2/3 | Private | MCC | |
| 2026-04-23 | 1mo away | Ph2 Data | KRK-5622 | Phase 2 | Mid | Ovarian Ca | |
| 2026-04-24 | 1mo away | Ph3 Readout | Talavorutinib | NDA/BLA | Mid | FL | |
| 2026-04-24 | 1mo away | Ph2 Data | Zoribrutinib | Phase 1/2 | Private | MCL | |
| 2026-04-25 | 1mo away | Ph3 Readout | LMN-8636 | Phase 3 | Micro | LGS | |
| 2026-04-26 | 1mo away | Interim | Gelilemzoparlimab | Preclinical | Mid | DMD | |
| 2026-04-26 | 1mo away | Ph3 Readout | IPC-884 | Approved | Mid | NMOSD | |
| 2026-04-26 | 1mo away | PDUFA | Liraratamab | Phase 3 | Mid | Melanoma | |
| 2026-04-27 | 1mo away | Ph2 Data | Polamavacamten | Phase 2 | Small | Endometrial Ca | |
| 2026-04-27 | 1mo away | NDA | LMN-8636 | Phase 3 | Micro | LGS | |
| 2026-04-28 | 1mo away | Ph3 Readout | NVS-6360 | Approved | Large | FTD | |
| 2026-04-28 | 1mo away | Ph3 Readout | 207-5197 | Approved | Large | ET | |
| 2026-04-28 | 1mo away | Interim | Fixalucimab | Preclinical | Private | CRC | |
| 2026-04-28 | 1mo away | Fast Track | MRK-853 | Phase 1 | Large | Endometrial Ca | |
| 2026-04-28 | 1mo away | Conference | Riluzasiran | Phase 2/3 | Mid | Epilepsy | |
| 2026-05-01 | 2mo away | Ph3 Readout | Zoriosocimab | Approved | Mid | UC | |
| 2026-05-01 | 2mo away | Ph3 Readout | 002-5533 | Phase 2/3 | Mid | NSCLC | |
| 2026-05-01 | 2mo away | Conference | JUB-6215 | Phase 2/3 | Small | OCD | |
| 2026-05-02 | 2mo away | Ph3 Readout | PHA-4842 | Approved | Small | Melanoma | |
| 2026-05-02 | 2mo away | Ph3 Readout | Rimatinib | NDA/BLA | Private | ADHD | |
| 2026-05-02 | 2mo away | Ph3 Readout | Kemasacituzumab | Approved | Private | CTCL | |
| 2026-05-02 | 2mo away | BTD | VEC-8813 | Phase 3 | Private | MCC | |
| 2026-05-03 | 2mo away | Orphan Drug | PIE-7717 | Preclinical | Private | RSV | |
| 2026-05-04 | 2mo away | Conference | LEG-9870 | Phase 1 | Large | WM | |
| 2026-05-04 | 2mo away | NDA | PFE-2191 | NDA/BLA | Large | MCC | |
| 2026-05-04 | 2mo away | BTD | GSK-4334 | Preclinical | Large | LN | |
| 2026-05-05 | 2mo away | Ph2 Data | Zenonaritide | Phase 1/2 | Mid | ALL | |
| 2026-05-05 | 2mo away | Ph3 Readout | ACE-6753 | Phase 2/3 | Micro | Asthma | |
| 2026-05-05 | 2mo away | Ph3 Readout | Capisertib | NDA/BLA | Private | UC | |
| 2026-05-05 | 2mo away | Ph2 Data | Tiraderotide | Phase 2 | Private | Ewing Sarcoma | |
| 2026-05-05 | 2mo away | Ph1 Dose Esc | ILM-4317 | NDA/BLA | Large | SCD | |
| 2026-05-06 | 2mo away | Ph3 Readout | Pexamavacamten | NDA/BLA | Large | Heart Failure | |
| 2026-05-06 | 2mo away | Ph3 Readout | STA-IIT-458 | Phase 3 | Private | HS | |
| 2026-05-06 | 2mo away | Interim | Adagraosocimab | Preclinical | Private | MM | |
| 2026-05-07 | 2mo away | Ph3 Readout | MDG-611 | Approved | Mid | Angelman | |
| 2026-05-07 | 2mo away | Ph2 Data | Suraosocimab | Phase 1/2 | Private | Dravet | |
| 2026-05-07 | 2mo away | Ph3 Readout | Polatenlimab | NDA/BLA | Private | Migraine | |
| 2026-05-08 | 2mo away | Ph3 Readout | Pexatenlimab | Approved | Private | Ewing Sarcoma | |
| 2026-05-08 | 2mo away | Ph1 Dose Esc | GMA-729 | Phase 2 | Large | TTR Amyloidosis | |
| 2026-05-09 | 2mo away | Ph2 Data | Riboderotide | Phase 2 | Mid | ET | |
| 2026-05-10 | 2mo away | Ph3 Readout | Riluinavolisib | NDA/BLA | Large | MM | |
| 2026-05-10 | 2mo away | Ph3 Readout | Doxasotorasib | Phase 2/3 | Large | Angelman | |
| 2026-05-10 | 2mo away | Ph3 Readout | ATL-9462 | Phase 2/3 | Private | Ovarian Ca | |
| 2026-05-10 | 2mo away | Interim | Datoglumide | Phase 1 | Micro | GIST | |
| 2026-05-11 | 2mo away | Interim | Talasotorasib | Preclinical | Mid | TTR Amyloidosis | |
| 2026-05-11 | 2mo away | Ph2 Data | MIR-6154 | Phase 2 | Micro | NSCLC | |
| 2026-05-11 | 2mo away | Ph3 Readout | AIP-1890 | Phase 3 | Small | Pompe | |
| 2026-05-11 | 2mo away | Ph3 Readout | ELA-1012 | NDA/BLA | Mid | Heart Failure | |
| 2026-05-12 | 2mo away | Ph3 Readout | EVO-1057 | Phase 3 | Private | Huntington's | |
| 2026-05-12 | 2mo away | Ph3 Readout | Elrasacituzumab | NDA/BLA | Small | HS | |
| 2026-05-13 | 2mo away | Ph3 Readout | LLY-9749 | Phase 3 | Large | WM | |
| 2026-05-13 | 2mo away | Ph3 Readout | 002-6973 | Approved | Mid | Celiac | |
| 2026-05-15 | 2mo away | Ph3 Readout | 369-8021 | Approved | Large | DMD | |
| 2026-05-15 | 2mo away | Ph3 Readout | Capibrutinib | Phase 3 | Micro | Alzheimer's | |
| 2026-05-15 | 2mo away | PDUFA | Gozesertib | Phase 1/2 | Micro | Dravet | |
| 2026-05-16 | 2mo away | Ph2 Data | MBX-6478 | Phase 1/2 | Small | TTR Amyloidosis | |
| 2026-05-16 | 2mo away | Interim | IMT-6167 | Phase 1 | Small | Pancreatic Ca | |
| 2026-05-16 | 2mo away | Fast Track | KIA-7048 | Phase 3 | Private | ADHD | |
| 2026-05-16 | 2mo away | EMA Filing | Bemasotorasib | Phase 1/2 | Private | PAH | |
| 2026-05-17 | 2mo away | Ph3 Readout | Tirarapivir | Approved | Large | Parkinson's | |
| 2026-05-17 | 2mo away | Ph3 Readout | AAR-3535 | Phase 3 | Small | SCD | |
| 2026-05-18 | 2mo away | Ph3 Readout | Oxylanthanum Carbonate | Phase 3 | Micro | CKD | |
| 2026-05-18 | 2mo away | Ph3 Readout | Gelirasimod | Phase 3 | Micro | Wilms | |
| 2026-05-18 | 2mo away | Ph3 Readout | TUR-4034 | Phase 2/3 | Private | Psoriasis | |
| 2026-05-18 | 2mo away | Orphan Drug | Tixacilimab | Phase 2/3 | Private | Endometrial Ca | |
| 2026-05-18 | 2mo away | Ph1 Dose Esc | MAP-6526 | Approved | Private | Heart Failure | |
| 2026-05-18 | 2mo away | Enrollment Complete | IMM-5834 | Phase 2 | Private | ADPKD | |
| 2026-05-19 | 2mo away | Ph3 Readout | Teralucimab | Approved | Micro | ADPKD | |
| 2026-05-19 | 2mo away | EMA Filing | Talazanubrutinib | Phase 1/2 | Small | PNH | |
| 2026-05-19 | 2mo away | EMA Filing | Sovainavolisib | NDA/BLA | Mid | FSGS | |
| 2026-05-19 | 2mo away | Fast Track | SEV-IIT-977 | Phase 3 | Private | Cervical Ca | |
| 2026-05-20 | 2mo away | Ph2 Data | TLX-9433 | Phase 2 | Mid | NSCLC | |
| 2026-05-20 | 2mo away | Ph2 Data | GW-1242 | Phase 1/2 | Private | Huntington's | |
| 2026-05-20 | 2mo away | Ph3 Readout | LAB-7111 | NDA/BLA | Private | NB | |
| 2026-05-20 | 2mo away | Ph3 Readout | CDX-409 | Approved | Small | NB | |
| 2026-05-20 | 2mo away | Enrollment Complete | Teralucimab | Phase 1 | Small | Melanoma | |
| 2026-05-21 | 2mo away | Interim | Olparelsin | Preclinical | Private | MS | |
| 2026-05-21 | 2mo away | Ph3 Readout | Gozezumab | Approved | Small | BCC | |
| 2026-05-21 | 2mo away | Conference | BIV-3779 | Phase 2/3 | Micro | FSGS | |
| 2026-05-22 | 2mo away | Interim | Pexasotorasib | Phase 1 | Micro | MDS | |
| 2026-05-23 | 2mo away | Ph3 Readout | Ribozanubrutinib | Approved | Large | GBM | |
| 2026-05-23 | 2mo away | AdCom | TAK-8730 | Phase 2 | Large | Cholangiocarcinoma | |
| 2026-05-24 | 2mo away | Ph3 Readout | Mirilucimab | NDA/BLA | Small | RB | |
| 2026-05-24 | 2mo away | NDA | TAI-4908 | Phase 3 | Private | MDS | |
| 2026-05-25 | 2mo away | Ph3 Readout | 452-5750 | NDA/BLA | Large | CSU | |
| 2026-05-26 | 2mo away | Ph2 Data | SOB-2861 | Phase 2 | Large | CKD | |
| 2026-05-26 | 2mo away | Ph3 Readout | Darasacituzumab | Phase 2/3 | Mid | IPF | |
| 2026-05-26 | 2mo away | Interim | 456-4277 | Preclinical | Micro | PSP | |
| 2026-05-26 | 2mo away | Interim | BSL-7024 | Phase 1 | Small | SCD | |
| 2026-05-26 | 2mo away | Interim | 415-7241 | Phase 1 | Micro | CF | |
| 2026-05-26 | 2mo away | Enrollment Complete | JNJ-2735 | Phase 2/3 | Large | RCC | |
| 2026-05-27 | 2mo away | Ph3 Readout | VYG-2970 | Phase 3 | Small | LN | |
| 2026-06-01 | 3mo away | Ph2 Data | Rilutenlimab | Phase 2 | Large | SMA | |
| 2026-06-02 | 3mo away | Interim | Rimaosocimab | Preclinical | Large | Dravet | |
| 2026-06-02 | 3mo away | Ph3 Readout | Polarasimod | Phase 3 | Small | DMD | |
| 2026-06-02 | 3mo away | EMA Filing | Elrazumab | NDA/BLA | Private | Pancreatic Ca | |
| 2026-06-03 | 3mo away | Ph3 Readout | Adagrafotisoran | Phase 2/3 | Private | MM | |
| 2026-06-03 | 3mo away | Ph3 Readout | Daranesiran | Approved | Small | IPF | |
| 2026-06-03 | 3mo away | BTD | ORC-7732 | Phase 3 | Private | Crohn's | |
| 2026-06-04 | 3mo away | Ph3 Readout | RHH-8550 | Approved | Large | CRC | |
| 2026-06-04 | 3mo away | Conference | SAV-5205 | NDA/BLA | Small | Psoriasis | |
| 2026-06-05 | 3mo away | Ph3 Readout | TER-1034 | Phase 3 | Private | Melanoma | |
| 2026-06-05 | 3mo away | Ph3 Readout | Sovaratamab | Phase 2/3 | Micro | CKD | |
| 2026-06-05 | 3mo away | Ph3 Readout | 453-4569 | Phase 2/3 | Mid | Parkinson's | |
| 2026-06-06 | 3mo away | Interim | AMG-2752 | Preclinical | Large | Myelofibrosis | |
| 2026-06-06 | 3mo away | Ph2 Data | LRM-3193 | Phase 2 | Small | Myelofibrosis | |
| 2026-06-06 | 3mo away | Ph3 Readout | Sotozanubrutinib | Phase 2/3 | Private | PAH | |
| 2026-06-06 | 3mo away | Orphan Drug | PBL-3756 | Phase 1/2 | Micro | PV | |
| 2026-06-07 | 3mo away | Ph3 Readout | Sotoglumide | Phase 2/3 | Private | CKD | |
| 2026-06-07 | 3mo away | BTD | Semaosocimab | Phase 2/3 | Mid | PNH | |
| 2026-06-08 | 3mo away | Ph2 Data | MOM-2836 | Phase 1/2 | Private | RB | |
| 2026-06-08 | 3mo away | Ph2 Data | Rimavorutinib | Phase 2 | Mid | LN | |
| 2026-06-08 | 3mo away | Ph2 Data | CUR-8000 | Phase 2 | Private | Ewing Sarcoma | |
| 2026-06-08 | 3mo away | Ph3 Readout | Datorapivir | Phase 2/3 | Small | HS | |
| 2026-06-09 | 3mo away | Ph3 Readout | Pexaderotide | NDA/BLA | Mid | Rett | |
| 2026-06-10 | 3mo away | Ph3 Readout | ARC-6205 | NDA/BLA | Private | PTSD | |
| 2026-06-10 | 3mo away | Conference | Pexatuximab | Phase 2 | Micro | MG | |
| 2026-06-12 | 3mo away | Interim | NUV-2032 | Preclinical | Mid | ET | |
| 2026-06-12 | 3mo away | Ph3 Readout | SND-9531 | Phase 3 | Mid | Melanoma | |
| 2026-06-12 | 3mo away | Ph3 Readout | Lisotapinarof | Approved | Private | Melanoma | |
| 2026-06-12 | 3mo away | Ph1 Dose Esc | Riboinavolisib | Phase 1/2 | Private | DMD | |
| 2026-06-13 | 3mo away | Ph3 Readout | TER-5062 | Phase 2/3 | Small | Wet AMD | |
| 2026-06-13 | 3mo away | Interim | ZNT-6525 | Phase 1 | Small | Pancreatic Ca | |
| 2026-06-13 | 3mo away | Ph3 Readout | STA-IIT-276 | Phase 3 | Private | Migraine | |
| 2026-06-13 | 3mo away | BTD | BGN-8936 | Phase 1/2 | Large | IPF | |
| 2026-06-14 | 3mo away | EMA Filing | Miritinib | Approved | Private | SLE | |
| 2026-06-15 | 3mo away | Interim | Fixanesiran | Preclinical | Large | Endometrial Ca | |
| 2026-06-15 | 3mo away | Ph3 Readout | VES-7360 | Approved | Private | LN | |
| 2026-06-15 | 3mo away | Ph3 Readout | RIK-IIT-635 | NDA/BLA | Private | RCC | |
| 2026-06-16 | 3mo away | Ph3 Readout | Zorivorutinib | Approved | Large | T2D | |
| 2026-06-17 | 3mo away | Ph3 Readout | Nirasacituzumab | Phase 3 | Large | SMA | |
| 2026-06-18 | 3mo away | Ph3 Readout | SNY-5894 | Approved | Large | FSGS | |
| 2026-06-18 | 3mo away | Ph3 Readout | Ribozanubrutinib | Approved | Large | LGS | |
| 2026-06-18 | 3mo away | Ph3 Readout | Sematenlimab | Phase 3 | Large | T2D | |
| 2026-06-18 | 3mo away | Ph3 Readout | AER-8916 | Approved | Private | GA | |
| 2026-06-19 | 3mo away | Ph3 Readout | ENC-8622 | Phase 3 | Private | Angelman | |
| 2026-06-19 | 3mo away | NDA | Bemazumab | Phase 2/3 | Private | RB | |
| 2026-06-20 | 3mo away | Interim | CHA-IIT-687 | Phase 1 | Private | AS | |
| 2026-06-20 | 3mo away | Ph3 Readout | ALL-5401 | NDA/BLA | Private | DMD | |
| 2026-06-20 | 3mo away | Ph3 Readout | 068-872 | Approved | Large | SCLC | |
| 2026-06-20 | 3mo away | Ph2 Data | Zorizumab | Phase 1/2 | Private | GA | |
| 2026-06-21 | 3mo away | Ph3 Readout | Zorivorutinib | Approved | Large | MM | |
| 2026-06-21 | 3mo away | Interim | UCS-IIT-166 | Phase 1 | Private | HNSCC | |
| 2026-06-21 | 3mo away | Ph3 Readout | TES-8356 | NDA/BLA | Private | Ewing Sarcoma | |
| 2026-06-21 | 3mo away | Interim | Peminesiran | Phase 1 | Private | Obesity | |
| 2026-06-23 | 3mo away | Interim | Zenotapinarof | Preclinical | Large | Cholangiocarcinoma | |
| 2026-06-23 | 3mo away | Ph3 Readout | Mavutuximab | Phase 2/3 | Large | Hemophilia A | |
| 2026-06-23 | 3mo away | Interim | PCV-2362 | Phase 1 | Mid | PSP | |
| 2026-06-23 | 3mo away | Interim | Sototenlimab | Preclinical | Mid | PBC | |
| 2026-06-23 | 3mo away | Enrollment Complete | Lisoderotide | Phase 2 | Private | Schizophrenia | |
| 2026-06-24 | 3mo away | Ph3 Readout | CLL-8422 | Approved | Small | OCD | |
| 2026-06-24 | 3mo away | Ph3 Readout | XBI-1781 | Phase 3 | Small | ADPKD | |
| 2026-06-24 | 3mo away | Ph3 Readout | Ribotapinarof | NDA/BLA | Large | Rett | |
| 2026-06-25 | 3mo away | Interim | MAS-IIT-787 | Phase 1 | Private | Heart Failure | |
| 2026-06-25 | 3mo away | Ph3 Readout | VEE-8520 | NDA/BLA | Large | AML | |
| 2026-06-25 | 3mo away | AdCom | PAR-6401 | Phase 1 | Micro | PsA | |
| 2026-06-25 | 3mo away | PDUFA | TRD-3150 | Preclinical | Small | BCC | |
| 2026-06-26 | 3mo away | Ph3 Readout | 300-2164 | Phase 3 | Mid | MCL | |
| 2026-06-26 | 3mo away | Ph3 Readout | Semafutibatinib | Phase 3 | Private | Rett | |
| 2026-06-26 | 3mo away | Ph3 Readout | Adagratapinarof | Phase 3 | Private | GIST | |
| 2026-06-27 | 3mo away | Ph3 Readout | ASN-4879 | Phase 3 | Mid | PSP | |
| 2026-06-27 | 3mo away | Ph3 Readout | Polazasiran | Phase 3 | Private | IgAN | |
| 2026-06-27 | 3mo away | Ph2 Data | Mavusotorasib | Phase 1/2 | Private | RA | |
| 2026-06-27 | 3mo away | Ph2 Data | QUA-2029 | Phase 1/2 | Private | GBM | |
| 2026-06-27 | 3mo away | AdCom | Lisolucimab | Approved | Large | Narcolepsy | |
| 2026-06-28 | 3mo away | Ph3 Readout | Tirzepatide | Approved | Large | T2D | |
| 2026-07-01 | 4mo away | Ph3 Readout | Zanutinib | Phase 2/3 | Large | IgAN | |
| 2026-07-01 | 4mo away | Ph3 Readout | Zoriosocimab | Phase 3 | Mid | NMOSD | |
| 2026-07-01 | 4mo away | Ph3 Readout | GEN-516 | Phase 2/3 | Private | NB | |
| 2026-07-01 | 4mo away | Interim | HOS-IIT-510 | Preclinical | Private | Prostate Ca | |
| 2026-07-01 | 4mo away | Conference | MAN-3628 | Phase 1 | Mid | CLL | |
| 2026-07-04 | 4mo away | Ph1 Dose Esc | UCL-IIT-799 | Preclinical | Private | PBC | |
| 2026-07-05 | 4mo away | Interim | Motainavolisib | Phase 1 | Private | Asthma | |
| 2026-07-05 | 4mo away | Ph1 Dose Esc | AZN-8281 | Phase 1 | Large | RSV | |
| 2026-07-07 | 4mo away | Ph3 Readout | AZN-8478 | NDA/BLA | Large | Fabry | |
| 2026-07-07 | 4mo away | Ph2 Data | STA-5151 | Phase 1/2 | Small | Pompe | |
| 2026-07-08 | 4mo away | Interim | IPN-3758 | Phase 1 | Large | LGS | |
| 2026-07-08 | 4mo away | Ph3 Readout | INS-6048 | NDA/BLA | Private | Hemophilia A | |
| 2026-07-08 | 4mo away | Ph2 Data | 654-1692 | Phase 2 | Small | PNH | |
| 2026-07-08 | 4mo away | BTD | DUK-IIT-769 | Approved | Private | ALS | |
| 2026-07-08 | 4mo away | BTD | COR-7645 | NDA/BLA | Private | Crohn's | |
| 2026-07-09 | 4mo away | Interim | 180-3597 | Preclinical | Mid | LGS | |
| 2026-07-09 | 4mo away | NDA | NOI-8348 | Preclinical | Private | FL | |
| 2026-07-10 | 4mo away | Ph3 Readout | Nidatenlimab | Approved | Small | BCC | |
| 2026-07-11 | 4mo away | Ph3 Readout | SAG-8067 | NDA/BLA | Small | Thymoma | |
| 2026-07-12 | 4mo away | Ph3 Readout | Daralucimab | Phase 2/3 | Private | SLE | |
| 2026-07-13 | 4mo away | Ph3 Readout | Polazasiran | Phase 3 | Private | IgAN | |
| 2026-07-13 | 4mo away | Ph3 Readout | Sotocapivasertib | Approved | Micro | RSV | |
| 2026-07-13 | 4mo away | NDA | CSL-8235 | Phase 1/2 | Large | Atopic Derm | |
| 2026-07-14 | 4mo away | Interim | Voxazanubrutinib | Preclinical | Private | SCLC | |
| 2026-07-14 | 4mo away | Interim | PRE-6102 | Preclinical | Private | CSU | |
| 2026-07-14 | 4mo away | PDUFA | Zoribrutinib | Preclinical | Large | LGS | |
| 2026-07-14 | 4mo away | PDUFA | Rimamavacamten | Phase 1 | Large | Ewing Sarcoma | |
| 2026-07-14 | 4mo away | NDA | TEC-1111 | Phase 1/2 | Large | LN | |
| 2026-07-15 | 4mo away | Interim | ALK-4522 | Phase 1 | Mid | HS | |
| 2026-07-16 | 4mo away | Fast Track | LAE-3866 | Phase 1/2 | Private | Ewing Sarcoma | |
| 2026-07-17 | 4mo away | Interim | Teraratamab | Preclinical | Mid | Rett | |
| 2026-07-17 | 4mo away | Ph3 Readout | Mirimavacamten | Approved | Micro | Angelman | |
| 2026-07-18 | 4mo away | Ph3 Readout | Teratenlimab | Approved | Micro | PNH | |
| 2026-07-18 | 4mo away | Ph2 Data | Tirasertib | Phase 1/2 | Private | MG | |
| 2026-07-19 | 4mo away | Ph2 Data | 992-6426 | Phase 2 | Mid | Narcolepsy | |
| 2026-07-19 | 4mo away | Ph2 Data | MEI-6717 | Phase 2 | Micro | FSGS | |
| 2026-07-19 | 4mo away | BTD | Zanusotorasib | Phase 2/3 | Large | HCC | |
| 2026-07-19 | 4mo away | BTD | Adagraosocimab | Preclinical | Private | HS | |
| 2026-07-19 | 4mo away | Enrollment Complete | TES-1600 | Phase 1/2 | Private | CKD | |
| 2026-07-20 | 4mo away | Interim | CYD-4746 | Phase 1 | Micro | Bladder Ca | |
| 2026-07-20 | 4mo away | Ph3 Readout | AVT-4398 | Phase 3 | Large | MM | |
| 2026-07-21 | 4mo away | Ph3 Readout | ELO-2344 | Phase 3 | Private | Prostate Ca | |
| 2026-07-21 | 4mo away | Interim | Motabrutinib | Preclinical | Private | UC | |
| 2026-07-21 | 4mo away | Ph3 Readout | Doxarasimod | Phase 3 | Private | CSU | |
| 2026-07-21 | 4mo away | Ph3 Readout | Nidarelsin | Approved | Small | Obesity | |
| 2026-07-22 | 4mo away | Interim | Miriosocimab | Phase 1 | Large | Dravet | |
| 2026-07-22 | 4mo away | Interim | Lirazanubrutinib | Phase 1 | Large | PTSD | |
| 2026-07-22 | 4mo away | Ph2 Data | Rimasotorasib | Phase 1/2 | Small | Melanoma | |
| 2026-07-23 | 4mo away | Interim | TNY-3110 | Preclinical | Small | Alzheimer's | |
| 2026-07-23 | 4mo away | Interim | INS-3736 | Phase 1 | Private | Crohn's | |
| 2026-07-23 | 4mo away | Ph2 Data | Riboderotide | Phase 2 | Mid | ET | |
| 2026-07-23 | 4mo away | Interim | RAB-IIT-533 | Preclinical | Private | UC | |
| 2026-07-24 | 4mo away | Ph3 Readout | Capifutibatinib | Phase 3 | Large | MCL | |
| 2026-07-24 | 4mo away | Ph3 Readout | SEN-3594 | Phase 2/3 | Private | CTCL | |
| 2026-07-24 | 4mo away | Ph1 Dose Esc | RCK-5227 | Phase 1 | Mid | Dravet | |
| 2026-07-25 | 4mo away | Ph2 Data | Semalemzoparlimab | Phase 1/2 | Private | Wet AMD | |
| 2026-07-25 | 4mo away | Interim | GRF-2905 | Phase 1 | Mid | FSGS | |
| 2026-07-25 | 4mo away | Interim | STA-6220 | Phase 1 | Private | MS | |
| 2026-07-25 | 4mo away | Conference | Sotosacituzumab | Approved | Large | Breast Ca | |
| 2026-07-26 | 4mo away | Ph2 Data | Nidatinib | Phase 2 | Micro | Atopic Derm | |
| 2026-07-26 | 4mo away | Interim | VEE-7651 | Preclinical | Large | MDD | |
| 2026-07-26 | 4mo away | EMA Filing | BIV-3779 | Phase 2/3 | Micro | FSGS | |
| 2026-07-27 | 4mo away | Ph3 Readout | BIG-3814 | Approved | Private | Hemophilia A | |
| 2026-07-27 | 4mo away | Ph3 Readout | Tixarelsin | Phase 2/3 | Mid | EoE | |
| 2026-07-27 | 4mo away | BTD | ILM-2412 | Phase 3 | Large | HS | |
| 2026-07-28 | 4mo away | Interim | Fixabrutinib | Phase 1 | Private | RB | |
| 2026-07-28 | 4mo away | Interim | Sovarapivir | Preclinical | Mid | EoE | |
| 2026-07-28 | 4mo away | NDA | Ceviglumide | Phase 3 | Large | Urothelial Ca | |
| 2026-08-01 | 5mo away | Ph3 Readout | Nidatenlimab | Approved | Small | BCC | |
| 2026-08-02 | 5mo away | Ph3 Readout | Zanurapivir | NDA/BLA | Small | CKD | |
| 2026-08-03 | 5mo away | Ph3 Readout | Lisozanubrutinib | NDA/BLA | Small | Heart Failure | |
| 2026-08-03 | 5mo away | Ph2 Data | Rilulucimab | Phase 2 | Large | LGS | |
| 2026-08-03 | 5mo away | Ph3 Readout | Pexaderotide | Phase 3 | Private | Cholangiocarcinoma | |
| 2026-08-03 | 5mo away | Ph2 Data | FER-3003 | Phase 1/2 | Private | Wilms | |
| 2026-08-03 | 5mo away | Ph2 Data | HET-7567 | Phase 2 | Private | SLE | |
| 2026-08-04 | 5mo away | AdCom | Elracagene | NDA/BLA | Large | MG | |
| 2026-08-04 | 5mo away | Fast Track | Zorinesiran | Phase 2/3 | Small | Pompe | |
| 2026-08-06 | 5mo away | Ph3 Readout | 488-6881 | Phase 2/3 | Small | MG | |
| 2026-08-07 | 5mo away | Ph3 Readout | Motainavolisib | NDA/BLA | Large | Angelman | |
| 2026-08-07 | 5mo away | Ph3 Readout | Motavorutinib | NDA/BLA | Private | Wet AMD | |
| 2026-08-07 | 5mo away | Interim | Polatuximab | Phase 1 | Micro | Ewing Sarcoma | |
| 2026-08-09 | 5mo away | Ph2 Data | QUA-2029 | Phase 1/2 | Private | GBM | |
| 2026-08-09 | 5mo away | Ph3 Readout | Mirifotisoran | Approved | Mid | CML | |
| 2026-08-09 | 5mo away | Interim | MEN-8522 | Phase 1 | Private | MM | |
| 2026-08-09 | 5mo away | Orphan Drug | BIO-6952 | NDA/BLA | Private | TTR Amyloidosis | |
| 2026-08-10 | 5mo away | Interim | Fixainavolisib | Preclinical | Large | HS | |
| 2026-08-10 | 5mo away | Ph3 Readout | Semazanubrutinib | Phase 3 | Micro | Cervical Ca | |
| 2026-08-10 | 5mo away | Orphan Drug | BIO-IIT-937 | Preclinical | Private | Myelofibrosis | |
| 2026-08-10 | 5mo away | Enrollment Complete | AMO-1639 | Phase 2 | Private | Wet AMD | |
| 2026-08-11 | 5mo away | Ph2 Data | 109-3699 | Phase 2 | Mid | CML | |
| 2026-08-11 | 5mo away | Ph3 Readout | Fixasacituzumab | NDA/BLA | Micro | UC | |
| 2026-08-11 | 5mo away | Ph3 Readout | Lisomavacamten | NDA/BLA | Small | CF | |
| 2026-08-12 | 5mo away | Interim | EGR-8971 | Phase 1 | Small | AML | |
| 2026-08-13 | 5mo away | Ph2 Data | HCM-8303 | Phase 2 | Mid | Wet AMD | |
| 2026-08-13 | 5mo away | Ph2 Data | Nidazumab | Phase 1/2 | Private | ADPKD | |
| 2026-08-13 | 5mo away | Ph2 Data | Rimavorutinib | Phase 2 | Mid | LN | |
| 2026-08-13 | 5mo away | Interim | Lisosertib | Phase 1 | Large | FTD | |
| 2026-08-13 | 5mo away | Ph3 Readout | RYT-3886 | Phase 2/3 | Mid | RB | |
| 2026-08-13 | 5mo away | Ph3 Readout | LPC-975 | Phase 2/3 | Mid | Schizophrenia | |
| 2026-08-14 | 5mo away | Ph3 Readout | SNY-2934 | Phase 3 | Large | ADHD | |
| 2026-08-14 | 5mo away | Ph3 Readout | Bemanesiran | Phase 3 | Large | MDD | |
| 2026-08-14 | 5mo away | Ph3 Readout | Adagralemzoparlimab | Approved | Small | Migraine | |
| 2026-08-14 | 5mo away | Ph3 Readout | IPC-884 | Approved | Mid | NMOSD | |
| 2026-08-15 | 5mo away | Ph2 Data | Ivozasiran | Phase 2 | Small | ALL | |
| 2026-08-15 | 5mo away | Ph2 Data | Ribozasiran | Phase 1/2 | Private | EoE | |
| 2026-08-15 | 5mo away | Ph3 Readout | 115-4305 | NDA/BLA | Micro | SMA | |
| 2026-08-15 | 5mo away | EMA Filing | YB-6541 | Phase 3 | Private | HNSCC | |
| 2026-08-15 | 5mo away | NDA | SWT-3857 | Phase 1 | Mid | GIST | |
| 2026-08-15 | 5mo away | Conference | CON-4833 | Phase 2/3 | Private | MCC | |
| 2026-08-16 | 5mo away | Ph3 Readout | JNJ-8232 | NDA/BLA | Large | NMOSD | |
| 2026-08-16 | 5mo away | Ph3 Readout | BLU-5648 | Approved | Small | PTSD | |
| 2026-08-16 | 5mo away | Ph3 Readout | Bemacapivasertib | NDA/BLA | Micro | ACC | |
| 2026-08-16 | 5mo away | Ph3 Readout | Olpanaritide | Phase 2/3 | Private | HNSCC | |
| 2026-08-16 | 5mo away | PDUFA | IRC-IIT-265 | Phase 1/2 | Private | Angelman | |
| 2026-08-16 | 5mo away | Ph1 Dose Esc | OCT-7288 | Phase 2/3 | Private | ALS | |
| 2026-08-17 | 5mo away | Interim | ABD-3507 | Preclinical | Private | Dravet | |
| 2026-08-18 | 5mo away | Ph3 Readout | CIP-213 | Approved | Large | Gastric Ca | |
| 2026-08-18 | 5mo away | Interim | IPS-8044 | Preclinical | Micro | NB | |
| 2026-08-18 | 5mo away | Ph3 Readout | Ribozanubrutinib | Phase 2/3 | Micro | HCC | |
| 2026-08-18 | 5mo away | Ph3 Readout | Rimacilimab | Phase 3 | Private | ALL | |
| 2026-08-19 | 5mo away | Interim | PFE-5501 | Phase 1 | Large | Alzheimer's | |
| 2026-08-19 | 5mo away | Ph3 Readout | Miriosocimab | Approved | Large | Pompe | |
| 2026-08-20 | 5mo away | Ph3 Readout | TAK-9344 | Phase 3 | Large | Thymoma | |
| 2026-08-20 | 5mo away | Ph3 Readout | Teratinib | Phase 2/3 | Small | Parkinson's | |
| 2026-08-20 | 5mo away | Interim | NAN-2606 | Phase 1 | Micro | BCC | |
| 2026-08-20 | 5mo away | Interim | OGN-5336 | Phase 1 | Mid | CKD | |
| 2026-08-20 | 5mo away | Ph3 Readout | Zorilucimab | Approved | Private | WM | |
| 2026-08-21 | 5mo away | Ph3 Readout | Voxaderotide | Approved | Mid | PsA | |
| 2026-08-21 | 5mo away | Ph3 Readout | Capilucimab | Phase 3 | Private | Bladder Ca | |
| 2026-08-21 | 5mo away | Interim | Daranesiran | Preclinical | Private | ALS | |
| 2026-08-21 | 5mo away | Conference | QUO-8015 | Phase 1 | Private | GIST | |
| 2026-08-22 | 5mo away | Ph3 Readout | Datozasiran | NDA/BLA | Large | UC | |
| 2026-08-22 | 5mo away | Ph3 Readout | 187-8157 | Phase 2/3 | Mid | Breast Ca | |
| 2026-08-22 | 5mo away | Ph3 Readout | Tixatapinarof | Approved | Small | NMOSD | |
| 2026-08-22 | 5mo away | EMA Filing | Sotosacituzumab | Phase 2/3 | Small | SMA | |
| 2026-08-23 | 5mo away | Ph3 Readout | BMY-8678 | Approved | Large | AS | |
| 2026-08-23 | 5mo away | Interim | Zanuderotide | Phase 1 | Micro | PTSD | |
| 2026-08-23 | 5mo away | Ph3 Readout | STA-2404 | NDA/BLA | Private | Huntington's | |
| 2026-08-23 | 5mo away | Orphan Drug | SWO-IIT-148 | Approved | Private | HS | |
| 2026-08-23 | 5mo away | Ph1 Dose Esc | Lisosacituzumab | Phase 1/2 | Private | Pompe | |
| 2026-08-24 | 5mo away | Fast Track | Capitenlimab | Phase 1 | Micro | ALS | |
| 2026-08-25 | 5mo away | Ph2 Data | MRK-2473 | Phase 1/2 | Large | AML | |
| 2026-08-25 | 5mo away | Ph2 Data | STA-IIT-824 | Phase 1/2 | Private | Thymoma | |
| 2026-08-25 | 5mo away | Ph2 Data | 451-4283 | Phase 2 | Mid | ADHD | |
| 2026-08-25 | 5mo away | Ph3 Readout | Ceviglumide | Phase 3 | Large | Pompe | |
| 2026-08-26 | 5mo away | Ph3 Readout | SLR-5251 | Phase 3 | Small | Angelman | |
| 2026-08-26 | 5mo away | Ph3 Readout | CAD-8013 | Phase 3 | Micro | Ovarian Ca | |
| 2026-08-26 | 5mo away | Ph3 Readout | AJA-7840 | NDA/BLA | Private | RA | |
| 2026-08-26 | 5mo away | Ph3 Readout | Pexalucimab | Phase 3 | Private | RA | |
| 2026-08-27 | 5mo away | Interim | Bemabrutinib | Phase 1 | Mid | NB | |
| 2026-08-28 | 5mo away | Ph2 Data | Mirirasimod | Phase 2 | Large | RCC | |
| 2026-08-28 | 5mo away | Ph2 Data | YB-4895 | Phase 1/2 | Private | RB | |
| 2026-08-28 | 5mo away | Ph1 Dose Esc | TRV-9337 | Approved | Micro | AML | |
| 2026-09-01 | 6mo away | Interim | Sovazumab | Phase 1 | Private | NMOSD | |
| 2026-09-01 | 6mo away | Ph3 Readout | Bemaderotide | Phase 2/3 | Mid | Ovarian Ca | |
| 2026-09-02 | 6mo away | Ph3 Readout | ALG-2734 | Approved | Micro | Angelman | |
| 2026-09-02 | 6mo away | Enrollment Complete | MYG-2072 | Phase 2 | Mid | Cholangiocarcinoma | |
| 2026-09-04 | 6mo away | Ph3 Readout | NBI-3153 | Approved | Large | Bladder Ca | |
| 2026-09-04 | 6mo away | Ph2 Data | Nidarapivir | Phase 1/2 | Small | NMOSD | |
| 2026-09-04 | 6mo away | Ph3 Readout | CHI-2221 | Phase 3 | Private | AML | |
| 2026-09-05 | 6mo away | Ph2 Data | DYN-8432 | Phase 1/2 | Small | MDD | |
| 2026-09-06 | 6mo away | Ph2 Data | ARX-3681 | Phase 2 | Small | RA | |
| 2026-09-06 | 6mo away | Ph2 Data | PBL-3756 | Phase 1/2 | Micro | PV | |
| 2026-09-06 | 6mo away | Ph3 Readout | TXM-5550 | NDA/BLA | Micro | Heart Failure | |
| 2026-09-06 | 6mo away | Ph3 Readout | INT-6808 | Approved | Private | MS | |
| 2026-09-07 | 6mo away | EMA Filing | Nidarelsin | Phase 2/3 | Small | Thymoma | |
| 2026-09-08 | 6mo away | Ph3 Readout | NOB-8652 | Approved | Private | WM | |
| 2026-09-08 | 6mo away | Conference | ASA-IIT-449 | Approved | Private | Hemophilia A | |
| 2026-09-10 | 6mo away | Interim | Rimabrutinib | Preclinical | Micro | Migraine | |
| 2026-09-11 | 6mo away | Interim | Gelinaritide | Preclinical | Large | HNSCC | |
| 2026-09-11 | 6mo away | Ph2 Data | Elralucimab | Phase 2 | Mid | Epilepsy | |
| 2026-09-12 | 6mo away | Ph3 Readout | DPH-273 | NDA/BLA | Mid | Wilms | |
| 2026-09-14 | 6mo away | Interim | Motatinib | Preclinical | Mid | HCC | |
| 2026-09-14 | 6mo away | Ph3 Readout | Adagralucimab | NDA/BLA | Small | LN | |
| 2026-09-14 | 6mo away | Ph3 Readout | Lisozumab | NDA/BLA | Private | LN | |
| 2026-09-14 | 6mo away | Interim | ORN-2989 | Phase 1 | Mid | Myelofibrosis | |
| 2026-09-14 | 6mo away | Fast Track | Ivozasiran | Phase 1/2 | Micro | FSGS | |
| 2026-09-15 | 6mo away | Interim | MET-3015 | Preclinical | Private | MCL | |
| 2026-09-15 | 6mo away | Ph2 Data | Rimatenlimab | Phase 2 | Large | Cervical Ca | |
| 2026-09-15 | 6mo away | Ph1 Dose Esc | 450-7627 | Phase 1/2 | Mid | Schizophrenia | |
| 2026-09-16 | 6mo away | Ph2 Data | Teratenlimab | Phase 2 | Private | Urothelial Ca | |
| 2026-09-17 | 6mo away | Ph3 Readout | Lisoosocimab | Approved | Mid | EoE | |
| 2026-09-17 | 6mo away | Ph3 Readout | NCI-IIT-512 | Approved | Private | ALL | |
| 2026-09-18 | 6mo away | Ph3 Readout | Talarelsin | Phase 3 | Micro | Rett | |
| 2026-09-18 | 6mo away | Enrollment Complete | AJA-5085 | Preclinical | Mid | Schizophrenia | |
| 2026-09-19 | 6mo away | Interim | AII-IIT-879 | Preclinical | Private | HS | |
| 2026-09-21 | 6mo away | Ph3 Readout | ADA-4330 | Approved | Private | LGS | |
| 2026-09-21 | 6mo away | Fast Track | Tezerapivir | Preclinical | Small | Migraine | |
| 2026-09-22 | 6mo away | Ph3 Readout | UTH-9370 | NDA/BLA | Large | NSCLC | |
| 2026-09-23 | 6mo away | Enrollment Complete | Zenosertib | Phase 2/3 | Mid | CTCL | |
| 2026-09-24 | 6mo away | Ph3 Readout | CON-4833 | Phase 2/3 | Private | SMA | |
| 2026-09-24 | 6mo away | Interim | Tiranesiran | Preclinical | Private | NB | |
| 2026-09-24 | 6mo away | Ph3 Readout | Polalemzoparlimab | Approved | Private | Hemophilia A | |
| 2026-09-24 | 6mo away | NDA | UCS-IIT-951 | Phase 2 | Private | GA | |
| 2026-09-25 | 6mo away | Ph3 Readout | SRP-9822 | Phase 3 | Large | BCC | |
| 2026-09-25 | 6mo away | Enrollment Complete | SWT-8357 | Phase 1 | Mid | ET | |
| 2026-09-26 | 6mo away | Ph3 Readout | Olpazasiran | Phase 3 | Private | ADHD | |
| 2026-09-27 | 6mo away | BTD | TEM-5063 | Preclinical | Mid | AS | |
| 2026-10-01 | 7mo away | Interim | 600-2830 | Preclinical | Large | Atopic Derm | |
| 2026-10-01 | 7mo away | Interim | DYN-1761 | Phase 1 | Private | LN | |
| 2026-10-02 | 7mo away | Ph3 Readout | BIO-708 | Phase 2/3 | Private | MCC | |
| 2026-10-02 | 7mo away | Conference | HOR-3601 | Phase 1/2 | Private | Thymoma | |
| 2026-10-02 | 7mo away | Enrollment Complete | Gelibrutinib | NDA/BLA | Large | RB | |
| 2026-10-05 | 7mo away | Ph3 Readout | KAR-9558 | Approved | Private | HS | |
| 2026-10-05 | 7mo away | Ph1 Dose Esc | IMV-3466 | Phase 1 | Mid | SCLC | |
| 2026-10-06 | 7mo away | Interim | Fixainavolisib | Preclinical | Large | HS | |
| 2026-10-06 | 7mo away | Interim | FOR-4809 | Phase 1 | Private | MCC | |
| 2026-10-07 | 7mo away | Ph3 Readout | AZN-5171 | Approved | Large | PV | |
| 2026-10-07 | 7mo away | Ph3 Readout | RUI-IIT-588 | NDA/BLA | Private | PNH | |
| 2026-10-08 | 7mo away | Ph3 Readout | NVO-1361 | Phase 3 | Large | Urothelial Ca | |
| 2026-10-09 | 7mo away | Ph2 Data | Semainavolisib | Phase 2 | Mid | LGS | |
| 2026-10-09 | 7mo away | EMA Filing | ASA-IIT-161 | Phase 3 | Private | Huntington's | |
| 2026-10-10 | 7mo away | Ph3 Readout | Cevitinib | Phase 3 | Large | Atopic Derm | |
| 2026-10-10 | 7mo away | BTD | Capilucimab | Phase 3 | Private | Bladder Ca | |
| 2026-10-11 | 7mo away | Ph3 Readout | Capifutibatinib | Phase 3 | Large | RB | |
| 2026-10-11 | 7mo away | Interim | Datocilimab | Phase 1 | Small | Psoriasis | |
| 2026-10-11 | 7mo away | Ph2 Data | NIA-IIT-441 | Phase 2 | Private | EoE | |
| 2026-10-11 | 7mo away | Ph3 Readout | Datorasimod | NDA/BLA | Private | NB | |
| 2026-10-11 | 7mo away | Ph3 Readout | 415-3897 | Phase 3 | Large | Ewing Sarcoma | |
| 2026-10-12 | 7mo away | AdCom | DAN-IIT-542 | Phase 2 | Private | Fabry | |
| 2026-10-13 | 7mo away | Ph2 Data | MRN-7601 | Phase 2 | Large | NASH | |
| 2026-10-13 | 7mo away | Ph2 Data | Talatinib | Phase 2 | Micro | DMD | |
| 2026-10-13 | 7mo away | Fast Track | 4D-8297 | Phase 1/2 | Private | Heart Failure | |
| 2026-10-13 | 7mo away | EMA Filing | GIM-IIT-993 | NDA/BLA | Private | FTD | |
| 2026-10-14 | 7mo away | Ph3 Readout | CGO-9628 | Phase 2/3 | Mid | Fabry | |
| 2026-10-14 | 7mo away | Ph3 Readout | Gozebrutinib | Approved | Mid | Wilms | |
| 2026-10-14 | 7mo away | Ph3 Readout | Zanutinib | Approved | Micro | ADHD | |
| 2026-10-14 | 7mo away | EMA Filing | Gozederotide | NDA/BLA | Micro | LGS | |
| 2026-10-15 | 7mo away | Ph3 Readout | Miriosocimab | Phase 3 | Private | MG | |
| 2026-10-16 | 7mo away | Ph2 Data | Talatuximab | Phase 1/2 | Mid | PAH | |
| 2026-10-16 | 7mo away | Ph2 Data | Bemasotorasib | Phase 1/2 | Private | PAH | |
| 2026-10-17 | 7mo away | Ph2 Data | Gelisacituzumab | Phase 2 | Private | RSV | |
| 2026-10-17 | 7mo away | Conference | TOL-8761 | Phase 2 | Private | MCL | |
| 2026-10-17 | 7mo away | EMA Filing | Zoriosocimab | Phase 3 | Mid | NSCLC | |
| 2026-10-18 | 7mo away | Interim | Adagratapinarof | Preclinical | Large | HS | |
| 2026-10-18 | 7mo away | Interim | EUP-4341 | Preclinical | Private | Hemophilia A | |
| 2026-10-18 | 7mo away | AdCom | MRN-7409 | NDA/BLA | Large | MCC | |
| 2026-10-19 | 7mo away | Ph3 Readout | TES-3466 | NDA/BLA | Private | FSGS | |
| 2026-10-19 | 7mo away | Ph3 Readout | ZYN-3484 | Phase 2/3 | Micro | Migraine | |
| 2026-10-19 | 7mo away | Ph2 Data | 600-5291 | Phase 2 | Mid | OCD | |
| 2026-10-20 | 7mo away | Ph2 Data | Semasertib | Phase 2 | Small | ALS | |
| 2026-10-20 | 7mo away | BTD | DAI-7966 | Preclinical | Private | MG | |
| 2026-10-21 | 7mo away | Ph3 Readout | ABB-7516 | Phase 3 | Large | TTR Amyloidosis | |
| 2026-10-21 | 7mo away | Ph3 Readout | Adagrazasiran | Approved | Private | CLL | |
| 2026-10-21 | 7mo away | Ph2 Data | Sovarelsin | Phase 1/2 | Mid | MS | |
| 2026-10-21 | 7mo away | Ph1 Dose Esc | PCV-5987 | Phase 2/3 | Mid | RSV | |
| 2026-10-21 | 7mo away | NDA | Capicilimab | Phase 2/3 | Small | HNSCC | |
| 2026-10-22 | 7mo away | Ph3 Readout | Tirabrutinib | Approved | Mid | Psoriasis | |
| 2026-10-22 | 7mo away | Ph3 Readout | VEC-8813 | Phase 3 | Private | UC | |
| 2026-10-23 | 7mo away | Ph3 Readout | Pemiglumide | NDA/BLA | Mid | MM | |
| 2026-10-23 | 7mo away | Ph3 Readout | ERY-9084 | NDA/BLA | Micro | Ewing Sarcoma | |
| 2026-10-23 | 7mo away | Conference | Pexaosocimab | Phase 2 | Large | CKD | |
| 2026-10-24 | 7mo away | Ph2 Data | Daracilimab | Phase 2 | Large | Prostate Ca | |
| 2026-10-24 | 7mo away | BTD | NCI-IIT-143 | Phase 1/2 | Private | ALL | |
| 2026-10-25 | 7mo away | Ph3 Readout | Teratinib | NDA/BLA | Mid | LN | |
| 2026-10-26 | 7mo away | Ph2 Data | Capilemzoparlimab | Phase 2 | Private | Bladder Ca | |
| 2026-10-26 | 7mo away | Interim | Daratenlimab | Phase 1 | Micro | CKD | |
| 2026-10-26 | 7mo away | Ph3 Readout | Sovazumab | NDA/BLA | Private | BCC | |
| 2026-10-26 | 7mo away | Conference | MEN-8522 | Phase 1 | Private | MM | |
| 2026-10-27 | 7mo away | Ph3 Readout | CST-7277 | Phase 2/3 | Mid | AML | |
| 2026-10-27 | 7mo away | EMA Filing | Motamavacamten | Preclinical | Micro | PBC | |
| 2026-10-27 | 7mo away | AdCom | ORP-8634 | Phase 1/2 | Private | Huntington's | |
| 2026-10-28 | 7mo away | Fast Track | GLP-5658 | Phase 2/3 | Mid | CSU | |
| 2026-10-28 | 7mo away | NDA | BCA-6126 | Phase 2/3 | Micro | ALS | |
| 2026-11-01 | 8mo away | Ph2 Data | CLB-2823 | Phase 2 | Micro | MDS | |
| 2026-11-01 | 8mo away | Interim | FYB-2633 | Phase 1 | Small | Alzheimer's | |
| 2026-11-02 | 8mo away | Ph3 Readout | Motanaritide | Approved | Mid | PV | |
| 2026-11-02 | 8mo away | Interim | Pexavorutinib | Preclinical | Private | MCL | |
| 2026-11-03 | 8mo away | Interim | DAN-IIT-673 | Preclinical | Private | RA | |
| 2026-11-03 | 8mo away | Interim | CLO-7126 | Preclinical | Private | NB | |
| 2026-11-03 | 8mo away | Ph3 Readout | SCR-7300 | NDA/BLA | Private | CLL | |
| 2026-11-03 | 8mo away | Ph2 Data | ZTS-7862 | Phase 1/2 | Large | MDS | |
| 2026-11-04 | 8mo away | Ph3 Readout | Motainavolisib | NDA/BLA | Large | Pompe | |
| 2026-11-04 | 8mo away | Ph2 Data | DAI-6285 | Phase 1/2 | Private | Pompe | |
| 2026-11-04 | 8mo away | Ph1 Dose Esc | Miriglumide | Phase 3 | Large | SMA | |
| 2026-11-05 | 8mo away | Ph3 Readout | ATH-6254 | Approved | Private | PsA | |
| 2026-11-06 | 8mo away | Interim | Polalucimab | Preclinical | Mid | Thymoma | |
| 2026-11-07 | 8mo away | Ph3 Readout | VYG-2970 | Phase 3 | Small | ACC | |
| 2026-11-08 | 8mo away | Ph2 Data | Liravorutinib | Phase 1/2 | Small | HNSCC | |
| 2026-11-08 | 8mo away | Ph3 Readout | Talazumab | Phase 2/3 | Mid | LGS | |
| 2026-11-08 | 8mo away | Ph2 Data | 300-6800 | Phase 1/2 | Mid | IPF | |
| 2026-11-08 | 8mo away | NDA | ATO-3461 | Phase 1 | Micro | SCD | |
| 2026-11-09 | 8mo away | Ph3 Readout | SNY-9600 | NDA/BLA | Large | UC | |
| 2026-11-10 | 8mo away | Ph3 Readout | LLY-4358 | Phase 3 | Large | TTR Amyloidosis | |
| 2026-11-10 | 8mo away | Ph2 Data | Olpafotisoran | Phase 2 | Micro | T2D | |
| 2026-11-10 | 8mo away | Conference | Tiracilimab | Phase 1 | Micro | ALS | |
| 2026-11-11 | 8mo away | Ph3 Readout | Nidarelsin | Phase 2/3 | Private | TTR Amyloidosis | |
| 2026-11-11 | 8mo away | Interim | Suraderotide | Phase 1 | Private | Thymoma | |
| 2026-11-11 | 8mo away | Ph3 Readout | Olpazasiran | Phase 3 | Private | ADHD | |
| 2026-11-12 | 8mo away | Ph3 Readout | IVE-9723 | Phase 3 | Private | PNH | |
| 2026-11-12 | 8mo away | Conference | ENC-4310 | Phase 1/2 | Private | Pompe | |
| 2026-11-13 | 8mo away | Ph2 Data | MRK-3745 | Phase 2 | Large | PSP | |
| 2026-11-13 | 8mo away | Ph2 Data | NIA-IIT-413 | Phase 2 | Private | MDD | |
| 2026-11-13 | 8mo away | AdCom | DIV-3233 | Phase 2/3 | Large | Cervical Ca | |
| 2026-11-15 | 8mo away | Interim | GIL-4361 | Preclinical | Large | CML | |
| 2026-11-15 | 8mo away | Ph3 Readout | DUK-IIT-640 | NDA/BLA | Private | MCL | |
| 2026-11-15 | 8mo away | Interim | Daramavacamten | Preclinical | Private | Wet AMD | |
| 2026-11-15 | 8mo away | Ph3 Readout | Gelilemzoparlimab | Approved | Private | MDD | |
| 2026-11-15 | 8mo away | Ph3 Readout | INT-6808 | Approved | Private | MS | |
| 2026-11-15 | 8mo away | AdCom | EOR-IIT-726 | Phase 1 | Private | Breast Ca | |
| 2026-11-16 | 8mo away | Fast Track | Pexanaritide | NDA/BLA | Small | Schizophrenia | |
| 2026-11-17 | 8mo away | Ph3 Readout | Elrabrutinib | Phase 3 | Micro | Endometrial Ca | |
| 2026-11-18 | 8mo away | Interim | Ivosotorasib | Preclinical | Large | HCC | |
| 2026-11-18 | 8mo away | Ph3 Readout | Tirainavolisib | Approved | Large | Schizophrenia | |
| 2026-11-19 | 8mo away | Ph3 Readout | 068-872 | Approved | Large | SCLC | |
| 2026-11-19 | 8mo away | Conference | LLY-3251 | Phase 2 | Large | SCD | |
| 2026-11-20 | 8mo away | Ph2 Data | Voxatapinarof | Phase 2 | Private | Ovarian Ca | |
| 2026-11-20 | 8mo away | Ph3 Readout | Bemasertib | Phase 3 | Mid | Heart Failure | |
| 2026-11-20 | 8mo away | Fast Track | Voxasotorasib | Phase 3 | Private | Ewing Sarcoma | |
| 2026-11-21 | 8mo away | NDA | CHI-3542 | Phase 2 | Private | HNSCC | |
| 2026-11-22 | 8mo away | Ph2 Data | Tixatapinarof | Phase 1/2 | Mid | CSU | |
| 2026-11-22 | 8mo away | Ph3 Readout | IPN-4133 | NDA/BLA | Large | Wilms | |
| 2026-11-22 | 8mo away | Interim | CLL-5354 | Preclinical | Small | Heart Failure | |
| 2026-11-22 | 8mo away | Ph3 Readout | Pexainavolisib | Phase 3 | Private | MG | |
| 2026-11-22 | 8mo away | Ph1 Dose Esc | Gelinaritide | Preclinical | Large | HNSCC | |
| 2026-11-23 | 8mo away | Ph3 Readout | Ivovorutinib | NDA/BLA | Private | MCC | |
| 2026-11-23 | 8mo away | Interim | Lisonaritide | Preclinical | Small | WM | |
| 2026-11-23 | 8mo away | Fast Track | GUS-IIT-662 | Preclinical | Private | PTSD | |
| 2026-11-24 | 8mo away | Ph3 Readout | Doxarasimod | NDA/BLA | Large | BCC | |
| 2026-11-24 | 8mo away | Ph2 Data | Kemazanubrutinib | Phase 1/2 | Small | RB | |
| 2026-11-24 | 8mo away | Fast Track | Datorasimod | Approved | Micro | Huntington's | |
| 2026-11-25 | 8mo away | Ph2 Data | SCI-9093 | Phase 1/2 | Private | GIST | |
| 2026-11-25 | 8mo away | Ph2 Data | 417-3039 | Phase 2 | Micro | FTD | |
| 2026-11-26 | 8mo away | BTD | TXG-6755 | Approved | Mid | CML | |
| 2026-11-27 | 8mo away | NDA | MIR-6154 | Phase 2 | Micro | Celiac | |
| 2026-11-28 | 8mo away | Ph3 Readout | ORC-9172 | Phase 3 | Private | OCD | |
| 2026-11-28 | 8mo away | Interim | 414-5700 | Preclinical | Small | MM | |
| 2026-11-28 | 8mo away | Ph3 Readout | APN-2677 | NDA/BLA | Mid | MCC | |
| 2026-11-28 | 8mo away | Ph1 Dose Esc | Doxafotisoran | Phase 3 | Private | AS | |
| 2026-11-28 | 8mo away | Enrollment Complete | Zenorelsin | NDA/BLA | Mid | Psoriasis | |
| 2026-12-01 | 9mo away | Ph2 Data | SAM-IIT-954 | Phase 1/2 | Private | Dravet | |
| 2026-12-01 | 9mo away | Ph3 Readout | Nidasertib | Approved | Mid | MDS | |
| 2026-12-02 | 9mo away | Ph2 Data | WST-2406 | Phase 2 | Large | Thymoma | |
| 2026-12-02 | 9mo away | PDUFA | Semaglumide | Phase 3 | Private | Myelofibrosis | |
| 2026-12-03 | 9mo away | Ph3 Readout | Teraosocimab | Approved | Large | MS | |
| 2026-12-04 | 9mo away | Interim | Motainavolisib | Phase 1 | Private | Myelofibrosis | |
| 2026-12-04 | 9mo away | Ph3 Readout | AIP-7637 | NDA/BLA | Small | Fabry | |
| 2026-12-04 | 9mo away | Fast Track | ELE-7041 | Preclinical | Micro | DLBCL | |
| 2026-12-05 | 9mo away | Ph3 Readout | 002-1797 | Approved | Mid | Huntington's | |
| 2026-12-05 | 9mo away | Ph3 Readout | Talacagene | Phase 2/3 | Private | Breast Ca | |
| 2026-12-05 | 9mo away | Interim | IDX-785 | Phase 1 | Large | Crohn's | |
| 2026-12-06 | 9mo away | Interim | Nirafotisoran | Preclinical | Private | CTCL | |
| 2026-12-06 | 9mo away | Ph3 Readout | Fixazasiran | Phase 2/3 | Private | FTD | |
| 2026-12-06 | 9mo away | BTD | Nidaosocimab | Phase 1 | Mid | RB | |
| 2026-12-07 | 9mo away | Interim | INS-408 | Phase 1 | Private | LGS | |
| 2026-12-07 | 9mo away | Ph3 Readout | Adagrazasiran | Approved | Private | Psoriasis | |
| 2026-12-08 | 9mo away | Ph3 Readout | Ivovorutinib | NDA/BLA | Private | MCC | |
| 2026-12-09 | 9mo away | EMA Filing | SNY-5783 | Phase 1/2 | Large | SLE | |
| 2026-12-10 | 9mo away | Ph3 Readout | Teraosocimab | Phase 3 | Private | Migraine | |
| 2026-12-10 | 9mo away | PDUFA | Ivonaritide | Phase 2 | Micro | Heart Failure | |
| 2026-12-11 | 9mo away | Interim | HCM-2035 | Preclinical | Mid | HS | |
| 2026-12-12 | 9mo away | Ph2 Data | Liravorutinib | Phase 1/2 | Small | HNSCC | |
| 2026-12-12 | 9mo away | Ph3 Readout | SLR-5251 | Phase 3 | Small | GBM | |
| 2026-12-12 | 9mo away | Interim | GEN-3979 | Phase 1 | Private | IPF | |
| 2026-12-12 | 9mo away | Ph3 Readout | TUR-4491 | NDA/BLA | Private | Crohn's | |
| 2026-12-13 | 9mo away | Ph3 Readout | MED-9563 | Approved | Private | Prostate Ca | |
| 2026-12-13 | 9mo away | Orphan Drug | Polatuximab | Phase 1/2 | Micro | Thymoma | |
| 2026-12-13 | 9mo away | EMA Filing | RAR-440 | Phase 2 | Mid | MG | |
| 2026-12-14 | 9mo away | Ph1 Dose Esc | PMC-7054 | Phase 2 | Micro | CRC | |
| 2026-12-14 | 9mo away | Orphan Drug | PEK-IIT-794 | Phase 1/2 | Private | Obesity | |
| 2026-12-16 | 9mo away | Interim | CN-9071 | Preclinical | Private | Rett | |
| 2026-12-16 | 9mo away | Ph3 Readout | DIC-4437 | Approved | Private | RA | |
| 2026-12-17 | 9mo away | Ph3 Readout | KAR-9558 | Approved | Private | HS | |
| 2026-12-17 | 9mo away | Ph3 Readout | TER-2947 | Phase 3 | Private | Urothelial Ca | |
| 2026-12-19 | 9mo away | Ph3 Readout | Olpaglumide | Approved | Mid | Epilepsy | |
| 2026-12-19 | 9mo away | Interim | Polainavolisib | Preclinical | Micro | NMOSD | |
| 2026-12-19 | 9mo away | Orphan Drug | JNJ-179 | Approved | Large | DMD | |
| 2026-12-20 | 9mo away | Ph3 Readout | Rilutinib | Phase 3 | Small | SMA | |
| 2026-12-20 | 9mo away | Ph2 Data | Ivomavacamten | Phase 1/2 | Large | PSP | |
| 2026-12-20 | 9mo away | AdCom | Zoricapivasertib | Phase 2 | Large | Asthma | |
| 2026-12-21 | 9mo away | Interim | Ceviglumide | Phase 1 | Micro | Obesity | |
| 2026-12-21 | 9mo away | Ph1 Dose Esc | VEC-6874 | Phase 2/3 | Private | FL | |
| 2026-12-23 | 9mo away | Ph3 Readout | Bemarapivir | Approved | Large | CKD | |
| 2026-12-24 | 9mo away | Interim | Nirafotisoran | Preclinical | Private | CTCL | |
| 2026-12-24 | 9mo away | Ph2 Data | 418-6056 | Phase 1/2 | Mid | NB | |
| 2026-12-25 | 9mo away | Ph3 Readout | Talaglumide | NDA/BLA | Micro | Asthma | |
| 2026-12-25 | 9mo away | Interim | PAC-8776 | Preclinical | Small | Rett | |
| 2026-12-26 | 9mo away | Interim | SPI-1775 | Preclinical | Private | RB | |
| 2026-12-26 | 9mo away | Conference | Doxarelsin | Phase 1/2 | Private | ACC | |
| 2026-12-26 | 9mo away | Conference | RIC-4332 | Phase 3 | Mid | Cholangiocarcinoma | |
| 2026-12-26 | 9mo away | Orphan Drug | ABB-3060 | Phase 2 | Large | Migraine | |
| 2026-12-27 | 9mo away | Interim | Zorizumab | Phase 1 | Large | Obesity | |
| 2026-12-27 | 9mo away | Ph2 Data | CRD-4273 | Phase 1/2 | Micro | Psoriasis | |
| 2026-12-27 | 9mo away | Ph1 Dose Esc | VRN-4215 | Preclinical | Mid | Cervical Ca | |
| 2026-12-28 | 9mo away | PDUFA | Talafotisoran | Phase 1 | Private | Melanoma | |
| 2027-01-01 | 10mo away | Ph3 Readout | ONC-9948 | Approved | Private | ET | |
| 2027-01-02 | 10mo away | Ph3 Readout | LEG-6533 | NDA/BLA | Large | Migraine | |
| 2027-01-02 | 10mo away | Ph3 Readout | CAR-9866 | Phase 3 | Micro | CTCL | |
| 2027-01-02 | 10mo away | Ph3 Readout | CRI-9527 | Phase 3 | Private | HNSCC | |
| 2027-01-02 | 10mo away | Ph3 Readout | SYN-451 | NDA/BLA | Private | EoE | |
| 2027-01-03 | 10mo away | Ph2 Data | SNY-7254 | Phase 2 | Large | FSGS | |
| 2027-01-03 | 10mo away | Interim | Gozefutibatinib | Preclinical | Private | EoE | |
| 2027-01-08 | 10mo away | Interim | Sovafutibatinib | Phase 1 | Private | Huntington's | |
| 2027-01-09 | 10mo away | Ph3 Readout | AZN-5171 | Approved | Large | PV | |
| 2027-01-09 | 10mo away | Ph3 Readout | GEN-IIT-955 | Phase 2/3 | Private | Cholangiocarcinoma | |
| 2027-01-10 | 10mo away | Ph3 Readout | FRE-IIT-649 | Phase 3 | Private | Prostate Ca | |
| 2027-01-10 | 10mo away | Ph2 Data | Zanutenlimab | Phase 2 | Private | MM | |
| 2027-01-11 | 10mo away | Ph3 Readout | Lisosotorasib | Phase 3 | Micro | Melanoma | |
| 2027-01-11 | 10mo away | Interim | Sovainavolisib | Preclinical | Large | Obesity | |
| 2027-01-12 | 10mo away | Ph3 Readout | Fixafutibatinib | Phase 3 | Mid | CTCL | |
| 2027-01-12 | 10mo away | Ph2 Data | Gelirelsin | Phase 2 | Mid | SCD | |
| 2027-01-12 | 10mo away | Ph3 Readout | MAY-IIT-189 | Approved | Private | Thymoma | |
| 2027-01-12 | 10mo away | Ph2 Data | Teracagene | Phase 2 | Large | ET | |
| 2027-01-12 | 10mo away | Ph3 Readout | Motanaritide | Approved | Small | PNH | |
| 2027-01-13 | 10mo away | Ph2 Data | Fixaratamab | Phase 1/2 | Private | ADPKD | |
| 2027-01-14 | 10mo away | Ph3 Readout | Mavuzasiran | Phase 3 | Mid | Rett | |
| 2027-01-15 | 10mo away | Ph3 Readout | Capifutibatinib | Phase 3 | Large | Migraine | |
| 2027-01-15 | 10mo away | Ph3 Readout | Cevifutibatinib | Phase 3 | Micro | Heart Failure | |
| 2027-01-15 | 10mo away | Ph3 Readout | Lisozasiran | NDA/BLA | Small | ADPKD | |
| 2027-01-16 | 10mo away | Ph3 Readout | Peminaritide | NDA/BLA | Large | PNH | |
| 2027-01-16 | 10mo away | Ph3 Readout | IPN-4133 | NDA/BLA | Large | Wilms | |
| 2027-01-17 | 10mo away | Ph3 Readout | TAI-4908 | Phase 3 | Private | AML | |
| 2027-01-18 | 10mo away | Ph3 Readout | SND-5878 | NDA/BLA | Mid | SMA | |
| 2027-01-18 | 10mo away | Ph3 Readout | CHI-IIT-120 | Phase 2/3 | Private | GIST | |
| 2027-01-19 | 10mo away | Ph3 Readout | GIL-2259 | Approved | Large | ET | |
| 2027-01-19 | 10mo away | Ph3 Readout | VIR-5526 | Phase 3 | Small | HNSCC | |
| 2027-01-19 | 10mo away | Ph3 Readout | BLC-3714 | Approved | Mid | ALL | |
| 2027-01-20 | 10mo away | Interim | NVS-5439 | Preclinical | Large | SCD | |
| 2027-01-20 | 10mo away | Ph3 Readout | Elracilimab | NDA/BLA | Mid | GBM | |
| 2027-01-21 | 10mo away | Ph3 Readout | 208-7575 | Phase 2/3 | Micro | GIST | |
| 2027-01-21 | 10mo away | Ph3 Readout | 219-5261 | Phase 3 | Mid | Ovarian Ca | |
| 2027-01-21 | 10mo away | Ph3 Readout | INS-127 | Phase 2/3 | Private | Pancreatic Ca | |
| 2027-01-21 | 10mo away | Ph3 Readout | Riluderotide | Phase 2/3 | Private | Obesity | |
| 2027-01-22 | 10mo away | Ph3 Readout | Capibrutinib | Approved | Private | Obesity | |
| 2027-01-22 | 10mo away | Ph2 Data | Zanumavacamten | Phase 1/2 | Mid | BCC | |
| 2027-01-22 | 10mo away | Ph3 Readout | 600-5970 | Approved | Mid | Crohn's | |
| 2027-01-23 | 10mo away | Ph3 Readout | Polainavolisib | Phase 2/3 | Private | MDD | |
| 2027-01-24 | 10mo away | Ph2 Data | Pexatuximab | Phase 2 | Micro | MG | |
| 2027-01-25 | 10mo away | Interim | SGM-7896 | Preclinical | Micro | EoE | |
| 2027-01-26 | 10mo away | Ph3 Readout | Capisertib | NDA/BLA | Private | UC | |
| 2027-01-27 | 10mo away | Ph3 Readout | Nidatenlimab | NDA/BLA | Large | Breast Ca | |
| 2027-01-27 | 10mo away | Ph2 Data | AJA-3524 | Phase 1/2 | Private | Pancreatic Ca | |
| 2027-01-27 | 10mo away | Ph3 Readout | BCA-6126 | Phase 2/3 | Micro | ALS | |
| 2027-01-28 | 10mo away | Interim | ALE-8045 | Phase 1 | Private | MDD | |
| 2027-01-28 | 10mo away | Ph3 Readout | ZHE-9252 | Phase 3 | Private | Bladder Ca | |
| 2027-02-01 | 11mo away | Ph3 Readout | Terarelsin | Phase 3 | Private | Bladder Ca | |
| 2027-02-02 | 11mo away | Ph2 Data | PFE-2901 | Phase 2 | Large | CLL | |
| 2027-02-02 | 11mo away | Ph2 Data | Rimainavolisib | Phase 2 | Mid | Endometrial Ca | |
| 2027-02-02 | 11mo away | Ph3 Readout | Pemiratamab | Phase 2/3 | Small | IPF | |
| 2027-02-03 | 11mo away | Ph2 Data | MRN-7601 | Phase 2 | Large | NASH | |
| 2027-02-03 | 11mo away | Ph3 Readout | CHI-IIT-214 | Phase 3 | Private | Atopic Derm | |
| 2027-02-04 | 11mo away | Ph2 Data | Ivonesiran | Phase 1/2 | Mid | Obesity | |
| 2027-02-05 | 11mo away | Ph3 Readout | Datobrutinib | Phase 3 | Large | FTD | |
| 2027-02-05 | 11mo away | Ph2 Data | REG-2172 | Phase 1/2 | Large | Wilms | |
| 2027-02-05 | 11mo away | Ph3 Readout | Voxasotorasib | Phase 3 | Private | Ewing Sarcoma | |
| 2027-02-05 | 11mo away | Interim | Rilunaritide | Preclinical | Private | SCD | |
| 2027-02-05 | 11mo away | Ph2 Data | MVI-4741 | Phase 2 | Micro | UC | |
| 2027-02-06 | 11mo away | Ph3 Readout | NVO-9615 | Phase 2/3 | Large | PV | |
| 2027-02-06 | 11mo away | Interim | REG-647 | Preclinical | Large | Rett | |
| 2027-02-07 | 11mo away | Ph3 Readout | ERY-9084 | NDA/BLA | Micro | Ewing Sarcoma | |
| 2027-02-07 | 11mo away | Ph3 Readout | Kemaderotide | Approved | Micro | AML | |
| 2027-02-08 | 11mo away | Ph3 Readout | Exagamglogene autotemcel | Approved | Large | Thalassemia | |
| 2027-02-08 | 11mo away | Ph2 Data | Pexaglumide | Phase 1/2 | Private | CKD | |
| 2027-02-08 | 11mo away | Ph3 Readout | Talafotisoran | NDA/BLA | Private | Meso | |
| 2027-02-08 | 11mo away | Ph3 Readout | HAR-6503 | Approved | Private | Migraine | |
| 2027-02-08 | 11mo away | Ph2 Data | Semarasimod | Phase 1/2 | Small | HCC | |
| 2027-02-09 | 11mo away | Interim | QUO-8015 | Phase 1 | Private | CRC | |
| 2027-02-10 | 11mo away | Ph3 Readout | Elrazanubrutinib | NDA/BLA | Private | SCD | |
| 2027-02-10 | 11mo away | Ph3 Readout | JAN-1547 | Approved | Mid | MDS | |
| 2027-02-11 | 11mo away | Ph3 Readout | VRT-5441 | Phase 3 | Large | NB | |
| 2027-02-11 | 11mo away | Ph3 Readout | Fixainavolisib | Phase 2/3 | Micro | Migraine | |
| 2027-02-11 | 11mo away | Interim | 269-7185 | Preclinical | Mid | Ewing Sarcoma | |
| 2027-02-12 | 11mo away | Interim | Tezelucimab | Preclinical | Mid | SMA | |
| 2027-02-12 | 11mo away | Ph3 Readout | Rilulemzoparlimab | Approved | Micro | Cholangiocarcinoma | |
| 2027-02-13 | 11mo away | Ph3 Readout | Lisorapivir | Approved | Mid | MCL | |
| 2027-02-13 | 11mo away | Interim | Zenozasiran | Preclinical | Large | FSGS | |
| 2027-02-13 | 11mo away | Interim | Tixasotorasib | Preclinical | Large | LGS | |
| 2027-02-14 | 11mo away | Ph3 Readout | Sovaratamab | Phase 2/3 | Micro | Celiac | |
| 2027-02-15 | 11mo away | Ph2 Data | RVM-3746 | Phase 1/2 | Mid | IPF | |
| 2027-02-15 | 11mo away | Ph3 Readout | BLP-8787 | Approved | Micro | Huntington's | |
| 2027-02-15 | 11mo away | Ph3 Readout | Pemitenlimab | Phase 3 | Private | IPF | |
| 2027-02-15 | 11mo away | Ph2 Data | TEC-1111 | Phase 1/2 | Large | LN | |
| 2027-02-16 | 11mo away | Ph3 Readout | Adagracapivasertib | NDA/BLA | Large | Parkinson's | |
| 2027-02-16 | 11mo away | Interim | Gozeosocimab | Preclinical | Small | SLE | |
| 2027-02-16 | 11mo away | Ph3 Readout | Doxafotisoran | Phase 3 | Private | AS | |
| 2027-02-16 | 11mo away | Ph3 Readout | IMV-3202 | Approved | Mid | Parkinson's | |
| 2027-02-17 | 11mo away | Ph2 Data | ALM-8546 | Phase 1/2 | Small | Wet AMD | |
| 2027-02-18 | 11mo away | Ph3 Readout | ABB-3951 | Phase 2/3 | Large | Alzheimer's | |
| 2027-02-19 | 11mo away | Ph3 Readout | VCY-7977 | Phase 3 | Mid | Ewing Sarcoma | |
| 2027-02-20 | 11mo away | Interim | GSK-4334 | Preclinical | Large | LN | |
| 2027-02-20 | 11mo away | Interim | TEM-8322 | Preclinical | Mid | Asthma | |
| 2027-02-22 | 11mo away | Ph3 Readout | CON-544 | NDA/BLA | Private | SLE | |
| 2027-02-22 | 11mo away | Ph2 Data | CAD-5301 | Phase 1/2 | Large | ALL | |
| 2027-02-23 | 11mo away | Ph3 Readout | MRK-3812 | Phase 3 | Micro | RSV | |
| 2027-02-23 | 11mo away | Ph3 Readout | TES-8356 | NDA/BLA | Private | Ewing Sarcoma | |
| 2027-02-23 | 11mo away | Ph3 Readout | Pemivorutinib | NDA/BLA | Private | PSP | |
| 2027-02-23 | 11mo away | Ph3 Readout | KIA-7048 | Phase 3 | Private | UC | |
| 2027-02-24 | 11mo away | Interim | Doxazasiran | Phase 1 | Mid | BCC | |
| 2027-02-24 | 11mo away | Interim | TEV-8109 | Phase 1 | Large | HCC | |
| 2027-02-25 | 11mo away | Ph3 Readout | Nirabrutinib | Phase 2/3 | Large | CF | |
| 2027-02-26 | 11mo away | Interim | GIL-9779 | Phase 1 | Large | MDD | |
| 2027-02-26 | 11mo away | Interim | SWT-8357 | Phase 1 | Mid | ET | |
| 2027-02-27 | 11mo away | Interim | KAR-2338 | Preclinical | Private | CRC | |
| 2027-02-27 | 11mo away | Ph3 Readout | Zorirapivir | NDA/BLA | Private | NB | |
| 2027-02-28 | 11mo away | Ph3 Readout | COR-7645 | NDA/BLA | Private | Crohn's | |
| 2027-03-01 | 11mo away | Ph3 Readout | Polalemzoparlimab | Approved | Private | OCD | |
| 2027-03-02 | 12mo away | Ph3 Readout | TEM-4581 | Phase 2/3 | Mid | MCL | |
| 2027-03-04 | 12mo away | Ph3 Readout | 302-9165 | Approved | Mid | T2D | |
| 2027-03-04 | 12mo away | Ph3 Readout | ORB-4389 | Phase 3 | Private | T2D | |
| 2027-03-05 | 12mo away | Ph3 Readout | DIV-9629 | Phase 3 | Large | Urothelial Ca | |
| 2027-03-06 | 12mo away | Ph3 Readout | Voxazasiran | Phase 2/3 | Small | Thymoma | |
| 2027-03-06 | 12mo away | Ph2 Data | Lisotenlimab | Phase 1/2 | Private | AS | |
| 2027-03-06 | 12mo away | Ph3 Readout | Liravorutinib | Approved | Private | IPF | |
| 2027-03-07 | 12mo away | Interim | Olpainavolisib | Phase 1 | Large | CLL | |
| 2027-03-07 | 12mo away | Ph3 Readout | Ceviglumide | Phase 3 | Large | Pompe | |
| 2027-03-07 | 12mo away | Ph3 Readout | BRK-679 | Approved | Large | SCLC | |
| 2027-03-08 | 12mo away | Ph2 Data | RAR-440 | Phase 2 | Mid | MG | |
| 2027-03-08 | 12mo away | Ph3 Readout | Lisozumab | NDA/BLA | Private | LN | |
| 2027-03-09 | 12mo away | Interim | ALE-8045 | Phase 1 | Private | MG | |
| 2027-03-09 | 12mo away | Ph2 Data | GRA-2645 | Phase 2 | Small | NASH | |
| 2027-03-10 | 12mo away | Ph2 Data | Elrarapivir | Phase 2 | Mid | HS | |
| 2027-03-10 | 12mo away | Ph3 Readout | ACC-8527 | Approved | Private | NMOSD | |
| 2027-03-11 | 12mo away | Ph3 Readout | Nidaratamab | Phase 3 | Mid | MM | |
| 2027-03-11 | 12mo away | Ph2 Data | CAM-IIT-818 | Phase 1/2 | Private | Angelman | |
| 2027-03-11 | 12mo away | Ph3 Readout | Rilucapivasertib | Phase 2/3 | Micro | GA | |
| 2027-03-11 | 12mo away | Interim | DEC-1380 | Preclinical | Private | MDD | |
| 2027-03-12 | 12mo away | Interim | ASM-5108 | Phase 1 | Micro | Psoriasis | |
| 2027-03-12 | 12mo away | Ph3 Readout | Bemarapivir | Phase 2/3 | Mid | CSU | |
| 2027-03-12 | 12mo away | Interim | TAT-IIT-198 | Phase 1 | Private | PTSD | |
| 2027-03-12 | 12mo away | Ph3 Readout | Lisomavacamten | NDA/BLA | Small | CF | |
| 2027-03-12 | 12mo away | Ph3 Readout | Riluzumab | Approved | Large | PsA | |
| 2027-03-14 | 12mo away | Ph2 Data | Zanuinavolisib | Phase 2 | Mid | Meso | |
| 2027-03-14 | 12mo away | Interim | SEV-IIT-593 | Phase 1 | Private | Ovarian Ca | |
| 2027-03-16 | 1.0y away | Interim | MRK-1380 | Preclinical | Large | Prostate Ca | |
| 2027-03-16 | 1.0y away | Interim | Semazasiran | Phase 1 | Large | NMOSD | |
| 2027-03-16 | 1.0y away | Ph3 Readout | CRB-6490 | Approved | Micro | SMA | |
| 2027-03-16 | 1.0y away | Ph2 Data | NVC-9528 | Phase 2 | Mid | Bladder Ca | |
| 2027-03-17 | 1.0y away | Ph2 Data | IMM-2921 | Phase 1/2 | Private | FTD | |
| 2027-03-18 | 1.0y away | Ph3 Readout | Tezecilimab | Approved | Large | DLBCL | |
| 2027-03-18 | 1.0y away | Ph3 Readout | TCB-2352 | Approved | Micro | CSU | |
| 2027-03-18 | 1.0y away | Ph3 Readout | POL-5703 | Approved | Private | Migraine | |
| 2027-03-19 | 1.0y away | Ph2 Data | Polalucimab | Phase 2 | Micro | Fabry | |
| 2027-03-20 | 1.0y away | Ph3 Readout | Elrarasimod | NDA/BLA | Private | Asthma | |
| 2027-03-21 | 1.0y away | Interim | Elratuximab | Phase 1 | Private | GIST | |
| 2027-03-22 | 1.0y away | Ph3 Readout | Voxaderotide | NDA/BLA | Large | Schizophrenia | |
| 2027-03-23 | 1.0y away | Ph3 Readout | REG-8074 | Phase 2/3 | Large | PTSD | |
| 2027-03-24 | 1.0y away | Ph3 Readout | Suramavacamten | Phase 3 | Private | PAH | |
| 2027-03-24 | 1.0y away | Ph3 Readout | Miricapivasertib | Phase 3 | Private | Parkinson's | |
| 2027-03-24 | 1.0y away | Ph2 Data | DAI-6285 | Phase 1/2 | Private | Pompe | |
| 2027-03-24 | 1.0y away | Ph3 Readout | ALM-7482 | Approved | Mid | EoE | |
| 2027-03-24 | 1.0y away | Ph2 Data | EUP-1431 | Phase 2 | Private | MCC | |
| 2027-03-25 | 1.0y away | Ph2 Data | Rilurelsin | Phase 1/2 | Small | MCL | |
| 2027-03-25 | 1.0y away | Interim | MAN-3628 | Phase 1 | Mid | PsA | |
| 2027-03-25 | 1.0y away | Ph3 Readout | Tixainavolisib | Phase 3 | Mid | PV | |
| 2027-03-25 | 1.0y away | Ph3 Readout | Polacapivasertib | Approved | Small | CSU | |
| 2027-03-26 | 1.0y away | Ph2 Data | Voxarasimod | Phase 1/2 | Large | NB | |
| 2027-03-27 | 1.0y away | Ph3 Readout | BMY-8678 | Approved | Large | AS | |
| 2027-03-27 | 1.0y away | Ph3 Readout | HOM-3477 | Approved | Private | MCL | |
| 2027-03-28 | 1.0y away | Ph2 Data | AMP-408 | Phase 1/2 | Micro | Endometrial Ca | |
| 2027-04-01 | 1.0y away | Interim | Ivocapivasertib | Phase 1 | Large | Parkinson's | |
| 2027-04-04 | 1.1y away | Interim | Fixafutibatinib | Phase 1 | Small | Bladder Ca | |
| 2027-04-05 | 1.1y away | Ph3 Readout | Polazasiran | Phase 3 | Private | FSGS | |
| 2027-04-05 | 1.1y away | Ph3 Readout | Lisolemzoparlimab | Approved | Large | EoE | |
| 2027-04-05 | 1.1y away | Ph3 Readout | JAN-1547 | Approved | Mid | MDS | |
| 2027-04-06 | 1.1y away | Ph2 Data | KRK-5622 | Phase 2 | Mid | Ovarian Ca | |
| 2027-04-06 | 1.1y away | Interim | VEE-9538 | Phase 1 | Large | Celiac | |
| 2027-04-08 | 1.1y away | Ph2 Data | Voxacilimab | Phase 2 | Large | PV | |
| 2027-04-08 | 1.1y away | Ph3 Readout | Poladerotide | Phase 3 | Micro | PAH | |
| 2027-04-09 | 1.1y away | Ph3 Readout | Fixafutibatinib | Phase 3 | Mid | HS | |
| 2027-04-09 | 1.1y away | Ph3 Readout | INT-6808 | Approved | Private | MS | |
| 2027-04-10 | 1.1y away | Ph3 Readout | DSN-7360 | Approved | Large | FL | |
| 2027-04-10 | 1.1y away | Ph3 Readout | Olpasertib | Phase 3 | Micro | NB | |
| 2027-04-10 | 1.1y away | Ph3 Readout | Miriratamab | Phase 2/3 | Large | Gastric Ca | |
| 2027-04-12 | 1.1y away | Ph3 Readout | SCO-5362 | NDA/BLA | Private | MDD | |
| 2027-04-12 | 1.1y away | Ph3 Readout | Datoderotide | Phase 3 | Micro | RA | |
| 2027-04-12 | 1.1y away | Ph3 Readout | OCT-7288 | Phase 2/3 | Private | ALS | |
| 2027-04-12 | 1.1y away | Ph3 Readout | CAP-2067 | Phase 2/3 | Private | Melanoma | |
| 2027-04-13 | 1.1y away | Ph3 Readout | VRT-5441 | Phase 3 | Large | NB | |
| 2027-04-14 | 1.1y away | Ph2 Data | GLP-3342 | Phase 1/2 | Mid | MS | |
| 2027-04-14 | 1.1y away | Ph3 Readout | 644-5754 | Phase 3 | Mid | Celiac | |
| 2027-04-19 | 1.1y away | Interim | ARG-6988 | Preclinical | Large | Wet AMD | |
| 2027-04-20 | 1.1y away | Ph3 Readout | NUR-9873 | Phase 3 | Micro | Crohn's | |
| 2027-04-20 | 1.1y away | Ph3 Readout | POL-5703 | Approved | Private | Migraine | |
| 2027-04-21 | 1.1y away | Interim | CGE-1556 | Phase 1 | Small | GBM | |
| 2027-04-21 | 1.1y away | Interim | Sovanesiran | Phase 1 | Small | IPF | |
| 2027-04-21 | 1.1y away | Ph3 Readout | G1-2036 | Phase 3 | Private | LGS | |
| 2027-04-21 | 1.1y away | Ph3 Readout | VEC-8813 | Phase 3 | Private | MCC | |
| 2027-04-24 | 1.1y away | Interim | Mavucagene | Preclinical | Mid | Psoriasis | |
| 2027-04-24 | 1.1y away | Ph3 Readout | 450-6746 | Approved | Mid | FSGS | |
| 2027-04-25 | 1.1y away | Ph3 Readout | Exagamglogene autotemcel | Approved | Large | SCD | |
| 2027-04-25 | 1.1y away | Ph2 Data | MDG-4513 | Phase 1/2 | Mid | CLL | |
| 2027-04-25 | 1.1y away | Ph3 Readout | Miritinib | Approved | Private | PAH | |
| 2027-04-26 | 1.1y away | Interim | Teralucimab | Phase 1 | Small | AS | |
| 2027-04-27 | 1.1y away | Ph3 Readout | Voxavorutinib | NDA/BLA | Private | Fabry | |
| 2027-04-28 | 1.1y away | Ph3 Readout | Sovarelsin | Phase 2/3 | Large | CSU | |
| 2027-05-01 | 1.1y away | Ph3 Readout | INS-6048 | NDA/BLA | Private | Hemophilia A | |
| 2027-05-01 | 1.1y away | Interim | Sovazumab | Phase 1 | Private | Melanoma | |
| 2027-05-02 | 1.1y away | Interim | Surazumab | Preclinical | Micro | ADPKD | |
| 2027-05-02 | 1.1y away | Ph3 Readout | Polarasimod | Phase 3 | Small | DMD | |
| 2027-05-03 | 1.1y away | Ph3 Readout | SNY-4496 | Phase 2/3 | Large | CSU | |
| 2027-05-03 | 1.1y away | Ph2 Data | Peminaritide | Phase 1/2 | Private | Cervical Ca | |
| 2027-05-04 | 1.1y away | Ph3 Readout | URG-1959 | Phase 3 | Small | BCC | |
| 2027-05-04 | 1.1y away | Ph3 Readout | Adagraosocimab | Approved | Large | Melanoma | |
| 2027-05-05 | 1.1y away | Ph2 Data | RHH-3592 | Phase 1/2 | Large | FSGS | |
| 2027-05-05 | 1.1y away | Interim | ZTS-7367 | Preclinical | Large | Narcolepsy | |
| 2027-05-06 | 1.1y away | Ph3 Readout | Nirainavolisib | Phase 3 | Private | OCD | |
| 2027-05-06 | 1.1y away | Ph3 Readout | ONC-9294 | Approved | Micro | TTR Amyloidosis | |
| 2027-05-06 | 1.1y away | Ph2 Data | CAL-5800 | Phase 1/2 | Small | Heart Failure | |
| 2027-05-07 | 1.1y away | Ph2 Data | Semasertib | Phase 2 | Small | UC | |
| 2027-05-08 | 1.1y away | Ph3 Readout | Zoriratamab | Approved | Mid | CML | |
| 2027-05-09 | 1.1y away | Interim | Talainavolisib | Preclinical | Large | ADHD | |
| 2027-05-10 | 1.1y away | Ph2 Data | 116-9380 | Phase 2 | Micro | RCC | |
| 2027-05-12 | 1.2y away | Ph3 Readout | ACR-6734 | Approved | Micro | RCC | |
| 2027-05-15 | 1.2y away | Ph3 Readout | MAS-IIT-619 | Phase 2/3 | Private | DLBCL | |
| 2027-05-16 | 1.2y away | Ph3 Readout | 450-5704 | Phase 2/3 | Large | Thymoma | |
| 2027-05-19 | 1.2y away | Ph3 Readout | RLY-4615 | Phase 3 | Micro | Prostate Ca | |
| 2027-05-19 | 1.2y away | Ph3 Readout | Talazasiran | Approved | Small | ADPKD | |
| 2027-05-20 | 1.2y away | Ph3 Readout | Datovorutinib | Approved | Micro | ADHD | |
| 2027-05-20 | 1.2y away | Ph2 Data | Polasertib | Phase 1/2 | Small | Bladder Ca | |
| 2027-05-22 | 1.2y away | Ph2 Data | Polatinib | Phase 2 | Private | Rett | |
| 2027-05-23 | 1.2y away | Ph2 Data | SLD-1824 | Phase 2 | Small | NB | |
| 2027-05-23 | 1.2y away | Ph3 Readout | Doxarasimod | Phase 3 | Private | MDD | |
| 2027-05-23 | 1.2y away | Ph2 Data | MIR-4070 | Phase 1/2 | Mid | Huntington's | |
| 2027-05-24 | 1.2y away | Ph3 Readout | Mavuinavolisib | NDA/BLA | Mid | Pompe | |
| 2027-05-25 | 1.2y away | Ph3 Readout | IPN-129 | Approved | Large | WM | |
| 2027-05-25 | 1.2y away | Interim | AVE-232 | Phase 1 | Private | HS | |
| 2027-05-26 | 1.2y away | Ph2 Data | Poladerotide | Phase 1/2 | Small | Cholangiocarcinoma | |
| 2027-05-27 | 1.2y away | Ph3 Readout | JNJ-179 | Approved | Large | SCLC | |
| 2027-06-01 | 1.2y away | Ph3 Readout | TUR-1584 | Phase 2/3 | Private | GA | |
| 2027-06-01 | 1.2y away | Ph3 Readout | MOL-8666 | Approved | Micro | PV | |
| 2027-06-02 | 1.2y away | Ph2 Data | MRN-8133 | Phase 2 | Large | Fabry | |
| 2027-06-02 | 1.2y away | Ph2 Data | Rilulucimab | Phase 2 | Large | LGS | |
| 2027-06-03 | 1.2y away | Ph2 Data | Rilunaritide | Phase 2 | Micro | Melanoma | |
| 2027-06-03 | 1.2y away | Ph3 Readout | TAB-303 | Phase 3 | Private | GBM | |
| 2027-06-03 | 1.2y away | Ph3 Readout | KAR-IIT-192 | Phase 3 | Private | Fabry | |
| 2027-06-03 | 1.2y away | Ph3 Readout | HOS-IIT-667 | Phase 3 | Private | Wilms | |
| 2027-06-04 | 1.2y away | Ph3 Readout | Polacagene | Approved | Micro | UC | |
| 2027-06-05 | 1.2y away | Ph3 Readout | Kemanaritide | Phase 3 | Small | ACC | |
| 2027-06-05 | 1.2y away | Ph3 Readout | Zenozumab | Phase 3 | Small | Meso | |
| 2027-06-05 | 1.2y away | Ph3 Readout | Ivozasiran | Phase 3 | Mid | ADPKD | |
| 2027-06-05 | 1.2y away | Ph3 Readout | EVO-1057 | Phase 3 | Private | T2D | |
| 2027-06-06 | 1.2y away | Ph3 Readout | TUR-4491 | NDA/BLA | Private | Crohn's | |
| 2027-06-07 | 1.2y away | Ph3 Readout | BGN-3859 | Approved | Large | ACC | |
| 2027-06-07 | 1.2y away | Interim | CN-9071 | Preclinical | Private | Melanoma | |
| 2027-06-07 | 1.2y away | Ph2 Data | Suranaritide | Phase 1/2 | Private | SMA | |
| 2027-06-08 | 1.2y away | Ph3 Readout | 002-6973 | Approved | Mid | RCC | |
| 2027-06-09 | 1.2y away | Ph2 Data | NVO-9630 | Phase 2 | Large | IgAN | |
| 2027-06-10 | 1.2y away | Interim | RLY-2544 | Preclinical | Micro | Psoriasis | |
| 2027-06-11 | 1.2y away | Ph3 Readout | BII-4342 | Phase 2/3 | Large | IgAN | |
| 2027-06-12 | 1.2y away | Interim | Olpasotorasib | Preclinical | Mid | SCLC | |
| 2027-06-14 | 1.2y away | Ph2 Data | Rilunesiran | Phase 1/2 | Mid | GA | |
| 2027-06-14 | 1.2y away | Ph3 Readout | Lisofotisoran | Approved | Large | RA | |
| 2027-06-15 | 1.2y away | Ph3 Readout | Ribosacituzumab | Approved | Large | DLBCL | |
| 2027-06-15 | 1.2y away | Ph3 Readout | AZN-7403 | Phase 2/3 | Large | FTD | |
| 2027-06-15 | 1.2y away | Interim | Sotorapivir | Phase 1 | Micro | NMOSD | |
| 2027-06-15 | 1.2y away | Ph3 Readout | GOS-5370 | Phase 2/3 | Micro | Parkinson's | |
| 2027-06-16 | 1.3y away | Ph3 Readout | 459-1094 | Phase 3 | Micro | ALL | |
| 2027-06-17 | 1.3y away | Ph3 Readout | Capifutibatinib | Phase 3 | Large | MCL | |
| 2027-06-17 | 1.3y away | Ph2 Data | TER-8481 | Phase 1/2 | Private | GBM | |
| 2027-06-17 | 1.3y away | Ph3 Readout | Lisozasiran | NDA/BLA | Mid | PNH | |
| 2027-06-18 | 1.3y away | Interim | GSK-2051 | Phase 1 | Large | Migraine | |
| 2027-06-20 | 1.3y away | Ph3 Readout | MRU-1869 | Approved | Mid | RB | |
| 2027-06-21 | 1.3y away | Interim | Talalemzoparlimab | Phase 1 | Large | RA | |
| 2027-06-21 | 1.3y away | Ph3 Readout | Pemiderotide | Phase 2/3 | Micro | CKD | |
| 2027-06-21 | 1.3y away | Interim | Mavuinavolisib | Phase 1 | Mid | IgAN | |
| 2027-06-21 | 1.3y away | Ph2 Data | Talazanubrutinib | Phase 1/2 | Small | PNH | |
| 2027-06-22 | 1.3y away | Interim | Cevimavacamten | Phase 1 | Micro | RSV | |
| 2027-06-23 | 1.3y away | Interim | Fixacagene | Preclinical | Private | NSCLC | |
| 2027-06-23 | 1.3y away | Interim | ABD-5382 | Preclinical | Private | ACC | |
| 2027-06-24 | 1.3y away | Ph3 Readout | Exagamglogene autotemcel | Approved | Large | Thalassemia | |
| 2027-06-25 | 1.3y away | Ph3 Readout | Terafutibatinib | Phase 2/3 | Private | PAH | |
| 2027-06-25 | 1.3y away | Interim | VES-1701 | Phase 1 | Private | HS | |
| 2027-06-26 | 1.3y away | Ph2 Data | DAN-IIT-542 | Phase 2 | Private | Fabry | |
| 2027-06-26 | 1.3y away | Ph2 Data | BTA-3746 | Phase 2 | Micro | MCC | |
| 2027-06-26 | 1.3y away | Ph3 Readout | MAP-6526 | Approved | Private | Heart Failure | |
| 2027-06-26 | 1.3y away | Ph3 Readout | Rimarapivir | Phase 3 | Small | IPF | |
| 2027-06-26 | 1.3y away | Ph3 Readout | Doxacagene | Approved | Mid | BCC | |
| 2027-06-27 | 1.3y away | Ph3 Readout | Lisosotorasib | Phase 3 | Micro | Melanoma | |
| 2027-06-27 | 1.3y away | Ph3 Readout | RIC-4332 | Phase 3 | Mid | BCC | |
| 2027-06-28 | 1.3y away | Ph2 Data | Mirilemzoparlimab | Phase 2 | Private | GA | |
| 2027-06-28 | 1.3y away | Interim | Olpasertib | Preclinical | Micro | LN | |
| 2027-07-01 | 1.3y away | Ph3 Readout | BAY-3684 | Approved | Large | NMOSD | |
| 2027-07-01 | 1.3y away | Ph2 Data | 4D-8297 | Phase 1/2 | Private | Heart Failure | |
| 2027-07-01 | 1.3y away | Ph3 Readout | Fixatinib | Phase 2/3 | Large | IPF | |
| 2027-07-03 | 1.3y away | Ph2 Data | Datocapivasertib | Phase 1/2 | Small | GBM | |
| 2027-07-05 | 1.3y away | Ph3 Readout | VRT-1576 | Phase 2/3 | Large | PSP | |
| 2027-07-05 | 1.3y away | Ph3 Readout | SEN-3594 | Phase 2/3 | Private | CTCL | |
| 2027-07-06 | 1.3y away | Ph3 Readout | GIM-IIT-646 | Phase 3 | Private | PsA | |
| 2027-07-07 | 1.3y away | Ph3 Readout | Datobrutinib | Phase 3 | Large | FTD | |
| 2027-07-07 | 1.3y away | Ph3 Readout | Lisonesiran | NDA/BLA | Small | GA | |
| 2027-07-07 | 1.3y away | Ph3 Readout | APM-4255 | NDA/BLA | Micro | Myelofibrosis | |
| 2027-07-07 | 1.3y away | Ph2 Data | STA-4766 | Phase 1/2 | Private | T2D | |
| 2027-07-08 | 1.3y away | Ph3 Readout | Tixacapivasertib | Approved | Micro | MG | |
| 2027-07-08 | 1.3y away | Ph3 Readout | Sovazanubrutinib | Phase 2/3 | Mid | SMA | |
| 2027-07-09 | 1.3y away | Ph3 Readout | ACA-2691 | Phase 3 | Mid | CF | |
| 2027-07-09 | 1.3y away | Ph3 Readout | Ribomavacamten | Phase 3 | Private | PSP | |
| 2027-07-09 | 1.3y away | Ph3 Readout | ALE-9377 | Approved | Private | HCC | |
| 2027-07-10 | 1.3y away | Ph2 Data | Surabrutinib | Phase 2 | Private | DLBCL | |
| 2027-07-11 | 1.3y away | Ph3 Readout | DSN-3066 | Phase 3 | Large | CLL | |
| 2027-07-11 | 1.3y away | Ph3 Readout | IDI-2657 | Approved | Small | Melanoma | |
| 2027-07-12 | 1.3y away | Ph3 Readout | Rimasertib | Phase 3 | Mid | Rett | |
| 2027-07-12 | 1.3y away | Ph3 Readout | CRS-337 | Phase 2/3 | Mid | PTSD | |
| 2027-07-12 | 1.3y away | Ph3 Readout | JOH-IIT-455 | Approved | Private | Huntington's | |
| 2027-07-12 | 1.3y away | Ph3 Readout | Adagralemzoparlimab | Approved | Small | PV | |
| 2027-07-12 | 1.3y away | Ph3 Readout | REC-7914 | NDA/BLA | Mid | Bladder Ca | |
| 2027-07-13 | 1.3y away | Ph3 Readout | Rimazanubrutinib | NDA/BLA | Private | CSU | |
| 2027-07-14 | 1.3y away | Ph2 Data | Cevizasiran | Phase 1/2 | Mid | CF | |
| 2027-07-14 | 1.3y away | Ph3 Readout | ACR-6734 | Approved | Micro | RCC | |
| 2027-07-15 | 1.3y away | Ph2 Data | MIR-8412 | Phase 1/2 | Private | Endometrial Ca | |
| 2027-07-16 | 1.3y away | Ph3 Readout | EVO-1057 | Phase 3 | Private | T2D | |
| 2027-07-16 | 1.3y away | Interim | KRK-8556 | Phase 1 | Mid | Rett | |
| 2027-07-17 | 1.3y away | Ph2 Data | Polamavacamten | Phase 2 | Small | Endometrial Ca | |
| 2027-07-18 | 1.3y away | Ph3 Readout | NGM-3123 | Phase 3 | Small | IgAN | |
| 2027-07-18 | 1.3y away | Ph2 Data | Gelitenlimab | Phase 1/2 | Private | ACC | |
| 2027-07-21 | 1.3y away | Ph2 Data | Mavucagene | Phase 1/2 | Private | Rett | |
| 2027-07-21 | 1.3y away | Ph3 Readout | PHL-685 | Approved | Small | Cholangiocarcinoma | |
| 2027-07-22 | 1.3y away | Ph3 Readout | MRK-9679 | NDA/BLA | Large | Meso | |
| 2027-07-24 | 1.4y away | Ph2 Data | TOL-8761 | Phase 2 | Private | MCL | |
| 2027-07-24 | 1.4y away | Ph3 Readout | Niraratamab | Phase 2/3 | Small | MDD | |
| 2027-07-26 | 1.4y away | Ph3 Readout | Talainavolisib | Phase 2/3 | Private | FTD | |
| 2027-07-26 | 1.4y away | Interim | NKT-344 | Phase 1 | Small | GA | |
| 2027-07-26 | 1.4y away | Ph3 Readout | Mavuderotide | Approved | Private | Wilms | |
| 2027-07-27 | 1.4y away | Ph2 Data | INT-5527 | Phase 2 | Private | Ewing Sarcoma | |
| 2027-07-27 | 1.4y away | Interim | Ribotuximab | Phase 1 | Private | WM | |
| 2027-08-01 | 1.4y away | Ph2 Data | BAY-6520 | Phase 2 | Large | FSGS | |
| 2027-08-01 | 1.4y away | Ph2 Data | VIR-5831 | Phase 1/2 | Mid | Ovarian Ca | |
| 2027-08-02 | 1.4y away | Ph3 Readout | G1-2036 | Phase 3 | Private | LGS | |
| 2027-08-02 | 1.4y away | Ph2 Data | Ivozasiran | Phase 1/2 | Micro | Epilepsy | |
| 2027-08-03 | 1.4y away | Ph3 Readout | Fixatuximab | Phase 3 | Private | Epilepsy | |
| 2027-08-04 | 1.4y away | Ph2 Data | TER-8735 | Phase 1/2 | Small | Narcolepsy | |
| 2027-08-05 | 1.4y away | Interim | MOM-9396 | Phase 1 | Private | Huntington's | |
| 2027-08-05 | 1.4y away | Ph3 Readout | AMY-7629 | Phase 2/3 | Private | TTR Amyloidosis | |
| 2027-08-06 | 1.4y away | Ph3 Readout | BER-6094 | Phase 3 | Private | OCD | |
| 2027-08-06 | 1.4y away | Interim | KAR-IIT-216 | Phase 1 | Private | ADHD | |
| 2027-08-06 | 1.4y away | Ph3 Readout | 002-1797 | Approved | Mid | Huntington's | |
| 2027-08-07 | 1.4y away | Interim | ZYD-7355 | Phase 1 | Large | Melanoma | |
| 2027-08-08 | 1.4y away | Interim | Motazanubrutinib | Preclinical | Large | LN | |
| 2027-08-09 | 1.4y away | Interim | Cevirasimod | Preclinical | Mid | Ovarian Ca | |
| 2027-08-09 | 1.4y away | Ph2 Data | Adagrainavolisib | Phase 2 | Private | Cholangiocarcinoma | |
| 2027-08-10 | 1.4y away | Ph2 Data | TRV-1449 | Phase 2 | Micro | GBM | |
| 2027-08-10 | 1.4y away | Interim | Rimabrutinib | Phase 1 | Private | Myelofibrosis | |
| 2027-08-11 | 1.4y away | Ph3 Readout | 115-4305 | NDA/BLA | Micro | SMA | |
| 2027-08-12 | 1.4y away | Ph2 Data | Ribotuximab | Phase 2 | Large | CML | |
| 2027-08-12 | 1.4y away | Interim | GUS-IIT-662 | Preclinical | Private | PTSD | |
| 2027-08-13 | 1.4y away | Ph3 Readout | ITC-879 | Approved | Large | Bladder Ca | |
| 2027-08-13 | 1.4y away | Interim | Sototenlimab | Preclinical | Mid | PBC | |
| 2027-08-13 | 1.4y away | Ph3 Readout | Kemalucimab | Phase 2/3 | Private | Crohn's | |
| 2027-08-14 | 1.4y away | Interim | DSN-5254 | Phase 1 | Large | Hemophilia A | |
| 2027-08-14 | 1.4y away | Ph3 Readout | Cevicilimab | Phase 3 | Private | Dravet | |
| 2027-08-15 | 1.4y away | Ph3 Readout | Bemarapivir | Approved | Mid | NMOSD | |
| 2027-08-15 | 1.4y away | Ph3 Readout | Zenosertib | Phase 2/3 | Mid | CTCL | |
| 2027-08-16 | 1.4y away | Ph3 Readout | Talavorutinib | NDA/BLA | Mid | FL | |
| 2027-08-16 | 1.4y away | Ph3 Readout | CAR-9866 | Phase 3 | Micro | Wilms | |
| 2027-08-17 | 1.4y away | Interim | GIL-9142 | Phase 1 | Large | EoE | |
| 2027-08-17 | 1.4y away | Ph3 Readout | ORY-4744 | Phase 2/3 | Micro | Celiac | |
| 2027-08-17 | 1.4y away | Ph3 Readout | LAB-3189 | Phase 3 | Private | CTCL | |
| 2027-08-18 | 1.4y away | Ph3 Readout | Gelisertib | Approved | Large | Psoriasis | |
| 2027-08-18 | 1.4y away | Interim | ORN-2989 | Phase 1 | Mid | DMD | |
| 2027-08-19 | 1.4y away | Ph3 Readout | SLD-2973 | NDA/BLA | Small | Hemophilia A | |
| 2027-08-19 | 1.4y away | Ph3 Readout | PRO-4197 | Approved | Private | Wilms | |
| 2027-08-21 | 1.4y away | Ph2 Data | MSK-IIT-346 | Phase 2 | Private | PAH | |
| 2027-08-21 | 1.4y away | Interim | Zoritenlimab | Preclinical | Private | ADPKD | |
| 2027-08-21 | 1.4y away | Ph2 Data | CHR-2584 | Phase 2 | Private | Psoriasis | |
| 2027-08-21 | 1.4y away | Interim | PLR-1516 | Phase 1 | Small | MDD | |
| 2027-08-21 | 1.4y away | Ph3 Readout | Liralemzoparlimab | Phase 3 | Private | Angelman | |
| 2027-08-21 | 1.4y away | Interim | RIK-IIT-299 | Preclinical | Private | Bladder Ca | |
| 2027-08-21 | 1.4y away | Ph3 Readout | Elrasacituzumab | NDA/BLA | Small | HS | |
| 2027-08-22 | 1.4y away | Ph3 Readout | Semafutibatinib | Phase 3 | Private | Crohn's | |
| 2027-08-23 | 1.4y away | Ph2 Data | EUP-1431 | Phase 2 | Private | DLBCL | |
| 2027-08-24 | 1.4y away | Ph3 Readout | Rimatenlimab | Phase 2/3 | Large | MCC | |
| 2027-08-24 | 1.4y away | Ph3 Readout | Sotozanubrutinib | Phase 2/3 | Mid | Fabry | |
| 2027-08-24 | 1.4y away | Ph3 Readout | Voxasertib | Phase 2/3 | Micro | Myelofibrosis | |
| 2027-08-25 | 1.4y away | Ph2 Data | Tiratuximab | Phase 2 | Mid | Heart Failure | |
| 2027-08-25 | 1.4y away | Ph3 Readout | Mavufotisoran | Approved | Large | HS | |
| 2027-08-26 | 1.4y away | Interim | Tirazanubrutinib | Phase 1 | Private | RA | |
| 2027-08-26 | 1.4y away | Ph3 Readout | Voxarapivir | NDA/BLA | Mid | Parkinson's | |
| 2027-08-27 | 1.4y away | Interim | Zenotinib | Phase 1 | Large | MCL | |
| 2027-08-27 | 1.4y away | Ph2 Data | RCU-6379 | Phase 1/2 | Mid | OCD | |
| 2027-08-27 | 1.4y away | Interim | REA-1693 | Preclinical | Private | NMOSD | |
| 2027-08-27 | 1.4y away | Interim | Capitinib | Phase 1 | Mid | CKD | |
| 2027-08-28 | 1.5y away | Interim | Ribozanubrutinib | Phase 1 | Large | ADHD | |
| 2027-08-28 | 1.5y away | Ph3 Readout | NBY-4130 | Phase 3 | Micro | OCD | |
| 2027-08-28 | 1.5y away | Ph2 Data | 195-9888 | Phase 1/2 | Small | PsA | |
| 2027-09-01 | 1.5y away | Ph3 Readout | NVO-7872 | NDA/BLA | Large | PTSD | |
| 2027-09-01 | 1.5y away | Ph3 Readout | Pemiglumide | NDA/BLA | Mid | MM | |
| 2027-09-02 | 1.5y away | Ph2 Data | RAR-1117 | Phase 1/2 | Mid | Endometrial Ca | |
| 2027-09-02 | 1.5y away | Interim | NYK-4396 | Preclinical | Micro | Hemophilia A | |
| 2027-09-03 | 1.5y away | Ph2 Data | Voxacilimab | Phase 2 | Large | PV | |
| 2027-09-03 | 1.5y away | Interim | BAY-8733 | Preclinical | Large | PTSD | |
| 2027-09-03 | 1.5y away | Ph3 Readout | Talazasiran | NDA/BLA | Mid | HS | |
| 2027-09-03 | 1.5y away | Ph3 Readout | SWO-IIT-993 | Approved | Private | CF | |
| 2027-09-03 | 1.5y away | Ph2 Data | Gozeosocimab | Phase 1/2 | Private | Schizophrenia | |
| 2027-09-05 | 1.5y away | Ph2 Data | BGN-8936 | Phase 1/2 | Large | IPF | |
| 2027-09-05 | 1.5y away | Ph3 Readout | 207-5197 | Approved | Large | ET | |
| 2027-09-05 | 1.5y away | Ph3 Readout | SLR-5251 | Phase 3 | Small | GBM | |
| 2027-09-07 | 1.5y away | Ph3 Readout | AGI-4446 | Phase 3 | Mid | LGS | |
| 2027-09-07 | 1.5y away | Interim | Lirasacituzumab | Preclinical | Small | Melanoma | |
| 2027-09-08 | 1.5y away | Interim | AMG-415 | Phase 1 | Large | ET | |
| 2027-09-08 | 1.5y away | Ph3 Readout | GRF-8988 | Phase 2/3 | Mid | Heart Failure | |
| 2027-09-09 | 1.5y away | Ph3 Readout | ALL-5401 | NDA/BLA | Private | DMD | |
| 2027-09-09 | 1.5y away | Interim | Doxafotisoran | Phase 1 | Large | SMA | |
| 2027-09-10 | 1.5y away | Ph3 Readout | Motanesiran | Phase 2/3 | Small | BCC | |
| 2027-09-11 | 1.5y away | Interim | Capitapinarof | Preclinical | Private | Cholangiocarcinoma | |
| 2027-09-12 | 1.5y away | Ph3 Readout | SUV-4226 | Phase 3 | Mid | Melanoma | |
| 2027-09-14 | 1.5y away | Ph2 Data | TSH-7567 | Phase 1/2 | Small | BCC | |
| 2027-09-14 | 1.5y away | Ph2 Data | Fixatuximab | Phase 1/2 | Mid | AML | |
| 2027-09-15 | 1.5y away | Ph3 Readout | Voxafotisoran | Phase 3 | Mid | MM | |
| 2027-09-15 | 1.5y away | Ph3 Readout | AMB-7870 | Phase 3 | Private | ADPKD | |
| 2027-09-16 | 1.5y away | Ph2 Data | Zoriosocimab | Phase 2 | Private | Psoriasis | |
| 2027-09-18 | 1.5y away | Ph3 Readout | Exagamglogene autotemcel | Approved | Large | Thalassemia | |
| 2027-09-18 | 1.5y away | Ph2 Data | RAR-1117 | Phase 1/2 | Mid | Endometrial Ca | |
| 2027-09-18 | 1.5y away | Ph3 Readout | Tezeratamab | Phase 3 | Small | Asthma | |
| 2027-09-18 | 1.5y away | Interim | Lirazanubrutinib | Phase 1 | Large | PTSD | |
| 2027-09-19 | 1.5y away | Ph3 Readout | Tiratapinarof | NDA/BLA | Mid | SLE | |
| 2027-09-19 | 1.5y away | Ph3 Readout | ZEN-2386 | Phase 3 | Private | FTD | |
| 2027-09-20 | 1.5y away | Ph3 Readout | CEL-9671 | NDA/BLA | Private | PSP | |
| 2027-09-21 | 1.5y away | Ph3 Readout | Voxanaritide | Approved | Mid | NSCLC | |
| 2027-09-22 | 1.5y away | Ph2 Data | Sotofutibatinib | Phase 1/2 | Private | Myelofibrosis | |
| 2027-09-22 | 1.5y away | Ph2 Data | Nidatinib | Phase 2 | Micro | Atopic Derm | |
| 2027-09-22 | 1.5y away | Ph3 Readout | ACE-6753 | Phase 2/3 | Micro | Asthma | |
| 2027-09-23 | 1.5y away | Interim | Capitapinarof | Preclinical | Private | Cholangiocarcinoma | |
| 2027-09-23 | 1.5y away | Ph3 Readout | Mirinaritide | Phase 2/3 | Mid | ADHD | |
| 2027-09-23 | 1.5y away | Ph3 Readout | RLF-5973 | Phase 3 | Micro | Breast Ca | |
| 2027-09-24 | 1.5y away | Ph2 Data | HOR-3601 | Phase 1/2 | Private | RB | |
| 2027-09-26 | 1.5y away | Interim | Tiramavacamten | Preclinical | Large | Meso | |
| 2027-09-26 | 1.5y away | Ph3 Readout | Darasacituzumab | Phase 2/3 | Mid | MDS | |
| 2027-09-26 | 1.5y away | Ph3 Readout | Elrasotorasib | NDA/BLA | Micro | Wet AMD | |
| 2027-09-27 | 1.5y away | Ph3 Readout | Sematenlimab | Phase 3 | Large | T2D | |
| 2027-09-27 | 1.5y away | Interim | RUI-IIT-202 | Phase 1 | Private | OCD | |
| 2027-09-28 | 1.5y away | Ph2 Data | Niramavacamten | Phase 2 | Large | Meso | |
| 2027-09-28 | 1.5y away | Ph3 Readout | Tixatapinarof | Approved | Small | NMOSD | |
| 2027-09-28 | 1.5y away | Interim | Pexasacituzumab | Preclinical | Small | LGS | |
| 2027-10-01 | 1.5y away | Ph3 Readout | XEN-577 | Phase 2/3 | Mid | Myelofibrosis | |
| 2027-10-01 | 1.5y away | Ph3 Readout | RLY-4615 | Phase 3 | Micro | Prostate Ca | |
| 2027-10-01 | 1.5y away | Ph3 Readout | ORC-2834 | Phase 2/3 | Private | Obesity | |
| 2027-10-01 | 1.5y away | Ph3 Readout | BIO-IIT-742 | Phase 3 | Private | IgAN | |
| 2027-10-01 | 1.5y away | Ph3 Readout | Ivotenlimab | Approved | Private | PsA | |
| 2027-10-02 | 1.5y away | Ph3 Readout | RIN-582 | Phase 3 | Private | IgAN | |
| 2027-10-02 | 1.5y away | Ph2 Data | INH-2936 | Phase 2 | Private | Pompe | |
| 2027-10-02 | 1.5y away | Interim | Polazasiran | Preclinical | Mid | Prostate Ca | |
| 2027-10-03 | 1.5y away | Ph2 Data | MGX-6815 | Phase 2 | Small | Gastric Ca | |
| 2027-10-03 | 1.5y away | Ph2 Data | CHI-IIT-951 | Phase 2 | Private | Thymoma | |
| 2027-10-03 | 1.5y away | Ph3 Readout | Adagraosocimab | Approved | Large | Melanoma | |
| 2027-10-03 | 1.5y away | Ph3 Readout | A-568 | Approved | Large | RB | |
| 2027-10-04 | 1.6y away | Ph2 Data | Teravorutinib | Phase 2 | Large | ALL | |
| 2027-10-05 | 1.6y away | Ph3 Readout | CON-372 | Approved | Private | Thymoma | |
| 2027-10-05 | 1.6y away | Ph3 Readout | ABU-7780 | Phase 2/3 | Micro | ACC | |
| 2027-10-06 | 1.6y away | Ph3 Readout | ASN-7408 | NDA/BLA | Mid | PSP | |
| 2027-10-07 | 1.6y away | Interim | Sotosacituzumab | Phase 1 | Large | ALL | |
| 2027-10-07 | 1.6y away | Ph2 Data | PRT-4395 | Phase 2 | Micro | GBM | |
| 2027-10-08 | 1.6y away | Ph3 Readout | Sovasotorasib | NDA/BLA | Private | RSV | |
| 2027-10-09 | 1.6y away | Ph3 Readout | Pemitapinarof | Approved | Large | FTD | |
| 2027-10-09 | 1.6y away | Ph3 Readout | Fixaosocimab | Phase 2/3 | Mid | PTSD | |
| 2027-10-09 | 1.6y away | Ph2 Data | DAN-IIT-482 | Phase 2 | Private | UC | |
| 2027-10-09 | 1.6y away | Ph3 Readout | Adagrazumab | Phase 3 | Private | SCLC | |
| 2027-10-10 | 1.6y away | Ph2 Data | VRT-9481 | Phase 1/2 | Large | MS | |
| 2027-10-10 | 1.6y away | Ph3 Readout | BII-8315 | NDA/BLA | Large | Prostate Ca | |
| 2027-10-11 | 1.6y away | Ph3 Readout | Doxafotisoran | NDA/BLA | Large | Pompe | |
| 2027-10-12 | 1.6y away | Interim | TAK-1836 | Preclinical | Large | Prostate Ca | |
| 2027-10-13 | 1.6y away | Ph3 Readout | Sovaglumide | Phase 3 | Large | Thymoma | |
| 2027-10-13 | 1.6y away | Ph3 Readout | Tezesotorasib | Phase 2/3 | Private | Meso | |
| 2027-10-14 | 1.6y away | Ph3 Readout | SGM-3567 | Phase 2/3 | Micro | Asthma | |
| 2027-10-14 | 1.6y away | Ph3 Readout | Bemaosocimab | Phase 3 | Private | Rett | |
| 2027-10-14 | 1.6y away | Ph3 Readout | FRO-9633 | Phase 3 | Private | FTD | |
| 2027-10-15 | 1.6y away | Interim | Rilunaritide | Phase 1 | Small | Wilms | |
| 2027-10-15 | 1.6y away | Ph3 Readout | Talarasimod | Phase 3 | Private | DLBCL | |
| 2027-10-16 | 1.6y away | Interim | Rimanesiran | Phase 1 | Mid | RSV | |
| 2027-10-16 | 1.6y away | Ph3 Readout | DNA-3921 | NDA/BLA | Small | Psoriasis | |
| 2027-10-20 | 1.6y away | Ph3 Readout | Adagracapivasertib | Approved | Private | Dravet | |
| 2027-10-20 | 1.6y away | Ph3 Readout | NTR-8128 | Phase 3 | Large | ALS | |
| 2027-10-20 | 1.6y away | Ph3 Readout | Kemacapivasertib | Phase 2/3 | Private | EoE | |
| 2027-10-20 | 1.6y away | Ph2 Data | VIR-5831 | Phase 1/2 | Mid | Ovarian Ca | |
| 2027-10-21 | 1.6y away | Ph2 Data | BNT-8090 | Phase 2 | Large | Parkinson's | |
| 2027-10-21 | 1.6y away | Ph3 Readout | Tixainavolisib | Phase 3 | Mid | Schizophrenia | |
| 2027-10-23 | 1.6y away | Ph3 Readout | Pexasertib | Approved | Private | ADPKD | |
| 2027-10-24 | 1.6y away | Interim | Rilutenlimab | Preclinical | Private | RSV | |
| 2027-10-24 | 1.6y away | Interim | XTA-2008 | Preclinical | Private | Celiac | |
| 2027-10-25 | 1.6y away | Ph3 Readout | APT-892 | Approved | Micro | Meso | |
| 2027-10-25 | 1.6y away | Interim | VAL-4454 | Preclinical | Small | NB | |
| 2027-10-26 | 1.6y away | Ph3 Readout | DSN-3066 | Phase 3 | Large | CLL | |
| 2027-10-26 | 1.6y away | Ph3 Readout | Polaglumide | Phase 3 | Small | MS | |
| 2027-10-26 | 1.6y away | Ph3 Readout | MRK-6740 | Phase 2/3 | Large | ALS | |
| 2027-10-27 | 1.6y away | Ph2 Data | Talacapivasertib | Phase 1/2 | Private | LN | |
| 2027-10-27 | 1.6y away | Ph2 Data | Elralemzoparlimab | Phase 1/2 | Private | Pompe | |
| 2027-11-01 | 1.6y away | Ph3 Readout | 207-5197 | Approved | Large | Schizophrenia | |
| 2027-11-01 | 1.6y away | Ph3 Readout | Zoricapivasertib | Phase 3 | Micro | Huntington's | |
| 2027-11-01 | 1.6y away | Ph3 Readout | Elracapivasertib | Approved | Small | Atopic Derm | |
| 2027-11-01 | 1.6y away | Interim | Pemizumab | Phase 1 | Mid | MM | |
| 2027-11-01 | 1.6y away | Ph3 Readout | CRI-9527 | Phase 3 | Private | HNSCC | |
| 2027-11-01 | 1.6y away | Interim | NAT-IIT-296 | Preclinical | Private | NB | |
| 2027-11-01 | 1.6y away | Ph3 Readout | Zanufotisoran | Approved | Small | NSCLC | |
| 2027-11-03 | 1.6y away | Ph3 Readout | NVE-9059 | Approved | Private | CLL | |
| 2027-11-04 | 1.6y away | Interim | Polalemzoparlimab | Phase 1 | Small | NASH | |
| 2027-11-04 | 1.6y away | Ph2 Data | 600-5291 | Phase 2 | Mid | Parkinson's | |
| 2027-11-05 | 1.6y away | Ph3 Readout | Miritinib | Approved | Private | Bladder Ca | |
| 2027-11-05 | 1.6y away | Interim | EYE-7734 | Phase 1 | Micro | Pompe | |
| 2027-11-05 | 1.6y away | Interim | Teraosocimab | Phase 1 | Mid | FL | |
| 2027-11-06 | 1.6y away | Ph2 Data | BGN-8936 | Phase 1/2 | Large | Angelman | |
| 2027-11-07 | 1.6y away | Ph2 Data | Zenotuximab | Phase 1/2 | Private | ALL | |
| 2027-11-08 | 1.6y away | Ph3 Readout | Terarelsin | Phase 3 | Private | Bladder Ca | |
| 2027-11-08 | 1.6y away | Ph3 Readout | MRN-6769 | Phase 2/3 | Small | Fabry | |
| 2027-11-08 | 1.6y away | Ph3 Readout | Kematinib | Approved | Private | Cholangiocarcinoma | |
| 2027-11-08 | 1.6y away | Ph3 Readout | OBS-1681 | Phase 3 | Private | MDS | |
| 2027-11-08 | 1.6y away | Ph3 Readout | AIP-1890 | Phase 3 | Small | GA | |
| 2027-11-08 | 1.6y away | Ph3 Readout | PRI-IIT-296 | NDA/BLA | Private | SCD | |
| 2027-11-08 | 1.6y away | Ph3 Readout | CAM-IIT-544 | NDA/BLA | Private | Wilms | |
| 2027-11-09 | 1.7y away | Ph3 Readout | Polatuximab | Approved | Mid | PNH | |
| 2027-11-09 | 1.7y away | Ph3 Readout | Gelirasimod | Phase 3 | Micro | Schizophrenia | |
| 2027-11-11 | 1.7y away | Ph3 Readout | Tezecilimab | Approved | Large | DLBCL | |
| 2027-11-11 | 1.7y away | Ph3 Readout | Tirarapivir | Approved | Large | Parkinson's | |
| 2027-11-11 | 1.7y away | Ph3 Readout | FRE-IIT-285 | NDA/BLA | Private | PsA | |
| 2027-11-11 | 1.7y away | Ph3 Readout | Datorelsin | NDA/BLA | Small | PSP | |
| 2027-11-13 | 1.7y away | Interim | 532-7053 | Phase 1 | Large | Ovarian Ca | |
| 2027-11-13 | 1.7y away | Ph3 Readout | Darafutibatinib | Approved | Micro | IgAN | |
| 2027-11-14 | 1.7y away | Ph2 Data | Sotoratamab | Phase 2 | Large | CLL | |
| 2027-11-15 | 1.7y away | Interim | SWT-8357 | Phase 1 | Mid | ET | |
| 2027-11-15 | 1.7y away | Ph2 Data | Zenoderotide | Phase 1/2 | Micro | EoE | |
| 2027-11-15 | 1.7y away | Ph2 Data | STA-4766 | Phase 1/2 | Private | PSP | |
| 2027-11-16 | 1.7y away | Interim | Doxazanubrutinib | Phase 1 | Large | Cholangiocarcinoma | |
| 2027-11-16 | 1.7y away | Interim | Lirazumab | Phase 1 | Private | SMA | |
| 2027-11-17 | 1.7y away | Interim | Capitapinarof | Preclinical | Large | PBC | |
| 2027-11-17 | 1.7y away | Ph2 Data | NKT-8115 | Phase 2 | Small | TTR Amyloidosis | |
| 2027-11-17 | 1.7y away | Ph3 Readout | DER-2537 | Phase 2/3 | Private | IgAN | |
| 2027-11-17 | 1.7y away | Ph3 Readout | BLC-6641 | Phase 3 | Mid | NASH | |
| 2027-11-18 | 1.7y away | Ph3 Readout | Ivofotisoran | NDA/BLA | Private | Epilepsy | |
| 2027-11-19 | 1.7y away | Ph3 Readout | RVM-7089 | Phase 3 | Mid | MM | |
| 2027-11-19 | 1.7y away | Ph2 Data | CAL-3191 | Phase 1/2 | Micro | UC | |
| 2027-11-19 | 1.7y away | Ph3 Readout | 453-4974 | NDA/BLA | Mid | MCC | |
| 2027-11-20 | 1.7y away | Ph3 Readout | JNJ-179 | Approved | Large | Narcolepsy | |
| 2027-11-20 | 1.7y away | Interim | SUN-5027 | Preclinical | Large | CML | |
| 2027-11-20 | 1.7y away | Interim | Rimanesiran | Phase 1 | Small | Pompe | |
| 2027-11-20 | 1.7y away | Interim | Zorifotisoran | Preclinical | Micro | Parkinson's | |
| 2027-11-21 | 1.7y away | Ph2 Data | SNY-5783 | Phase 1/2 | Large | SLE | |
| 2027-11-21 | 1.7y away | Ph3 Readout | RIC-4332 | Phase 3 | Mid | BCC | |
| 2027-11-23 | 1.7y away | Ph3 Readout | Zanufutibatinib | NDA/BLA | Large | RB | |
| 2027-11-24 | 1.7y away | Ph3 Readout | FRE-IIT-874 | NDA/BLA | Private | NMOSD | |
| 2027-11-24 | 1.7y away | Ph3 Readout | Datonesiran | NDA/BLA | Private | UC | |
| 2027-11-25 | 1.7y away | Ph3 Readout | Semasertib | Phase 2/3 | Private | MG | |
| 2027-11-27 | 1.7y away | Ph3 Readout | Gozenesiran | NDA/BLA | Micro | MG | |
| 2027-11-27 | 1.7y away | Ph3 Readout | BIG-3814 | Approved | Private | Hemophilia A | |
| 2027-12-01 | 1.7y away | Ph2 Data | GLA-2545 | Phase 2 | Mid | FL | |
| 2027-12-02 | 1.7y away | Ph3 Readout | ADA-4330 | Approved | Private | CKD | |
| 2027-12-03 | 1.7y away | Ph3 Readout | Mavuratamab | NDA/BLA | Mid | PAH | |
| 2027-12-03 | 1.7y away | Interim | Elranesiran | Phase 1 | Private | NSCLC | |
| 2027-12-03 | 1.7y away | Interim | Capitenlimab | Phase 1 | Micro | ALS | |
| 2027-12-04 | 1.7y away | Ph2 Data | Semainavolisib | Phase 2 | Large | WM | |
| 2027-12-04 | 1.7y away | Ph3 Readout | VRT-5853 | Phase 3 | Large | Narcolepsy | |
| 2027-12-04 | 1.7y away | Ph2 Data | MOR-3925 | Phase 1/2 | Private | Myelofibrosis | |
| 2027-12-04 | 1.7y away | Interim | Polalemzoparlimab | Phase 1 | Small | Pompe | |
| 2027-12-04 | 1.7y away | Ph3 Readout | Teracapivasertib | Phase 2/3 | Small | NMOSD | |
| 2027-12-05 | 1.7y away | Ph3 Readout | 644-5754 | Phase 3 | Mid | CSU | |
| 2027-12-05 | 1.7y away | Ph3 Readout | AVX-9264 | Phase 2/3 | Small | NSCLC | |
| 2027-12-05 | 1.7y away | Ph3 Readout | NGM-3123 | Phase 3 | Small | IgAN | |
| 2027-12-05 | 1.7y away | Ph2 Data | TOR-2843 | Phase 1/2 | Mid | PV | |
| 2027-12-07 | 1.7y away | Ph2 Data | ROY-IIT-847 | Phase 1/2 | Private | CKD | |
| 2027-12-07 | 1.7y away | Ph3 Readout | RUI-IIT-543 | Phase 2/3 | Private | Cervical Ca | |
| 2027-12-08 | 1.7y away | Interim | VRT-1891 | Phase 1 | Large | Heart Failure | |
| 2027-12-10 | 1.7y away | Ph3 Readout | SAV-8261 | NDA/BLA | Small | SMA | |
| 2027-12-10 | 1.7y away | Ph3 Readout | Fixatenlimab | NDA/BLA | Private | Meso | |
| 2027-12-11 | 1.7y away | Ph3 Readout | Mavulucimab | NDA/BLA | Mid | CSU | |
| 2027-12-12 | 1.7y away | Ph2 Data | MEM-IIT-110 | Phase 1/2 | Private | ADHD | |
| 2027-12-12 | 1.7y away | Ph3 Readout | Datofutibatinib | Approved | Small | GBM | |
| 2027-12-12 | 1.7y away | Ph3 Readout | Capibrutinib | Approved | Private | Obesity | |
| 2027-12-14 | 1.7y away | Interim | BIO-3214 | Preclinical | Mid | IPF | |
| 2027-12-15 | 1.7y away | Ph2 Data | Gozelucimab | Phase 1/2 | Large | MDD | |
| 2027-12-15 | 1.7y away | Ph3 Readout | NOR-4666 | Phase 3 | Private | ADPKD | |
| 2027-12-15 | 1.7y away | Interim | Zanurelsin | Preclinical | Private | T2D | |
| 2027-12-15 | 1.7y away | Ph3 Readout | URG-1959 | Phase 3 | Small | BCC | |
| 2027-12-17 | 1.8y away | Ph3 Readout | Zanuosocimab | Phase 3 | Large | SLE | |
| 2027-12-18 | 1.8y away | Interim | Olpazasiran | Preclinical | Private | Heart Failure | |
| 2027-12-18 | 1.8y away | Ph2 Data | 601-7487 | Phase 2 | Large | LGS | |
| 2027-12-19 | 1.8y away | Ph2 Data | Niraratamab | Phase 2 | Private | MDD | |
| 2027-12-19 | 1.8y away | Interim | Cevilemzoparlimab | Preclinical | Private | NMOSD | |
| 2027-12-20 | 1.8y away | Interim | PAS-2221 | Preclinical | Small | AS | |
| 2027-12-20 | 1.8y away | Interim | NOI-8348 | Preclinical | Private | Fabry | |
| 2027-12-22 | 1.8y away | Ph3 Readout | Bemainavolisib | NDA/BLA | Small | HS | |
| 2027-12-22 | 1.8y away | Ph3 Readout | 300-2164 | Phase 3 | Mid | MCL | |
| 2027-12-22 | 1.8y away | Interim | Niratenlimab | Phase 1 | Mid | SCLC | |
| 2027-12-23 | 1.8y away | Ph3 Readout | Miricapivasertib | Phase 3 | Private | Parkinson's | |
| 2027-12-24 | 1.8y away | Ph3 Readout | AZN-6870 | Phase 2/3 | Large | NSCLC | |
| 2027-12-24 | 1.8y away | Ph2 Data | Doxalucimab | Phase 1/2 | Private | OCD | |
| 2027-12-24 | 1.8y away | Interim | Sovafutibatinib | Phase 1 | Private | Huntington's | |
| 2027-12-24 | 1.8y away | Ph3 Readout | PBL-710 | Approved | Micro | Alzheimer's | |
| 2027-12-24 | 1.8y away | Ph2 Data | Gelizumab | Phase 1/2 | Mid | EoE | |
| 2027-12-24 | 1.8y away | Ph3 Readout | NAT-IIT-995 | Approved | Private | MCC | |
| 2027-12-24 | 1.8y away | Ph3 Readout | Mavuzumab | NDA/BLA | Private | FTD | |
| 2027-12-25 | 1.8y away | Ph2 Data | PMV-7390 | Phase 2 | Micro | Atopic Derm | |
| 2027-12-25 | 1.8y away | Ph3 Readout | ADA-2164 | Approved | Private | Bladder Ca | |
| 2027-12-26 | 1.8y away | Interim | Kemamavacamten | Preclinical | Private | MCL | |
| 2027-12-26 | 1.8y away | Ph3 Readout | AII-IIT-903 | NDA/BLA | Private | EoE | |
| 2027-12-26 | 1.8y away | Ph3 Readout | Doxacilimab | NDA/BLA | Large | HCC | |
| 2027-12-27 | 1.8y away | Ph3 Readout | QUO-3159 | Approved | Private | HS | |
| 2027-12-27 | 1.8y away | Ph3 Readout | LAU-4167 | NDA/BLA | Mid | SCD | |
| 2027-12-27 | 1.8y away | Interim | BIO-IIT-157 | Phase 1 | Private | NB | |
| 2027-12-28 | 1.8y away | Interim | Nidazumab | Phase 1 | Private | PsA | |
| 2027-12-28 | 1.8y away | Ph3 Readout | LOG-8406 | Phase 3 | Private | CF | |
| 2028-01-01 | 1.8y away | Ph3 Readout | LLY-4358 | Phase 3 | Large | Migraine | |
| 2028-01-01 | 1.8y away | Ph3 Readout | Tezevorutinib | Approved | Micro | Angelman | |
| 2028-01-01 | 1.8y away | Ph2 Data | AVI-386 | Phase 1/2 | Small | SCLC | |
| 2028-01-02 | 1.8y away | Ph3 Readout | TOR-3576 | NDA/BLA | Mid | Ovarian Ca | |
| 2028-01-03 | 1.8y away | Ph3 Readout | GSK-7987 | Phase 3 | Large | MG | |
| 2028-01-03 | 1.8y away | Ph2 Data | Pemifotisoran | Phase 1/2 | Small | Celiac | |
| 2028-01-03 | 1.8y away | Ph2 Data | 212-6798 | Phase 1/2 | Small | Breast Ca | |
| 2028-01-04 | 1.8y away | Ph2 Data | REG-861 | Phase 2 | Large | SLE | |
| 2028-01-04 | 1.8y away | Ph3 Readout | Bemarapivir | Phase 2/3 | Mid | CSU | |
| 2028-01-04 | 1.8y away | Ph2 Data | NAN-6418 | Phase 2 | Micro | Alzheimer's | |
| 2028-01-05 | 1.8y away | Ph3 Readout | Semainavolisib | Phase 2/3 | Large | Urothelial Ca | |
| 2028-01-05 | 1.8y away | Ph3 Readout | Ribomavacamten | Phase 3 | Private | Meso | |
| 2028-01-06 | 1.8y away | Ph3 Readout | Capicagene | Approved | Private | Asthma | |
| 2028-01-06 | 1.8y away | Ph3 Readout | Elrarasimod | NDA/BLA | Private | Asthma | |
| 2028-01-06 | 1.8y away | Ph2 Data | 195-9888 | Phase 1/2 | Small | PsA | |
| 2028-01-06 | 1.8y away | Ph3 Readout | VIN-1694 | Approved | Private | Epilepsy | |
| 2028-01-07 | 1.8y away | Ph3 Readout | Mirinesiran | Phase 3 | Private | MS | |
| 2028-01-07 | 1.8y away | Ph3 Readout | Talaglumide | NDA/BLA | Micro | TTR Amyloidosis | |
| 2028-01-07 | 1.8y away | Ph3 Readout | SVA-6795 | NDA/BLA | Small | NB | |
| 2028-01-07 | 1.8y away | Ph2 Data | MRE-7592 | Phase 1/2 | Micro | ALL | |
| 2028-01-07 | 1.8y away | Ph3 Readout | KIA-7048 | Phase 3 | Private | UC | |
| 2028-01-08 | 1.8y away | Interim | Adagrazumab | Phase 1 | Micro | IgAN | |
| 2028-01-09 | 1.8y away | Ph2 Data | Daralemzoparlimab | Phase 1/2 | Private | Pancreatic Ca | |
| 2028-01-10 | 1.8y away | Ph3 Readout | AVA-8598 | Phase 2/3 | Private | Parkinson's | |
| 2028-01-11 | 1.8y away | Ph3 Readout | CTM-2131 | Phase 3 | Micro | FL | |
| 2028-01-11 | 1.8y away | Ph2 Data | KNS-8287 | Phase 2 | Mid | Wet AMD | |
| 2028-01-11 | 1.8y away | Ph3 Readout | Polarasimod | Approved | Micro | MG | |
| 2028-01-11 | 1.8y away | Ph3 Readout | PHO-7143 | Phase 2/3 | Small | Rett | |
| 2028-01-11 | 1.8y away | Ph3 Readout | LUP-4095 | Phase 2/3 | Mid | Endometrial Ca | |
| 2028-01-12 | 1.8y away | Ph3 Readout | 450-5704 | Phase 2/3 | Large | GIST | |
| 2028-01-13 | 1.8y away | Ph2 Data | Tezezasiran | Phase 2 | Private | ADPKD | |
| 2028-01-13 | 1.8y away | Ph3 Readout | Polavorutinib | Phase 3 | Private | NASH | |
| 2028-01-13 | 1.8y away | Interim | Liramavacamten | Preclinical | Micro | Urothelial Ca | |
| 2028-01-14 | 1.8y away | Ph2 Data | Adagraderotide | Phase 2 | Micro | MG | |
| 2028-01-15 | 1.8y away | Ph2 Data | Zenorasimod | Phase 2 | Small | CSU | |
| 2028-01-15 | 1.8y away | Ph3 Readout | Datoderotide | Phase 3 | Micro | NASH | |
| 2028-01-16 | 1.8y away | Interim | GYR-4594 | Preclinical | Private | DLBCL | |
| 2028-01-16 | 1.8y away | Ph3 Readout | DRR-2203 | Phase 2/3 | Micro | Bladder Ca | |
| 2028-01-16 | 1.8y away | Interim | PRI-IIT-117 | Preclinical | Private | Bladder Ca | |
| 2028-01-17 | 1.8y away | Ph3 Readout | RHH-8550 | Approved | Large | CRC | |
| 2028-01-17 | 1.8y away | Ph3 Readout | Kemazumab | Approved | Small | NSCLC | |
| 2028-01-18 | 1.8y away | Interim | Fixalucimab | Preclinical | Private | CRC | |
| 2028-01-20 | 1.8y away | Ph3 Readout | Bemanesiran | Phase 3 | Large | MDD | |
| 2028-01-21 | 1.9y away | Ph3 Readout | DAN-IIT-767 | NDA/BLA | Private | SCLC | |
| 2028-01-22 | 1.9y away | Ph2 Data | Sotozanubrutinib | Phase 1/2 | Micro | CTCL | |
| 2028-01-23 | 1.9y away | Interim | Sovafotisoran | Preclinical | Private | Gastric Ca | |
| 2028-01-23 | 1.9y away | Ph3 Readout | Polarasimod | Approved | Micro | Wet AMD | |
| 2028-01-24 | 1.9y away | Ph3 Readout | Terasacituzumab | NDA/BLA | Large | HCC | |
| 2028-01-25 | 1.9y away | Ph3 Readout | Elranaritide | NDA/BLA | Private | IPF | |
| 2028-01-27 | 1.9y away | Ph3 Readout | VYG-2970 | Phase 3 | Small | LN | |
| 2028-01-27 | 1.9y away | Interim | Fixatapinarof | Preclinical | Large | NB | |
| 2028-01-27 | 1.9y away | Interim | Tirazanubrutinib | Preclinical | Small | SCLC | |
| 2028-01-28 | 1.9y away | Ph2 Data | Terazumab | Phase 2 | Small | PV | |
| 2028-01-28 | 1.9y away | Ph2 Data | CVA-2171 | Phase 1/2 | Small | Parkinson's | |
| 2028-01-28 | 1.9y away | Ph3 Readout | 601-626 | Approved | Large | WM | |
| 2028-02-01 | 1.9y away | Ph3 Readout | BMR-9762 | Phase 3 | Large | Psoriasis | |
| 2028-02-01 | 1.9y away | Interim | Nidatuximab | Preclinical | Micro | Myelofibrosis | |
| 2028-02-02 | 1.9y away | Ph3 Readout | Kemafotisoran | Phase 3 | Small | OCD | |
| 2028-02-03 | 1.9y away | Interim | EVO-481 | Preclinical | Private | Schizophrenia | |
| 2028-02-04 | 1.9y away | Ph3 Readout | Miritinib | Approved | Private | PAH | |
| 2028-02-04 | 1.9y away | Interim | MAG-3823 | Phase 1 | Private | TTR Amyloidosis | |
| 2028-02-05 | 1.9y away | Interim | RDY-3640 | Preclinical | Large | HNSCC | |
| 2028-02-05 | 1.9y away | Interim | BCY-3228 | Preclinical | Small | Meso | |
| 2028-02-06 | 1.9y away | Ph3 Readout | Rilucapivasertib | Phase 2/3 | Small | NASH | |
| 2028-02-06 | 1.9y away | Ph2 Data | LAU-2489 | Phase 2 | Mid | HS | |
| 2028-02-06 | 1.9y away | Ph3 Readout | Tixacilimab | Phase 2/3 | Private | Endometrial Ca | |
| 2028-02-08 | 1.9y away | Ph3 Readout | Rimazasiran | Approved | Micro | RA | |
| 2028-02-09 | 1.9y away | Ph3 Readout | Doxacagene | Approved | Large | PsA | |
| 2028-02-11 | 1.9y away | Ph2 Data | BIO-8650 | Phase 2 | Mid | NASH | |
| 2028-02-12 | 1.9y away | Interim | SDG-1247 | Phase 1 | Mid | Prostate Ca | |
| 2028-02-12 | 1.9y away | Ph2 Data | Mavurasimod | Phase 2 | Micro | GBM | |
| 2028-02-13 | 1.9y away | Ph3 Readout | Lisoosocimab | Approved | Mid | EoE | |
| 2028-02-14 | 1.9y away | Ph3 Readout | Lisonaritide | Phase 3 | Large | ET | |
| 2028-02-15 | 1.9y away | Ph2 Data | BMR-1165 | Phase 2 | Large | IPF | |
| 2028-02-15 | 1.9y away | Ph2 Data | Fixalucimab | Phase 2 | Mid | Cervical Ca | |
| 2028-02-16 | 1.9y away | Interim | Polatinib | Phase 1 | Private | Psoriasis | |
| 2028-02-16 | 1.9y away | Interim | EQR-8061 | Phase 1 | Private | MCC | |
| 2028-02-16 | 1.9y away | Ph3 Readout | Kemanesiran | Phase 3 | Private | EoE | |
| 2028-02-17 | 1.9y away | Ph3 Readout | Gozebrutinib | Approved | Mid | CRC | |
| 2028-02-17 | 1.9y away | Interim | QUA-617 | Phase 1 | Private | SMA | |
| 2028-02-17 | 1.9y away | Ph3 Readout | SCI-9998 | Approved | Private | Prostate Ca | |
| 2028-02-18 | 1.9y away | Ph3 Readout | Daranesiran | Phase 2/3 | Private | ALS | |
| 2028-02-19 | 1.9y away | Ph2 Data | 456-9934 | Phase 1/2 | Micro | Crohn's | |
| 2028-02-20 | 1.9y away | Ph3 Readout | Datoglumide | Approved | Large | SLE | |
| 2028-02-20 | 1.9y away | Ph3 Readout | Gelifutibatinib | Approved | Private | MS | |
| 2028-02-21 | 1.9y away | Ph3 Readout | Miritinib | Phase 3 | Large | PNH | |
| 2028-02-21 | 1.9y away | Interim | Elralucimab | Phase 1 | Large | Bladder Ca | |
| 2028-02-22 | 1.9y away | Ph3 Readout | JNJ-2735 | Phase 2/3 | Large | GBM | |
| 2028-02-22 | 1.9y away | Ph3 Readout | Tirarelsin | NDA/BLA | Mid | T2D | |
| 2028-02-23 | 1.9y away | Ph3 Readout | UCL-IIT-586 | Phase 3 | Private | Breast Ca | |
| 2028-02-23 | 1.9y away | Interim | DER-1141 | Preclinical | Private | MCL | |
| 2028-02-24 | 1.9y away | Interim | Ivocapivasertib | Phase 1 | Private | Endometrial Ca | |
| 2028-02-25 | 1.9y away | Interim | RHH-974 | Preclinical | Large | IPF | |
| 2028-02-25 | 1.9y away | Ph3 Readout | RGN-9803 | NDA/BLA | Small | SLE | |
| 2028-02-26 | 1.9y away | Interim | Zenoosocimab | Phase 1 | Private | RA | |
| 2028-02-28 | 2.0y away | Ph3 Readout | Elracapivasertib | Phase 3 | Mid | DMD | |
| 2028-02-28 | 2.0y away | Ph3 Readout | CIP-213 | Approved | Large | Gastric Ca | |
| 2028-03-03 | 2.0y away | Ph2 Data | GRA-2645 | Phase 2 | Small | GBM | |
| 2028-03-03 | 2.0y away | Ph2 Data | Sovasertib | Phase 2 | Small | Gastric Ca | |
| 2028-03-04 | 2.0y away | Ph3 Readout | Ivorasimod | Approved | Private | MDS | |
| 2028-03-05 | 2.0y away | Interim | Semaosocimab | Phase 1 | Large | T2D | |
| 2028-03-06 | 2.0y away | Ph3 Readout | Kematinib | Phase 3 | Micro | FTD | |
| 2028-03-07 | 2.0y away | Ph3 Readout | RAR-5994 | Phase 2/3 | Mid | GA | |
| 2028-03-08 | 2.0y away | Ph3 Readout | Mavuglumide | Approved | Large | MCL | |
| 2028-03-08 | 2.0y away | Ph3 Readout | RCK-1666 | Approved | Mid | CSU | |
| 2028-03-08 | 2.0y away | Ph3 Readout | Lisosotorasib | Phase 3 | Micro | MCL | |
| 2028-03-09 | 2.0y away | Interim | Tezetapinarof | Phase 1 | Private | NASH | |
| 2028-03-09 | 2.0y away | Ph3 Readout | 086-8509 | Phase 2/3 | Small | MG | |
| 2028-03-09 | 2.0y away | Ph3 Readout | Fixazasiran | Approved | Micro | Thymoma | |
| 2028-03-09 | 2.0y away | Ph2 Data | Mirisacituzumab | Phase 2 | Large | Asthma | |
| 2028-03-14 | 2.0y away | Ph3 Readout | Terazumab | Phase 3 | Mid | Hemophilia A | |
| 2028-03-14 | 2.0y away | Ph3 Readout | Semaglumide | Approved | Small | Bladder Ca | |
| 2028-03-14 | 2.0y away | Interim | Talanesiran | Preclinical | Large | Pompe | |
| 2028-03-16 | 2.0y away | Ph3 Readout | PFE-7550 | Phase 3 | Large | Asthma | |
| 2028-03-16 | 2.0y away | Interim | Geliglumide | Phase 1 | Large | ACC | |
| 2028-03-16 | 2.0y away | Ph3 Readout | Pemimavacamten | Phase 2/3 | Micro | GIST | |
| 2028-03-17 | 2.0y away | Interim | REG-2328 | Phase 1 | Large | Schizophrenia | |
| 2028-03-17 | 2.0y away | Ph3 Readout | MAP-6526 | Approved | Private | NMOSD | |
| 2028-03-17 | 2.0y away | Ph2 Data | NAT-IIT-525 | Phase 1/2 | Private | DLBCL | |
| 2028-03-17 | 2.0y away | Ph3 Readout | Rimaratamab | NDA/BLA | Micro | Obesity | |
| 2028-03-18 | 2.0y away | Ph2 Data | INC-1582 | Phase 1/2 | Large | Heart Failure | |
| 2028-03-18 | 2.0y away | Ph2 Data | Zenonaritide | Phase 1/2 | Mid | ALL | |
| 2028-03-19 | 2.0y away | Ph3 Readout | CON-4833 | Phase 2/3 | Private | SMA | |
| 2028-03-19 | 2.0y away | Ph2 Data | Semarasimod | Phase 1/2 | Mid | PBC | |
| 2028-03-19 | 2.0y away | Interim | SLN-495 | Phase 1 | Small | RCC | |
| 2028-03-20 | 2.0y away | Interim | OBS-1037 | Preclinical | Private | FSGS | |
| 2028-03-20 | 2.0y away | Interim | 459-2528 | Preclinical | Micro | PNH | |
| 2028-03-21 | 2.0y away | Ph3 Readout | Rilufotisoran | NDA/BLA | Large | HCC | |
| 2028-03-21 | 2.0y away | Ph2 Data | SEC-7279 | Phase 2 | Private | Melanoma | |
| 2028-03-21 | 2.0y away | Ph2 Data | 416-6807 | Phase 2 | Micro | MDS | |
| 2028-03-22 | 2.0y away | Ph3 Readout | Capitapinarof | Phase 3 | Micro | ADHD | |
| 2028-03-23 | 2.0y away | Ph2 Data | TSH-7567 | Phase 1/2 | Small | MCL | |
| 2028-03-23 | 2.0y away | Ph3 Readout | Sovalucimab | NDA/BLA | Private | TTR Amyloidosis | |
| 2028-03-23 | 2.0y away | Ph3 Readout | Nidanesiran | Approved | Private | RA | |
| 2028-03-24 | 2.0y away | Ph3 Readout | Tirarapivir | Approved | Large | PAH | |
| 2028-03-25 | 2.0y away | Ph2 Data | Polatuximab | Phase 1/2 | Micro | Thymoma | |
| 2028-03-25 | 2.0y away | Ph2 Data | Talarasimod | Phase 1/2 | Private | FL | |
| 2028-03-25 | 2.0y away | Interim | Lisonaritide | Preclinical | Small | WM | |
| 2028-03-25 | 2.0y away | Ph2 Data | Zanurapivir | Phase 2 | Micro | BCC | |
| 2028-03-26 | 2.0y away | Ph2 Data | Capilemzoparlimab | Phase 2 | Private | Bladder Ca | |
| 2028-03-26 | 2.0y away | Ph2 Data | FRE-IIT-416 | Phase 2 | Private | Hemophilia A | |
| 2028-03-26 | 2.0y away | Ph3 Readout | EXA-6597 | Phase 2/3 | Large | Gastric Ca | |
| 2028-03-26 | 2.0y away | Ph3 Readout | Darafutibatinib | Approved | Micro | ET | |
| 2028-03-27 | 2.0y away | Interim | TUR-6841 | Phase 1 | Private | OCD | |
| 2028-03-27 | 2.0y away | Ph2 Data | SUP-4355 | Phase 2 | Mid | RCC | |
| 2028-03-28 | 2.0y away | Ph3 Readout | Ivorelsin | Approved | Large | GBM | |
| 2028-03-28 | 2.0y away | Ph3 Readout | Geliderotide | Phase 3 | Private | MG | |
| 2028-04-01 | 2.0y away | Interim | Elrainavolisib | Preclinical | Mid | LGS | |
| 2028-04-03 | 2.1y away | Ph3 Readout | Miriderotide | NDA/BLA | Large | Rett | |
| 2028-04-03 | 2.1y away | Interim | AFF-3518 | Phase 1 | Private | PBC | |
| 2028-04-03 | 2.1y away | Ph2 Data | Talamavacamten | Phase 1/2 | Small | Myelofibrosis | |
| 2028-04-04 | 2.1y away | Interim | Motarapivir | Preclinical | Large | Heart Failure | |
| 2028-04-04 | 2.1y away | Ph3 Readout | NCI-IIT-878 | Approved | Private | IgAN | |
| 2028-04-04 | 2.1y away | Interim | NIA-IIT-528 | Phase 1 | Private | PsA | |
| 2028-04-04 | 2.1y away | Ph3 Readout | Capicagene | Approved | Private | PsA | |
| 2028-04-04 | 2.1y away | Ph2 Data | SHI-2889 | Phase 2 | Private | CKD | |
| 2028-04-04 | 2.1y away | Ph3 Readout | Bemazumab | Phase 2/3 | Private | Meso | |
| 2028-04-04 | 2.1y away | Interim | MAG-3823 | Phase 1 | Private | RA | |
| 2028-04-04 | 2.1y away | Ph3 Readout | Motazumab | Phase 3 | Micro | Fabry | |
| 2028-04-05 | 2.1y away | Ph3 Readout | Fixatuximab | Phase 3 | Private | Psoriasis | |
| 2028-04-06 | 2.1y away | Ph2 Data | TLX-9196 | Phase 1/2 | Mid | CSU | |
| 2028-04-06 | 2.1y away | Ph3 Readout | IMV-1446 | Approved | Micro | CRC | |
| 2028-04-07 | 2.1y away | Ph2 Data | Talatuximab | Phase 1/2 | Mid | Fabry | |
| 2028-04-08 | 2.1y away | Ph2 Data | CRS-6525 | Phase 2 | Mid | Ovarian Ca | |
| 2028-04-10 | 2.1y away | Ph3 Readout | Fixaderotide | Phase 2/3 | Small | FTD | |
| 2028-04-11 | 2.1y away | Ph3 Readout | BEA-2615 | Phase 3 | Mid | Epilepsy | |
| 2028-04-12 | 2.1y away | Ph3 Readout | Mavulucimab | NDA/BLA | Mid | CSU | |
| 2028-04-12 | 2.1y away | Interim | Talavorutinib | Phase 1 | Small | Parkinson's | |
| 2028-04-12 | 2.1y away | Ph3 Readout | Zanulemzoparlimab | Phase 3 | Private | FTD | |
| 2028-04-12 | 2.1y away | Ph2 Data | IMM-5834 | Phase 2 | Private | ALS | |
| 2028-04-13 | 2.1y away | Ph3 Readout | Olpasacituzumab | Phase 3 | Small | Bladder Ca | |
| 2028-04-13 | 2.1y away | Ph3 Readout | Datovorutinib | Approved | Micro | ADHD | |
| 2028-04-13 | 2.1y away | Interim | Lisosacituzumab | Phase 1 | Mid | CSU | |
| 2028-04-14 | 2.1y away | Ph2 Data | Rimainavolisib | Phase 2 | Large | PNH | |
| 2028-04-15 | 2.1y away | Interim | NUW-823 | Phase 1 | Micro | Pompe | |
| 2028-04-15 | 2.1y away | Interim | CNT-6977 | Preclinical | Micro | PSP | |
| 2028-04-15 | 2.1y away | Ph3 Readout | MYO-9608 | NDA/BLA | Private | Ewing Sarcoma | |
| 2028-04-15 | 2.1y away | Ph3 Readout | Kemazumab | Approved | Small | NSCLC | |
| 2028-04-15 | 2.1y away | Interim | SIR-IIT-176 | Preclinical | Private | IgAN | |
| 2028-04-15 | 2.1y away | Ph2 Data | EGI-5078 | Phase 2 | Private | PSP | |
| 2028-04-16 | 2.1y away | Ph2 Data | IMV-6752 | Phase 2 | Private | FL | |
| 2028-04-16 | 2.1y away | Ph2 Data | SHI-2989 | Phase 2 | Private | ADPKD | |
| 2028-04-16 | 2.1y away | Interim | Dararelsin | Preclinical | Private | DLBCL | |
| 2028-04-16 | 2.1y away | Ph3 Readout | TAB-3211 | Phase 3 | Private | PAH | |
| 2028-04-17 | 2.1y away | Ph3 Readout | Gelisertib | Approved | Large | Psoriasis | |
| 2028-04-19 | 2.1y away | Ph3 Readout | Talainavolisib | Approved | Small | ADPKD | |
| 2028-04-19 | 2.1y away | Ph3 Readout | Gozebrutinib | Approved | Mid | CRC | |
| 2028-04-19 | 2.1y away | Ph3 Readout | Zoriosocimab | Approved | Private | MDD | |
| 2028-04-19 | 2.1y away | Ph3 Readout | Kemafotisoran | Phase 3 | Small | OCD | |
| 2028-04-20 | 2.1y away | Ph2 Data | Fixatapinarof | Phase 2 | Private | Schizophrenia | |
| 2028-04-21 | 2.1y away | Interim | GEN-IIT-770 | Phase 1 | Private | Melanoma | |
| 2028-04-22 | 2.1y away | Interim | MED-3086 | Preclinical | Private | AML | |
| 2028-04-24 | 2.1y away | Interim | 153-2292 | Preclinical | Small | PNH | |
| 2028-04-25 | 2.1y away | Ph2 Data | Talafutibatinib | Phase 1/2 | Large | CF | |
| 2028-04-25 | 2.1y away | Interim | Daranesiran | Preclinical | Private | Cholangiocarcinoma | |
| 2028-04-26 | 2.1y away | Ph3 Readout | SWO-IIT-447 | Approved | Private | OCD | |
| 2028-04-27 | 2.1y away | Ph3 Readout | 207-5197 | Approved | Large | ET | |
| 2028-04-27 | 2.1y away | Interim | Tezesertib | Phase 1 | Large | IgAN | |
| 2028-04-28 | 2.1y away | Ph3 Readout | DIC-4437 | Approved | Private | RA | |
| 2028-05-01 | 2.1y away | Interim | FOR-4809 | Phase 1 | Private | MCC | |
| 2028-05-01 | 2.1y away | Ph3 Readout | NUW-6701 | Approved | Micro | DLBCL | |
| 2028-05-01 | 2.1y away | Ph3 Readout | Capifotisoran | Approved | Mid | CTCL | |
| 2028-05-01 | 2.1y away | Ph3 Readout | ZYM-7222 | Approved | Private | Cervical Ca | |
| 2028-05-02 | 2.1y away | Ph3 Readout | ZYN-1124 | NDA/BLA | Micro | HNSCC | |
| 2028-05-02 | 2.1y away | Interim | Liravorutinib | Preclinical | Private | GIST | |
| 2028-05-02 | 2.1y away | Ph2 Data | AMB-378 | Phase 2 | Private | PsA | |
| 2028-05-03 | 2.1y away | Ph3 Readout | ARE-3396 | Phase 3 | Private | PsA | |
| 2028-05-03 | 2.1y away | Interim | Doxasertib | Preclinical | Private | UC | |
| 2028-05-03 | 2.1y away | Ph2 Data | NIC-5654 | Phase 1/2 | Private | DMD | |
| 2028-05-03 | 2.1y away | Ph3 Readout | Rimanesiran | Phase 2/3 | Mid | Myelofibrosis | |
| 2028-05-04 | 2.1y away | Ph3 Readout | MAP-6526 | Approved | Private | ACC | |
| 2028-05-04 | 2.1y away | Interim | CAM-IIT-461 | Phase 1 | Private | CML | |
| 2028-05-05 | 2.1y away | Interim | MRU-8112 | Preclinical | Mid | Huntington's | |
| 2028-05-05 | 2.1y away | Interim | Elracapivasertib | Preclinical | Mid | LGS | |
| 2028-05-05 | 2.1y away | Ph3 Readout | ACH-2340 | Phase 3 | Private | FSGS | |
| 2028-05-07 | 2.1y away | Ph3 Readout | Lisosotorasib | NDA/BLA | Large | Wilms | |
| 2028-05-07 | 2.1y away | Ph3 Readout | KIA-5275 | Phase 2/3 | Private | Schizophrenia | |
| 2028-05-09 | 2.1y away | Ph3 Readout | Sotosacituzumab | Approved | Large | Breast Ca | |
| 2028-05-10 | 2.2y away | Ph3 Readout | 302-9165 | Approved | Mid | Pompe | |
| 2028-05-10 | 2.2y away | Ph2 Data | Zoricilimab | Phase 2 | Small | IgAN | |
| 2028-05-11 | 2.2y away | Ph2 Data | BMR-1165 | Phase 2 | Large | GA | |
| 2028-05-11 | 2.2y away | Ph2 Data | Rimatenlimab | Phase 1/2 | Private | CML | |
| 2028-05-11 | 2.2y away | Ph3 Readout | AUT-9774 | Phase 2/3 | Small | HS | |
| 2028-05-12 | 2.2y away | Ph3 Readout | OMG-4087 | NDA/BLA | Micro | PNH | |
| 2028-05-12 | 2.2y away | Ph3 Readout | COR-899 | Phase 2/3 | Private | PAH | |
| 2028-05-12 | 2.2y away | Interim | Lisolemzoparlimab | Preclinical | Mid | Heart Failure | |
| 2028-05-15 | 2.2y away | Ph2 Data | NVO-9087 | Phase 1/2 | Large | LGS | |
| 2028-05-15 | 2.2y away | Ph3 Readout | ADP-7169 | Approved | Small | Atopic Derm | |
| 2028-05-16 | 2.2y away | Interim | REC-373 | Phase 1 | Mid | LGS | |
| 2028-05-17 | 2.2y away | Ph3 Readout | Mirifotisoran | Approved | Mid | PSP | |
| 2028-05-18 | 2.2y away | Ph3 Readout | RDY-8710 | Approved | Large | ADHD | |
| 2028-05-18 | 2.2y away | Ph3 Readout | Kemamavacamten | Phase 3 | Large | NSCLC | |
| 2028-05-19 | 2.2y away | Ph3 Readout | Motafutibatinib | Approved | Private | GBM | |
| 2028-05-20 | 2.2y away | Ph3 Readout | Doxalemzoparlimab | Approved | Mid | WM | |
| 2028-05-20 | 2.2y away | Ph3 Readout | Polalucimab | Phase 3 | Large | CML | |
| 2028-05-20 | 2.2y away | Ph3 Readout | IMM-2816 | Approved | Private | LGS | |
| 2028-05-20 | 2.2y away | Ph3 Readout | 300-9245 | NDA/BLA | Mid | SMA | |
| 2028-05-20 | 2.2y away | Interim | Zenovorutinib | Preclinical | Private | Endometrial Ca | |
| 2028-05-20 | 2.2y away | Ph3 Readout | 051-5335 | Phase 3 | Mid | FTD | |
| 2028-05-20 | 2.2y away | Ph3 Readout | Zanurelsin | NDA/BLA | Private | MDD | |
| 2028-05-20 | 2.2y away | Ph3 Readout | INS-IIT-594 | Approved | Private | Celiac | |
| 2028-05-21 | 2.2y away | Ph2 Data | Zanuderotide | Phase 1/2 | Large | CKD | |
| 2028-05-21 | 2.2y away | Ph3 Readout | ABB-7516 | Phase 3 | Large | TTR Amyloidosis | |
| 2028-05-21 | 2.2y away | Ph3 Readout | ELV-1411 | NDA/BLA | Small | SLE | |
| 2028-05-21 | 2.2y away | Ph3 Readout | Gelitapinarof | Approved | Small | PNH | |
| 2028-05-21 | 2.2y away | Ph2 Data | Rilutenlimab | Phase 2 | Large | Hemophilia A | |
| 2028-05-21 | 2.2y away | Ph2 Data | FRE-IIT-323 | Phase 2 | Private | Asthma | |
| 2028-05-21 | 2.2y away | Ph3 Readout | GR-6650 | NDA/BLA | Private | Parkinson's | |
| 2028-05-22 | 2.2y away | Ph3 Readout | CAM-IIT-257 | Phase 2/3 | Private | ACC | |
| 2028-05-23 | 2.2y away | Ph3 Readout | Capibrutinib | Phase 3 | Micro | Alzheimer's | |
| 2028-05-23 | 2.2y away | Ph3 Readout | Rimafotisoran | Phase 2/3 | Private | HS | |
| 2028-05-23 | 2.2y away | Ph3 Readout | Pexainavolisib | Phase 3 | Private | MG | |
| 2028-05-23 | 2.2y away | Ph3 Readout | Talainavolisib | Approved | Large | Atopic Derm | |
| 2028-05-24 | 2.2y away | Ph2 Data | Polatuximab | Phase 1/2 | Micro | Pancreatic Ca | |
| 2028-05-24 | 2.2y away | Ph2 Data | Darasertib | Phase 1/2 | Private | Migraine | |
| 2028-05-24 | 2.2y away | Interim | ALK-4522 | Phase 1 | Mid | HS | |
| 2028-05-25 | 2.2y away | Ph2 Data | BIO-7835 | Phase 1/2 | Private | OCD | |
| 2028-05-25 | 2.2y away | Ph3 Readout | 300-8538 | NDA/BLA | Mid | ADPKD | |
| 2028-05-26 | 2.2y away | Ph3 Readout | Zorizumab | Approved | Mid | PAH | |
| 2028-05-26 | 2.2y away | Interim | Rimavorutinib | Phase 1 | Private | OCD | |
| 2028-05-27 | 2.2y away | Ph3 Readout | Doxacagene | Approved | Large | PsA | |
| 2028-05-28 | 2.2y away | Ph3 Readout | Suracagene | Phase 3 | Large | Endometrial Ca | |
| 2028-06-01 | 2.2y away | Interim | ALK-5502 | Phase 1 | Mid | Huntington's | |
| 2028-06-01 | 2.2y away | Ph3 Readout | 300-6128 | NDA/BLA | Mid | PBC | |
| 2028-06-02 | 2.2y away | Ph3 Readout | ROI-9675 | NDA/BLA | Mid | IPF | |
| 2028-06-02 | 2.2y away | Ph3 Readout | SNG-5665 | Phase 2/3 | Micro | RB | |
| 2028-06-02 | 2.2y away | Ph3 Readout | BSG-8809 | Approved | Micro | EoE | |
| 2028-06-02 | 2.2y away | Ph3 Readout | Lisosotorasib | Phase 3 | Mid | CSU | |
| 2028-06-03 | 2.2y away | Ph3 Readout | Lisonaritide | Phase 3 | Large | GBM | |
| 2028-06-03 | 2.2y away | Ph3 Readout | A-3864 | NDA/BLA | Large | PNH | |
| 2028-06-03 | 2.2y away | Ph3 Readout | ZEN-2386 | Phase 3 | Private | OCD | |
| 2028-06-04 | 2.2y away | Ph3 Readout | Capifutibatinib | Phase 2/3 | Private | CSU | |
| 2028-06-04 | 2.2y away | Ph3 Readout | INH-5545 | Phase 3 | Private | Melanoma | |
| 2028-06-05 | 2.2y away | Ph3 Readout | Niracilimab | Phase 3 | Private | LN | |
| 2028-06-05 | 2.2y away | Ph3 Readout | CEL-1794 | Approved | Private | OCD | |
| 2028-06-06 | 2.2y away | Ph2 Data | Polalucimab | Phase 1/2 | Mid | LGS | |
| 2028-06-06 | 2.2y away | Ph3 Readout | Olpacagene | NDA/BLA | Micro | Myelofibrosis | |
| 2028-06-07 | 2.2y away | Interim | Pemiosocimab | Phase 1 | Private | CF | |
| 2028-06-08 | 2.2y away | Interim | Tezerapivir | Preclinical | Small | Gastric Ca | |
| 2028-06-08 | 2.2y away | Ph3 Readout | Bemaderotide | Phase 2/3 | Mid | Urothelial Ca | |
| 2028-06-08 | 2.2y away | Ph2 Data | ZYD-5095 | Phase 2 | Large | PTSD | |
| 2028-06-08 | 2.2y away | Ph3 Readout | NAT-IIT-794 | Approved | Private | CML | |
| 2028-06-08 | 2.2y away | Ph3 Readout | Elratuximab | NDA/BLA | Small | MS | |
| 2028-06-08 | 2.2y away | Interim | VEE-457 | Phase 1 | Large | CF | |
| 2028-06-09 | 2.2y away | Ph2 Data | APN-6857 | Phase 2 | Mid | GIST | |
| 2028-06-10 | 2.2y away | Ph3 Readout | AMG-2597 | Phase 2/3 | Large | CSU | |
| 2028-06-10 | 2.2y away | Interim | PCI-3652 | Phase 1 | Micro | Ovarian Ca | |
| 2028-06-11 | 2.2y away | Interim | Cevizanubrutinib | Preclinical | Large | Wilms | |
| 2028-06-11 | 2.2y away | Ph3 Readout | Nidaratamab | Phase 3 | Mid | MM | |
| 2028-06-11 | 2.2y away | Ph3 Readout | Nirainavolisib | Phase 3 | Private | FTD | |
| 2028-06-11 | 2.2y away | Interim | PIE-7717 | Preclinical | Private | RSV | |
| 2028-06-12 | 2.2y away | Ph3 Readout | VIG-1206 | Phase 3 | Micro | GIST | |
| 2028-06-12 | 2.2y away | Ph3 Readout | BER-6094 | Phase 3 | Private | NB | |
| 2028-06-13 | 2.2y away | Ph3 Readout | Olpasacituzumab | Phase 3 | Small | Bladder Ca | |
| 2028-06-14 | 2.2y away | Ph3 Readout | LLY-9749 | Phase 3 | Large | PAH | |
| 2028-06-14 | 2.2y away | Ph2 Data | TAK-8730 | Phase 2 | Large | Cholangiocarcinoma | |
| 2028-06-14 | 2.2y away | Ph2 Data | Doxarelsin | Phase 1/2 | Private | ACC | |
| 2028-06-15 | 2.3y away | Ph2 Data | Bemasotorasib | Phase 2 | Mid | ACC | |
| 2028-06-15 | 2.3y away | Ph3 Readout | Bemaderotide | Phase 3 | Mid | TTR Amyloidosis | |
| 2028-06-16 | 2.3y away | Ph2 Data | PFE-3703 | Phase 1/2 | Large | TTR Amyloidosis | |
| 2028-06-17 | 2.3y away | Ph3 Readout | GIM-IIT-548 | Phase 3 | Private | HCC | |
| 2028-06-18 | 2.3y away | Ph3 Readout | MRU-1869 | Approved | Mid | RB | |
| 2028-06-18 | 2.3y away | Ph3 Readout | 452-308 | NDA/BLA | Large | AML | |
| 2028-06-20 | 2.3y away | Interim | DIV-7153 | Preclinical | Large | Alzheimer's | |
| 2028-06-20 | 2.3y away | Ph3 Readout | SEV-IIT-977 | Phase 3 | Private | Cervical Ca | |
| 2028-06-21 | 2.3y away | Interim | UCL-IIT-777 | Preclinical | Private | Crohn's | |
| 2028-06-21 | 2.3y away | Ph2 Data | ELO-7744 | Phase 2 | Private | CF | |
| 2028-06-21 | 2.3y away | Interim | REC-373 | Phase 1 | Mid | CML | |
| 2028-06-22 | 2.3y away | Ph3 Readout | Sotosacituzumab | Approved | Large | Breast Ca | |
| 2028-06-22 | 2.3y away | Ph3 Readout | Bemasertib | Phase 3 | Mid | Heart Failure | |
| 2028-06-23 | 2.3y away | Ph3 Readout | SLR-5251 | Phase 3 | Small | ADPKD | |
| 2028-06-23 | 2.3y away | Ph3 Readout | Rimanaritide | Phase 2/3 | Mid | NASH | |
| 2028-06-23 | 2.3y away | Interim | Voxacapivasertib | Preclinical | Private | ET | |
| 2028-06-23 | 2.3y away | Ph3 Readout | Semazanubrutinib | Phase 3 | Micro | Parkinson's | |
| 2028-06-23 | 2.3y away | Ph2 Data | BPT-5103 | Phase 2 | Micro | Epilepsy | |
| 2028-06-24 | 2.3y away | Ph2 Data | Ribotuximab | Phase 2 | Large | CML | |
| 2028-06-24 | 2.3y away | Ph3 Readout | NEU-3101 | NDA/BLA | Private | Asthma | |
| 2028-06-24 | 2.3y away | Ph2 Data | 601-7487 | Phase 2 | Large | LGS | |
| 2028-06-24 | 2.3y away | Interim | SIA-2247 | Preclinical | Private | LGS | |
| 2028-06-24 | 2.3y away | Interim | VCY-7974 | Phase 1 | Mid | EoE | |
| 2028-06-25 | 2.3y away | Ph2 Data | HCM-8303 | Phase 2 | Mid | Wet AMD | |
| 2028-06-26 | 2.3y away | Ph3 Readout | Elrabrutinib | Phase 3 | Private | Cervical Ca | |
| 2028-06-27 | 2.3y away | Ph3 Readout | TXM-5550 | NDA/BLA | Micro | Epilepsy | |
| 2028-06-28 | 2.3y away | Ph2 Data | NCI-IIT-143 | Phase 2 | Private | RB | |
| 2028-07-01 | 2.3y away | Ph3 Readout | Sotocapivasertib | Approved | Micro | RSV | |
| 2028-07-02 | 2.3y away | Ph3 Readout | Riboinavolisib | Phase 2/3 | Large | IPF | |
| 2028-07-02 | 2.3y away | Interim | Daratenlimab | Phase 1 | Micro | CKD | |
| 2028-07-02 | 2.3y away | Ph3 Readout | STA-IIT-233 | Phase 3 | Private | HS | |
| 2028-07-02 | 2.3y away | Ph3 Readout | Tixatuximab | Phase 3 | Private | MDD | |
| 2028-07-03 | 2.3y away | Ph3 Readout | Lisotapinarof | Approved | Private | Melanoma | |
| 2028-07-03 | 2.3y away | Interim | GLO-7885 | Phase 1 | Private | Huntington's | |
| 2028-07-04 | 2.3y away | Ph2 Data | KIN-IIT-763 | Phase 1/2 | Private | RA | |
| 2028-07-05 | 2.3y away | Ph3 Readout | APT-892 | Approved | Micro | PNH | |
| 2028-07-05 | 2.3y away | Ph3 Readout | LMN-9194 | Approved | Micro | NMOSD | |
| 2028-07-05 | 2.3y away | Interim | Riluratamab | Preclinical | Small | NB | |
| 2028-07-05 | 2.3y away | Ph3 Readout | Motanesiran | Phase 2/3 | Small | Rett | |
| 2028-07-06 | 2.3y away | Ph3 Readout | BMR-9762 | Phase 3 | Large | Psoriasis | |
| 2028-07-06 | 2.3y away | Interim | THE-3484 | Phase 1 | Private | Crohn's | |
| 2028-07-07 | 2.3y away | Ph3 Readout | NAT-IIT-496 | NDA/BLA | Private | SLE | |
| 2028-07-08 | 2.3y away | Interim | Pemitinib | Preclinical | Mid | FL | |
| 2028-07-08 | 2.3y away | Interim | 992-9448 | Preclinical | Mid | MM | |
| 2028-07-08 | 2.3y away | Ph3 Readout | 459-1094 | Phase 3 | Micro | ALL | |
| 2028-07-09 | 2.3y away | Ph3 Readout | TAT-IIT-832 | NDA/BLA | Private | Alzheimer's | |
| 2028-07-10 | 2.3y away | Ph2 Data | ABB-3060 | Phase 2 | Large | Migraine | |
| 2028-07-10 | 2.3y away | Ph3 Readout | SAM-IIT-637 | Phase 2/3 | Private | FTD | |
| 2028-07-10 | 2.3y away | Ph3 Readout | GIM-IIT-993 | NDA/BLA | Private | FTD | |
| 2028-07-10 | 2.3y away | Ph3 Readout | PRQ-3485 | NDA/BLA | Micro | Crohn's | |
| 2028-07-10 | 2.3y away | Ph3 Readout | ALD-7113 | Phase 3 | Private | Pompe | |
| 2028-07-10 | 2.3y away | Interim | Daranesiran | Preclinical | Private | Cholangiocarcinoma | |
| 2028-07-10 | 2.3y away | Interim | MIR-1203 | Phase 1 | Private | Prostate Ca | |
| 2028-07-11 | 2.3y away | Ph3 Readout | Elraosocimab | Phase 3 | Private | HCC | |
| 2028-07-12 | 2.3y away | Interim | Motabrutinib | Preclinical | Private | UC | |
| 2028-07-13 | 2.3y away | Interim | CHI-IIT-162 | Preclinical | Private | CML | |
| 2028-07-13 | 2.3y away | Ph3 Readout | Elrazanubrutinib | NDA/BLA | Small | PAH | |
| 2028-07-13 | 2.3y away | Ph3 Readout | Gelicapivasertib | Approved | Mid | Epilepsy | |
| 2028-07-15 | 2.3y away | Ph3 Readout | Datobrutinib | Phase 3 | Large | FTD | |
| 2028-07-15 | 2.3y away | Ph3 Readout | Adagrainavolisib | Phase 2/3 | Private | ADPKD | |
| 2028-07-16 | 2.3y away | Ph3 Readout | Terazumab | Phase 3 | Mid | MS | |
| 2028-07-16 | 2.3y away | Interim | Ivozasiran | Preclinical | Micro | UC | |
| 2028-07-16 | 2.3y away | Ph3 Readout | Lisoderotide | Phase 3 | Private | LGS | |
| 2028-07-16 | 2.3y away | Ph3 Readout | PHA-5173 | Phase 3 | Small | LN | |
| 2028-07-17 | 2.3y away | Ph2 Data | FRE-IIT-864 | Phase 2 | Private | Bladder Ca | |
| 2028-07-17 | 2.3y away | Ph3 Readout | Kemalucimab | Phase 2/3 | Private | MCC | |
| 2028-07-18 | 2.3y away | Interim | 600-2830 | Preclinical | Large | Atopic Derm | |
| 2028-07-19 | 2.3y away | Ph2 Data | Capiosocimab | Phase 1/2 | Private | IPF | |
| 2028-07-19 | 2.3y away | Interim | Capitenlimab | Phase 1 | Micro | ALS | |
| 2028-07-21 | 2.3y away | Interim | Tiracilimab | Phase 1 | Micro | MDS | |
| 2028-07-21 | 2.3y away | Ph2 Data | 618-5050 | Phase 2 | Mid | Psoriasis | |
| 2028-07-21 | 2.3y away | Interim | PET-IIT-224 | Preclinical | Private | Gastric Ca | |
| 2028-07-22 | 2.4y away | Ph2 Data | CHR-2685 | Phase 2 | Private | Prostate Ca | |
| 2028-07-22 | 2.4y away | Interim | Niratenlimab | Phase 1 | Mid | SCLC | |
| 2028-07-23 | 2.4y away | Ph2 Data | 003-1437 | Phase 2 | Small | RA | |
| 2028-07-24 | 2.4y away | Ph2 Data | ALN-5628 | Phase 1/2 | Large | LN | |
| 2028-07-24 | 2.4y away | Ph3 Readout | CAT-8632 | Phase 2/3 | Private | SLE | |
| 2028-07-25 | 2.4y away | Ph3 Readout | Semasacituzumab | Phase 3 | Large | Celiac | |
| 2028-07-27 | 2.4y away | Interim | 450-3790 | Preclinical | Mid | T2D | |
| 2028-07-27 | 2.4y away | Ph2 Data | Elrarapivir | Phase 2 | Small | NB | |
| 2028-07-27 | 2.4y away | Ph3 Readout | CRI-9527 | Phase 3 | Private | PBC | |
| 2028-07-27 | 2.4y away | Ph3 Readout | RIC-5834 | Phase 2/3 | Private | Alzheimer's | |
| 2028-08-01 | 2.4y away | Interim | Pexarelsin | Phase 1 | Large | FL | |
| 2028-08-01 | 2.4y away | Ph3 Readout | SUV-4226 | Phase 3 | Mid | Melanoma | |
| 2028-08-02 | 2.4y away | Ph3 Readout | SWO-IIT-827 | Phase 2/3 | Private | DLBCL | |
| 2028-08-02 | 2.4y away | Ph3 Readout | Sovafutibatinib | NDA/BLA | Mid | LN | |
| 2028-08-03 | 2.4y away | Interim | Capiglumide | Preclinical | Large | Asthma | |
| 2028-08-03 | 2.4y away | Ph3 Readout | Capilucimab | Phase 3 | Private | Bladder Ca | |
| 2028-08-03 | 2.4y away | Ph3 Readout | ASK-5918 | Phase 2/3 | Private | Melanoma | |
| 2028-08-04 | 2.4y away | Ph2 Data | DAW-8159 | Phase 2 | Mid | Dravet | |
| 2028-08-04 | 2.4y away | Ph3 Readout | Semalemzoparlimab | Phase 3 | Private | Huntington's | |
| 2028-08-04 | 2.4y away | Ph2 Data | PBL-1430 | Phase 1/2 | Micro | Ovarian Ca | |
| 2028-08-04 | 2.4y away | Ph3 Readout | ZTS-9629 | Phase 3 | Large | ADHD | |
| 2028-08-05 | 2.4y away | Ph3 Readout | DUK-IIT-634 | Approved | Private | Schizophrenia | |
| 2028-08-06 | 2.4y away | Ph3 Readout | Lisonaritide | Phase 3 | Large | GBM | |
| 2028-08-06 | 2.4y away | Interim | TAK-5300 | Phase 1 | Large | CML | |
| 2028-08-06 | 2.4y away | Ph3 Readout | Olpatenlimab | Phase 3 | Small | PBC | |
| 2028-08-07 | 2.4y away | Interim | Niralucimab | Phase 1 | Mid | NB | |
| 2028-08-07 | 2.4y away | Ph3 Readout | MAY-IIT-825 | Approved | Private | RA | |
| 2028-08-08 | 2.4y away | Interim | DIV-7153 | Preclinical | Large | IPF | |
| 2028-08-09 | 2.4y away | Interim | ION-3857 | Preclinical | Mid | MCL | |
| 2028-08-09 | 2.4y away | Ph3 Readout | BLP-8787 | Approved | Micro | Huntington's | |
| 2028-08-10 | 2.4y away | Ph3 Readout | Adagrafutibatinib | Phase 3 | Small | Crohn's | |
| 2028-08-10 | 2.4y away | Ph3 Readout | BER-6094 | Phase 3 | Private | OCD | |
| 2028-08-10 | 2.4y away | Interim | SEV-IIT-582 | Preclinical | Private | Crohn's | |
| 2028-08-11 | 2.4y away | Ph3 Readout | ARC-5137 | Approved | Private | SCD | |
| 2028-08-11 | 2.4y away | Interim | Liracapivasertib | Phase 1 | Mid | Myelofibrosis | |
| 2028-08-11 | 2.4y away | Interim | Nidanesiran | Preclinical | Private | TTR Amyloidosis | |
| 2028-08-11 | 2.4y away | Interim | FUD-IIT-666 | Preclinical | Private | Asthma | |
| 2028-08-12 | 2.4y away | Ph2 Data | Zenotuximab | Phase 1/2 | Private | ALL | |
| 2028-08-12 | 2.4y away | Ph3 Readout | Mirisertib | Phase 3 | Private | ADPKD | |
| 2028-08-12 | 2.4y away | Ph3 Readout | REC-3246 | Phase 2/3 | Mid | Breast Ca | |
| 2028-08-12 | 2.4y away | Ph2 Data | Mirimavacamten | Phase 1/2 | Mid | Bladder Ca | |
| 2028-08-13 | 2.4y away | Interim | MRU-8112 | Preclinical | Mid | DMD | |
| 2028-08-13 | 2.4y away | Ph3 Readout | NUW-6701 | Approved | Micro | Urothelial Ca | |
| 2028-08-14 | 2.4y away | Ph2 Data | CHA-IIT-927 | Phase 1/2 | Private | HCC | |
| 2028-08-15 | 2.4y away | Ph3 Readout | BEL-9345 | NDA/BLA | Private | Wilms | |
| 2028-08-15 | 2.4y away | Ph2 Data | MOR-6182 | Phase 1/2 | Private | HS | |
| 2028-08-15 | 2.4y away | Ph3 Readout | CAN-IIT-252 | Phase 3 | Private | ADHD | |
| 2028-08-17 | 2.4y away | Interim | AVE-4742 | Phase 1 | Private | PsA | |
| 2028-08-18 | 2.4y away | Ph3 Readout | Tirainavolisib | Phase 3 | Private | Parkinson's | |
| 2028-08-18 | 2.4y away | Ph3 Readout | ALD-7113 | Phase 3 | Private | Pompe | |
| 2028-08-19 | 2.4y away | Ph3 Readout | Lisoderotide | Phase 3 | Private | Fabry | |
| 2028-08-19 | 2.4y away | Ph2 Data | RIK-IIT-812 | Phase 2 | Private | Celiac | |
| 2028-08-20 | 2.4y away | Ph3 Readout | BIO-6952 | NDA/BLA | Private | ALS | |
| 2028-08-21 | 2.4y away | Ph3 Readout | Tirabrutinib | Approved | Mid | Obesity | |
| 2028-08-21 | 2.4y away | Ph2 Data | Voxazanubrutinib | Phase 1/2 | Private | PNH | |
| 2028-08-21 | 2.4y away | Ph3 Readout | Lisotapinarof | NDA/BLA | Private | NMOSD | |
| 2028-08-23 | 2.4y away | Ph2 Data | Gozesotorasib | Phase 1/2 | Mid | HCC | |
| 2028-08-24 | 2.4y away | Ph3 Readout | Mirifotisoran | Approved | Mid | CML | |
| 2028-08-25 | 2.4y away | Ph3 Readout | Pexaosocimab | NDA/BLA | Large | FTD | |
| 2028-08-25 | 2.4y away | Interim | 452-8741 | Phase 1 | Large | PSP | |
| 2028-08-25 | 2.4y away | Ph2 Data | CAN-4040 | Phase 1/2 | Micro | LGS | |
| 2028-08-26 | 2.4y away | Ph3 Readout | 369-8021 | Approved | Large | DMD | |
| 2028-08-26 | 2.4y away | Ph3 Readout | Ivoratamab | Phase 2/3 | Small | ADPKD | |
| 2028-08-27 | 2.5y away | Ph3 Readout | GIL-2259 | Approved | Large | ET | |
| 2028-08-28 | 2.5y away | Ph2 Data | CSL-8235 | Phase 1/2 | Large | FL | |
| 2028-08-28 | 2.5y away | Ph3 Readout | BBI-9525 | NDA/BLA | Mid | IPF | |
| 2028-09-01 | 2.5y away | Ph3 Readout | NVO-9615 | Phase 2/3 | Large | PV | |
| 2028-09-01 | 2.5y away | Ph2 Data | RCU-6379 | Phase 1/2 | Mid | OCD | |
| 2028-09-01 | 2.5y away | Ph3 Readout | CAR-9866 | Phase 3 | Micro | Wilms | |
| 2028-09-01 | 2.5y away | Interim | Lisotuximab | Phase 1 | Private | PBC | |
| 2028-09-01 | 2.5y away | Ph2 Data | IRC-IIT-214 | Phase 2 | Private | Rett | |
| 2028-09-02 | 2.5y away | Ph2 Data | Tixalucimab | Phase 1/2 | Micro | CML | |
| 2028-09-03 | 2.5y away | Ph2 Data | Voxabrutinib | Phase 1/2 | Small | CML | |
| 2028-09-05 | 2.5y away | Ph2 Data | Adagrarapivir | Phase 1/2 | Mid | CML | |
| 2028-09-06 | 2.5y away | Ph3 Readout | XTA-4333 | Approved | Private | Breast Ca | |
| 2028-09-06 | 2.5y away | Ph3 Readout | Mirisertib | Phase 3 | Private | Fabry | |
| 2028-09-06 | 2.5y away | Ph3 Readout | Gozefutibatinib | NDA/BLA | Private | SCD | |
| 2028-09-07 | 2.5y away | Ph3 Readout | Sovacapivasertib | Phase 3 | Large | Schizophrenia | |
| 2028-09-07 | 2.5y away | Ph3 Readout | CER-4594 | Phase 3 | Private | Celiac | |
| 2028-09-08 | 2.5y away | Interim | BRK-4512 | Preclinical | Large | PAH | |
| 2028-09-09 | 2.5y away | Ph3 Readout | Polalemzoparlimab | Phase 3 | Micro | WM | |
| 2028-09-09 | 2.5y away | Ph3 Readout | BIO-IIT-514 | Approved | Private | Ewing Sarcoma | |
| 2028-09-10 | 2.5y away | Interim | MEM-IIT-677 | Preclinical | Private | WM | |
| 2028-09-10 | 2.5y away | Ph3 Readout | Surazumab | Phase 2/3 | Private | HS | |
| 2028-09-10 | 2.5y away | Ph3 Readout | Lisorasimod | Phase 2/3 | Private | Fabry | |
| 2028-09-10 | 2.5y away | Interim | TNY-3110 | Preclinical | Small | Alzheimer's | |
| 2028-09-10 | 2.5y away | Interim | DAI-7966 | Preclinical | Private | MG | |
| 2028-09-10 | 2.5y away | Ph3 Readout | Tixarelsin | Phase 2/3 | Mid | MCC | |
| 2028-09-11 | 2.5y away | Interim | Teratenlimab | Preclinical | Small | FSGS | |
| 2028-09-12 | 2.5y away | Ph3 Readout | Motavorutinib | Phase 3 | Large | LN | |
| 2028-09-12 | 2.5y away | Ph3 Readout | Adagratapinarof | Phase 3 | Private | GIST | |
| 2028-09-13 | 2.5y away | Ph3 Readout | PET-IIT-604 | NDA/BLA | Private | LN | |
| 2028-09-15 | 2.5y away | Ph3 Readout | CGO-2579 | Approved | Mid | Hemophilia A | |
| 2028-09-15 | 2.5y away | Interim | Talavorutinib | Phase 1 | Small | Parkinson's | |
| 2028-09-15 | 2.5y away | Interim | Ivozumab | Phase 1 | Private | HCC | |
| 2028-09-15 | 2.5y away | Ph2 Data | EMS-5854 | Phase 2 | Private | DLBCL | |
| 2028-09-16 | 2.5y away | Ph2 Data | ARG-3265 | Phase 1/2 | Large | MM | |
| 2028-09-16 | 2.5y away | Interim | FUD-IIT-103 | Preclinical | Private | RA | |
| 2028-09-16 | 2.5y away | Ph3 Readout | Doxacilimab | NDA/BLA | Large | Cholangiocarcinoma | |
| 2028-09-17 | 2.5y away | Ph3 Readout | Lisotapinarof | Approved | Private | Melanoma | |
| 2028-09-17 | 2.5y away | Ph3 Readout | ATH-2491 | Approved | Micro | CSU | |
| 2028-09-18 | 2.5y away | Ph3 Readout | Kemaderotide | Approved | Micro | AML | |
| 2028-09-19 | 2.5y away | Ph3 Readout | ALK-9856 | Approved | Mid | T2D | |
| 2028-09-20 | 2.5y away | Ph3 Readout | Ribosacituzumab | Approved | Large | DLBCL | |
| 2028-09-20 | 2.5y away | Ph3 Readout | Mavutuximab | Approved | Mid | CF | |
| 2028-09-21 | 2.5y away | Ph3 Readout | TAR-1794 | NDA/BLA | Mid | CSU | |
| 2028-09-21 | 2.5y away | Interim | RGE-6554 | Phase 1 | Mid | Endometrial Ca | |
| 2028-09-21 | 2.5y away | Ph3 Readout | Fixatuximab | Approved | Large | Prostate Ca | |
| 2028-09-22 | 2.5y away | Ph2 Data | Pexafotisoran | Phase 1/2 | Private | Parkinson's | |
| 2028-09-22 | 2.5y away | Ph3 Readout | Rilufutibatinib | Phase 3 | Private | Narcolepsy | |
| 2028-09-22 | 2.5y away | Ph3 Readout | Zorilucimab | Approved | Private | CLL | |
| 2028-09-23 | 2.5y away | Interim | Niratinib | Preclinical | Private | CML | |
| 2028-09-24 | 2.5y away | Ph3 Readout | Terazumab | NDA/BLA | Mid | HS | |
| 2028-09-24 | 2.5y away | Ph3 Readout | Kemanaritide | Phase 3 | Small | ACC | |
| 2028-09-26 | 2.5y away | Ph3 Readout | UCB-7696 | NDA/BLA | Large | SCLC | |
| 2028-09-26 | 2.5y away | Ph3 Readout | UCS-IIT-264 | Phase 3 | Private | CF | |
| 2028-09-26 | 2.5y away | Ph3 Readout | NBS-1842 | NDA/BLA | Micro | LN | |
| 2028-09-26 | 2.5y away | Ph3 Readout | Doxazanubrutinib | Phase 3 | Private | PV | |
| 2028-09-26 | 2.5y away | Ph3 Readout | Nirasacituzumab | Phase 3 | Large | Melanoma | |
| 2028-09-27 | 2.5y away | Ph2 Data | Datofotisoran | Phase 1/2 | Private | MCC | |
| 2028-09-28 | 2.5y away | Ph3 Readout | STO-2663 | Approved | Small | T2D | |
| 2028-09-28 | 2.5y away | Ph3 Readout | Tezecilimab | Approved | Private | NB | |
| 2028-09-28 | 2.5y away | Ph3 Readout | Adagrafutibatinib | Phase 3 | Small | Crohn's | |
| 2028-09-28 | 2.5y away | Interim | Tixasacituzumab | Phase 1 | Large | Gastric Ca | |
| 2028-10-01 | 2.5y away | Ph2 Data | Zanuratamab | Phase 1/2 | Large | Meso | |
| 2028-10-01 | 2.5y away | Ph2 Data | Mirisotorasib | Phase 1/2 | Small | Celiac | |
| 2028-10-02 | 2.5y away | Ph3 Readout | Semalucimab | Phase 3 | Mid | DMD | |
| 2028-10-03 | 2.6y away | Interim | SAM-IIT-777 | Phase 1 | Private | Hemophilia A | |
| 2028-10-03 | 2.6y away | Ph2 Data | PLU-3424 | Phase 2 | Private | ACC | |
| 2028-10-04 | 2.6y away | Ph3 Readout | Kematenlimab | Phase 3 | Micro | ADHD | |
| 2028-10-04 | 2.6y away | Interim | ASA-IIT-613 | Preclinical | Private | PBC | |
| 2028-10-05 | 2.6y away | Interim | Elralucimab | Phase 1 | Small | T2D | |
| 2028-10-05 | 2.6y away | Ph3 Readout | Polazumab | Phase 3 | Private | IgAN | |
| 2028-10-06 | 2.6y away | Ph3 Readout | MRK-6781 | Approved | Large | PsA | |
| 2028-10-06 | 2.6y away | Ph3 Readout | Kemanaritide | Phase 3 | Small | ACC | |
| 2028-10-07 | 2.6y away | Ph3 Readout | Tezetapinarof | Phase 3 | Mid | FTD | |
| 2028-10-07 | 2.6y away | Ph3 Readout | Lisozasiran | NDA/BLA | Small | Myelofibrosis | |
| 2028-10-08 | 2.6y away | Ph3 Readout | 600-1653 | NDA/BLA | Large | Pompe | |
| 2028-10-08 | 2.6y away | Ph2 Data | 618-7080 | Phase 2 | Mid | ACC | |
| 2028-10-09 | 2.6y away | Interim | Fixafutibatinib | Preclinical | Private | NB | |
| 2028-10-09 | 2.6y away | Ph3 Readout | Ivoinavolisib | Phase 2/3 | Private | ADHD | |
| 2028-10-10 | 2.6y away | Ph2 Data | ARX-3681 | Phase 2 | Small | RA | |
| 2028-10-12 | 2.6y away | Ph3 Readout | BNT-5232 | NDA/BLA | Large | Epilepsy | |
| 2028-10-12 | 2.6y away | Ph3 Readout | CIR-2997 | Phase 2/3 | Private | SCLC | |
| 2028-10-15 | 2.6y away | Ph3 Readout | CAT-8632 | Phase 2/3 | Private | SLE | |
| 2028-10-16 | 2.6y away | Interim | Olpazumab | Phase 1 | Large | RB | |
| 2028-10-16 | 2.6y away | Ph2 Data | Gozesertib | Phase 1/2 | Micro | Pompe | |
| 2028-10-17 | 2.6y away | Interim | Ceviosocimab | Preclinical | Small | WM | |
| 2028-10-18 | 2.6y away | Ph3 Readout | Capifutibatinib | Phase 3 | Large | RB | |
| 2028-10-19 | 2.6y away | Ph3 Readout | Doxacapivasertib | Phase 3 | Large | Dravet | |
| 2028-10-19 | 2.6y away | Ph2 Data | Geliderotide | Phase 1/2 | Large | DMD | |
| 2028-10-19 | 2.6y away | Ph3 Readout | ECO-IIT-203 | Phase 3 | Private | ACC | |
| 2028-10-19 | 2.6y away | Ph3 Readout | NDR-1720 | Phase 3 | Micro | Huntington's | |
| 2028-10-20 | 2.6y away | Interim | RHH-5389 | Preclinical | Large | Prostate Ca | |
| 2028-10-20 | 2.6y away | Ph3 Readout | CHI-2221 | Phase 3 | Private | AML | |
| 2028-10-21 | 2.6y away | Ph3 Readout | TER-5062 | Phase 2/3 | Small | Wet AMD | |
| 2028-10-21 | 2.6y away | Ph2 Data | CHI-3542 | Phase 2 | Private | Breast Ca | |
| 2028-10-21 | 2.6y away | Interim | MIM-9595 | Preclinical | Private | RSV | |
| 2028-10-21 | 2.6y away | Interim | Voxainavolisib | Preclinical | Private | SMA | |
| 2028-10-23 | 2.6y away | Interim | Pexasertib | Preclinical | Private | GBM | |
| 2028-10-23 | 2.6y away | Ph3 Readout | Kematinib | Approved | Private | Cholangiocarcinoma | |
| 2028-10-23 | 2.6y away | Ph3 Readout | AVT-4398 | Phase 3 | Large | MM | |
| 2028-10-24 | 2.6y away | Ph3 Readout | 086-7390 | Phase 2/3 | Small | Cervical Ca | |
| 2028-10-25 | 2.6y away | Ph3 Readout | SAM-IIT-936 | Phase 3 | Private | NSCLC | |
| 2028-10-26 | 2.6y away | Ph3 Readout | LLY-1592 | NDA/BLA | Large | SMA | |
| 2028-10-26 | 2.6y away | Ph3 Readout | Niratinib | NDA/BLA | Small | Urothelial Ca | |
| 2028-10-26 | 2.6y away | Ph3 Readout | Pexatenlimab | Approved | Private | Ewing Sarcoma | |
| 2028-10-26 | 2.6y away | Ph3 Readout | Talalemzoparlimab | Phase 2/3 | Large | Bladder Ca | |
| 2028-10-28 | 2.6y away | Ph3 Readout | AZN-1715 | Phase 3 | Large | Psoriasis | |
| 2028-11-01 | 2.6y away | Ph3 Readout | Tezecilimab | Approved | Large | DLBCL | |
| 2028-11-01 | 2.6y away | Ph3 Readout | 095-6690 | NDA/BLA | Micro | SCLC | |
| 2028-11-02 | 2.6y away | Ph3 Readout | Olpatenlimab | Phase 3 | Small | PBC | |
| 2028-11-02 | 2.6y away | Interim | ADI-2736 | Preclinical | Private | Ewing Sarcoma | |
| 2028-11-02 | 2.6y away | Ph3 Readout | Tirainavolisib | Phase 3 | Private | Parkinson's | |
| 2028-11-02 | 2.6y away | Ph3 Readout | Rimasacituzumab | Phase 3 | Large | CF | |
| 2028-11-02 | 2.6y away | Ph3 Readout | Sotomavacamten | NDA/BLA | Private | NSCLC | |
| 2028-11-03 | 2.6y away | Interim | QUO-6518 | Preclinical | Private | ET | |
| 2028-11-04 | 2.6y away | Ph3 Readout | MRK-6781 | Approved | Large | PsA | |
| 2028-11-04 | 2.6y away | Ph3 Readout | ABB-8696 | Phase 3 | Large | FTD | |
| 2028-11-05 | 2.6y away | Interim | GRF-8977 | Phase 1 | Mid | RSV | |
| 2028-11-05 | 2.6y away | Interim | ACH-7772 | Phase 1 | Private | Crohn's | |
| 2028-11-06 | 2.6y away | Ph3 Readout | Zenorelsin | NDA/BLA | Mid | RSV | |
| 2028-11-06 | 2.6y away | Interim | Ribotuximab | Phase 1 | Private | WM | |
| 2028-11-07 | 2.6y away | Ph2 Data | SEO-IIT-994 | Phase 2 | Private | GBM | |
| 2028-11-07 | 2.6y away | Ph2 Data | Zanufotisoran | Phase 1/2 | Private | Melanoma | |
| 2028-11-07 | 2.6y away | Ph2 Data | Olpatenlimab | Phase 1/2 | Micro | WM | |
| 2028-11-08 | 2.7y away | Ph3 Readout | Gozederotide | NDA/BLA | Micro | Narcolepsy | |
| 2028-11-09 | 2.7y away | Ph2 Data | PMC-7054 | Phase 2 | Micro | CRC | |
| 2028-11-09 | 2.7y away | Ph2 Data | PMV-7390 | Phase 2 | Micro | SCLC | |
| 2028-11-10 | 2.7y away | Ph3 Readout | Gelicilimab | Phase 3 | Mid | Huntington's | |
| 2028-11-10 | 2.7y away | Ph3 Readout | AII-IIT-727 | Phase 2/3 | Private | Pompe | |
| 2028-11-12 | 2.7y away | Ph2 Data | Pemilemzoparlimab | Phase 1/2 | Large | TTR Amyloidosis | |
| 2028-11-12 | 2.7y away | Ph3 Readout | ALD-5252 | Phase 2/3 | Small | MM | |
| 2028-11-13 | 2.7y away | Ph3 Readout | PFE-7550 | Phase 3 | Large | Asthma | |
| 2028-11-13 | 2.7y away | Interim | Polazanubrutinib | Phase 1 | Small | Fabry | |
| 2028-11-14 | 2.7y away | Ph3 Readout | ALK-9856 | Approved | Mid | T2D | |
| 2028-11-14 | 2.7y away | Ph3 Readout | CDX-409 | Approved | Small | NB | |
| 2028-11-15 | 2.7y away | Interim | Talalemzoparlimab | Phase 1 | Large | ACC | |
| 2028-11-15 | 2.7y away | Ph3 Readout | CGO-2579 | Approved | Mid | Hemophilia A | |
| 2028-11-15 | 2.7y away | Ph3 Readout | Sovaglumide | Phase 3 | Large | OCD | |
| 2028-11-16 | 2.7y away | Ph3 Readout | Rimainavolisib | Phase 3 | Large | GA | |
| 2028-11-17 | 2.7y away | Ph3 Readout | Zanulemzoparlimab | NDA/BLA | Small | Schizophrenia | |
| 2028-11-17 | 2.7y away | Ph3 Readout | Polarapivir | NDA/BLA | Mid | CML | |
| 2028-11-18 | 2.7y away | Ph3 Readout | 450-7253 | Approved | Mid | PNH | |
| 2028-11-18 | 2.7y away | Interim | Doxafutibatinib | Phase 1 | Small | NASH | |
| 2028-11-18 | 2.7y away | Interim | Niracagene | Preclinical | Private | Heart Failure | |
| 2028-11-19 | 2.7y away | Interim | MOR-7494 | Phase 1 | Private | EoE | |
| 2028-11-19 | 2.7y away | Interim | Polafutibatinib | Preclinical | Private | NASH | |
| 2028-11-20 | 2.7y away | Ph3 Readout | LLY-8369 | Approved | Large | Ewing Sarcoma | |
| 2028-11-20 | 2.7y away | Ph2 Data | AJA-7822 | Phase 2 | Private | PsA | |
| 2028-11-20 | 2.7y away | Interim | IRC-IIT-452 | Phase 1 | Private | Gastric Ca | |
| 2028-11-22 | 2.7y away | Ph3 Readout | Taladerotide | Phase 2/3 | Small | NASH | |
| 2028-11-22 | 2.7y away | Ph3 Readout | POL-5703 | Approved | Private | Migraine | |
| 2028-11-22 | 2.7y away | Ph3 Readout | ROY-IIT-404 | Approved | Private | SCLC | |
| 2028-11-24 | 2.7y away | Interim | EGI-7413 | Phase 1 | Private | LN | |
| 2028-11-24 | 2.7y away | Interim | Gozefutibatinib | Preclinical | Private | EoE | |
| 2028-11-25 | 2.7y away | Ph3 Readout | GUS-IIT-564 | Phase 3 | Private | PSP | |
| 2028-11-25 | 2.7y away | Ph3 Readout | Pemibrutinib | Approved | Micro | LGS | |
| 2028-11-26 | 2.7y away | Ph3 Readout | Semalemzoparlimab | Phase 3 | Private | Huntington's | |
| 2028-11-27 | 2.7y away | Ph3 Readout | Zoribrutinib | Phase 2/3 | Private | Huntington's | |
| 2028-11-27 | 2.7y away | Ph3 Readout | Lisonesiran | NDA/BLA | Private | DLBCL | |
| 2028-11-28 | 2.7y away | Ph3 Readout | Lisoderotide | Phase 3 | Private | Fabry | |
| 2028-11-28 | 2.7y away | Ph3 Readout | Kemanesiran | Phase 3 | Mid | MDS | |
| 2028-12-01 | 2.7y away | Ph3 Readout | BIG-3814 | Approved | Private | Hemophilia A | |
| 2028-12-01 | 2.7y away | Ph3 Readout | OBS-7968 | Approved | Private | Huntington's | |
| 2028-12-02 | 2.7y away | Ph3 Readout | Pexainavolisib | Approved | Private | MM | |
| 2028-12-03 | 2.7y away | Ph3 Readout | FRE-IIT-954 | Phase 2/3 | Private | Endometrial Ca | |
| 2028-12-03 | 2.7y away | Ph2 Data | Rimasacituzumab | Phase 2 | Mid | MCL | |
| 2028-12-03 | 2.7y away | Ph3 Readout | Gelizasiran | Phase 2/3 | Mid | Thymoma | |
| 2028-12-04 | 2.7y away | Interim | Capicilimab | Phase 1 | Mid | DMD | |
| 2028-12-04 | 2.7y away | Ph2 Data | SLD-1824 | Phase 2 | Small | NB | |
| 2028-12-04 | 2.7y away | Interim | REA-6162 | Preclinical | Private | FTD | |
| 2028-12-05 | 2.7y away | Ph3 Readout | 225-3371 | Approved | Micro | DLBCL | |
| 2028-12-06 | 2.7y away | Ph2 Data | Zenoderotide | Phase 1/2 | Micro | Ovarian Ca | |
| 2028-12-07 | 2.7y away | Ph3 Readout | FRE-IIT-769 | Phase 2/3 | Private | AML | |
| 2028-12-07 | 2.7y away | Ph2 Data | NTR-7891 | Phase 1/2 | Large | NASH | |
| 2028-12-08 | 2.7y away | Ph2 Data | EGI-5078 | Phase 2 | Private | BCC | |
| 2028-12-09 | 2.7y away | Ph3 Readout | VYG-2970 | Phase 3 | Small | LN | |
| 2028-12-09 | 2.7y away | Ph2 Data | 002-2150 | Phase 2 | Mid | CF | |
| 2028-12-10 | 2.7y away | Ph3 Readout | Tixatapinarof | Approved | Small | NMOSD | |
| 2028-12-10 | 2.7y away | Interim | Teratenlimab | Preclinical | Small | FTD | |
| 2028-12-11 | 2.7y away | Ph3 Readout | Rimainavolisib | Phase 3 | Large | GA | |
| 2028-12-11 | 2.7y away | Ph3 Readout | Datolucimab | Approved | Small | Rett | |
| 2028-12-13 | 2.7y away | Ph2 Data | 450-7627 | Phase 1/2 | Mid | Schizophrenia | |
| 2028-12-13 | 2.7y away | Ph3 Readout | SWO-IIT-148 | Approved | Private | HS | |
| 2028-12-14 | 2.7y away | Ph2 Data | Doxaosocimab | Phase 1/2 | Small | NMOSD | |
| 2028-12-14 | 2.7y away | Ph3 Readout | INO-9184 | Phase 2/3 | Small | Endometrial Ca | |
| 2028-12-14 | 2.7y away | Ph2 Data | INS-860 | Phase 2 | Private | CLL | |
| 2028-12-15 | 2.8y away | Ph2 Data | DSG-6263 | Phase 1/2 | Small | Breast Ca | |
| 2028-12-15 | 2.8y away | Ph3 Readout | IDI-2657 | Approved | Small | Melanoma | |
| 2028-12-16 | 2.8y away | Ph2 Data | BBI-8786 | Phase 2 | Mid | MDD | |
| 2028-12-17 | 2.8y away | Ph3 Readout | 450-8514 | Phase 3 | Large | PsA | |
| 2028-12-18 | 2.8y away | Ph2 Data | Cevizasiran | Phase 1/2 | Mid | CF | |
| 2028-12-19 | 2.8y away | Interim | Dararelsin | Preclinical | Private | DLBCL | |
| 2028-12-19 | 2.8y away | Interim | WAT-2618 | Preclinical | Large | WM | |
| 2028-12-20 | 2.8y away | Ph3 Readout | Capiderotide | NDA/BLA | Mid | MM | |
| 2028-12-21 | 2.8y away | Ph3 Readout | LLY-4358 | Phase 3 | Large | Narcolepsy | |
| 2028-12-22 | 2.8y away | Interim | Zanurapivir | Phase 1 | Mid | Meso | |
| 2028-12-22 | 2.8y away | Interim | Olpazasiran | Preclinical | Private | TTR Amyloidosis | |
| 2028-12-22 | 2.8y away | Ph3 Readout | 532-4982 | Phase 3 | Large | SCD | |
| 2028-12-22 | 2.8y away | Ph3 Readout | Datozanubrutinib | NDA/BLA | Large | T2D | |
| 2028-12-23 | 2.8y away | Interim | Zanurapivir | Phase 1 | Mid | Alzheimer's | |
| 2028-12-23 | 2.8y away | Interim | ATO-3461 | Phase 1 | Micro | SCD | |
| 2028-12-25 | 2.8y away | Ph2 Data | APG-2066 | Phase 2 | Mid | GBM | |
| 2028-12-25 | 2.8y away | Interim | Lirainavolisib | Preclinical | Small | Psoriasis | |
| 2028-12-26 | 2.8y away | Ph2 Data | ZYM-7428 | Phase 1/2 | Mid | RCC | |
| 2028-12-26 | 2.8y away | Ph3 Readout | CTM-2131 | Phase 3 | Micro | FL | |
| 2028-12-26 | 2.8y away | Interim | Liravorutinib | Preclinical | Private | GIST | |
| 2028-12-27 | 2.8y away | Ph3 Readout | Peminaritide | NDA/BLA | Mid | CKD | |
| 2028-12-27 | 2.8y away | Ph3 Readout | A-3864 | NDA/BLA | Large | PNH | |
| 2028-12-28 | 2.8y away | Ph3 Readout | EME-6317 | Approved | Private | Crohn's | |
| 2029-01-01 | 2.8y away | Ph3 Readout | Cevitapinarof | Phase 2/3 | Micro | Angelman | |
| 2029-01-02 | 2.8y away | Ph2 Data | Nidacagene | Phase 2 | Private | Urothelial Ca | |
| 2029-01-02 | 2.8y away | Ph2 Data | ASP-8596 | Phase 2 | Private | Rett | |
| 2029-01-03 | 2.8y away | Ph3 Readout | Nidavorutinib | NDA/BLA | Micro | Ovarian Ca | |
| 2029-01-03 | 2.8y away | Interim | Terazanubrutinib | Preclinical | Private | RSV | |
| 2029-01-03 | 2.8y away | Ph3 Readout | Doxacapivasertib | Phase 2/3 | Small | PBC | |
| 2029-01-03 | 2.8y away | Ph3 Readout | ADA-2164 | Approved | Private | Bladder Ca | |
| 2029-01-04 | 2.8y away | Ph3 Readout | Tezetapinarof | Phase 3 | Mid | FTD | |
| 2029-01-04 | 2.8y away | Ph3 Readout | Kemasacituzumab | Approved | Private | CTCL | |
| 2029-01-05 | 2.8y away | Ph2 Data | Capirelsin | Phase 2 | Small | Bladder Ca | |
| 2029-01-06 | 2.8y away | Ph3 Readout | CLR-3690 | Phase 3 | Micro | Melanoma | |
| 2029-01-06 | 2.8y away | Ph3 Readout | PHA-9567 | Phase 2/3 | Small | IPF | |
| 2029-01-06 | 2.8y away | Ph2 Data | NTR-7700 | Phase 1/2 | Large | Asthma | |
| 2029-01-08 | 2.8y away | Ph3 Readout | APT-892 | Approved | Micro | Meso | |
| 2029-01-08 | 2.8y away | Ph3 Readout | Rilunaritide | Approved | Micro | Rett | |
| 2029-01-08 | 2.8y away | Ph3 Readout | Mavuderotide | Approved | Private | Wilms | |
| 2029-01-09 | 2.8y away | Ph3 Readout | Polatuximab | Approved | Mid | PNH | |
| 2029-01-09 | 2.8y away | Ph3 Readout | GUS-IIT-951 | Approved | Private | LGS | |
| 2029-01-09 | 2.8y away | Ph3 Readout | Surasacituzumab | Phase 3 | Private | SCD | |
| 2029-01-10 | 2.8y away | Interim | Fixatuximab | Preclinical | Large | FTD | |
| 2029-01-10 | 2.8y away | Ph3 Readout | Pemitenlimab | Phase 3 | Private | NSCLC | |
| 2029-01-11 | 2.8y away | Ph3 Readout | RHH-1969 | Approved | Large | PBC | |
| 2029-01-11 | 2.8y away | Ph2 Data | Pexazanubrutinib | Phase 1/2 | Small | Pancreatic Ca | |
| 2029-01-11 | 2.8y away | Ph3 Readout | 051-2746 | Phase 2/3 | Mid | SCD | |
| 2029-01-11 | 2.8y away | Ph3 Readout | CIR-2997 | Phase 2/3 | Private | SCLC | |
| 2029-01-12 | 2.8y away | Ph2 Data | Fixaratamab | Phase 1/2 | Private | Urothelial Ca | |
| 2029-01-12 | 2.8y away | Ph3 Readout | Miricapivasertib | Phase 3 | Private | CTCL | |
| 2029-01-12 | 2.8y away | Ph3 Readout | SIA-1629 | Phase 2/3 | Private | FL | |
| 2029-01-13 | 2.8y away | Ph3 Readout | Bemazumab | Phase 2/3 | Private | Meso | |
| 2029-01-14 | 2.8y away | Ph3 Readout | RLA-6817 | Phase 3 | Mid | BCC | |
| 2029-01-15 | 2.8y away | Interim | MRK-853 | Phase 1 | Large | RSV | |
| 2029-01-15 | 2.8y away | Ph2 Data | Voxacilimab | Phase 1/2 | Large | NB | |
| 2029-01-15 | 2.8y away | Ph3 Readout | Nidafutibatinib | NDA/BLA | Micro | FTD | |
| 2029-01-15 | 2.8y away | Interim | 109-1876 | Preclinical | Mid | SLE | |
| 2029-01-16 | 2.8y away | Ph3 Readout | Tirzepatide | Approved | Large | T2D | |
| 2029-01-16 | 2.8y away | Ph3 Readout | Zoriosocimab | Approved | Mid | SMA | |
| 2029-01-17 | 2.8y away | Ph3 Readout | HOR-3482 | Phase 3 | Private | SMA | |
| 2029-01-18 | 2.8y away | Ph3 Readout | GIL-2037 | Approved | Large | CLL | |
| 2029-01-18 | 2.8y away | Ph3 Readout | NEO-620 | Phase 2/3 | Mid | CRC | |
| 2029-01-19 | 2.8y away | Ph3 Readout | ECO-IIT-550 | Phase 3 | Private | RCC | |
| 2029-01-19 | 2.8y away | Ph2 Data | AAD-5814 | Phase 2 | Private | MDS | |
| 2029-01-19 | 2.8y away | Ph3 Readout | Lisoderotide | Phase 3 | Private | Urothelial Ca | |
| 2029-01-21 | 2.9y away | Ph3 Readout | QUO-3159 | Approved | Private | HS | |
| 2029-01-21 | 2.9y away | Ph3 Readout | Miricapivasertib | NDA/BLA | Private | NASH | |
| 2029-01-21 | 2.9y away | Ph3 Readout | VEC-6874 | Phase 2/3 | Private | FL | |
| 2029-01-22 | 2.9y away | Interim | VRT-4938 | Preclinical | Large | PBC | |
| 2029-01-22 | 2.9y away | Ph3 Readout | Mirilucimab | NDA/BLA | Small | RB | |
| 2029-01-23 | 2.9y away | Interim | Capiratamab | Phase 1 | Private | Atopic Derm | |
| 2029-01-23 | 2.9y away | Interim | Kemanesiran | Phase 1 | Private | Rett | |
| 2029-01-23 | 2.9y away | Ph3 Readout | Capifotisoran | Approved | Mid | PBC | |
| 2029-01-26 | 2.9y away | Interim | REG-7737 | Preclinical | Large | Epilepsy | |
| 2029-01-26 | 2.9y away | Ph3 Readout | Talainavolisib | Approved | Large | Atopic Derm | |
| 2029-01-26 | 2.9y away | Ph3 Readout | Fixatuximab | Phase 3 | Private | Epilepsy | |
| 2029-01-27 | 2.9y away | Ph3 Readout | Rimainavolisib | Phase 3 | Large | GA | |
| 2029-01-28 | 2.9y away | Ph3 Readout | Ribozanubrutinib | Approved | Large | LGS | |
| 2029-01-28 | 2.9y away | Ph3 Readout | Rimanaritide | Phase 3 | Private | SLE | |
| 2029-02-01 | 2.9y away | Ph3 Readout | Gelicapivasertib | Approved | Mid | Epilepsy | |
| 2029-02-01 | 2.9y away | Ph3 Readout | ZHE-740 | Approved | Private | PBC | |
| 2029-02-02 | 2.9y away | Ph3 Readout | TVT-9611 | NDA/BLA | Small | Narcolepsy | |
| 2029-02-03 | 2.9y away | Ph3 Readout | Motacapivasertib | NDA/BLA | Mid | Epilepsy | |
| 2029-02-03 | 2.9y away | Ph3 Readout | Tezecilimab | Approved | Private | NB | |
| 2029-02-03 | 2.9y away | Ph3 Readout | Rilucapivasertib | Phase 2/3 | Private | AML | |
| 2029-02-05 | 2.9y away | Ph3 Readout | ARG-314 | Approved | Large | Endometrial Ca | |
| 2029-02-05 | 2.9y away | Ph3 Readout | JAN-1547 | Approved | Mid | MDS | |
| 2029-02-06 | 2.9y away | Ph3 Readout | Mavuzasiran | Phase 3 | Mid | Rett | |
| 2029-02-06 | 2.9y away | Ph3 Readout | DAS-6981 | Phase 2/3 | Private | PSP | |
| 2029-02-06 | 2.9y away | Ph3 Readout | Pexatinib | Phase 3 | Private | Ovarian Ca | |
| 2029-02-06 | 2.9y away | Ph2 Data | WES-IIT-947 | Phase 2 | Private | IPF | |
| 2029-02-07 | 2.9y away | Interim | MRK-5413 | Phase 1 | Large | NASH | |
| 2029-02-07 | 2.9y away | Ph3 Readout | Fixatuximab | Approved | Large | ALL | |
| 2029-02-08 | 2.9y away | Ph3 Readout | Nidasertib | Approved | Mid | MDS | |
| 2029-02-08 | 2.9y away | Ph3 Readout | FDM-9341 | Phase 2/3 | Small | Migraine | |
| 2029-02-09 | 2.9y away | Ph2 Data | ABL-5779 | Phase 1/2 | Private | ADHD | |
| 2029-02-09 | 2.9y away | Ph2 Data | Tezevorutinib | Phase 1/2 | Small | Dravet | |
| 2029-02-10 | 2.9y away | Ph3 Readout | SMM-5951 | Phase 2/3 | Mid | Angelman | |
| 2029-02-11 | 2.9y away | Ph3 Readout | Rilufutibatinib | Phase 3 | Private | CRC | |
| 2029-02-11 | 2.9y away | Ph3 Readout | BLC-3714 | Approved | Mid | SCD | |
| 2029-02-12 | 2.9y away | Interim | HYP-6990 | Preclinical | Mid | Pompe | |
| 2029-02-12 | 2.9y away | Ph3 Readout | Mavuzumab | NDA/BLA | Private | PBC | |
| 2029-02-13 | 2.9y away | Ph3 Readout | Miriglumide | Phase 3 | Large | Pancreatic Ca | |
| 2029-02-13 | 2.9y away | Ph2 Data | IMM-2921 | Phase 1/2 | Private | FTD | |
| 2029-02-13 | 2.9y away | Ph2 Data | NER-1837 | Phase 1/2 | Micro | Prostate Ca | |
| 2029-02-14 | 2.9y away | Ph3 Readout | NVO-7840 | Phase 2/3 | Large | HCC | |
| 2029-02-14 | 2.9y away | Ph3 Readout | Teratinib | Phase 2/3 | Small | T2D | |
| 2029-02-14 | 2.9y away | Ph2 Data | MGX-6815 | Phase 2 | Small | Gastric Ca | |
| 2029-02-15 | 2.9y away | Ph3 Readout | HOV-IIT-732 | Phase 3 | Private | Prostate Ca | |
| 2029-02-15 | 2.9y away | Ph3 Readout | Ivotinib | Phase 3 | Private | CTCL | |
| 2029-02-16 | 2.9y away | Ph3 Readout | 452-308 | NDA/BLA | Large | AML | |
| 2029-02-17 | 2.9y away | Ph3 Readout | Nidarelsin | Phase 2/3 | Small | Thymoma | |
| 2029-02-17 | 2.9y away | Interim | Rilubrutinib | Phase 1 | Micro | CRC | |
| 2029-02-17 | 2.9y away | Ph3 Readout | Surainavolisib | NDA/BLA | Small | BCC | |
| 2029-02-17 | 2.9y away | Ph3 Readout | 415-3897 | Phase 3 | Large | Fabry | |
| 2029-02-17 | 2.9y away | Interim | 654-2851 | Preclinical | Small | ALL | |
| 2029-02-17 | 2.9y away | Ph2 Data | Lisonesiran | Phase 2 | Mid | CTCL | |
| 2029-02-18 | 2.9y away | Ph3 Readout | AZN-1715 | Phase 3 | Large | SMA | |
| 2029-02-18 | 2.9y away | Ph3 Readout | Lirarelsin | Approved | Private | Pancreatic Ca | |
| 2029-02-18 | 2.9y away | Ph3 Readout | CHA-IIT-602 | NDA/BLA | Private | RA | |
| 2029-02-18 | 2.9y away | Ph3 Readout | ABB-7827 | NDA/BLA | Private | MDS | |
| 2029-02-19 | 2.9y away | Ph3 Readout | JNJ-179 | Approved | Large | DMD | |
| 2029-02-19 | 2.9y away | Ph2 Data | ONS-2940 | Phase 2 | Micro | SCLC | |
| 2029-02-19 | 2.9y away | Ph2 Data | DMA-2916 | Phase 1/2 | Micro | ADPKD | |
| 2029-02-20 | 2.9y away | Ph3 Readout | ALN-3284 | Phase 2/3 | Large | PV | |
| 2029-02-20 | 2.9y away | Ph3 Readout | BLR-6474 | Approved | Micro | NMOSD | |
| 2029-02-20 | 2.9y away | Ph2 Data | Mirirelsin | Phase 1/2 | Small | CF | |
| 2029-02-21 | 2.9y away | Ph3 Readout | Mavulucimab | NDA/BLA | Large | Pompe | |
| 2029-02-22 | 2.9y away | Ph2 Data | RCE-4101 | Phase 1/2 | Small | Celiac | |
| 2029-02-22 | 2.9y away | Ph3 Readout | Liravorutinib | Approved | Private | GA | |
| 2029-02-24 | 2.9y away | Ph3 Readout | Ivotuximab | NDA/BLA | Large | MS | |
| 2029-02-24 | 2.9y away | Interim | Terainavolisib | Preclinical | Mid | ALL | |
| 2029-02-24 | 2.9y away | Ph3 Readout | Motamavacamten | Phase 3 | Small | Wet AMD | |
| 2029-02-24 | 2.9y away | Ph3 Readout | Fixaratamab | Approved | Mid | Endometrial Ca | |
| 2029-02-28 | 3.0y away | Interim | ARG-1924 | Preclinical | Large | T2D | |
| 2029-02-28 | 3.0y away | Ph3 Readout | Bemarelsin | Phase 2/3 | Private | HNSCC | |
| 2029-02-28 | 3.0y away | Ph2 Data | 109-3699 | Phase 2 | Mid | CML | |
| 2029-03-01 | 3.0y away | Ph2 Data | Peminaritide | Phase 1/2 | Private | Cervical Ca | |
| 2029-03-02 | 3.0y away | Interim | UCL-IIT-899 | Preclinical | Private | PsA | |
| 2029-03-02 | 3.0y away | Ph2 Data | Riboosocimab | Phase 2 | Private | PV | |
| 2029-03-03 | 3.0y away | Ph2 Data | RCE-2070 | Phase 1/2 | Small | Hemophilia A | |
| 2029-03-03 | 3.0y away | Ph3 Readout | Geliglumide | Phase 2/3 | Small | MCL | |
| 2029-03-04 | 3.0y away | Ph2 Data | Lirarasimod | Phase 1/2 | Micro | T2D | |
| 2029-03-04 | 3.0y away | Interim | IMM-5415 | Preclinical | Private | Parkinson's | |
| 2029-03-06 | 3.0y away | Ph3 Readout | JAZ-8729 | Phase 2/3 | Mid | AS | |
| 2029-03-06 | 3.0y away | Ph3 Readout | Gelicapivasertib | Approved | Mid | Epilepsy | |
| 2029-03-06 | 3.0y away | Interim | 416-1749 | Preclinical | Micro | MDS | |
| 2029-03-07 | 3.0y away | Ph2 Data | SCI-9093 | Phase 1/2 | Private | GIST | |
| 2029-03-07 | 3.0y away | Interim | Cevilemzoparlimab | Preclinical | Private | NMOSD | |
| 2029-03-07 | 3.0y away | Interim | GR-8075 | Preclinical | Private | Rett | |
| 2029-03-08 | 3.0y away | Interim | Tixaratamab | Preclinical | Micro | SLE | |
| 2029-03-09 | 3.0y away | Ph3 Readout | Zorirelsin | Phase 3 | Large | Psoriasis | |
| 2029-03-09 | 3.0y away | Interim | MEI-1324 | Preclinical | Private | Cholangiocarcinoma | |
| 2029-03-09 | 3.0y away | Ph3 Readout | Zoritinib | Approved | Private | PBC | |
| 2029-03-10 | 3.0y away | Ph3 Readout | Sotobrutinib | NDA/BLA | Small | FTD | |
| 2029-03-12 | 3.0y away | Ph3 Readout | BII-5240 | Phase 2/3 | Large | Wet AMD | |
| 2029-03-12 | 3.0y away | Ph3 Readout | Mavucapivasertib | NDA/BLA | Small | PsA | |
| 2029-03-12 | 3.0y away | Interim | CLL-5354 | Preclinical | Small | Heart Failure | |
| 2029-03-12 | 3.0y away | Ph3 Readout | Ribocilimab | Phase 3 | Small | Wilms | |
| 2029-03-12 | 3.0y away | Ph3 Readout | Voxatenlimab | Approved | Large | PBC | |
| 2029-03-13 | 3.0y away | Ph3 Readout | Tezecilimab | NDA/BLA | Large | Angelman | |
| 2029-03-13 | 3.0y away | Ph3 Readout | Doxazanubrutinib | Phase 3 | Private | Schizophrenia | |
| 2029-03-13 | 3.0y away | Ph3 Readout | Zorisertib | Approved | Private | Thymoma | |
| 2029-03-15 | 3.0y away | Interim | Tixaratamab | Preclinical | Micro | Migraine | |
| 2029-03-16 | 3.0y away | Ph3 Readout | KTO-5045 | Approved | Micro | ALS | |
| 2029-03-16 | 3.0y away | Ph3 Readout | VAL-6020 | Phase 2/3 | Private | Urothelial Ca | |
| 2029-03-17 | 3.0y away | Ph3 Readout | JNJ-8637 | NDA/BLA | Large | Celiac | |
| 2029-03-17 | 3.0y away | Ph3 Readout | Tixatenlimab | Approved | Private | UC | |
| 2029-03-17 | 3.0y away | Ph3 Readout | Polarasimod | Approved | Micro | Wet AMD | |
| 2029-03-17 | 3.0y away | Ph3 Readout | Rimavorutinib | Phase 3 | Private | CTCL | |
| 2029-03-18 | 3.0y away | Ph3 Readout | HAL-9635 | Phase 2/3 | Large | MS | |
| 2029-03-18 | 3.0y away | Ph2 Data | PLU-3424 | Phase 2 | Private | Wet AMD | |
| 2029-03-19 | 3.0y away | Ph3 Readout | Voxanaritide | Approved | Mid | AML | |
| 2029-03-22 | 3.0y away | Ph3 Readout | AMG-1919 | Phase 2/3 | Large | GBM | |
| 2029-03-23 | 3.0y away | Ph3 Readout | ACC-8527 | Approved | Private | NMOSD | |
| 2029-03-24 | 3.0y away | Ph2 Data | INC-5849 | Phase 2 | Large | Psoriasis | |
| 2029-03-24 | 3.0y away | Ph3 Readout | NDR-1720 | Phase 3 | Micro | Huntington's | |
| 2029-03-24 | 3.0y away | Ph2 Data | PBY-3950 | Phase 2 | Micro | Endometrial Ca | |
| 2029-03-25 | 3.0y away | Ph3 Readout | Cevimavacamten | NDA/BLA | Mid | RSV | |
| 2029-03-25 | 3.0y away | Ph3 Readout | VEE-8520 | NDA/BLA | Large | AML | |
| 2029-03-27 | 3.0y away | Ph3 Readout | VRT-1576 | Phase 2/3 | Large | Cholangiocarcinoma | |
| 2029-03-27 | 3.0y away | Interim | Capitinib | Phase 1 | Large | Celiac | |
| 2029-03-27 | 3.0y away | Ph3 Readout | DIV-9629 | Phase 3 | Large | Urothelial Ca | |
| 2029-03-28 | 3.0y away | Ph2 Data | Tezevorutinib | Phase 1/2 | Small | Dravet | |
| 2029-04-01 | 3.0y away | Interim | NCI-IIT-415 | Preclinical | Private | Heart Failure | |
| 2029-04-01 | 3.0y away | Ph3 Readout | TWS-2496 | Phase 2/3 | Mid | Meso | |
| 2029-04-01 | 3.0y away | Interim | VEE-7651 | Preclinical | Large | MDD | |
| 2029-04-02 | 3.0y away | Ph3 Readout | Rilutinib | Phase 3 | Small | Heart Failure | |
| 2029-04-04 | 3.1y away | Ph2 Data | GUS-IIT-540 | Phase 1/2 | Private | Dravet | |
| 2029-04-05 | 3.1y away | Ph3 Readout | 051-5335 | Phase 3 | Mid | FTD | |
| 2029-04-06 | 3.1y away | Ph2 Data | Pexatuximab | Phase 2 | Micro | MG | |
| 2029-04-08 | 3.1y away | Ph2 Data | Sotoratamab | Phase 2 | Large | MCL | |
| 2029-04-08 | 3.1y away | Ph2 Data | Voxacapivasertib | Phase 1/2 | Small | MS | |
| 2029-04-09 | 3.1y away | Ph2 Data | Tiracapivasertib | Phase 2 | Small | SMA | |
| 2029-04-09 | 3.1y away | Ph3 Readout | ARE-3396 | Phase 3 | Private | PsA | |
| 2029-04-10 | 3.1y away | Ph3 Readout | SNY-2934 | Phase 3 | Large | ADHD | |
| 2029-04-10 | 3.1y away | Ph3 Readout | ASN-7038 | Phase 3 | Mid | Bladder Ca | |
| 2029-04-10 | 3.1y away | Ph3 Readout | Rilufutibatinib | NDA/BLA | Private | CRC | |
| 2029-04-10 | 3.1y away | Ph3 Readout | Tirasertib | Phase 2/3 | Large | RCC | |
| 2029-04-11 | 3.1y away | Interim | Fixanesiran | Preclinical | Large | Endometrial Ca | |
| 2029-04-11 | 3.1y away | Ph3 Readout | Zanurapivir | NDA/BLA | Small | PBC | |
| 2029-04-11 | 3.1y away | Interim | CHA-IIT-211 | Phase 1 | Private | Bladder Ca | |
| 2029-04-12 | 3.1y away | Ph3 Readout | Cevifutibatinib | Phase 3 | Micro | Atopic Derm | |
| 2029-04-12 | 3.1y away | Ph3 Readout | Sovasacituzumab | Phase 2/3 | Micro | Celiac | |
| 2029-04-12 | 3.1y away | Ph3 Readout | IPC-884 | Approved | Mid | NMOSD | |
| 2029-04-12 | 3.1y away | Ph3 Readout | Talatenlimab | Approved | Small | SCD | |
| 2029-04-13 | 3.1y away | Ph3 Readout | LLY-8369 | Approved | Large | DLBCL | |
| 2029-04-13 | 3.1y away | Interim | SAN-4302 | Phase 1 | Small | Alzheimer's | |
| 2029-04-13 | 3.1y away | Interim | YB-3858 | Preclinical | Private | MM | |
| 2029-04-14 | 3.1y away | Interim | Datotapinarof | Phase 1 | Mid | Thymoma | |
| 2029-04-14 | 3.1y away | Interim | Bemavorutinib | Preclinical | Large | CKD | |
| 2029-04-14 | 3.1y away | Ph3 Readout | Sematuximab | Phase 2/3 | Micro | NSCLC | |
| 2029-04-17 | 3.1y away | Ph3 Readout | Lisosotorasib | Phase 3 | Micro | MCL | |
| 2029-04-18 | 3.1y away | Ph3 Readout | INB-9118 | Phase 3 | Small | Parkinson's | |
| 2029-04-19 | 3.1y away | Ph3 Readout | Talarelsin | Phase 3 | Micro | Rett | |
| 2029-04-20 | 3.1y away | Interim | MRN-8225 | Preclinical | Large | MS | |
| 2029-04-21 | 3.1y away | Interim | Ribozanubrutinib | Phase 1 | Large | SMA | |
| 2029-04-21 | 3.1y away | Ph3 Readout | PHL-685 | Approved | Small | Cholangiocarcinoma | |
| 2029-04-22 | 3.1y away | Ph3 Readout | SAM-IIT-139 | Phase 3 | Private | Celiac | |
| 2029-04-23 | 3.1y away | Ph3 Readout | Elrarapivir | NDA/BLA | Large | Rett | |
| 2029-04-23 | 3.1y away | Ph3 Readout | FLA-9061 | NDA/BLA | Private | SCD | |
| 2029-04-23 | 3.1y away | Interim | Gelicapivasertib | Preclinical | Mid | UC | |
| 2029-04-24 | 3.1y away | Ph3 Readout | SRP-9822 | Phase 3 | Large | BCC | |
| 2029-04-25 | 3.1y away | Ph2 Data | IDI-7416 | Phase 2 | Small | Ovarian Ca | |
| 2029-04-26 | 3.1y away | Ph2 Data | Semamavacamten | Phase 1/2 | Mid | Epilepsy | |
| 2029-04-26 | 3.1y away | Ph2 Data | SEP-123 | Phase 1/2 | Small | MDS | |
| 2029-04-26 | 3.1y away | Ph2 Data | Miricilimab | Phase 2 | Large | HCC | |
| 2029-04-26 | 3.1y away | Ph2 Data | MRK-7986 | Phase 1/2 | Large | Ewing Sarcoma | |
| 2029-04-26 | 3.1y away | Ph3 Readout | Fixazasiran | Phase 2/3 | Private | FTD | |
| 2029-04-27 | 3.1y away | Ph3 Readout | ASK-1666 | Approved | Private | Melanoma | |
| 2029-04-28 | 3.1y away | Ph3 Readout | Zorirapivir | NDA/BLA | Private | NB | |
| 2029-05-04 | 3.1y away | Ph3 Readout | ARC-5137 | Approved | Private | SCD | |
| 2029-05-04 | 3.1y away | Ph2 Data | GLO-9650 | Phase 2 | Private | Fabry | |
| 2029-05-05 | 3.1y away | Interim | Semazasiran | Phase 1 | Large | NMOSD | |
| 2029-05-05 | 3.1y away | Ph3 Readout | STA-2404 | NDA/BLA | Private | Huntington's | |
| 2029-05-06 | 3.1y away | Ph3 Readout | Tixazanubrutinib | Approved | Private | PTSD | |
| 2029-05-06 | 3.1y away | Interim | NAT-IIT-319 | Phase 1 | Private | MG | |
| 2029-05-07 | 3.1y away | Ph3 Readout | Ribomavacamten | Phase 3 | Private | Fabry | |
| 2029-05-08 | 3.1y away | Interim | EOR-IIT-912 | Phase 1 | Private | Hemophilia A | |
| 2029-05-08 | 3.1y away | Ph3 Readout | Nirarasimod | Phase 2/3 | Private | NMOSD | |
| 2029-05-09 | 3.1y away | Ph3 Readout | BLU-5648 | Approved | Small | PTSD | |
| 2029-05-09 | 3.1y away | Ph2 Data | RIK-IIT-251 | Phase 1/2 | Private | HS | |
| 2029-05-10 | 3.2y away | Ph3 Readout | Sotovorutinib | Approved | Large | MDS | |
| 2029-05-10 | 3.2y away | Ph3 Readout | Lisocagene | Phase 2/3 | Private | PV | |
| 2029-05-10 | 3.2y away | Ph3 Readout | Datocapivasertib | NDA/BLA | Private | Fabry | |
| 2029-05-10 | 3.2y away | Ph3 Readout | 002-6973 | Approved | Mid | RCC | |
| 2029-05-11 | 3.2y away | Ph3 Readout | Lirabrutinib | Phase 2/3 | Private | Breast Ca | |
| 2029-05-12 | 3.2y away | Ph3 Readout | Zorinaritide | NDA/BLA | Private | Wet AMD | |
| 2029-05-12 | 3.2y away | Interim | Ribozanubrutinib | Phase 1 | Small | RB | |
| 2029-05-13 | 3.2y away | Ph3 Readout | Zoriinavolisib | Phase 2/3 | Private | Myelofibrosis | |
| 2029-05-14 | 3.2y away | Ph2 Data | CUR-8000 | Phase 2 | Private | Ewing Sarcoma | |
| 2029-05-14 | 3.2y away | Interim | GRF-2905 | Phase 1 | Mid | EoE | |
| 2029-05-15 | 3.2y away | Ph2 Data | BGN-3305 | Phase 2 | Large | Parkinson's | |
| 2029-05-15 | 3.2y away | Ph3 Readout | MAY-IIT-516 | Phase 3 | Private | ALS | |
| 2029-05-16 | 3.2y away | Ph2 Data | Riluratamab | Phase 2 | Mid | CKD | |
| 2029-05-16 | 3.2y away | Ph3 Readout | 219-3907 | Approved | Micro | PV | |
| 2029-05-18 | 3.2y away | Ph3 Readout | Zoriosocimab | Approved | Mid | CKD | |
| 2029-05-18 | 3.2y away | Ph3 Readout | Zoriderotide | Phase 3 | Mid | T2D | |
| 2029-05-19 | 3.2y away | Ph3 Readout | Tezecilimab | Approved | Private | NB | |
| 2029-05-19 | 3.2y away | Ph3 Readout | AII-IIT-890 | Approved | Private | Prostate Ca | |
| 2029-05-20 | 3.2y away | Ph3 Readout | MRK-8368 | Phase 3 | Large | SCLC | |
| 2029-05-20 | 3.2y away | Interim | Pemitinib | Preclinical | Mid | Endometrial Ca | |
| 2029-05-23 | 3.2y away | Ph3 Readout | Adagrazumab | Phase 2/3 | Large | Heart Failure | |
| 2029-05-24 | 3.2y away | Ph3 Readout | Talafotisoran | Phase 2/3 | Mid | GA | |
| 2029-05-24 | 3.2y away | Ph3 Readout | Terafutibatinib | Phase 3 | Private | UC | |
| 2029-05-26 | 3.2y away | Ph3 Readout | Talatinib | Approved | Private | MCC | |
| 2029-05-27 | 3.2y away | Interim | BTA-1886 | Phase 1 | Micro | Thymoma | |
| 2029-06-02 | 3.2y away | Ph2 Data | PFE-5767 | Phase 1/2 | Large | MCL | |
| 2029-06-02 | 3.2y away | Ph3 Readout | CAD-8013 | Phase 3 | Micro | Ovarian Ca | |
| 2029-06-03 | 3.2y away | Ph3 Readout | 415-4068 | NDA/BLA | Large | NB | |
| 2029-06-03 | 3.2y away | Interim | SLN-2895 | Preclinical | Small | CSU | |
| 2029-06-04 | 3.2y away | Ph3 Readout | Pemitapinarof | Approved | Large | FTD | |
| 2029-06-04 | 3.2y away | Interim | Datoglumide | Phase 1 | Micro | GIST | |
| 2029-06-04 | 3.2y away | Ph3 Readout | DEC-4099 | Phase 3 | Private | RSV | |
| 2029-06-05 | 3.2y away | Ph3 Readout | Rimacilimab | Phase 3 | Private | Ovarian Ca | |
| 2029-06-05 | 3.2y away | Ph3 Readout | ACH-2340 | Phase 3 | Private | Meso | |
| 2029-06-06 | 3.2y away | Ph2 Data | Riboglumide | Phase 2 | Micro | Epilepsy | |
| 2029-06-08 | 3.2y away | Ph3 Readout | Tixasotorasib | Approved | Private | Wet AMD | |
| 2029-06-08 | 3.2y away | Ph3 Readout | NCN-3378 | NDA/BLA | Micro | RSV | |
| 2029-06-09 | 3.2y away | Ph3 Readout | Datoinavolisib | NDA/BLA | Large | PSP | |
| 2029-06-10 | 3.2y away | Ph2 Data | ESC-2972 | Phase 2 | Private | Wilms | |
| 2029-06-11 | 3.2y away | Ph3 Readout | TAB-3211 | Phase 3 | Private | PAH | |
| 2029-06-12 | 3.2y away | Interim | Pexanesiran | Phase 1 | Large | NB | |
| 2029-06-14 | 3.2y away | Ph3 Readout | RIC-2161 | Phase 2/3 | Mid | T2D | |
| 2029-06-15 | 3.2y away | Ph3 Readout | Voxaderotide | Approved | Mid | PsA | |
| 2029-06-15 | 3.2y away | Ph2 Data | Zanumavacamten | Phase 2 | Mid | MS | |
| 2029-06-15 | 3.2y away | Interim | Rimabrutinib | Phase 1 | Private | PV | |
| 2029-06-17 | 3.3y away | Interim | Tiranaritide | Preclinical | Small | Psoriasis | |
| 2029-06-18 | 3.3y away | Ph3 Readout | G1-8409 | Phase 3 | Private | RCC | |
| 2029-06-18 | 3.3y away | Ph3 Readout | Lisonesiran | NDA/BLA | Private | DLBCL | |
| 2029-06-18 | 3.3y away | Ph2 Data | Tixatinib | Phase 2 | Private | Parkinson's | |
| 2029-06-18 | 3.3y away | Ph3 Readout | INS-IIT-513 | Phase 3 | Private | FSGS | |
| 2029-06-20 | 3.3y away | Ph3 Readout | Tirasotorasib | NDA/BLA | Large | CML | |
| 2029-06-20 | 3.3y away | Interim | Nidaglumide | Preclinical | Mid | MG | |
| 2029-06-20 | 3.3y away | Ph3 Readout | Lisozanubrutinib | Approved | Micro | FSGS | |
| 2029-06-20 | 3.3y away | Ph2 Data | JAM-4301 | Phase 1/2 | Private | Narcolepsy | |
| 2029-06-21 | 3.3y away | Interim | BMY-4586 | Preclinical | Large | SCD | |
| 2029-06-21 | 3.3y away | Ph3 Readout | 452-670 | Approved | Large | Cervical Ca | |
| 2029-06-21 | 3.3y away | Ph2 Data | IMM-5834 | Phase 2 | Private | ALS | |
| 2029-06-21 | 3.3y away | Ph2 Data | Kemazanubrutinib | Phase 1/2 | Small | RB | |
| 2029-06-21 | 3.3y away | Ph3 Readout | RLF-2389 | Approved | Micro | Atopic Derm | |
| 2029-06-23 | 3.3y away | Ph3 Readout | POL-2127 | Approved | Private | RCC | |
| 2029-06-23 | 3.3y away | Ph3 Readout | ADA-4330 | Approved | Private | LGS | |
| 2029-06-24 | 3.3y away | Ph3 Readout | JAN-1547 | Approved | Mid | MDS | |
| 2029-06-25 | 3.3y away | Ph3 Readout | Zanumavacamten | Phase 2/3 | Large | MDS | |
| 2029-06-25 | 3.3y away | Ph3 Readout | Sematenlimab | Phase 3 | Large | Heart Failure | |
| 2029-06-25 | 3.3y away | Interim | Polasertib | Phase 1 | Large | LN | |
| 2029-06-26 | 3.3y away | Ph3 Readout | Mirivorutinib | Phase 3 | Private | Alzheimer's | |
| 2029-06-26 | 3.3y away | Ph3 Readout | OBS-1681 | Phase 3 | Private | MDS | |
| 2029-06-27 | 3.3y away | Ph3 Readout | HOS-IIT-835 | Phase 3 | Private | MS | |
| 2029-06-28 | 3.3y away | Ph2 Data | BVN-7642 | Phase 2 | Mid | MCL | |
| 2029-06-28 | 3.3y away | Interim | Talaosocimab | Phase 1 | Private | FSGS | |
| 2029-07-01 | 3.3y away | Ph3 Readout | SCR-7300 | NDA/BLA | Private | CLL | |
| 2029-07-01 | 3.3y away | Ph2 Data | SEN-1840 | Phase 2 | Private | Rett | |
| 2029-07-02 | 3.3y away | Ph3 Readout | Geliderotide | NDA/BLA | Large | CML | |
| 2029-07-02 | 3.3y away | Ph3 Readout | Sovainavolisib | NDA/BLA | Mid | UC | |
| 2029-07-02 | 3.3y away | Ph3 Readout | LPC-7933 | Phase 3 | Mid | CSU | |
| 2029-07-03 | 3.3y away | Interim | Pexasotorasib | Phase 1 | Micro | Wilms | |
| 2029-07-03 | 3.3y away | Ph3 Readout | CAR-3300 | Approved | Private | Bladder Ca | |
| 2029-07-04 | 3.3y away | Ph3 Readout | ROY-IIT-791 | Phase 2/3 | Private | PTSD | |
| 2029-07-05 | 3.3y away | Ph2 Data | GLY-2161 | Phase 1/2 | Micro | TTR Amyloidosis | |
| 2029-07-05 | 3.3y away | Interim | EXA-3015 | Phase 1 | Large | Endometrial Ca | |
| 2029-07-06 | 3.3y away | Ph3 Readout | RLA-6817 | Phase 3 | Mid | BCC | |
| 2029-07-06 | 3.3y away | Ph3 Readout | CON-372 | Approved | Private | Thymoma | |
| 2029-07-07 | 3.3y away | Ph3 Readout | Tirazanubrutinib | NDA/BLA | Private | NB | |
| 2029-07-08 | 3.3y away | Ph3 Readout | SNG-5665 | Phase 2/3 | Micro | RB | |
| 2029-07-08 | 3.3y away | Ph3 Readout | PCI-4776 | Phase 3 | Micro | HNSCC | |
| 2029-07-09 | 3.3y away | Ph2 Data | Polazasiran | Phase 2 | Large | MM | |
| 2029-07-10 | 3.3y away | Interim | Pexazasiran | Preclinical | Large | AS | |
| 2029-07-11 | 3.3y away | Ph3 Readout | DSN-3066 | Phase 3 | Large | PsA | |
| 2029-07-11 | 3.3y away | Ph3 Readout | FRO-509 | Approved | Private | GIST | |
| 2029-07-12 | 3.3y away | Ph2 Data | Mirituximab | Phase 2 | Private | ALS | |
| 2029-07-13 | 3.3y away | Ph3 Readout | Cevinaritide | Phase 3 | Mid | DLBCL | |
| 2029-07-13 | 3.3y away | Ph3 Readout | CRB-6490 | Approved | Micro | Myelofibrosis | |
| 2029-07-13 | 3.3y away | Ph3 Readout | Elrabrutinib | Phase 3 | Micro | Endometrial Ca | |
| 2029-07-13 | 3.3y away | Ph3 Readout | BRK-7538 | Phase 2/3 | Large | Cholangiocarcinoma | |
| 2029-07-14 | 3.3y away | Ph3 Readout | Lirazasiran | Phase 3 | Private | Hemophilia A | |
| 2029-07-15 | 3.3y away | Ph3 Readout | Motaderotide | Phase 2/3 | Private | Pancreatic Ca | |
| 2029-07-15 | 3.3y away | Interim | Tirazanubrutinib | Preclinical | Small | SCLC | |
| 2029-07-17 | 3.3y away | Ph3 Readout | RAP-2478 | Phase 3 | Small | PBC | |
| 2029-07-17 | 3.3y away | Ph3 Readout | ZYN-1124 | NDA/BLA | Micro | HNSCC | |
| 2029-07-17 | 3.3y away | Interim | Semafotisoran | Phase 1 | Private | Migraine | |
| 2029-07-17 | 3.3y away | Ph2 Data | LAB-8428 | Phase 2 | Mid | HNSCC | |
| 2029-07-18 | 3.3y away | Ph3 Readout | Tirainavolisib | Approved | Large | PBC | |
| 2029-07-18 | 3.3y away | Ph2 Data | Pexazanubrutinib | Phase 1/2 | Small | Pancreatic Ca | |
| 2029-07-19 | 3.3y away | Ph3 Readout | IMV-3202 | Approved | Mid | Parkinson's | |
| 2029-07-20 | 3.3y away | Ph3 Readout | STA-IIT-542 | Phase 2/3 | Private | IgAN | |
| 2029-07-20 | 3.3y away | Ph3 Readout | NBY-4130 | Phase 3 | Micro | OCD | |
| 2029-07-22 | 3.4y away | Ph2 Data | Sovacagene | Phase 1/2 | Mid | SMA | |
| 2029-07-22 | 3.4y away | Ph2 Data | Lisonesiran | Phase 1/2 | Mid | TTR Amyloidosis | |
| 2029-07-22 | 3.4y away | Ph3 Readout | TNG-8610 | NDA/BLA | Small | RB | |
| 2029-07-22 | 3.4y away | Ph3 Readout | EOR-IIT-541 | Phase 2/3 | Private | RSV | |
| 2029-07-23 | 3.4y away | Ph2 Data | PFE-5767 | Phase 1/2 | Large | MCL | |
| 2029-07-23 | 3.4y away | Ph2 Data | Polasacituzumab | Phase 1/2 | Micro | IPF | |
| 2029-07-23 | 3.4y away | Ph3 Readout | Bemaosocimab | Phase 3 | Private | Rett | |
| 2029-07-24 | 3.4y away | Ph2 Data | Adagrarapivir | Phase 1/2 | Mid | CML | |
| 2029-07-24 | 3.4y away | Ph2 Data | NER-1837 | Phase 1/2 | Micro | Prostate Ca | |
| 2029-07-24 | 3.4y away | Ph3 Readout | Gelicilimab | Phase 3 | Mid | UC | |
| 2029-07-24 | 3.4y away | Ph2 Data | BOE-3317 | Phase 1/2 | Private | Myelofibrosis | |
| 2029-07-25 | 3.4y away | Ph2 Data | ZYM-7428 | Phase 1/2 | Mid | RCC | |
| 2029-07-27 | 3.4y away | Interim | PEK-IIT-150 | Phase 1 | Private | CML | |
| 2029-07-27 | 3.4y away | Interim | Mavuinavolisib | Phase 1 | Mid | CKD | |
| 2029-07-27 | 3.4y away | Ph3 Readout | 002-6973 | Approved | Mid | RCC | |
| 2029-07-28 | 3.4y away | Interim | Adagratapinarof | Preclinical | Large | HS | |
| 2029-08-01 | 3.4y away | Interim | Darasotorasib | Preclinical | Small | ALS | |
| 2029-08-02 | 3.4y away | Ph3 Readout | Pexamavacamten | NDA/BLA | Large | Heart Failure | |
| 2029-08-03 | 3.4y away | Ph3 Readout | HOR-3482 | Phase 3 | Private | SMA | |
| 2029-08-03 | 3.4y away | Ph2 Data | Rimasacituzumab | Phase 2 | Mid | MCL | |
| 2029-08-04 | 3.4y away | Ph2 Data | Doxazumab | Phase 1/2 | Micro | MS | |
| 2029-08-06 | 3.4y away | Ph3 Readout | 302-9165 | Approved | Mid | T2D | |
| 2029-08-08 | 3.4y away | Ph2 Data | 699-6202 | Phase 1/2 | Small | T2D | |
| 2029-08-08 | 3.4y away | Ph2 Data | 002-8467 | Phase 1/2 | Mid | Ewing Sarcoma | |
| 2029-08-09 | 3.4y away | Ph3 Readout | LOG-8406 | Phase 3 | Private | CF | |
| 2029-08-09 | 3.4y away | Ph3 Readout | 415-3897 | Phase 3 | Large | Fabry | |
| 2029-08-09 | 3.4y away | Interim | Capimavacamten | Phase 1 | Mid | CRC | |
| 2029-08-10 | 3.4y away | Interim | CAM-IIT-713 | Phase 1 | Private | Wilms | |
| 2029-08-10 | 3.4y away | Ph3 Readout | MED-9563 | Approved | Private | Prostate Ca | |
| 2029-08-11 | 3.4y away | Interim | 452-3353 | Preclinical | Large | ACC | |
| 2029-08-11 | 3.4y away | Ph2 Data | MRK-3890 | Phase 2 | Large | GBM | |
| 2029-08-13 | 3.4y away | Ph3 Readout | CAM-IIT-380 | NDA/BLA | Private | Gastric Ca | |
| 2029-08-13 | 3.4y away | Interim | Mavuinavolisib | Preclinical | Micro | CSU | |
| 2029-08-13 | 3.4y away | Interim | SWT-3857 | Phase 1 | Mid | FL | |
| 2029-08-13 | 3.4y away | Ph2 Data | Ribozumab | Phase 1/2 | Private | MCL | |
| 2029-08-14 | 3.4y away | Ph3 Readout | ATA-3814 | NDA/BLA | Small | HS | |
| 2029-08-15 | 3.4y away | Ph3 Readout | Talarelsin | NDA/BLA | Micro | Pancreatic Ca | |
| 2029-08-15 | 3.4y away | Interim | Kemamavacamten | Preclinical | Private | BCC | |
| 2029-08-15 | 3.4y away | Ph3 Readout | Tiralucimab | NDA/BLA | Private | MDS | |
| 2029-08-16 | 3.4y away | Interim | Daracilimab | Preclinical | Micro | Endometrial Ca | |
| 2029-08-18 | 3.4y away | Ph3 Readout | BSG-8809 | Approved | Micro | PTSD | |
| 2029-08-18 | 3.4y away | Ph3 Readout | Cevirapivir | Approved | Small | HCC | |
| 2029-08-19 | 3.4y away | Ph3 Readout | AGI-4446 | Phase 3 | Mid | LGS | |
| 2029-08-20 | 3.4y away | Interim | RIN-657 | Phase 1 | Private | CML | |
| 2029-08-21 | 3.4y away | Ph3 Readout | Olpalemzoparlimab | Approved | Micro | SLE | |
| 2029-08-22 | 3.4y away | Ph3 Readout | TRV-9337 | Approved | Micro | AML | |
| 2029-08-24 | 3.4y away | Interim | Rimatinib | Phase 1 | Small | CTCL | |
| 2029-08-24 | 3.4y away | Ph3 Readout | MSK-IIT-725 | Phase 2/3 | Private | Asthma | |
| 2029-08-25 | 3.4y away | Ph3 Readout | RIN-582 | Phase 3 | Private | IgAN | |
| 2029-08-27 | 3.4y away | Ph3 Readout | NVS-5126 | Phase 3 | Large | Celiac | |
| 2029-08-27 | 3.4y away | Ph3 Readout | VBI-124 | Phase 2/3 | Micro | Melanoma | |
| 2029-08-28 | 3.5y away | Interim | Sovafotisoran | Phase 1 | Mid | CF | |
| 2029-09-02 | 3.5y away | Ph3 Readout | AKR-4818 | Approved | Mid | GBM | |
| 2029-09-02 | 3.5y away | Ph3 Readout | Nirasertib | Phase 2/3 | Private | MCC | |
| 2029-09-02 | 3.5y away | Interim | Voxazanubrutinib | Preclinical | Private | SCLC | |
| 2029-09-02 | 3.5y away | Ph2 Data | Teratenlimab | Phase 2 | Private | Urothelial Ca | |
| 2029-09-03 | 3.5y away | Ph2 Data | Voxafutibatinib | Phase 1/2 | Mid | CRC | |
| 2029-09-03 | 3.5y away | Ph2 Data | Elrabrutinib | Phase 2 | Private | CTCL | |
| 2029-09-03 | 3.5y away | Ph3 Readout | ASA-IIT-599 | Phase 2/3 | Private | Angelman | |
| 2029-09-04 | 3.5y away | Interim | CAR-9528 | Preclinical | Private | Pompe | |
| 2029-09-05 | 3.5y away | Ph3 Readout | RCU-2903 | NDA/BLA | Mid | RA | |
| 2029-09-05 | 3.5y away | Ph2 Data | IST-1570 | Phase 1/2 | Private | SCLC | |
| 2029-09-07 | 3.5y away | Ph2 Data | Miritapinarof | Phase 2 | Small | Pancreatic Ca | |
| 2029-09-07 | 3.5y away | Ph2 Data | CAL-3191 | Phase 1/2 | Micro | UC | |
| 2029-09-08 | 3.5y away | Ph3 Readout | Ivoratamab | Phase 2/3 | Small | ADPKD | |
| 2029-09-09 | 3.5y away | Interim | DSN-6862 | Preclinical | Large | NASH | |
| 2029-09-09 | 3.5y away | Ph3 Readout | AKR-4818 | Approved | Mid | Urothelial Ca | |
| 2029-09-10 | 3.5y away | Ph2 Data | CUV-6674 | Phase 1/2 | Small | MCL | |
| 2029-09-10 | 3.5y away | Ph3 Readout | PCL-8414 | Phase 2/3 | Micro | RCC | |
| 2029-09-10 | 3.5y away | Ph3 Readout | Tirasotorasib | Approved | Micro | MCL | |
| 2029-09-10 | 3.5y away | Ph2 Data | SRR-6281 | Phase 1/2 | Small | ALL | |
| 2029-09-11 | 3.5y away | Interim | 452-2449 | Preclinical | Large | SLE | |
| 2029-09-11 | 3.5y away | Ph3 Readout | NAT-IIT-452 | Phase 3 | Private | GBM | |
| 2029-09-12 | 3.5y away | Interim | NVS-8902 | Preclinical | Large | Melanoma | |
| 2029-09-12 | 3.5y away | Ph3 Readout | Zorinesiran | Phase 2/3 | Small | CLL | |
| 2029-09-12 | 3.5y away | Ph3 Readout | Datomavacamten | Approved | Small | Wilms | |
| 2029-09-13 | 3.5y away | Interim | Zorisotorasib | Phase 1 | Large | PAH | |
| 2029-09-13 | 3.5y away | Ph2 Data | AUR-9187 | Phase 2 | Mid | Cholangiocarcinoma | |
| 2029-09-14 | 3.5y away | Ph3 Readout | IMM-2816 | Approved | Private | T2D | |
| 2029-09-14 | 3.5y away | Ph2 Data | Ribotinib | Phase 1/2 | Private | Meso | |
| 2029-09-14 | 3.5y away | Ph3 Readout | RYT-8232 | Phase 2/3 | Mid | Wilms | |
| 2029-09-14 | 3.5y away | Ph2 Data | Gozefutibatinib | Phase 1/2 | Small | T2D | |
| 2029-09-16 | 3.5y away | Ph2 Data | IMV-6044 | Phase 1/2 | Private | DLBCL | |
| 2029-09-16 | 3.5y away | Ph3 Readout | Rimazasiran | Approved | Micro | T2D | |
| 2029-09-16 | 3.5y away | Ph3 Readout | Mavulucimab | NDA/BLA | Private | Hemophilia A | |
| 2029-09-16 | 3.5y away | Ph2 Data | Fixatuximab | Phase 1/2 | Mid | AML | |
| 2029-09-17 | 3.5y away | Interim | Nidazumab | Phase 1 | Private | PsA | |
| 2029-09-17 | 3.5y away | Ph3 Readout | Kemafutibatinib | Phase 3 | Private | DLBCL | |
| 2029-09-17 | 3.5y away | Ph2 Data | Datotuximab | Phase 1/2 | Private | SCLC | |
| 2029-09-18 | 3.5y away | Interim | Suraosocimab | Phase 1 | Private | FSGS | |
| 2029-09-18 | 3.5y away | Ph3 Readout | PLR-762 | Approved | Small | PV | |
| 2029-09-19 | 3.5y away | Ph2 Data | FRE-IIT-854 | Phase 1/2 | Private | Ewing Sarcoma | |
| 2029-09-21 | 3.5y away | Ph3 Readout | Ribozanubrutinib | Phase 2/3 | Micro | HCC | |
| 2029-09-22 | 3.5y away | Interim | Mavuinavolisib | Preclinical | Micro | CSU | |
| 2029-09-22 | 3.5y away | Ph3 Readout | ONC-9294 | Approved | Micro | T2D | |
| 2029-09-22 | 3.5y away | Ph3 Readout | Kemamavacamten | Phase 3 | Large | NSCLC | |
| 2029-09-23 | 3.5y away | Ph2 Data | MRN-8133 | Phase 2 | Large | Fabry | |
| 2029-09-24 | 3.5y away | Ph3 Readout | TOR-3576 | NDA/BLA | Mid | Ovarian Ca | |
| 2029-09-25 | 3.5y away | Ph3 Readout | 225-7610 | NDA/BLA | Micro | Dravet | |
| 2029-09-26 | 3.5y away | Ph3 Readout | Zorivorutinib | Approved | Large | Prostate Ca | |
| 2029-09-26 | 3.5y away | Interim | LPC-4508 | Phase 1 | Mid | Thymoma | |
| 2029-09-27 | 3.5y away | Interim | ISO-9327 | Phase 1 | Private | MS | |
| 2029-09-27 | 3.5y away | Ph3 Readout | Nidatenlimab | Approved | Small | BCC | |
| 2029-09-27 | 3.5y away | Ph3 Readout | TUR-4928 | Phase 2/3 | Private | HNSCC | |
| 2029-09-27 | 3.5y away | Ph3 Readout | Daranesiran | Approved | Small | IPF | |
| 2029-09-28 | 3.5y away | Ph3 Readout | Pexaderotide | Phase 3 | Private | Cholangiocarcinoma | |
| 2029-09-28 | 3.5y away | Ph3 Readout | TER-1034 | Phase 3 | Private | Melanoma | |
| 2029-09-28 | 3.5y away | Ph3 Readout | Capibrutinib | NDA/BLA | Large | Celiac | |
| 2029-09-28 | 3.5y away | Ph3 Readout | MOL-8666 | Approved | Micro | RB | |
| 2029-09-28 | 3.5y away | Ph2 Data | DER-8696 | Phase 1/2 | Private | NSCLC | |
| 2029-10-01 | 3.5y away | Interim | BAY-8733 | Preclinical | Large | PTSD | |
| 2029-10-02 | 3.5y away | Interim | Darasertib | Phase 1 | Private | Migraine | |
| 2029-10-02 | 3.5y away | Ph3 Readout | Semasertib | Phase 2/3 | Private | MG | |
| 2029-10-03 | 3.6y away | Ph3 Readout | Riluzasiran | Phase 2/3 | Mid | Epilepsy | |
| 2029-10-04 | 3.6y away | Interim | Ribotinib | Phase 1 | Micro | Fabry | |
| 2029-10-04 | 3.6y away | Interim | Mavurapivir | Phase 1 | Private | FTD | |
| 2029-10-04 | 3.6y away | Ph2 Data | GLO-9650 | Phase 2 | Private | RCC | |
| 2029-10-04 | 3.6y away | Ph3 Readout | Rilusertib | Phase 3 | Micro | Crohn's | |
| 2029-10-05 | 3.6y away | Ph3 Readout | Doxarapivir | Phase 3 | Large | FTD | |
| 2029-10-05 | 3.6y away | Ph3 Readout | INO-2656 | Approved | Small | SCD | |
| 2029-10-05 | 3.6y away | Ph3 Readout | Daranaritide | Phase 2/3 | Large | Wet AMD | |
| 2029-10-06 | 3.6y away | Ph3 Readout | Fixacagene | Approved | Small | MM | |
| 2029-10-07 | 3.6y away | Ph2 Data | ABB-8985 | Phase 2 | Large | PAH | |
| 2029-10-07 | 3.6y away | Ph3 Readout | Liratinib | NDA/BLA | Mid | Meso | |
| 2029-10-07 | 3.6y away | Interim | ABB-879 | Phase 1 | Private | ALS | |
| 2029-10-07 | 3.6y away | Interim | Darasertib | Phase 1 | Private | MDD | |
| 2029-10-08 | 3.6y away | Interim | DSN-5254 | Phase 1 | Large | Hemophilia A | |
| 2029-10-10 | 3.6y away | Ph2 Data | VND-7068 | Phase 2 | Small | PBC | |
| 2029-10-10 | 3.6y away | Interim | Niraglumide | Preclinical | Mid | CML | |
| 2029-10-11 | 3.6y away | Ph3 Readout | Fixaosocimab | Phase 2/3 | Mid | CRC | |
| 2029-10-11 | 3.6y away | Ph2 Data | 451-4283 | Phase 2 | Mid | HCC | |
| 2029-10-12 | 3.6y away | Ph3 Readout | Rimanaritide | Phase 3 | Private | Meso | |
| 2029-10-13 | 3.6y away | Ph3 Readout | NUV-283 | Phase 3 | Mid | Parkinson's | |
| 2029-10-13 | 3.6y away | Ph3 Readout | ENC-8622 | Phase 3 | Private | Celiac | |
| 2029-10-13 | 3.6y away | Ph3 Readout | ABB-7827 | NDA/BLA | Private | MDS | |
| 2029-10-14 | 3.6y away | Ph3 Readout | Gozederotide | NDA/BLA | Micro | Narcolepsy | |
| 2029-10-15 | 3.6y away | Ph3 Readout | Zorisotorasib | Approved | Micro | HCC | |
| 2029-10-15 | 3.6y away | Ph2 Data | TES-1600 | Phase 1/2 | Private | CKD | |
| 2029-10-16 | 3.6y away | Ph3 Readout | CHA-IIT-901 | Approved | Private | PAH | |
| 2029-10-16 | 3.6y away | Ph3 Readout | Polacilimab | NDA/BLA | Small | RCC | |
| 2029-10-16 | 3.6y away | Ph3 Readout | Gelirasimod | NDA/BLA | Private | BCC | |
| 2029-10-17 | 3.6y away | Ph3 Readout | BEL-9345 | NDA/BLA | Private | NSCLC | |
| 2029-10-18 | 3.6y away | Ph3 Readout | Doxaderotide | Phase 3 | Private | Thymoma | |
| 2029-10-18 | 3.6y away | Ph3 Readout | Doxazasiran | Phase 2/3 | Private | PSP | |
| 2029-10-18 | 3.6y away | Ph3 Readout | LAB-7111 | NDA/BLA | Private | NB | |
| 2029-10-19 | 3.6y away | Ph3 Readout | GMA-5010 | Phase 3 | Large | SCLC | |
| 2029-10-19 | 3.6y away | Ph3 Readout | SRP-9822 | Phase 3 | Large | BCC | |
| 2029-10-19 | 3.6y away | Interim | AMB-4811 | Preclinical | Private | Prostate Ca | |
| 2029-10-19 | 3.6y away | Ph3 Readout | 003-4903 | Phase 3 | Small | MCC | |
| 2029-10-20 | 3.6y away | Ph3 Readout | MDG-611 | Approved | Mid | AS | |
| 2029-10-20 | 3.6y away | Ph3 Readout | Zoriosocimab | Approved | Mid | SMA | |
| 2029-10-21 | 3.6y away | Ph3 Readout | NVS-5126 | Phase 3 | Large | RA | |
| 2029-10-21 | 3.6y away | Interim | PCL-2819 | Preclinical | Micro | Prostate Ca | |
| 2029-10-21 | 3.6y away | Ph2 Data | JAM-4301 | Phase 1/2 | Private | Narcolepsy | |
| 2029-10-22 | 3.6y away | Ph3 Readout | SAG-8067 | NDA/BLA | Small | Thymoma | |
| 2029-10-22 | 3.6y away | Interim | EME-9677 | Phase 1 | Private | WM | |
| 2029-10-22 | 3.6y away | Interim | Capitinib | Phase 1 | Mid | CKD | |
| 2029-10-24 | 3.6y away | Ph3 Readout | IPN-129 | Approved | Large | Angelman | |
| 2029-10-26 | 3.6y away | Ph3 Readout | Lirainavolisib | Approved | Micro | CML | |
| 2029-10-27 | 3.6y away | Ph2 Data | APN-1617 | Phase 2 | Mid | PSP | |
| 2029-10-28 | 3.6y away | Ph2 Data | Riboinavolisib | Phase 1/2 | Private | DMD | |
| 2029-11-02 | 3.6y away | Ph3 Readout | CON-372 | Approved | Private | Narcolepsy | |
| 2029-11-02 | 3.6y away | Ph3 Readout | FRO-509 | Approved | Private | CKD | |
| 2029-11-03 | 3.6y away | Ph3 Readout | NBY-4130 | Phase 3 | Micro | OCD | |
| 2029-11-04 | 3.6y away | Interim | COR-4726 | Preclinical | Private | Thymoma | |
| 2029-11-04 | 3.6y away | Interim | Polatapinarof | Phase 1 | Micro | Schizophrenia | |
| 2029-11-05 | 3.6y away | Interim | GNL-2086 | Preclinical | Micro | Thymoma | |
| 2029-11-05 | 3.6y away | Interim | Polatinib | Preclinical | Micro | MG | |
| 2029-11-05 | 3.6y away | Ph3 Readout | Nirasacituzumab | Phase 2/3 | Private | Narcolepsy | |
| 2029-11-06 | 3.6y away | Interim | Bemasertib | Phase 1 | Private | NSCLC | |
| 2029-11-08 | 3.6y away | Ph2 Data | LLY-3251 | Phase 2 | Large | SCD | |
| 2029-11-08 | 3.6y away | Ph2 Data | Fixatinib | Phase 1/2 | Micro | Migraine | |
| 2029-11-09 | 3.7y away | Ph3 Readout | ABB-1817 | Phase 3 | Large | Dravet | |
| 2029-11-09 | 3.7y away | Ph3 Readout | AZN-5171 | Approved | Large | PV | |
| 2029-11-09 | 3.7y away | Ph2 Data | RNA-5263 | Phase 1/2 | Mid | AS | |
| 2029-11-10 | 3.7y away | Ph3 Readout | SWO-IIT-590 | Phase 2/3 | Private | ACC | |
| 2029-11-10 | 3.7y away | Ph2 Data | INT-9034 | Phase 1/2 | Private | NASH | |
| 2029-11-11 | 3.7y away | Ph2 Data | Pemiratamab | Phase 2 | Mid | Migraine | |
| 2029-11-13 | 3.7y away | Ph3 Readout | 219-3907 | Approved | Micro | PV | |
| 2029-11-13 | 3.7y away | Interim | Rilutapinarof | Phase 1 | Private | Obesity | |
| 2029-11-13 | 3.7y away | Ph2 Data | Tezerelsin | Phase 1/2 | Small | Crohn's | |
| 2029-11-14 | 3.7y away | Ph3 Readout | DSN-3066 | Phase 3 | Large | PTSD | |
| 2029-11-14 | 3.7y away | Interim | Cevirasimod | Preclinical | Mid | Thymoma | |
| 2029-11-15 | 3.7y away | Ph3 Readout | KIN-IIT-791 | Approved | Private | Breast Ca | |
| 2029-11-16 | 3.7y away | Ph3 Readout | EXA-4696 | Phase 2/3 | Small | ADHD | |
| 2029-11-16 | 3.7y away | Ph3 Readout | Tixatapinarof | Approved | Small | NMOSD | |
| 2029-11-18 | 3.7y away | Ph2 Data | Talazumab | Phase 1/2 | Mid | AS | |
| 2029-11-18 | 3.7y away | Interim | BIO-IIT-877 | Preclinical | Private | SCLC | |
| 2029-11-19 | 3.7y away | Interim | EME-9677 | Phase 1 | Private | WM | |
| 2029-11-19 | 3.7y away | Ph3 Readout | LAB-3189 | Phase 3 | Private | CTCL | |
| 2029-11-20 | 3.7y away | Interim | Elraratamab | Phase 1 | Small | Hemophilia A | |
| 2029-11-21 | 3.7y away | Interim | Zorizanubrutinib | Phase 1 | Large | Pompe | |
| 2029-11-21 | 3.7y away | Ph3 Readout | CAD-8013 | Phase 3 | Micro | Ovarian Ca | |
| 2029-11-21 | 3.7y away | Interim | Zoricapivasertib | Phase 1 | Mid | Urothelial Ca | |
| 2029-11-21 | 3.7y away | Ph2 Data | Ivonaritide | Phase 2 | Micro | Ovarian Ca | |
| 2029-11-23 | 3.7y away | Interim | Cevifutibatinib | Phase 1 | Mid | Pompe | |
| 2029-11-24 | 3.7y away | Interim | Datorapivir | Phase 1 | Large | Melanoma | |
| 2029-11-25 | 3.7y away | Ph3 Readout | UCB-7877 | NDA/BLA | Large | NMOSD | |
| 2029-11-25 | 3.7y away | Ph3 Readout | RAB-IIT-267 | Approved | Private | MCL | |
| 2029-11-26 | 3.7y away | Ph2 Data | REG-2172 | Phase 1/2 | Large | Wilms | |
| 2029-11-27 | 3.7y away | Interim | Tixazanubrutinib | Phase 1 | Private | NASH | |
| 2029-11-28 | 3.7y away | Ph3 Readout | NAT-IIT-338 | Approved | Private | CRC | |
| 2029-12-02 | 3.7y away | Ph3 Readout | ECO-IIT-552 | Phase 2/3 | Private | PsA | |
| 2029-12-02 | 3.7y away | Ph3 Readout | MRK-3812 | Phase 3 | Micro | PSP | |
| 2029-12-03 | 3.7y away | Ph3 Readout | CLE-136 | Phase 3 | Private | ACC | |
| 2029-12-04 | 3.7y away | Ph3 Readout | Elratenlimab | Phase 3 | Private | PAH | |
| 2029-12-05 | 3.7y away | Interim | LUC-2815 | Phase 1 | Micro | Atopic Derm | |
| 2029-12-05 | 3.7y away | Ph3 Readout | Lisozasiran | NDA/BLA | Private | NMOSD | |
| 2029-12-06 | 3.7y away | Ph2 Data | ABC-4950 | Phase 2 | Small | Bladder Ca | |
| 2029-12-06 | 3.7y away | Interim | Gozederotide | Preclinical | Micro | CTCL | |
| 2029-12-07 | 3.7y away | Ph3 Readout | SEA-4335 | Phase 3 | Private | Pompe | |
| 2029-12-07 | 3.7y away | Interim | ABL-1749 | Phase 1 | Private | ALL | |
| 2029-12-07 | 3.7y away | Ph3 Readout | Zanufotisoran | Approved | Private | CKD | |
| 2029-12-08 | 3.7y away | Ph3 Readout | BCA-2794 | Approved | Micro | PV | |
| 2029-12-08 | 3.7y away | Ph3 Readout | KIN-IIT-556 | Approved | Private | Pompe | |
| 2029-12-09 | 3.7y away | Ph3 Readout | ADP-7169 | Approved | Small | Atopic Derm | |
| 2029-12-09 | 3.7y away | Ph2 Data | IDI-7416 | Phase 2 | Small | Ovarian Ca | |
| 2029-12-10 | 3.7y away | Ph2 Data | Nidarapivir | Phase 1/2 | Small | NMOSD | |
| 2029-12-11 | 3.7y away | Ph2 Data | Sotoglumide | Phase 1/2 | Mid | Angelman | |
| 2029-12-12 | 3.7y away | Ph2 Data | GSK-6516 | Phase 1/2 | Large | Cervical Ca | |
| 2029-12-12 | 3.7y away | Ph3 Readout | Nidanesiran | Approved | Private | RA | |
| 2029-12-12 | 3.7y away | Interim | HYK-8507 | Phase 1 | Private | Cholangiocarcinoma | |
| 2029-12-12 | 3.7y away | Interim | Ceviglumide | Phase 1 | Micro | Gastric Ca | |
| 2029-12-12 | 3.7y away | Ph2 Data | Ribozumab | Phase 1/2 | Private | MCL | |
| 2029-12-13 | 3.7y away | Ph3 Readout | Olpatinib | NDA/BLA | Small | Crohn's | |
| 2029-12-13 | 3.7y away | Ph3 Readout | NDR-1720 | Phase 3 | Micro | Huntington's | |
| 2029-12-14 | 3.7y away | Ph3 Readout | BAY-3684 | Approved | Large | NMOSD | |
| 2029-12-14 | 3.7y away | Ph3 Readout | Adagravorutinib | Phase 3 | Private | IgAN | |
| 2029-12-15 | 3.8y away | Ph3 Readout | Adagralemzoparlimab | Approved | Small | Migraine | |
| 2029-12-16 | 3.8y away | Ph2 Data | INT-9034 | Phase 1/2 | Private | NASH | |
| 2029-12-17 | 3.8y away | Ph3 Readout | Ivolemzoparlimab | Approved | Micro | Bladder Ca | |
| 2029-12-18 | 3.8y away | Interim | Nidalemzoparlimab | Phase 1 | Micro | OCD | |
| 2029-12-19 | 3.8y away | Ph3 Readout | 219-3907 | Approved | Micro | Thymoma | |
| 2029-12-19 | 3.8y away | Ph3 Readout | Rimabrutinib | Approved | Micro | Parkinson's | |
| 2029-12-20 | 3.8y away | Ph3 Readout | RHH-7975 | Phase 3 | Large | FTD | |
| 2029-12-20 | 3.8y away | Ph3 Readout | Niranaritide | Phase 2/3 | Private | SMA | |
| 2029-12-21 | 3.8y away | Ph2 Data | Doxazumab | Phase 1/2 | Micro | MS | |
| 2029-12-22 | 3.8y away | Ph2 Data | ENC-4310 | Phase 1/2 | Private | Cholangiocarcinoma | |
| 2029-12-23 | 3.8y away | Interim | Nidaosocimab | Phase 1 | Mid | GIST | |
| 2029-12-24 | 3.8y away | Ph3 Readout | BLP-8287 | NDA/BLA | Micro | UC | |
| 2029-12-24 | 3.8y away | Ph2 Data | Polalemzoparlimab | Phase 1/2 | Private | Hemophilia A | |
| 2029-12-24 | 3.8y away | Ph3 Readout | Motasacituzumab | Approved | Private | MG | |
| 2029-12-25 | 3.8y away | Ph2 Data | Zoriosocimab | Phase 2 | Private | Psoriasis | |
| 2029-12-25 | 3.8y away | Interim | Polanesiran | Phase 1 | Mid | DMD | |
| 2030-01-01 | 3.8y away | Ph3 Readout | AGI-4446 | Phase 3 | Mid | LGS | |
| 2030-01-01 | 3.8y away | Ph3 Readout | Doxatenlimab | Phase 3 | Micro | Parkinson's | |
| 2030-01-02 | 3.8y away | Ph2 Data | Semasacituzumab | Phase 2 | Mid | GBM | |
| 2030-01-03 | 3.8y away | Ph2 Data | Fixatinib | Phase 1/2 | Micro | OCD | |
| 2030-01-04 | 3.8y away | Ph2 Data | ESC-2069 | Phase 1/2 | Private | LN | |
| 2030-01-04 | 3.8y away | Ph2 Data | PET-IIT-517 | Phase 2 | Private | PSP | |
| 2030-01-05 | 3.8y away | Ph2 Data | ABB-3060 | Phase 2 | Large | Migraine | |
| 2030-01-05 | 3.8y away | Ph3 Readout | Peminaritide | NDA/BLA | Mid | CKD | |
| 2030-01-05 | 3.8y away | Ph3 Readout | Elracapivasertib | Approved | Small | MDD | |
| 2030-01-06 | 3.8y away | Interim | BMY-4586 | Preclinical | Large | SCD | |
| 2030-01-06 | 3.8y away | Ph3 Readout | Motasacituzumab | NDA/BLA | Small | ACC | |
| 2030-01-06 | 3.8y away | Ph3 Readout | RAP-6712 | NDA/BLA | Micro | FL | |
| 2030-01-06 | 3.8y away | Interim | ORC-1969 | Phase 1 | Private | HS | |
| 2030-01-08 | 3.8y away | Interim | Cevisacituzumab | Preclinical | Large | MCL | |
| 2030-01-08 | 3.8y away | Ph3 Readout | Talatinib | Approved | Private | Narcolepsy | |
| 2030-01-08 | 3.8y away | Ph3 Readout | STA-IIT-619 | Approved | Private | RSV | |
| 2030-01-08 | 3.8y away | Interim | SPA-2229 | Phase 1 | Private | RA | |
| 2030-01-08 | 3.8y away | Ph3 Readout | Kemacapivasertib | Phase 2/3 | Private | IgAN | |
| 2030-01-09 | 3.8y away | Ph3 Readout | EXA-4696 | Phase 2/3 | Small | FSGS | |
| 2030-01-09 | 3.8y away | Ph3 Readout | Gozelemzoparlimab | Approved | Private | HCC | |
| 2030-01-09 | 3.8y away | Ph3 Readout | Suracagene | Phase 3 | Large | Atopic Derm | |
| 2030-01-10 | 3.8y away | Ph3 Readout | SEO-IIT-935 | Phase 2/3 | Private | Asthma | |
| 2030-01-11 | 3.8y away | Ph3 Readout | CLS-4466 | NDA/BLA | Micro | RA | |
| 2030-01-11 | 3.8y away | Interim | LPC-4508 | Phase 1 | Mid | GA | |
| 2030-01-11 | 3.8y away | Ph3 Readout | Lisosotorasib | Phase 3 | Mid | CSU | |
| 2030-01-12 | 3.8y away | Ph2 Data | DUK-IIT-581 | Phase 2 | Private | Gastric Ca | |
| 2030-01-13 | 3.8y away | Interim | Tiramavacamten | Preclinical | Large | Schizophrenia | |
| 2030-01-13 | 3.8y away | Ph3 Readout | Lisozumab | Phase 2/3 | Mid | AS | |
| 2030-01-14 | 3.8y away | Ph3 Readout | GLP-5658 | Phase 2/3 | Mid | Breast Ca | |
| 2030-01-14 | 3.8y away | Interim | SPI-1775 | Preclinical | Private | RB | |
| 2030-01-15 | 3.8y away | Ph3 Readout | STO-2663 | Approved | Small | Cholangiocarcinoma | |
| 2030-01-15 | 3.8y away | Interim | Elratapinarof | Preclinical | Private | Gastric Ca | |
| 2030-01-15 | 3.8y away | Ph3 Readout | FRO-9633 | Phase 3 | Private | FTD | |
| 2030-01-16 | 3.8y away | Interim | Pemiosocimab | Phase 1 | Private | CF | |
| 2030-01-17 | 3.8y away | Ph3 Readout | MRK-8368 | Phase 3 | Large | CLL | |
| 2030-01-17 | 3.8y away | Interim | Niracilimab | Phase 1 | Private | Narcolepsy | |
| 2030-01-17 | 3.8y away | Ph2 Data | Gelitenlimab | Phase 1/2 | Private | Rett | |
| 2030-01-17 | 3.8y away | Interim | Nidatenlimab | Phase 1 | Small | NASH | |
| 2030-01-18 | 3.8y away | Ph3 Readout | Elrarapivir | NDA/BLA | Large | Rett | |
| 2030-01-18 | 3.8y away | Interim | BBI-3709 | Phase 1 | Mid | RB | |
| 2030-01-18 | 3.8y away | Ph3 Readout | Sovalemzoparlimab | Phase 2/3 | Private | WM | |
| 2030-01-18 | 3.8y away | Interim | LIO-530 | Phase 1 | Private | PNH | |
| 2030-01-19 | 3.8y away | Interim | Zenotinib | Phase 1 | Large | GIST | |
| 2030-01-19 | 3.8y away | Ph2 Data | Nidavorutinib | Phase 2 | Private | NASH | |
| 2030-01-21 | 3.9y away | Ph2 Data | Niraglumide | Phase 1/2 | Micro | DLBCL | |
| 2030-01-22 | 3.9y away | Ph3 Readout | Lisoosocimab | Approved | Mid | EoE | |
| 2030-01-22 | 3.9y away | Interim | Tixaglumide | Preclinical | Small | ADPKD | |
| 2030-01-22 | 3.9y away | Interim | GLO-6047 | Preclinical | Private | FSGS | |
| 2030-01-23 | 3.9y away | Ph3 Readout | DPH-273 | NDA/BLA | Mid | Wilms | |
| 2030-01-25 | 3.9y away | Interim | AZN-8281 | Phase 1 | Large | GA | |
| 2030-01-26 | 3.9y away | Ph3 Readout | Datoglumide | Approved | Large | SLE | |
| 2030-01-26 | 3.9y away | Interim | Ivocapivasertib | Phase 1 | Large | Parkinson's | |
| 2030-01-27 | 3.9y away | Ph2 Data | INS-9902 | Phase 1/2 | Private | CLL | |
| 2030-01-27 | 3.9y away | Ph3 Readout | Gelicilimab | Phase 3 | Mid | UC | |
| 2030-01-27 | 3.9y away | Ph3 Readout | DEC-4099 | Phase 3 | Private | Cervical Ca | |
| 2030-01-28 | 3.9y away | Ph3 Readout | AZN-6294 | Phase 2/3 | Large | Epilepsy | |
| 2030-01-28 | 3.9y away | Ph3 Readout | Ivotenlimab | Approved | Private | PsA | |
| 2030-01-28 | 3.9y away | Ph3 Readout | Teraosocimab | Phase 3 | Private | Migraine | |
| 2030-02-01 | 3.9y away | Interim | Bemazumab | Phase 1 | Large | EoE | |
| 2030-02-02 | 3.9y away | Ph3 Readout | Ivorasimod | Approved | Private | CKD | |
| 2030-02-02 | 3.9y away | Interim | Zorizasiran | Phase 1 | Private | HS | |
| 2030-02-02 | 3.9y away | Ph3 Readout | Zoriosocimab | Phase 3 | Mid | MCC | |
| 2030-02-03 | 3.9y away | Interim | Olpasotorasib | Preclinical | Mid | SCLC | |
| 2030-02-04 | 3.9y away | Ph3 Readout | Semacilimab | Phase 3 | Private | GIST | |
| 2030-02-05 | 3.9y away | Ph3 Readout | BMY-8678 | Approved | Large | AS | |
| 2030-02-05 | 3.9y away | Interim | Rimavorutinib | Phase 1 | Private | OCD | |
| 2030-02-05 | 3.9y away | Ph3 Readout | Datorasimod | Phase 2/3 | Mid | Thymoma | |
| 2030-02-05 | 3.9y away | Ph3 Readout | Tirainavolisib | Approved | Mid | IPF | |
| 2030-02-06 | 3.9y away | Ph2 Data | Bematinib | Phase 2 | Large | FL | |
| 2030-02-08 | 3.9y away | Ph2 Data | UCS-IIT-951 | Phase 2 | Private | GA | |
| 2030-02-09 | 3.9y away | Ph2 Data | BIO-IIT-514 | Phase 1/2 | Private | SMA | |
| 2030-02-11 | 3.9y away | Ph3 Readout | Rilulemzoparlimab | Phase 2/3 | Large | Alzheimer's | |
| 2030-02-11 | 3.9y away | Interim | Lisocagene | Phase 1 | Private | RB | |
| 2030-02-11 | 3.9y away | Ph3 Readout | SYN-6765 | Approved | Small | Celiac | |
| 2030-02-11 | 3.9y away | Ph2 Data | Datozanubrutinib | Phase 2 | Mid | Hemophilia A | |
| 2030-02-12 | 3.9y away | Ph3 Readout | BRK-679 | Approved | Large | SCLC | |
| 2030-02-13 | 3.9y away | Ph3 Readout | Tezetapinarof | Phase 3 | Mid | FTD | |
| 2030-02-13 | 3.9y away | Interim | XBI-3618 | Phase 1 | Small | Cholangiocarcinoma | |
| 2030-02-13 | 3.9y away | Ph3 Readout | SIE-9908 | Phase 3 | Private | Ovarian Ca | |
| 2030-02-13 | 3.9y away | Ph3 Readout | 151-9555 | Phase 2/3 | Mid | FTD | |
| 2030-02-14 | 3.9y away | Ph3 Readout | Bemarelsin | Phase 2/3 | Private | HNSCC | |
| 2030-02-14 | 3.9y away | Ph3 Readout | DRR-2203 | Phase 2/3 | Micro | HCC | |
| 2030-02-14 | 3.9y away | Ph2 Data | 996-5071 | Phase 1/2 | Small | Schizophrenia | |
| 2030-02-15 | 3.9y away | Ph2 Data | CSL-4765 | Phase 1/2 | Large | LN | |
| 2030-02-15 | 3.9y away | Interim | 451-2703 | Phase 1 | Large | HNSCC | |
| 2030-02-15 | 3.9y away | Ph3 Readout | Nirarapivir | Approved | Mid | TTR Amyloidosis | |
| 2030-02-15 | 3.9y away | Ph3 Readout | Ivocilimab | NDA/BLA | Private | Asthma | |
| 2030-02-15 | 3.9y away | Ph3 Readout | Tirasertib | Phase 2/3 | Large | Hemophilia A | |
| 2030-02-16 | 3.9y away | Ph3 Readout | 051-5335 | Phase 3 | Mid | FTD | |
| 2030-02-16 | 3.9y away | Interim | MVI-2801 | Preclinical | Micro | CKD | |
| 2030-02-17 | 3.9y away | Ph3 Readout | Zorilucimab | NDA/BLA | Private | CF | |
| 2030-02-18 | 3.9y away | Ph3 Readout | BMY-8678 | Approved | Large | AS | |
| 2030-02-18 | 3.9y away | Ph3 Readout | Zenoinavolisib | NDA/BLA | Private | Ovarian Ca | |
| 2030-02-19 | 3.9y away | Ph3 Readout | Talarelsin | NDA/BLA | Micro | Pancreatic Ca | |
| 2030-02-19 | 3.9y away | Interim | MYO-1420 | Preclinical | Private | CLL | |
| 2030-02-19 | 3.9y away | Interim | Doxazasiran | Preclinical | Private | RB | |
| 2030-02-19 | 3.9y away | Ph2 Data | Adagraderotide | Phase 1/2 | Private | Schizophrenia | |
| 2030-02-20 | 3.9y away | Ph3 Readout | SIE-9908 | Phase 3 | Private | Ovarian Ca | |
| 2030-02-20 | 3.9y away | Ph3 Readout | Fixazasiran | Approved | Micro | Thymoma | |
| 2030-02-20 | 3.9y away | Ph2 Data | Tezeglumide | Phase 1/2 | Mid | IPF | |
| 2030-02-21 | 3.9y away | Ph2 Data | Polanaritide | Phase 1/2 | Private | MG | |
| 2030-02-23 | 3.9y away | Ph3 Readout | Tirazumab | Phase 2/3 | Private | ADPKD | |
| 2030-02-24 | 3.9y away | Ph3 Readout | ITA-9145 | NDA/BLA | Private | Angelman | |
| 2030-02-24 | 3.9y away | Ph3 Readout | Pexalucimab | Phase 3 | Private | CKD | |
| 2030-02-25 | 3.9y away | Ph3 Readout | Talainavolisib | Approved | Small | ACC | |
| 2030-02-25 | 3.9y away | Ph3 Readout | ARC-1235 | Phase 3 | Small | CRC | |
| 2030-02-26 | 4.0y away | Ph3 Readout | CSL-8153 | Approved | Large | LN | |
| 2030-02-27 | 4.0y away | Ph3 Readout | Mavuglumide | Approved | Large | MCL | |
| 2030-02-27 | 4.0y away | Ph3 Readout | Mirisertib | Phase 3 | Private | Fabry | |
| 2030-02-27 | 4.0y away | Ph2 Data | 456-7078 | Phase 1/2 | Small | Epilepsy | |
| 2030-03-01 | 4.0y away | Ph3 Readout | Elratuximab | Phase 3 | Small | Cervical Ca | |
| 2030-03-01 | 4.0y away | Ph3 Readout | CHI-IIT-401 | Phase 2/3 | Private | T2D | |
| 2030-03-01 | 4.0y away | Ph3 Readout | OBS-7968 | Approved | Private | Huntington's | |
| 2030-03-02 | 4.0y away | Ph3 Readout | Lisoderotide | Phase 3 | Private | Urothelial Ca | |
| 2030-03-03 | 4.0y away | Ph2 Data | Doxasotorasib | Phase 2 | Large | SMA | |
| 2030-03-04 | 4.0y away | Ph2 Data | ONC-2103 | Phase 1/2 | Small | CTCL | |
| 2030-03-05 | 4.0y away | Ph2 Data | SLN-6859 | Phase 2 | Small | FTD | |
| 2030-03-05 | 4.0y away | Ph3 Readout | 002-5533 | Phase 2/3 | Mid | NSCLC | |
| 2030-03-06 | 4.0y away | Ph3 Readout | GMA-5010 | Phase 3 | Large | SCLC | |
| 2030-03-06 | 4.0y away | Ph3 Readout | RUI-IIT-540 | Approved | Private | NSCLC | |
| 2030-03-07 | 4.0y away | Interim | Fixatuximab | Preclinical | Large | Parkinson's | |
| 2030-03-08 | 4.0y away | Ph3 Readout | UCS-IIT-265 | Phase 3 | Private | Thymoma | |
| 2030-03-08 | 4.0y away | Ph3 Readout | Bemazanubrutinib | Phase 2/3 | Private | BCC | |
| 2030-03-08 | 4.0y away | Interim | 109-1876 | Preclinical | Mid | SLE | |
| 2030-03-09 | 4.0y away | Ph3 Readout | ORC-9172 | Phase 3 | Private | OCD | |
| 2030-03-09 | 4.0y away | Ph3 Readout | MIN-2764 | Phase 3 | Private | SLE | |
| 2030-03-10 | 4.0y away | Ph3 Readout | WES-IIT-146 | Phase 2/3 | Private | Alzheimer's | |
| 2030-03-11 | 4.0y away | Interim | UCL-IIT-280 | Preclinical | Private | Migraine | |
| 2030-03-12 | 4.0y away | Ph3 Readout | VIG-6767 | Phase 2/3 | Micro | Rett | |
| 2030-03-12 | 4.0y away | Ph3 Readout | KAL-3067 | Phase 2/3 | Micro | TTR Amyloidosis | |
| 2030-03-12 | 4.0y away | Ph3 Readout | Nidacilimab | Approved | Mid | Psoriasis | |
| 2030-03-13 | 4.0y away | Ph3 Readout | GEN-IIT-455 | Phase 2/3 | Private | MS | |
| 2030-03-13 | 4.0y away | Ph3 Readout | OBS-1681 | Phase 3 | Private | MDS | |
| 2030-03-14 | 4.0y away | Interim | Zenonesiran | Preclinical | Large | Hemophilia A | |
| 2030-03-14 | 4.0y away | Interim | ALD-6159 | Phase 1 | Private | IPF | |
| 2030-03-15 | 4.0y away | Interim | CSL-7919 | Preclinical | Large | Endometrial Ca | |
| 2030-03-15 | 4.0y away | Interim | Bemasertib | Phase 1 | Private | NSCLC | |
| 2030-03-15 | 4.0y away | Ph2 Data | 996-4673 | Phase 1/2 | Small | BCC | |
| 2030-03-15 | 4.0y away | Ph3 Readout | HOS-IIT-591 | Phase 3 | Private | Heart Failure | |
| 2030-03-16 | 4.0y away | Ph3 Readout | Nidasacituzumab | Approved | Large | GBM | |
| 2030-03-16 | 4.0y away | Ph3 Readout | MRK-8368 | Phase 3 | Large | CLL | |
| 2030-03-16 | 4.0y away | Interim | Mavunesiran | Preclinical | Small | BCC | |
| 2030-03-16 | 4.0y away | Ph2 Data | Gozecilimab | Phase 2 | Mid | ET | |
| 2030-03-16 | 4.0y away | Ph3 Readout | Olpaglumide | Approved | Mid | Psoriasis | |
| 2030-03-16 | 4.0y away | Ph3 Readout | SIR-IIT-294 | Approved | Private | NASH | |
| 2030-03-17 | 4.0y away | Ph3 Readout | NBI-3153 | Approved | Large | Bladder Ca | |
| 2030-03-17 | 4.0y away | Ph3 Readout | Teratenlimab | Approved | Micro | PNH | |
| 2030-03-18 | 4.0y away | Interim | COR-2320 | Preclinical | Private | LN | |
| 2030-03-18 | 4.0y away | Interim | AII-IIT-938 | Preclinical | Private | Dravet | |
| 2030-03-19 | 4.0y away | Ph3 Readout | ZEN-8892 | Phase 2/3 | Private | RSV | |
| 2030-03-21 | 4.0y away | Ph2 Data | PMC-7054 | Phase 2 | Micro | CRC | |
| 2030-03-21 | 4.0y away | Ph3 Readout | CHI-IIT-594 | NDA/BLA | Private | MDS | |
| 2030-03-22 | 4.0y away | Ph3 Readout | PFE-7550 | Phase 3 | Large | Asthma | |
| 2030-03-22 | 4.0y away | Ph3 Readout | GSK-7987 | Phase 3 | Large | MG | |
| 2030-03-22 | 4.0y away | Ph3 Readout | HRT-9539 | NDA/BLA | Small | Wet AMD | |
| 2030-03-23 | 4.0y away | Ph2 Data | Elralucimab | Phase 2 | Mid | Heart Failure | |
| 2030-03-23 | 4.0y away | Interim | 000-7991 | Phase 1 | Mid | RCC | |
| 2030-03-23 | 4.0y away | Ph3 Readout | ASK-539 | NDA/BLA | Private | MG | |
| 2030-03-25 | 4.0y away | Interim | Voxafutibatinib | Phase 1 | Small | Migraine | |
| 2030-03-25 | 4.0y away | Ph3 Readout | Pemizasiran | NDA/BLA | Private | GBM | |
| 2030-03-25 | 4.0y away | Ph3 Readout | RUI-IIT-706 | NDA/BLA | Private | ALS | |
| 2030-03-26 | 4.0y away | Ph3 Readout | ELE-7872 | Phase 2/3 | Micro | CTCL | |
| 2030-03-26 | 4.0y away | Interim | Adagrazumab | Phase 1 | Micro | IgAN | |
| 2030-03-26 | 4.0y away | Interim | Suraglumide | Phase 1 | Private | Pompe | |
| 2030-03-27 | 4.0y away | Ph3 Readout | Semaglumide | Phase 3 | Private | Endometrial Ca | |
| 2030-03-28 | 4.0y away | Ph3 Readout | Cevifotisoran | Approved | Large | Narcolepsy | |
| 2030-03-28 | 4.0y away | Interim | GPC-2382 | Preclinical | Mid | Wet AMD | |
| 2030-04-01 | 4.0y away | Ph2 Data | Surarasimod | Phase 2 | Mid | FSGS | |
| 2030-04-01 | 4.0y away | Ph3 Readout | CRB-4064 | NDA/BLA | Micro | MM | |
| 2030-04-01 | 4.0y away | Interim | Polatuximab | Phase 1 | Micro | Ewing Sarcoma | |
| 2030-04-01 | 4.0y away | Ph3 Readout | Fixacagene | Approved | Small | Endometrial Ca | |
| 2030-04-02 | 4.0y away | Ph3 Readout | PST-2276 | Approved | Small | CML | |
| 2030-04-03 | 4.0y away | Ph2 Data | DAW-8159 | Phase 2 | Mid | Dravet | |
| 2030-04-03 | 4.0y away | Ph3 Readout | Niraderotide | Phase 2/3 | Mid | MG | |
| 2030-04-04 | 4.1y away | Ph2 Data | Tixalucimab | Phase 2 | Micro | DMD | |
| 2030-04-05 | 4.1y away | Ph3 Readout | TXG-6755 | Approved | Mid | SMA | |
| 2030-04-05 | 4.1y away | Ph2 Data | SCI-2060 | Phase 2 | Private | Dravet | |
| 2030-04-06 | 4.1y away | Ph3 Readout | CGE-1983 | Phase 2/3 | Micro | NMOSD | |
| 2030-04-07 | 4.1y away | Ph2 Data | Cevicapivasertib | Phase 2 | Mid | IPF | |
| 2030-04-07 | 4.1y away | Ph2 Data | Fixamavacamten | Phase 2 | Small | Ewing Sarcoma | |
| 2030-04-07 | 4.1y away | Interim | PEK-IIT-646 | Phase 1 | Private | Wet AMD | |
| 2030-04-07 | 4.1y away | Ph2 Data | Rimaratamab | Phase 2 | Private | IgAN | |
| 2030-04-07 | 4.1y away | Ph3 Readout | Pemifutibatinib | Phase 3 | Mid | Hemophilia A | |
| 2030-04-09 | 4.1y away | Ph2 Data | Adagrafutibatinib | Phase 2 | Large | UC | |
| 2030-04-11 | 4.1y away | Ph3 Readout | FOR-7299 | Phase 3 | Private | SLE | |
| 2030-04-11 | 4.1y away | Interim | BRK-5301 | Preclinical | Large | Cholangiocarcinoma | |
| 2030-04-12 | 4.1y away | Ph3 Readout | Rimanesiran | Phase 3 | Private | MDD | |
| 2030-04-13 | 4.1y away | Ph3 Readout | Zorilucimab | NDA/BLA | Private | CF | |
| 2030-04-13 | 4.1y away | Ph3 Readout | Adagrafutibatinib | Phase 3 | Small | IPF | |
| 2030-04-13 | 4.1y away | Ph2 Data | NAT-IIT-589 | Phase 1/2 | Private | OCD | |
| 2030-04-14 | 4.1y away | Ph3 Readout | APM-4255 | NDA/BLA | Micro | Myelofibrosis | |
| 2030-04-14 | 4.1y away | Ph3 Readout | CST-7277 | Phase 2/3 | Mid | AML | |
| 2030-04-15 | 4.1y away | Ph2 Data | LLY-6079 | Phase 2 | Large | HS | |
| 2030-04-15 | 4.1y away | Ph3 Readout | Polaglumide | Phase 3 | Small | CML | |
| 2030-04-15 | 4.1y away | Interim | Rilutapinarof | Phase 1 | Private | Parkinson's | |
| 2030-04-16 | 4.1y away | Ph3 Readout | SIR-IIT-898 | Phase 3 | Private | Rett | |
| 2030-04-17 | 4.1y away | Ph3 Readout | Talarapivir | Phase 2/3 | Large | ACC | |
| 2030-04-18 | 4.1y away | Ph2 Data | AMG-9654 | Phase 2 | Large | Huntington's | |
| 2030-04-18 | 4.1y away | Ph3 Readout | Sovacapivasertib | Phase 3 | Large | CRC | |
| 2030-04-19 | 4.1y away | Ph3 Readout | ORC-7732 | Phase 3 | Private | EoE | |
| 2030-04-20 | 4.1y away | Ph3 Readout | UCS-IIT-914 | Approved | Private | Alzheimer's | |
| 2030-04-20 | 4.1y away | Ph2 Data | Mirisacituzumab | Phase 2 | Large | Asthma | |
| 2030-04-21 | 4.1y away | Ph3 Readout | CRI-9527 | Phase 3 | Private | HNSCC | |
| 2030-04-23 | 4.1y away | Ph2 Data | GSK-6983 | Phase 2 | Large | Schizophrenia | |
| 2030-04-24 | 4.1y away | Ph3 Readout | PST-2276 | Approved | Small | CML | |
| 2030-04-24 | 4.1y away | Interim | Adagraratamab | Phase 1 | Private | PAH | |
| 2030-04-25 | 4.1y away | Ph3 Readout | Voxacagene | Phase 2/3 | Large | IgAN | |
| 2030-04-25 | 4.1y away | Ph2 Data | Ivotuximab | Phase 2 | Mid | NASH | |
| 2030-04-25 | 4.1y away | Ph3 Readout | IMA-217 | NDA/BLA | Private | Bladder Ca | |
| 2030-04-26 | 4.1y away | Ph3 Readout | ITC-6153 | Phase 3 | Large | Urothelial Ca | |
| 2030-04-26 | 4.1y away | Interim | Nidaratamab | Preclinical | Mid | Hemophilia A | |
| 2030-04-26 | 4.1y away | Ph2 Data | NAT-2164 | Phase 1/2 | Mid | Gastric Ca | |
| 2030-04-26 | 4.1y away | Ph3 Readout | Rimarapivir | Phase 3 | Small | Celiac | |
| 2030-04-26 | 4.1y away | Interim | PCI-3652 | Phase 1 | Micro | Ovarian Ca | |
| 2030-04-26 | 4.1y away | Ph3 Readout | SYN-6765 | Approved | Small | Celiac | |
| 2030-04-28 | 4.1y away | Ph2 Data | PFE-2901 | Phase 2 | Large | SMA | |
| 2030-04-28 | 4.1y away | Ph3 Readout | ADA-3632 | NDA/BLA | Private | FSGS | |
| 2030-05-03 | 4.1y away | Interim | Zanulemzoparlimab | Phase 1 | Private | NSCLC | |
| 2030-05-03 | 4.1y away | Ph3 Readout | Sovazasiran | Phase 3 | Private | NSCLC | |
| 2030-05-03 | 4.1y away | Interim | 459-2528 | Preclinical | Micro | PNH | |
| 2030-05-03 | 4.1y away | Interim | 095-5475 | Preclinical | Micro | RCC | |
| 2030-05-03 | 4.1y away | Interim | Fixazanubrutinib | Preclinical | Large | Ewing Sarcoma | |
| 2030-05-04 | 4.1y away | Ph3 Readout | HOR-3482 | Phase 3 | Private | Psoriasis | |
| 2030-05-04 | 4.1y away | Ph3 Readout | QUO-7972 | NDA/BLA | Private | Atopic Derm | |
| 2030-05-04 | 4.1y away | Ph3 Readout | OMG-4087 | NDA/BLA | Micro | PNH | |
| 2030-05-04 | 4.1y away | Interim | Doxafutibatinib | Phase 1 | Micro | MG | |
| 2030-05-04 | 4.1y away | Ph3 Readout | AVR-5957 | NDA/BLA | Micro | MCC | |
| 2030-05-04 | 4.1y away | Ph3 Readout | Lisoderotide | Phase 3 | Private | FTD | |
| 2030-05-05 | 4.1y away | Ph2 Data | CCC-2073 | Phase 1/2 | Micro | CTCL | |
| 2030-05-05 | 4.1y away | Ph2 Data | 002-8467 | Phase 1/2 | Mid | Epilepsy | |
| 2030-05-06 | 4.1y away | Ph2 Data | Talatenlimab | Phase 1/2 | Mid | MCC | |
| 2030-05-06 | 4.1y away | Ph3 Readout | Capicagene | Approved | Private | Asthma | |
| 2030-05-06 | 4.1y away | Ph3 Readout | Niranaritide | Phase 2/3 | Private | SMA | |
| 2030-05-06 | 4.1y away | Interim | DIV-5162 | Preclinical | Large | MS | |
| 2030-05-07 | 4.1y away | Ph3 Readout | MSN-5549 | NDA/BLA | Private | UC | |
| 2030-05-07 | 4.1y away | Interim | EGI-7413 | Phase 1 | Private | LN | |
| 2030-05-08 | 4.1y away | Ph2 Data | SEO-IIT-337 | Phase 1/2 | Private | Pompe | |
| 2030-05-09 | 4.1y away | Interim | AZN-3724 | Preclinical | Large | PSP | |
| 2030-05-09 | 4.1y away | Ph3 Readout | MRN-7409 | NDA/BLA | Large | PV | |
| 2030-05-09 | 4.1y away | Ph2 Data | CHA-IIT-658 | Phase 1/2 | Private | Bladder Ca | |
| 2030-05-09 | 4.1y away | Ph3 Readout | Tixainavolisib | Phase 3 | Mid | Schizophrenia | |
| 2030-05-09 | 4.1y away | Ph3 Readout | BLC-3714 | Approved | Mid | ALL | |
| 2030-05-11 | 4.2y away | Ph3 Readout | Elratenlimab | Phase 3 | Micro | Gastric Ca | |
| 2030-05-11 | 4.2y away | Ph2 Data | Teracagene | Phase 2 | Large | ET | |
| 2030-05-12 | 4.2y away | Ph2 Data | Semainavolisib | Phase 2 | Mid | LGS | |
| 2030-05-12 | 4.2y away | Ph3 Readout | VEC-8813 | Phase 3 | Private | Crohn's | |
| 2030-05-12 | 4.2y away | Ph3 Readout | Nidarelsin | Phase 2/3 | Micro | Asthma | |
| 2030-05-13 | 4.2y away | Ph3 Readout | SAV-8261 | NDA/BLA | Small | Gastric Ca | |
| 2030-05-13 | 4.2y away | Ph3 Readout | WIN-5410 | NDA/BLA | Micro | HCC | |
| 2030-05-14 | 4.2y away | Interim | ARG-3458 | Preclinical | Large | PV | |
| 2030-05-14 | 4.2y away | Interim | Polacagene | Preclinical | Micro | MS | |
| 2030-05-14 | 4.2y away | Ph3 Readout | Polalemzoparlimab | Approved | Private | MDD | |
| 2030-05-15 | 4.2y away | Ph3 Readout | Polazasiran | Phase 3 | Micro | MG | |
| 2030-05-16 | 4.2y away | Ph2 Data | ROI-3353 | Phase 1/2 | Mid | AS | |
| 2030-05-16 | 4.2y away | Ph3 Readout | VIN-1694 | Approved | Private | FSGS | |
| 2030-05-16 | 4.2y away | Interim | Sovazumab | Phase 1 | Mid | Narcolepsy | |
| 2030-05-17 | 4.2y away | Ph2 Data | SNY-5783 | Phase 1/2 | Large | Alzheimer's | |
| 2030-05-17 | 4.2y away | Ph2 Data | Fixatenlimab | Phase 1/2 | Large | Crohn's | |
| 2030-05-17 | 4.2y away | Ph3 Readout | MEI-1770 | Phase 2/3 | Micro | Heart Failure | |
| 2030-05-17 | 4.2y away | Ph3 Readout | Ribozasiran | Phase 2/3 | Micro | RCC | |
| 2030-05-18 | 4.2y away | Ph3 Readout | Fixazasiran | Approved | Micro | Thymoma | |
| 2030-05-18 | 4.2y away | Ph3 Readout | PLR-762 | Approved | Small | PV | |
| 2030-05-20 | 4.2y away | Ph2 Data | 416-6807 | Phase 2 | Micro | MDS | |
| 2030-05-21 | 4.2y away | Ph3 Readout | Cevinaritide | Phase 3 | Mid | PAH | |
| 2030-05-21 | 4.2y away | Ph3 Readout | JAM-9461 | Phase 2/3 | Private | SLE | |
| 2030-05-22 | 4.2y away | Ph2 Data | SOR-1685 | Phase 2 | Private | Prostate Ca | |
| 2030-05-23 | 4.2y away | Ph3 Readout | Pexaderotide | Phase 3 | Private | Cholangiocarcinoma | |
| 2030-05-23 | 4.2y away | Ph3 Readout | PRO-4197 | Approved | Private | Wilms | |
| 2030-05-24 | 4.2y away | Interim | UCB-8638 | Phase 1 | Large | GA | |
| 2030-05-25 | 4.2y away | Interim | AGE-4274 | Phase 1 | Micro | Breast Ca | |
| 2030-05-25 | 4.2y away | Ph3 Readout | RYT-9424 | Phase 2/3 | Mid | CF | |
| 2030-05-25 | 4.2y away | Ph2 Data | Tezesacituzumab | Phase 1/2 | Mid | Bladder Ca | |
| 2030-05-27 | 4.2y away | Interim | Rimamavacamten | Phase 1 | Large | Ewing Sarcoma | |
| 2030-05-27 | 4.2y away | Ph3 Readout | Doxarapivir | Phase 3 | Large | Huntington's | |
| 2030-05-27 | 4.2y away | Ph2 Data | GRF-4589 | Phase 2 | Mid | GIST | |
| 2030-05-27 | 4.2y away | Ph2 Data | 003-1437 | Phase 2 | Small | RA | |
| 2030-05-28 | 4.2y away | Interim | Rilubrutinib | Phase 1 | Micro | CRC | |
| 2030-05-28 | 4.2y away | Ph3 Readout | Ivozasiran | Phase 3 | Mid | ADPKD | |
| 2030-05-28 | 4.2y away | Ph3 Readout | Zoriratamab | Approved | Mid | CML | |
| 2030-06-01 | 4.2y away | Ph3 Readout | ELO-2344 | Phase 3 | Private | Prostate Ca | |
| 2030-06-02 | 4.2y away | Ph3 Readout | Rilurapivir | NDA/BLA | Small | NMOSD | |
| 2030-06-03 | 4.2y away | Ph2 Data | Teravorutinib | Phase 2 | Large | Angelman | |
| 2030-06-03 | 4.2y away | Ph3 Readout | ONC-9294 | Approved | Micro | T2D | |
| 2030-06-03 | 4.2y away | Ph2 Data | Zorinesiran | Phase 1/2 | Mid | IgAN | |
| 2030-06-03 | 4.2y away | Ph3 Readout | ZHE-740 | Approved | Private | OCD | |
| 2030-06-04 | 4.2y away | Ph3 Readout | SEO-IIT-219 | Approved | Private | Heart Failure | |
| 2030-06-04 | 4.2y away | Interim | Doxacilimab | Preclinical | Small | FTD | |
| 2030-06-06 | 4.2y away | Ph3 Readout | ENC-8622 | Phase 3 | Private | Celiac | |
| 2030-06-08 | 4.2y away | Ph3 Readout | Sovafutibatinib | Approved | Large | CTCL | |
| 2030-06-08 | 4.2y away | Ph3 Readout | EVO-4804 | Approved | Private | NB | |
| 2030-06-08 | 4.2y away | Ph2 Data | TCB-6877 | Phase 1/2 | Micro | NMOSD | |
| 2030-06-09 | 4.2y away | Ph3 Readout | LLY-1184 | NDA/BLA | Large | PV | |
| 2030-06-09 | 4.2y away | Ph2 Data | RPT-8672 | Phase 2 | Small | Psoriasis | |
| 2030-06-10 | 4.2y away | Ph2 Data | Bemasotorasib | Phase 2 | Mid | MCL | |
| 2030-06-11 | 4.2y away | Ph3 Readout | NUV-283 | Phase 3 | Mid | Parkinson's | |
| 2030-06-11 | 4.2y away | Ph3 Readout | Fixalucimab | NDA/BLA | Micro | PV | |
| 2030-06-12 | 4.2y away | Ph2 Data | Tirazasiran | Phase 1/2 | Private | Wilms | |
| 2030-06-12 | 4.2y away | Interim | Rimamavacamten | Preclinical | Private | Rett | |
| 2030-06-12 | 4.2y away | Ph3 Readout | AVT-8949 | Phase 3 | Large | Angelman | |
| 2030-06-13 | 4.2y away | Ph3 Readout | ZEA-9089 | Phase 2/3 | Mid | Melanoma | |
| 2030-06-13 | 4.2y away | Ph3 Readout | Capirasimod | Phase 3 | Micro | Obesity | |
| 2030-06-13 | 4.2y away | Interim | Zanurelsin | Preclinical | Private | T2D | |
| 2030-06-14 | 4.2y away | Interim | Mavuderotide | Preclinical | Small | CLL | |
| 2030-06-14 | 4.2y away | Ph3 Readout | Lisozasiran | NDA/BLA | Mid | GIST | |
| 2030-06-15 | 4.2y away | Ph2 Data | Voxarapivir | Phase 2 | Mid | Hemophilia A | |
| 2030-06-16 | 4.3y away | Interim | 180-6098 | Phase 1 | Mid | NMOSD | |
| 2030-06-17 | 4.3y away | Ph2 Data | NAT-IIT-326 | Phase 1/2 | Private | MS | |
| 2030-06-17 | 4.3y away | Ph3 Readout | Fixatuximab | Approved | Large | Prostate Ca | |
| 2030-06-18 | 4.3y away | Ph3 Readout | AMG-4531 | Phase 2/3 | Large | CLL | |
| 2030-06-18 | 4.3y away | Ph3 Readout | Pemisertib | NDA/BLA | Mid | PTSD | |
| 2030-06-18 | 4.3y away | Ph3 Readout | 002-1797 | Approved | Mid | Huntington's | |
| 2030-06-19 | 4.3y away | Interim | NOI-4498 | Phase 1 | Private | PsA | |
| 2030-06-20 | 4.3y away | Ph2 Data | Cevirelsin | Phase 2 | Large | AML | |
| 2030-06-22 | 4.3y away | Interim | Bemarelsin | Preclinical | Large | PV | |
| 2030-06-22 | 4.3y away | Ph2 Data | CSL-2468 | Phase 1/2 | Large | PAH | |
| 2030-06-23 | 4.3y away | Ph2 Data | TRV-9080 | Phase 1/2 | Micro | Ewing Sarcoma | |
| 2030-06-24 | 4.3y away | Ph2 Data | CSL-8235 | Phase 1/2 | Large | FL | |
| 2030-06-24 | 4.3y away | Ph3 Readout | Polalucimab | Phase 3 | Large | CML | |
| 2030-06-24 | 4.3y away | Interim | FOR-6391 | Preclinical | Private | WM | |
| 2030-06-24 | 4.3y away | Interim | TOT-3942 | Preclinical | Private | GA | |
| 2030-06-25 | 4.3y away | Ph3 Readout | Capirapivir | Approved | Mid | PV | |
| 2030-06-25 | 4.3y away | Interim | Rilutenlimab | Preclinical | Private | Schizophrenia | |
| 2030-06-25 | 4.3y away | Interim | Zanuratamab | Phase 1 | Private | TTR Amyloidosis | |
| 2030-06-25 | 4.3y away | Ph3 Readout | Polalemzoparlimab | Approved | Private | Hemophilia A | |
| 2030-06-26 | 4.3y away | Ph3 Readout | CN-8014 | Phase 2/3 | Private | CLL | |
| 2030-06-26 | 4.3y away | Ph3 Readout | Pemibrutinib | Approved | Micro | LGS | |
| 2030-06-28 | 4.3y away | Ph3 Readout | Nidatenlimab | NDA/BLA | Large | Breast Ca | |
| 2030-06-28 | 4.3y away | Ph2 Data | Zanunaritide | Phase 1/2 | Small | FSGS | |
| 2030-06-28 | 4.3y away | Interim | Polacagene | Preclinical | Micro | MS | |
| 2030-06-28 | 4.3y away | Ph3 Readout | Tirasotorasib | Approved | Micro | MCL | |
| 2030-06-28 | 4.3y away | Ph3 Readout | TRE-2745 | Phase 2/3 | Private | PAH | |
| 2030-07-01 | 4.3y away | Ph3 Readout | XTA-4333 | Approved | Private | Breast Ca | |
| 2030-07-01 | 4.3y away | Ph3 Readout | CNT-5081 | Phase 3 | Micro | PSP | |
| 2030-07-03 | 4.3y away | Ph3 Readout | Sovaderotide | Phase 2/3 | Large | SCLC | |
| 2030-07-03 | 4.3y away | Ph3 Readout | Gozebrutinib | Approved | Mid | CRC | |
| 2030-07-03 | 4.3y away | Interim | 195-4808 | Preclinical | Small | ALS | |
| 2030-07-03 | 4.3y away | Ph3 Readout | Rimavorutinib | Phase 3 | Private | Prostate Ca | |
| 2030-07-05 | 4.3y away | Ph3 Readout | RLA-6817 | Phase 3 | Mid | BCC | |
| 2030-07-05 | 4.3y away | Interim | DAR-2860 | Phase 1 | Micro | PV | |
| 2030-07-06 | 4.3y away | Ph2 Data | 488-733 | Phase 1/2 | Small | Celiac | |
| 2030-07-07 | 4.3y away | Ph3 Readout | Ribofutibatinib | Phase 2/3 | Large | AS | |
| 2030-07-07 | 4.3y away | Ph3 Readout | ASN-4879 | Phase 3 | Mid | PSP | |
| 2030-07-07 | 4.3y away | Ph3 Readout | G1-8409 | Phase 3 | Private | RCC | |
| 2030-07-07 | 4.3y away | Ph2 Data | Teranesiran | Phase 2 | Small | Wet AMD | |
| 2030-07-08 | 4.3y away | Ph3 Readout | Miriglumide | NDA/BLA | Large | Asthma | |
| 2030-07-09 | 4.3y away | Ph2 Data | Terarasimod | Phase 1/2 | Mid | Cervical Ca | |
| 2030-07-09 | 4.3y away | Interim | Liracapivasertib | Phase 1 | Mid | GA | |
| 2030-07-10 | 4.3y away | Interim | MOR-7494 | Phase 1 | Private | RB | |
| 2030-07-11 | 4.3y away | Ph2 Data | ABB-2476 | Phase 1/2 | Large | GA | |
| 2030-07-11 | 4.3y away | Ph2 Data | CAM-IIT-192 | Phase 2 | Private | ALS | |
| 2030-07-12 | 4.3y away | Interim | Rilunaritide | Preclinical | Private | PsA | |
| 2030-07-12 | 4.3y away | Ph3 Readout | 488-6595 | Approved | Small | GBM | |
| 2030-07-12 | 4.3y away | Ph3 Readout | URG-1959 | Phase 3 | Small | BCC | |
| 2030-07-12 | 4.3y away | Interim | ZYD-981 | Preclinical | Large | ADPKD | |
| 2030-07-13 | 4.3y away | Ph3 Readout | PFE-2191 | NDA/BLA | Large | MCC | |
| 2030-07-13 | 4.3y away | Ph3 Readout | 051-2746 | Phase 2/3 | Mid | Meso | |
| 2030-07-13 | 4.3y away | Ph2 Data | Ivozasiran | Phase 1/2 | Micro | ET | |
| 2030-07-14 | 4.3y away | Ph3 Readout | Sematuximab | Phase 2/3 | Micro | NSCLC | |
| 2030-07-14 | 4.3y away | Ph3 Readout | Ribotenlimab | NDA/BLA | Micro | MS | |
| 2030-07-15 | 4.3y away | Ph3 Readout | Ceviglumide | NDA/BLA | Large | IgAN | |
| 2030-07-15 | 4.3y away | Interim | ARG-1924 | Preclinical | Large | T2D | |
| 2030-07-16 | 4.3y away | Interim | AGO-242 | Preclinical | Private | HNSCC | |
| 2030-07-17 | 4.3y away | Ph2 Data | Nirarelsin | Phase 2 | Large | Celiac | |
| 2030-07-17 | 4.3y away | Ph2 Data | REG-3155 | Phase 1/2 | Large | Cervical Ca | |
| 2030-07-17 | 4.3y away | Ph3 Readout | Datomavacamten | Approved | Small | Wilms | |
| 2030-07-18 | 4.3y away | Ph3 Readout | Tixafotisoran | Phase 3 | Small | NB | |
| 2030-07-18 | 4.3y away | Ph3 Readout | Semazasiran | NDA/BLA | Large | Meso | |
| 2030-07-19 | 4.3y away | Ph3 Readout | AZN-5978 | Phase 2/3 | Large | ALS | |
| 2030-07-20 | 4.3y away | Ph3 Readout | SND-9531 | Phase 3 | Mid | Migraine | |
| 2030-07-20 | 4.3y away | Ph2 Data | Rilunesiran | Phase 1/2 | Mid | GA | |
| 2030-07-20 | 4.3y away | Ph2 Data | Elralemzoparlimab | Phase 1/2 | Private | Pompe | |
| 2030-07-21 | 4.3y away | Ph3 Readout | KRO-9986 | Phase 3 | Small | Obesity | |
| 2030-07-21 | 4.3y away | Ph3 Readout | Sovazasiran | Phase 3 | Private | NSCLC | |
| 2030-07-22 | 4.4y away | Ph3 Readout | Tixatapinarof | Approved | Mid | Asthma | |
| 2030-07-22 | 4.4y away | Ph3 Readout | Cevisertib | Phase 2/3 | Mid | Thymoma | |
| 2030-07-23 | 4.4y away | Ph3 Readout | JNJ-5094 | Phase 2/3 | Large | Heart Failure | |
| 2030-07-23 | 4.4y away | Ph3 Readout | Miriinavolisib | Phase 3 | Private | PBC | |
| 2030-07-23 | 4.4y away | Ph2 Data | MED-3942 | Phase 2 | Private | NSCLC | |
| 2030-07-23 | 4.4y away | Ph3 Readout | Polafotisoran | Phase 2/3 | Private | ALL | |
| 2030-07-24 | 4.4y away | Ph3 Readout | Ribocilimab | Phase 3 | Small | Wilms | |
| 2030-07-24 | 4.4y away | Ph3 Readout | IMV-1446 | Approved | Micro | CRC | |
| 2030-07-25 | 4.4y away | Ph2 Data | 299-6118 | Phase 1/2 | Micro | Melanoma | |
| 2030-07-26 | 4.4y away | Ph3 Readout | BWA-1517 | Approved | Micro | FTD | |
| 2030-07-27 | 4.4y away | Ph3 Readout | GAL-555 | Phase 3 | Private | Psoriasis | |
| 2030-07-27 | 4.4y away | Ph3 Readout | CNT-5081 | Phase 3 | Micro | LGS | |
| 2030-08-01 | 4.4y away | Ph3 Readout | Nidaglumide | Approved | Private | IgAN | |
| 2030-08-01 | 4.4y away | Ph3 Readout | Gozefutibatinib | NDA/BLA | Private | RA | |
| 2030-08-01 | 4.4y away | Ph3 Readout | ZTS-820 | NDA/BLA | Large | DMD | |
| 2030-08-03 | 4.4y away | Ph2 Data | SEC-7279 | Phase 2 | Private | Ovarian Ca | |
| 2030-08-04 | 4.4y away | Interim | Miriosocimab | Phase 1 | Large | Dravet | |
| 2030-08-04 | 4.4y away | Ph3 Readout | CIP-213 | Approved | Large | Gastric Ca | |
| 2030-08-04 | 4.4y away | Ph2 Data | Pexaglumide | Phase 1/2 | Private | NASH | |
| 2030-08-04 | 4.4y away | Ph3 Readout | Pemifutibatinib | Phase 3 | Mid | Hemophilia A | |
| 2030-08-04 | 4.4y away | Interim | Semacapivasertib | Preclinical | Mid | Breast Ca | |
| 2030-08-05 | 4.4y away | Interim | COR-9456 | Preclinical | Mid | SLE | |
| 2030-08-05 | 4.4y away | Ph3 Readout | Semaglumide | Approved | Small | Bladder Ca | |
| 2030-08-05 | 4.4y away | Ph3 Readout | Polarasimod | Approved | Micro | MG | |
| 2030-08-06 | 4.4y away | Ph3 Readout | 300-2164 | Phase 3 | Mid | MCL | |
| 2030-08-06 | 4.4y away | Ph3 Readout | ZHE-9252 | Phase 3 | Private | Bladder Ca | |
| 2030-08-07 | 4.4y away | Ph2 Data | Nidazumab | Phase 1/2 | Private | ADPKD | |
| 2030-08-08 | 4.4y away | Ph3 Readout | Ivotuximab | NDA/BLA | Large | Pancreatic Ca | |
| 2030-08-08 | 4.4y away | Ph2 Data | Lisonaritide | Phase 1/2 | Mid | HS | |
| 2030-08-09 | 4.4y away | Ph3 Readout | Lisorasimod | Phase 2/3 | Private | Fabry | |
| 2030-08-09 | 4.4y away | Ph3 Readout | Capibrutinib | Phase 3 | Micro | Pompe | |
| 2030-08-10 | 4.4y away | Ph3 Readout | 452-670 | Approved | Large | Cervical Ca | |
| 2030-08-10 | 4.4y away | Ph3 Readout | Olpaglumide | Phase 2/3 | Private | RCC | |
| 2030-08-10 | 4.4y away | Ph3 Readout | ENC-6986 | Approved | Private | MCC | |
| 2030-08-11 | 4.4y away | Ph3 Readout | Semaglumide | Phase 3 | Private | PV | |
| 2030-08-12 | 4.4y away | Interim | Terarapivir | Phase 1 | Micro | RB | |
| 2030-08-13 | 4.4y away | Ph2 Data | Tezecapivasertib | Phase 2 | Micro | Ewing Sarcoma | |
| 2030-08-14 | 4.4y away | Interim | Zanutuximab | Phase 1 | Micro | Cervical Ca | |
| 2030-08-14 | 4.4y away | Ph2 Data | WST-4138 | Phase 1/2 | Large | PTSD | |
| 2030-08-15 | 4.4y away | Ph3 Readout | TRV-9337 | Approved | Micro | AML | |
| 2030-08-15 | 4.4y away | Ph2 Data | LAE-3866 | Phase 1/2 | Private | Ewing Sarcoma | |
| 2030-08-15 | 4.4y away | Ph3 Readout | Nirasacituzumab | Phase 3 | Large | Melanoma | |
| 2030-08-16 | 4.4y away | Ph2 Data | DAW-5540 | Phase 2 | Mid | ALS | |
| 2030-08-16 | 4.4y away | Ph3 Readout | Liraratamab | Phase 3 | Mid | Cervical Ca | |
| 2030-08-16 | 4.4y away | Ph2 Data | MIR-8648 | Phase 1/2 | Private | Thymoma | |
| 2030-08-16 | 4.4y away | Ph2 Data | KAL-3824 | Phase 1/2 | Micro | NASH | |
| 2030-08-17 | 4.4y away | Interim | Olpatinib | Preclinical | Large | MS | |
| 2030-08-17 | 4.4y away | Ph3 Readout | Nidaratamab | Phase 3 | Mid | Asthma | |
| 2030-08-17 | 4.4y away | Interim | TRE-8359 | Preclinical | Private | HS | |
| 2030-08-17 | 4.4y away | Interim | CYA-8318 | Preclinical | Micro | Endometrial Ca | |
| 2030-08-18 | 4.4y away | Interim | 180-3597 | Preclinical | Mid | Ewing Sarcoma | |
| 2030-08-18 | 4.4y away | Ph3 Readout | IDY-3466 | NDA/BLA | Mid | IgAN | |
| 2030-08-18 | 4.4y away | Interim | KLB-5656 | Phase 1 | Mid | Cholangiocarcinoma | |
| 2030-08-19 | 4.4y away | Ph3 Readout | CSL-8153 | Approved | Large | LN | |
| 2030-08-22 | 4.4y away | Ph3 Readout | Kemanesiran | Approved | Small | MDD | |
| 2030-08-22 | 4.4y away | Interim | OGN-5336 | Phase 1 | Mid | Migraine | |
| 2030-08-23 | 4.4y away | Ph3 Readout | Elrazanubrutinib | NDA/BLA | Private | SCD | |
| 2030-08-24 | 4.4y away | Ph2 Data | NVE-9277 | Phase 2 | Private | Wet AMD | |
| 2030-08-25 | 4.4y away | Ph2 Data | SNY-9073 | Phase 2 | Large | Wilms | |
| 2030-08-25 | 4.4y away | Interim | Motarapivir | Preclinical | Large | Heart Failure | |
| 2030-08-25 | 4.4y away | Ph3 Readout | Olpalemzoparlimab | Approved | Micro | SLE | |
| 2030-08-26 | 4.4y away | Ph3 Readout | ATH-6254 | Approved | Private | PsA | |
| 2030-08-28 | 4.5y away | Ph3 Readout | ALD-5252 | Phase 2/3 | Small | Schizophrenia | |
| 2030-08-28 | 4.5y away | Ph3 Readout | GAL-555 | Phase 3 | Private | AML | |
| 2030-08-28 | 4.5y away | Ph2 Data | Doxatenlimab | Phase 2 | Small | EoE | |
| 2030-09-01 | 4.5y away | Ph3 Readout | ENT-2952 | Phase 3 | Small | Thymoma | |
| 2030-09-01 | 4.5y away | Ph3 Readout | Polatapinarof | Approved | Mid | MG | |
| 2030-09-01 | 4.5y away | Ph3 Readout | RLF-5973 | Phase 3 | Micro | Breast Ca | |
| 2030-09-02 | 4.5y away | Interim | Voxafotisoran | Phase 1 | Large | RB | |
| 2030-09-02 | 4.5y away | Interim | Zoricapivasertib | Phase 1 | Mid | GBM | |
| 2030-09-02 | 4.5y away | Ph2 Data | WST-4138 | Phase 1/2 | Large | PSP | |
| 2030-09-02 | 4.5y away | Ph3 Readout | VIR-467 | Phase 3 | Mid | PSP | |
| 2030-09-04 | 4.5y away | Ph3 Readout | Gelisertib | Approved | Large | Psoriasis | |
| 2030-09-04 | 4.5y away | Ph3 Readout | NUV-283 | Phase 3 | Mid | Parkinson's | |
| 2030-09-04 | 4.5y away | Ph3 Readout | Tiramavacamten | Phase 2/3 | Micro | ET | |
| 2030-09-04 | 4.5y away | Ph2 Data | KLB-9971 | Phase 1/2 | Mid | DMD | |
| 2030-09-04 | 4.5y away | Ph3 Readout | Cevivorutinib | Phase 2/3 | Micro | CLL | |
| 2030-09-05 | 4.5y away | Ph3 Readout | Adagravorutinib | Phase 3 | Private | IgAN | |
| 2030-09-05 | 4.5y away | Interim | Terafotisoran | Phase 1 | Small | NASH | |
| 2030-09-05 | 4.5y away | Interim | GLO-6047 | Preclinical | Private | FSGS | |
| 2030-09-05 | 4.5y away | Ph3 Readout | NEO-1964 | Phase 3 | Private | Epilepsy | |
| 2030-09-06 | 4.5y away | Interim | Zorizanubrutinib | Phase 1 | Large | Pompe | |
| 2030-09-07 | 4.5y away | Interim | Suraglumide | Phase 1 | Private | Pompe | |
| 2030-09-09 | 4.5y away | Ph2 Data | SHI-1915 | Phase 2 | Private | Myelofibrosis | |
| 2030-09-10 | 4.5y away | Ph3 Readout | NTL-2576 | NDA/BLA | Mid | Gastric Ca | |
| 2030-09-10 | 4.5y away | Interim | 069-1659 | Preclinical | Small | MDD | |
| 2030-09-10 | 4.5y away | Ph2 Data | BIO-1735 | Phase 2 | Private | HNSCC | |
| 2030-09-11 | 4.5y away | Ph3 Readout | Zanutinib | Phase 2/3 | Large | SCLC | |
| 2030-09-11 | 4.5y away | Ph3 Readout | Cevivorutinib | Phase 2/3 | Micro | CLL | |
| 2030-09-12 | 4.5y away | Ph3 Readout | Tixasotorasib | NDA/BLA | Private | Pancreatic Ca | |
| 2030-09-13 | 4.5y away | Ph3 Readout | Tirarapivir | Approved | Large | Parkinson's | |
| 2030-09-13 | 4.5y away | Interim | Geliglumide | Phase 1 | Private | BCC | |
| 2030-09-13 | 4.5y away | Ph2 Data | CLB-2823 | Phase 2 | Micro | MDS | |
| 2030-09-14 | 4.5y away | Interim | 451-3882 | Phase 1 | Large | Breast Ca | |
| 2030-09-14 | 4.5y away | Ph3 Readout | IMM-2816 | Approved | Private | ADPKD | |
| 2030-09-14 | 4.5y away | Interim | REM-8705 | Preclinical | Private | ACC | |
| 2030-09-14 | 4.5y away | Ph2 Data | OGN-4949 | Phase 1/2 | Mid | Urothelial Ca | |
| 2030-09-15 | 4.5y away | Ph2 Data | Olpaderotide | Phase 2 | Private | Thymoma | |
| 2030-09-16 | 4.5y away | Ph3 Readout | PCV-5987 | Phase 2/3 | Mid | RSV | |
| 2030-09-18 | 4.5y away | Interim | RUI-IIT-701 | Phase 1 | Private | SMA | |
| 2030-09-19 | 4.5y away | Ph3 Readout | Cevinaritide | Phase 2/3 | Large | CTCL | |
| 2030-09-19 | 4.5y away | Ph3 Readout | Adagracapivasertib | Approved | Private | Pompe | |
| 2030-09-22 | 4.5y away | Ph3 Readout | INH-5545 | Phase 3 | Private | Melanoma | |
| 2030-09-22 | 4.5y away | Interim | Voxazasiran | Phase 1 | Micro | Atopic Derm | |
| 2030-09-23 | 4.5y away | Ph3 Readout | SAM-IIT-636 | NDA/BLA | Private | AS | |
| 2030-09-23 | 4.5y away | Ph3 Readout | Datocilimab | Approved | Small | EoE | |
| 2030-09-24 | 4.5y away | Interim | Ceviderotide | Preclinical | Large | UC | |
| 2030-09-24 | 4.5y away | Ph2 Data | IMV-6044 | Phase 1/2 | Private | Ewing Sarcoma | |
| 2030-09-25 | 4.5y away | Ph2 Data | BGN-3305 | Phase 2 | Large | PsA | |
| 2030-09-25 | 4.5y away | Ph2 Data | TRV-9080 | Phase 1/2 | Micro | Ewing Sarcoma | |
| 2030-09-25 | 4.5y away | Interim | VRN-4215 | Preclinical | Mid | PNH | |
| 2030-09-25 | 4.5y away | Ph2 Data | Nirarapivir | Phase 2 | Large | RA | |
| 2030-09-25 | 4.5y away | Ph3 Readout | ORY-4744 | Phase 2/3 | Micro | Celiac | |
| 2030-09-25 | 4.5y away | Ph3 Readout | HOS-IIT-414 | NDA/BLA | Private | DMD | |
| 2030-09-26 | 4.5y away | Ph3 Readout | Sovalemzoparlimab | Phase 2/3 | Private | WM | |
| 2030-09-27 | 4.5y away | Ph2 Data | ALN-3958 | Phase 2 | Large | PNH | |
| 2030-09-27 | 4.5y away | Ph3 Readout | Zanutuximab | Phase 2/3 | Private | Asthma | |
| 2030-09-27 | 4.5y away | Ph3 Readout | MYG-309 | NDA/BLA | Mid | MM | |
| 2030-09-28 | 4.5y away | Ph3 Readout | Elrazumab | NDA/BLA | Private | Pancreatic Ca | |
| 2030-10-01 | 4.5y away | Ph2 Data | SRP-3270 | Phase 1/2 | Large | LGS | |
| 2030-10-01 | 4.5y away | Interim | Zorifotisoran | Preclinical | Micro | OCD | |
| 2030-10-02 | 4.5y away | Ph2 Data | Pexaosocimab | Phase 2 | Large | CKD | |
| 2030-10-03 | 4.6y away | Interim | Zoribrutinib | Preclinical | Large | NB | |
| 2030-10-03 | 4.6y away | Ph3 Readout | SYN-6765 | Approved | Small | PSP | |
| 2030-10-04 | 4.6y away | Ph2 Data | Nidasacituzumab | Phase 1/2 | Large | MG | |
| 2030-10-04 | 4.6y away | Ph3 Readout | Nirasacituzumab | Phase 3 | Large | Melanoma | |
| 2030-10-05 | 4.6y away | Interim | Tezezanubrutinib | Preclinical | Micro | PNH | |
| 2030-10-05 | 4.6y away | Ph3 Readout | Doxafotisoran | Phase 3 | Private | AS | |
| 2030-10-06 | 4.6y away | Ph2 Data | Fixatapinarof | Phase 2 | Private | Schizophrenia | |
| 2030-10-06 | 4.6y away | Ph2 Data | TOR-2843 | Phase 1/2 | Mid | ACC | |
| 2030-10-07 | 4.6y away | Ph3 Readout | VRT-5441 | Phase 3 | Large | NB | |
| 2030-10-07 | 4.6y away | Ph3 Readout | Polamavacamten | NDA/BLA | Private | Fabry | |
| 2030-10-08 | 4.6y away | Ph3 Readout | Ribocilimab | Phase 3 | Small | Wilms | |
| 2030-10-09 | 4.6y away | Ph3 Readout | Lisotapinarof | Approved | Private | Ewing Sarcoma | |
| 2030-10-09 | 4.6y away | Ph2 Data | ACO-697 | Phase 1/2 | Micro | Wilms | |
| 2030-10-09 | 4.6y away | Ph3 Readout | Tirainavolisib | Phase 3 | Private | Parkinson's | |
| 2030-10-10 | 4.6y away | Ph3 Readout | NAT-IIT-682 | Approved | Private | PsA | |
| 2030-10-10 | 4.6y away | Ph3 Readout | Pemicagene | Approved | Private | FSGS | |
| 2030-10-11 | 4.6y away | Ph3 Readout | FHT-3384 | NDA/BLA | Small | FTD | |
| 2030-10-11 | 4.6y away | Interim | RLY-2544 | Preclinical | Micro | CRC | |
| 2030-10-12 | 4.6y away | Ph3 Readout | Lirarelsin | Approved | Private | Pancreatic Ca | |
| 2030-10-12 | 4.6y away | Ph3 Readout | Fixalucimab | NDA/BLA | Micro | GIST | |
| 2030-10-13 | 4.6y away | Ph3 Readout | NOX-4885 | NDA/BLA | Micro | MDS | |
| 2030-10-14 | 4.6y away | Ph2 Data | AIM-9920 | Phase 2 | Private | T2D | |
| 2030-10-14 | 4.6y away | Ph3 Readout | RLF-2389 | Approved | Micro | Ovarian Ca | |
| 2030-10-14 | 4.6y away | Ph3 Readout | Nidaglumide | Approved | Private | MCC | |
| 2030-10-15 | 4.6y away | Ph3 Readout | Olpaosocimab | Approved | Private | RSV | |
| 2030-10-15 | 4.6y away | Ph3 Readout | HET-1500 | Phase 2/3 | Private | PBC | |
| 2030-10-16 | 4.6y away | Interim | Nidaratamab | Preclinical | Mid | Hemophilia A | |
| 2030-10-16 | 4.6y away | Ph2 Data | Mavutenlimab | Phase 2 | Private | Prostate Ca | |
| 2030-10-16 | 4.6y away | Ph3 Readout | NEO-1964 | Phase 3 | Private | Epilepsy | |
| 2030-10-17 | 4.6y away | Ph3 Readout | Zoriosocimab | Phase 3 | Small | Ewing Sarcoma | |
| 2030-10-17 | 4.6y away | Ph3 Readout | Tixatenlimab | Approved | Private | SCD | |
| 2030-10-17 | 4.6y away | Ph3 Readout | Doxabrutinib | Phase 2/3 | Private | ADHD | |
| 2030-10-18 | 4.6y away | Ph2 Data | Tezesotorasib | Phase 2 | Small | Dravet | |
| 2030-10-18 | 4.6y away | Ph3 Readout | XBI-1781 | Phase 3 | Small | ADPKD | |
| 2030-10-18 | 4.6y away | Ph2 Data | 117-5200 | Phase 2 | Large | SMA | |
| 2030-10-19 | 4.6y away | Interim | KAR-5490 | Phase 1 | Private | Epilepsy | |
| 2030-10-19 | 4.6y away | Ph3 Readout | Rimanaritide | Phase 3 | Private | MDS | |
| 2030-10-19 | 4.6y away | Ph3 Readout | SEV-IIT-475 | Approved | Private | LGS | |
| 2030-10-20 | 4.6y away | Ph3 Readout | Sovacapivasertib | Phase 3 | Large | CRC | |
| 2030-10-20 | 4.6y away | Ph3 Readout | Semasacituzumab | Phase 3 | Large | Celiac | |
| 2030-10-20 | 4.6y away | Ph2 Data | FRE-IIT-474 | Phase 2 | Private | HS | |
| 2030-10-20 | 4.6y away | Ph3 Readout | MAS-IIT-445 | NDA/BLA | Private | Psoriasis | |
| 2030-10-20 | 4.6y away | Ph3 Readout | VEE-3535 | NDA/BLA | Large | Myelofibrosis | |
| 2030-10-21 | 4.6y away | Interim | Zenoglumide | Preclinical | Micro | FTD | |
| 2030-10-21 | 4.6y away | Ph3 Readout | Elrabrutinib | Phase 3 | Private | Cervical Ca | |
| 2030-10-21 | 4.6y away | Ph3 Readout | Kematenlimab | Phase 2/3 | Private | Schizophrenia | |
| 2030-10-22 | 4.6y away | Ph3 Readout | UCS-IIT-783 | NDA/BLA | Private | Breast Ca | |
| 2030-10-22 | 4.6y away | Interim | Ceviosocimab | Preclinical | Small | WM | |
| 2030-10-22 | 4.6y away | Interim | Pemitinib | Preclinical | Large | DLBCL | |
| 2030-10-22 | 4.6y away | Ph3 Readout | ASK-6688 | NDA/BLA | Private | Pompe | |
| 2030-10-22 | 4.6y away | Interim | PAR-6401 | Phase 1 | Micro | PsA | |
| 2030-10-22 | 4.6y away | Interim | PAC-8776 | Preclinical | Small | Rett | |
| 2030-10-23 | 4.6y away | Ph3 Readout | ARC-5137 | Approved | Private | SCD | |
| 2030-10-24 | 4.6y away | Interim | MED-3086 | Preclinical | Private | AML | |
| 2030-10-24 | 4.6y away | Interim | PRO-1192 | Phase 1 | Private | FL | |
| 2030-10-24 | 4.6y away | Ph2 Data | GRF-1969 | Phase 1/2 | Mid | T2D | |
| 2030-10-25 | 4.6y away | Interim | Tezetinib | Phase 1 | Mid | Gastric Ca | |
| 2030-10-26 | 4.6y away | Ph3 Readout | Mirinaritide | Phase 2/3 | Mid | MCC | |
| 2030-10-26 | 4.6y away | Ph2 Data | MIM-1147 | Phase 2 | Private | Angelman | |
| 2030-10-26 | 4.6y away | Ph2 Data | Adagranesiran | Phase 2 | Private | LGS | |
| 2030-10-27 | 4.6y away | Ph3 Readout | Olpafutibatinib | Approved | Mid | Migraine | |
| 2030-10-27 | 4.6y away | Interim | GC-6461 | Preclinical | Private | CML | |
| 2030-10-27 | 4.6y away | Ph3 Readout | Sotoglumide | Phase 2/3 | Private | Obesity | |
| 2030-10-28 | 4.6y away | Ph3 Readout | TRI-2954 | Approved | Private | Dravet | |
| 2030-10-28 | 4.6y away | Ph3 Readout | MOL-8666 | Approved | Micro | PV | |
| 2030-10-28 | 4.6y away | Ph2 Data | Gozesotorasib | Phase 1/2 | Mid | HCC | |
| 2030-11-01 | 4.6y away | Ph2 Data | TRE-5650 | Phase 1/2 | Private | CKD | |
| 2030-11-01 | 4.6y away | Ph3 Readout | Nirazumab | Phase 2/3 | Small | HCC | |
| 2030-11-02 | 4.6y away | Ph2 Data | ZTS-7862 | Phase 1/2 | Large | MDS | |
| 2030-11-03 | 4.6y away | Ph3 Readout | Semalucimab | Phase 3 | Mid | DMD | |
| 2030-11-03 | 4.6y away | Ph3 Readout | TAB-303 | Phase 3 | Private | GBM | |
| 2030-11-05 | 4.6y away | Ph3 Readout | SAV-5205 | NDA/BLA | Small | Parkinson's | |
| 2030-11-05 | 4.6y away | Ph3 Readout | LPC-975 | Phase 2/3 | Mid | Schizophrenia | |
| 2030-11-05 | 4.6y away | Ph3 Readout | MRK-6740 | Phase 2/3 | Large | AS | |
| 2030-11-05 | 4.6y away | Ph3 Readout | VIN-2751 | Phase 2/3 | Private | MDD | |
| 2030-11-05 | 4.6y away | Ph2 Data | Riboosocimab | Phase 2 | Private | Cholangiocarcinoma | |
| 2030-11-06 | 4.6y away | Ph3 Readout | CGO-2579 | Approved | Mid | PBC | |
| 2030-11-07 | 4.6y away | Ph3 Readout | TEM-4581 | Phase 2/3 | Mid | Narcolepsy | |
| 2030-11-07 | 4.6y away | Ph2 Data | Fixatenlimab | Phase 1/2 | Micro | Crohn's | |
| 2030-11-08 | 4.6y away | Ph3 Readout | Darafutibatinib | NDA/BLA | Large | Pompe | |
| 2030-11-09 | 4.7y away | Ph2 Data | KYM-8808 | Phase 1/2 | Mid | AS | |
| 2030-11-09 | 4.7y away | Ph3 Readout | Datocapivasertib | Phase 2/3 | Private | HNSCC | |
| 2030-11-10 | 4.7y away | Ph3 Readout | INH-5545 | Phase 3 | Private | CML | |
| 2030-11-10 | 4.7y away | Interim | Olpacilimab | Phase 1 | Private | Urothelial Ca | |
| 2030-11-10 | 4.7y away | Ph3 Readout | PCI-4776 | Phase 3 | Micro | MM | |
| 2030-11-11 | 4.7y away | Ph3 Readout | Zoriosocimab | Approved | Mid | NB | |
| 2030-11-12 | 4.7y away | Ph3 Readout | ZYN-3484 | Phase 2/3 | Micro | Migraine | |
| 2030-11-12 | 4.7y away | Ph3 Readout | NBS-1842 | NDA/BLA | Micro | LN | |
| 2030-11-13 | 4.7y away | Ph3 Readout | Kemanaritide | Phase 3 | Small | ACC | |
| 2030-11-13 | 4.7y away | Interim | ELO-7470 | Preclinical | Private | MS | |
| 2030-11-13 | 4.7y away | Ph2 Data | Polalucimab | Phase 2 | Micro | Fabry | |
| 2030-11-13 | 4.7y away | Ph3 Readout | NTC-7741 | NDA/BLA | Private | SCLC | |
| 2030-11-14 | 4.7y away | Ph3 Readout | Zanurapivir | NDA/BLA | Large | LGS | |
| 2030-11-14 | 4.7y away | Ph3 Readout | RAP-2478 | Phase 3 | Small | PBC | |
| 2030-11-14 | 4.7y away | Ph2 Data | ASL-9777 | Phase 2 | Micro | UC | |
| 2030-11-15 | 4.7y away | Ph2 Data | Polasertib | Phase 1/2 | Small | Bladder Ca | |
| 2030-11-16 | 4.7y away | Ph3 Readout | PHL-685 | Approved | Small | Cholangiocarcinoma | |
| 2030-11-16 | 4.7y away | Ph3 Readout | TEV-7734 | Approved | Large | FL | |
| 2030-11-17 | 4.7y away | Ph3 Readout | CGE-1983 | Phase 2/3 | Micro | NMOSD | |
| 2030-11-18 | 4.7y away | Interim | BAY-3308 | Phase 1 | Large | GBM | |
| 2030-11-18 | 4.7y away | Ph2 Data | Lisosacituzumab | Phase 1/2 | Private | FTD | |
| 2030-11-19 | 4.7y away | Ph3 Readout | Voxasotorasib | Phase 3 | Private | AS | |
| 2030-11-19 | 4.7y away | Ph3 Readout | CAP-150 | NDA/BLA | Private | MG | |
| 2030-11-19 | 4.7y away | Interim | Motamavacamten | Preclinical | Micro | PBC | |
| 2030-11-19 | 4.7y away | Interim | CTT-403 | Phase 1 | Private | Hemophilia A | |
| 2030-11-20 | 4.7y away | Interim | Nidaosocimab | Phase 1 | Mid | GIST | |
| 2030-11-21 | 4.7y away | Ph3 Readout | XTA-4333 | Approved | Private | Breast Ca | |
| 2030-11-21 | 4.7y away | Ph3 Readout | Olpazumab | Approved | Private | Ewing Sarcoma | |
| 2030-11-23 | 4.7y away | Ph3 Readout | Rimafotisoran | Phase 2/3 | Private | HS | |
| 2030-11-24 | 4.7y away | Ph3 Readout | Gelizasiran | Phase 3 | Private | Migraine | |
| 2030-11-25 | 4.7y away | Interim | APT-1263 | Phase 1 | Micro | LN | |
| 2030-11-25 | 4.7y away | Ph3 Readout | Tixatenlimab | Approved | Private | UC | |
| 2030-11-25 | 4.7y away | Ph2 Data | GRF-1969 | Phase 1/2 | Mid | T2D | |
| 2030-11-25 | 4.7y away | Ph3 Readout | Suracagene | Phase 3 | Large | Atopic Derm | |
| 2030-11-25 | 4.7y away | Interim | Bemazanubrutinib | Preclinical | Mid | Crohn's | |
| 2030-11-26 | 4.7y away | Ph3 Readout | MOR-3625 | NDA/BLA | Private | Cervical Ca | |
| 2030-11-26 | 4.7y away | Ph3 Readout | Sotoderotide | Phase 3 | Micro | Alzheimer's | |
| 2030-11-27 | 4.7y away | Ph2 Data | HAL-996 | Phase 1/2 | Large | Huntington's | |
| 2030-11-28 | 4.7y away | Ph2 Data | Semarasimod | Phase 1/2 | Small | HCC | |
| 2030-12-02 | 4.7y away | Interim | Olpavorutinib | Preclinical | Mid | Narcolepsy | |
| 2030-12-02 | 4.7y away | Ph3 Readout | IMM-7144 | Approved | Private | EoE | |
| 2030-12-02 | 4.7y away | Interim | TAB-6074 | Preclinical | Private | PAH | |
| 2030-12-03 | 4.7y away | Interim | Daratuximab | Phase 1 | Large | Narcolepsy | |
| 2030-12-03 | 4.7y away | Interim | Bemabrutinib | Phase 1 | Mid | CF | |
| 2030-12-03 | 4.7y away | Ph2 Data | CAM-IIT-608 | Phase 1/2 | Private | Urothelial Ca | |
| 2030-12-04 | 4.7y away | Ph3 Readout | Lisolemzoparlimab | Approved | Large | HNSCC | |
| 2030-12-04 | 4.7y away | Ph3 Readout | Zanusotorasib | Phase 2/3 | Large | IPF | |
| 2030-12-06 | 4.7y away | Ph3 Readout | NVS-6360 | Approved | Large | FTD | |
| 2030-12-07 | 4.7y away | Interim | SLR-4773 | Preclinical | Small | FSGS | |
| 2030-12-08 | 4.7y away | Ph3 Readout | DEE-8943 | Phase 2/3 | Private | CML | |
| 2030-12-09 | 4.7y away | Ph3 Readout | CEL-1794 | Approved | Private | NMOSD | |
| 2030-12-09 | 4.7y away | Interim | Taladerotide | Phase 1 | Private | Obesity | |
| 2030-12-11 | 4.7y away | Ph3 Readout | ABB-3951 | Phase 2/3 | Large | Alzheimer's | |
| 2030-12-11 | 4.7y away | Ph3 Readout | Fixaglumide | Phase 2/3 | Large | Cervical Ca | |
| 2030-12-11 | 4.7y away | Ph2 Data | INH-2936 | Phase 2 | Private | HCC | |
| 2030-12-12 | 4.7y away | Ph3 Readout | Daratuximab | Approved | Mid | DLBCL | |
| 2030-12-12 | 4.7y away | Interim | Tezebrutinib | Preclinical | Private | LGS | |
| 2030-12-12 | 4.7y away | Interim | BEA-1452 | Phase 1 | Private | Rett | |
| 2030-12-13 | 4.7y away | Ph3 Readout | Doxarasimod | Phase 3 | Private | MDD | |
| 2030-12-13 | 4.7y away | Interim | FUD-IIT-297 | Preclinical | Private | Celiac | |
| 2030-12-14 | 4.7y away | Ph3 Readout | Pexainavolisib | Approved | Private | GA | |
| 2030-12-14 | 4.7y away | Ph3 Readout | Ceviosocimab | NDA/BLA | Private | CF | |
| 2030-12-14 | 4.7y away | Ph2 Data | Datocagene | Phase 2 | Mid | IgAN | |
| 2030-12-15 | 4.8y away | Ph3 Readout | Kemanesiran | Approved | Small | CLL | |
| 2030-12-15 | 4.8y away | Interim | Capizanubrutinib | Preclinical | Small | Ewing Sarcoma | |
| 2030-12-15 | 4.8y away | Ph3 Readout | Adagratapinarof | Phase 3 | Private | GIST | |
| 2030-12-16 | 4.8y away | Ph3 Readout | KIA-7048 | Phase 3 | Private | UC | |
| 2030-12-18 | 4.8y away | Ph3 Readout | Mirivorutinib | Phase 3 | Private | Alzheimer's | |
| 2030-12-20 | 4.8y away | Ph3 Readout | Lisocilimab | Phase 2/3 | Private | Heart Failure | |
| 2030-12-21 | 4.8y away | Ph3 Readout | Datomavacamten | Approved | Small | Wilms | |
| 2030-12-21 | 4.8y away | Ph3 Readout | SEV-IIT-392 | NDA/BLA | Private | Atopic Derm | |
| 2030-12-22 | 4.8y away | Interim | INT-3699 | Preclinical | Private | Angelman | |
| 2030-12-24 | 4.8y away | Interim | Doxazasiran | Preclinical | Private | RB | |
| 2030-12-24 | 4.8y away | Ph3 Readout | Motafutibatinib | Approved | Private | Meso | |
| 2030-12-24 | 4.8y away | Ph2 Data | Adagraderotide | Phase 2 | Micro | CSU | |
| 2030-12-25 | 4.8y away | Ph3 Readout | Voxamavacamten | Approved | Mid | Celiac | |
| 2030-12-25 | 4.8y away | Interim | Voxainavolisib | Preclinical | Private | SMA | |
| 2030-12-25 | 4.8y away | Ph3 Readout | RLF-2389 | Approved | Micro | MM | |
| 2030-12-26 | 4.8y away | Interim | Tixasotorasib | Preclinical | Small | IPF | |
| 2030-12-26 | 4.8y away | Ph2 Data | Tezetenlimab | Phase 2 | Private | MG | |
| 2030-12-27 | 4.8y away | Ph3 Readout | Capifutibatinib | Phase 2/3 | Private | CSU | |
| 2030-12-27 | 4.8y away | Ph3 Readout | UNC-3197 | NDA/BLA | Micro | RCC | |
| 2030-12-27 | 4.8y away | Ph3 Readout | AUT-9774 | Phase 2/3 | Small | MCC | |
| 2030-12-27 | 4.8y away | Ph2 Data | Pexavorutinib | Phase 1/2 | Private | Obesity | |
| 2030-12-28 | 4.8y away | Ph2 Data | Kemaratamab | Phase 1/2 | Small | UC | |
| 2030-12-28 | 4.8y away | Ph2 Data | Darasertib | Phase 1/2 | Private | Atopic Derm | |
| 2031-01-01 | 4.8y away | Ph2 Data | BII-1564 | Phase 2 | Large | DLBCL | |
| 2031-01-01 | 4.8y away | Ph3 Readout | NUV-283 | Phase 3 | Mid | Parkinson's | |
| 2031-01-01 | 4.8y away | Ph3 Readout | MED-9563 | Approved | Private | Prostate Ca | |
| 2031-01-02 | 4.8y away | Ph3 Readout | Surazasiran | NDA/BLA | Micro | Angelman | |
| 2031-01-03 | 4.8y away | Ph2 Data | Zenoderotide | Phase 1/2 | Micro | Ovarian Ca | |
| 2031-01-04 | 4.8y away | Ph2 Data | Zenoglumide | Phase 2 | Mid | AML | |
| 2031-01-05 | 4.8y away | Interim | 451-4848 | Preclinical | Large | GIST | |
| 2031-01-05 | 4.8y away | Ph3 Readout | Cevirapivir | Approved | Small | HCC | |
| 2031-01-05 | 4.8y away | Ph3 Readout | NTC-6338 | Approved | Private | Celiac | |
| 2031-01-06 | 4.8y away | Interim | DPH-7069 | Phase 1 | Micro | NMOSD | |
| 2031-01-06 | 4.8y away | Interim | Doxafotisoran | Phase 1 | Large | SMA | |
| 2031-01-07 | 4.8y away | Ph3 Readout | ENC-8622 | Phase 3 | Private | Urothelial Ca | |
| 2031-01-08 | 4.8y away | Ph3 Readout | LLY-4358 | Phase 3 | Large | Migraine | |
| 2031-01-10 | 4.8y away | Ph3 Readout | Capirapivir | Approved | Micro | ALS | |
| 2031-01-10 | 4.8y away | Interim | AII-IIT-336 | Preclinical | Private | NB | |
| 2031-01-11 | 4.8y away | Interim | Tezesotorasib | Preclinical | Micro | LN | |
| 2031-01-11 | 4.8y away | Ph3 Readout | RLY-4615 | Phase 3 | Micro | Prostate Ca | |
| 2031-01-11 | 4.8y away | Ph3 Readout | Kematinib | Approved | Private | Cholangiocarcinoma | |
| 2031-01-12 | 4.8y away | Ph3 Readout | Bemaglumide | Phase 3 | Mid | Prostate Ca | |
| 2031-01-12 | 4.8y away | Ph3 Readout | PHL-685 | Approved | Small | Ewing Sarcoma | |
| 2031-01-16 | 4.8y away | Ph3 Readout | Elrazanubrutinib | NDA/BLA | Mid | FSGS | |
| 2031-01-17 | 4.8y away | Ph3 Readout | NVO-2974 | NDA/BLA | Large | MCL | |
| 2031-01-19 | 4.8y away | Ph3 Readout | ACL-6459 | Phase 3 | Mid | FL | |
| 2031-01-19 | 4.8y away | Ph3 Readout | Zanufotisoran | Approved | Small | NSCLC | |
| 2031-01-21 | 4.9y away | Ph2 Data | BDT-405 | Phase 1/2 | Micro | CML | |
| 2031-01-21 | 4.9y away | Ph3 Readout | Olpasacituzumab | Approved | Private | ALL | |
| 2031-01-22 | 4.9y away | Ph3 Readout | AMG-9052 | Phase 2/3 | Large | MM | |
| 2031-01-22 | 4.9y away | Ph2 Data | IST-1205 | Phase 2 | Private | Thymoma | |
| 2031-01-23 | 4.9y away | Ph3 Readout | GIL-2259 | Approved | Large | ET | |
| 2031-01-23 | 4.9y away | Ph3 Readout | RUI-IIT-267 | Approved | Private | Hemophilia A | |
| 2031-01-24 | 4.9y away | Interim | NOR-5927 | Phase 1 | Private | Epilepsy | |
| 2031-01-24 | 4.9y away | Ph3 Readout | A-1206 | Phase 2/3 | Large | DMD | |
| 2031-01-25 | 4.9y away | Ph2 Data | HOR-3601 | Phase 1/2 | Private | RB | |
| 2031-01-25 | 4.9y away | Ph2 Data | AIM-9920 | Phase 2 | Private | Huntington's | |
| 2031-01-25 | 4.9y away | Ph2 Data | Geliderotide | Phase 2 | Mid | RCC | |
| 2031-01-28 | 4.9y away | Interim | Doxazasiran | Phase 1 | Mid | Breast Ca | |
| 2031-02-01 | 4.9y away | Ph3 Readout | MRK-3812 | Phase 3 | Micro | PSP | |
| 2031-02-01 | 4.9y away | Ph2 Data | 458-3114 | Phase 1/2 | Micro | Celiac | |
| 2031-02-02 | 4.9y away | Ph2 Data | IMV-2493 | Phase 2 | Mid | Schizophrenia | |
| 2031-02-02 | 4.9y away | Ph3 Readout | Mavufotisoran | Approved | Large | HS | |
| 2031-02-04 | 4.9y away | Ph3 Readout | Mavucagene | NDA/BLA | Private | CLL | |
| 2031-02-04 | 4.9y away | Ph3 Readout | Doxabrutinib | Phase 2/3 | Private | ADHD | |
| 2031-02-05 | 4.9y away | Ph3 Readout | Daralucimab | Phase 2/3 | Private | SLE | |
| 2031-02-05 | 4.9y away | Interim | Zanutuximab | Phase 1 | Micro | Cervical Ca | |
| 2031-02-05 | 4.9y away | Ph3 Readout | 453-180 | Phase 3 | Mid | AS | |
| 2031-02-06 | 4.9y away | Ph2 Data | BEA-4274 | Phase 1/2 | Mid | Schizophrenia | |
| 2031-02-06 | 4.9y away | Interim | Gozederotide | Preclinical | Micro | MM | |
| 2031-02-06 | 4.9y away | Ph3 Readout | PRT-8732 | Phase 2/3 | Mid | FL | |
| 2031-02-07 | 4.9y away | Ph3 Readout | Ivocilimab | NDA/BLA | Private | Obesity | |
| 2031-02-07 | 4.9y away | Interim | IDX-6209 | Preclinical | Large | CRC | |
| 2031-02-07 | 4.9y away | Ph3 Readout | Gelibrutinib | NDA/BLA | Large | Endometrial Ca | |
| 2031-02-08 | 4.9y away | Interim | ARA-160 | Phase 1 | Micro | Celiac | |
| 2031-02-08 | 4.9y away | Ph3 Readout | Ivosotorasib | Phase 2/3 | Micro | PBC | |
| 2031-02-09 | 4.9y away | Ph3 Readout | Rilufutibatinib | Phase 3 | Private | CRC | |
| 2031-02-10 | 4.9y away | Ph2 Data | IMV-6752 | Phase 2 | Private | Cholangiocarcinoma | |
| 2031-02-11 | 4.9y away | Interim | NVS-3297 | Preclinical | Large | WM | |
| 2031-02-11 | 4.9y away | Ph3 Readout | Datoglumide | Approved | Large | SLE | |
| 2031-02-11 | 4.9y away | Ph3 Readout | Sotorapivir | Approved | Large | PNH | |
| 2031-02-11 | 4.9y away | Ph3 Readout | Tixafotisoran | Phase 3 | Small | NB | |
| 2031-02-11 | 4.9y away | Ph2 Data | Voxavorutinib | Phase 2 | Micro | WM | |
| 2031-02-11 | 4.9y away | Ph3 Readout | FRO-509 | Approved | Private | CKD | |
| 2031-02-11 | 4.9y away | Ph2 Data | Adagratuximab | Phase 2 | Private | ALL | |
| 2031-02-11 | 4.9y away | Ph3 Readout | ZTS-9629 | Phase 3 | Large | ADHD | |
| 2031-02-12 | 4.9y away | Ph3 Readout | Fixaglumide | Phase 2/3 | Large | Thymoma | |
| 2031-02-12 | 4.9y away | Ph3 Readout | CER-4594 | Phase 3 | Private | RA | |
| 2031-02-12 | 4.9y away | Interim | Rimamavacamten | Preclinical | Private | ADPKD | |
| 2031-02-13 | 4.9y away | Ph3 Readout | TUR-4034 | Phase 2/3 | Private | Psoriasis | |
| 2031-02-14 | 4.9y away | Ph2 Data | DMA-2916 | Phase 1/2 | Micro | ADPKD | |
| 2031-02-14 | 4.9y away | Ph3 Readout | KOD-8391 | Phase 2/3 | Small | Meso | |
| 2031-02-16 | 4.9y away | Ph3 Readout | Tirasacituzumab | NDA/BLA | Mid | RA | |
| 2031-02-16 | 4.9y away | Ph2 Data | Tezesotorasib | Phase 2 | Small | Dravet | |
| 2031-02-16 | 4.9y away | Interim | ABL-1749 | Phase 1 | Private | ALL | |
| 2031-02-16 | 4.9y away | Interim | ZTS-7156 | Preclinical | Large | Crohn's | |
| 2031-02-16 | 4.9y away | Ph3 Readout | Ivosotorasib | Phase 2/3 | Mid | LN | |
| 2031-02-19 | 4.9y away | Ph3 Readout | Kemavorutinib | Phase 2/3 | Private | PV | |
| 2031-02-20 | 4.9y away | Ph3 Readout | Capirapivir | Approved | Mid | Obesity | |
| 2031-02-21 | 4.9y away | Ph3 Readout | ASN-7038 | Phase 3 | Mid | Bladder Ca | |
| 2031-02-21 | 4.9y away | Ph2 Data | Terazumab | Phase 2 | Small | PSP | |
| 2031-02-21 | 4.9y away | Ph3 Readout | RNA-7525 | Phase 2/3 | Mid | PV | |
| 2031-02-21 | 4.9y away | Ph3 Readout | Liracagene | NDA/BLA | Small | CLL | |
| 2031-02-22 | 4.9y away | Ph3 Readout | Sotobrutinib | NDA/BLA | Small | CF | |
| 2031-02-22 | 4.9y away | Ph2 Data | IMM-7074 | Phase 1/2 | Private | ALL | |
| 2031-02-22 | 4.9y away | Ph3 Readout | Capicagene | Approved | Private | Asthma | |
| 2031-02-22 | 4.9y away | Ph3 Readout | Zoriratamab | Approved | Mid | Schizophrenia | |
| 2031-02-23 | 4.9y away | Ph2 Data | Daracilimab | Phase 2 | Large | Prostate Ca | |
| 2031-02-23 | 4.9y away | Ph2 Data | Lisoderotide | Phase 1/2 | Mid | CLL | |
| 2031-02-23 | 4.9y away | Ph3 Readout | ZYM-7222 | Approved | Private | Cervical Ca | |
| 2031-02-26 | 5.0y away | Ph3 Readout | Tirarelsin | NDA/BLA | Mid | T2D | |
| 2031-02-27 | 5.0y away | Ph2 Data | Voxarasimod | Phase 1/2 | Large | NB | |
| 2031-02-27 | 5.0y away | Ph2 Data | ASM-4182 | Phase 2 | Micro | Ewing Sarcoma | |
| 2031-02-27 | 5.0y away | Ph3 Readout | Datorasimod | Approved | Micro | GBM | |
| 2031-02-27 | 5.0y away | Ph3 Readout | Niracilimab | Phase 3 | Private | PBC | |
| 2031-02-27 | 5.0y away | Ph3 Readout | Motafutibatinib | Approved | Private | Obesity | |
| 2031-03-01 | 5.0y away | Ph2 Data | ARG-3265 | Phase 1/2 | Large | MM | |
| 2031-03-01 | 5.0y away | Ph3 Readout | Adagrazumab | Phase 3 | Private | LGS | |
| 2031-03-01 | 5.0y away | Ph3 Readout | ALE-9377 | Approved | Private | HCC | |
| 2031-03-02 | 5.0y away | Ph3 Readout | Pemicapivasertib | Phase 3 | Large | HNSCC | |
| 2031-03-02 | 5.0y away | Ph3 Readout | ASA-IIT-476 | Phase 3 | Private | CLL | |
| 2031-03-02 | 5.0y away | Interim | NEO-5524 | Phase 1 | Mid | DLBCL | |
| 2031-03-04 | 5.0y away | Ph3 Readout | ZYM-3350 | Phase 2/3 | Private | DMD | |
| 2031-03-05 | 5.0y away | Interim | EYE-7734 | Phase 1 | Micro | Pompe | |
| 2031-03-07 | 5.0y away | Ph2 Data | IST-1205 | Phase 2 | Private | Thymoma | |
| 2031-03-07 | 5.0y away | Ph3 Readout | Poladerotide | Phase 3 | Micro | CML | |
| 2031-03-09 | 5.0y away | Ph3 Readout | RIN-7561 | Approved | Private | DMD | |
| 2031-03-09 | 5.0y away | Ph3 Readout | Rimabrutinib | Approved | Micro | LGS | |
| 2031-03-10 | 5.0y away | Ph2 Data | Fixalucimab | Phase 1/2 | Mid | MDD | |
| 2031-03-10 | 5.0y away | Ph3 Readout | KAR-9558 | Approved | Private | HS | |
| 2031-03-11 | 5.0y away | Ph2 Data | LLY-3251 | Phase 2 | Large | SCD | |
| 2031-03-12 | 5.0y away | Ph3 Readout | BMY-2495 | Phase 3 | Large | DLBCL | |
| 2031-03-12 | 5.0y away | Ph3 Readout | Gelizasiran | Phase 3 | Private | Bladder Ca | |
| 2031-03-12 | 5.0y away | Ph3 Readout | Mirirasimod | NDA/BLA | Private | PV | |
| 2031-03-13 | 5.0y away | Ph3 Readout | GIM-IIT-628 | Phase 2/3 | Private | Ewing Sarcoma | |
| 2031-03-13 | 5.0y away | Ph3 Readout | Datolucimab | Approved | Small | Rett | |
| 2031-03-13 | 5.0y away | Ph3 Readout | GC-7403 | Phase 2/3 | Private | GA | |
| 2031-03-13 | 5.0y away | Ph3 Readout | Daranaritide | Phase 2/3 | Large | Wet AMD | |
| 2031-03-15 | 5.0y away | Ph3 Readout | PRA-419 | Approved | Mid | ET | |
| 2031-03-16 | 5.0y away | Ph3 Readout | BCY-7343 | Phase 2/3 | Small | Myelofibrosis | |
| 2031-03-16 | 5.0y away | Interim | Suraderotide | Phase 1 | Private | Schizophrenia | |
| 2031-03-16 | 5.0y away | Ph3 Readout | Niralemzoparlimab | Phase 2/3 | Private | Hemophilia A | |
| 2031-03-17 | 5.0y away | Ph3 Readout | Capitapinarof | Phase 3 | Micro | Bladder Ca | |
| 2031-03-18 | 5.0y away | Interim | VRT-4938 | Preclinical | Large | Gastric Ca | |
| 2031-03-18 | 5.0y away | Ph3 Readout | AVE-316 | Phase 3 | Private | DLBCL | |
| 2031-03-18 | 5.0y away | Ph3 Readout | Rimalucimab | Phase 2/3 | Large | Cholangiocarcinoma | |
| 2031-03-19 | 5.0y away | Ph2 Data | ARG-1250 | Phase 2 | Large | Ewing Sarcoma | |
| 2031-03-19 | 5.0y away | Ph2 Data | Surarasimod | Phase 2 | Mid | CRC | |
| 2031-03-20 | 5.0y away | Ph3 Readout | CLL-8422 | Approved | Small | OCD | |
| 2031-03-21 | 5.0y away | Ph3 Readout | 369-789 | Phase 3 | Large | MS | |
| 2031-03-21 | 5.0y away | Ph2 Data | IVE-1037 | Phase 2 | Private | SLE | |
| 2031-03-22 | 5.0y away | Interim | RCU-8819 | Preclinical | Mid | Epilepsy | |
| 2031-03-24 | 5.0y away | Interim | Rimasotorasib | Phase 1 | Private | HNSCC | |
| 2031-03-24 | 5.0y away | Ph2 Data | NVC-9528 | Phase 2 | Mid | Bladder Ca | |
| 2031-03-25 | 5.0y away | Ph2 Data | KYM-8808 | Phase 1/2 | Mid | AS | |
| 2031-03-26 | 5.0y away | Ph2 Data | 456-7078 | Phase 1/2 | Small | Angelman | |
| 2031-03-26 | 5.0y away | Ph3 Readout | DNA-3921 | NDA/BLA | Small | Rett | |
| 2031-03-27 | 5.0y away | Ph3 Readout | 601-626 | Approved | Large | Gastric Ca | |
| 2031-03-27 | 5.0y away | Ph3 Readout | RIK-IIT-829 | Phase 3 | Private | MS | |
| 2031-03-27 | 5.0y away | Ph3 Readout | Rilulemzoparlimab | Approved | Micro | Cholangiocarcinoma | |
| 2031-03-28 | 5.0y away | Ph3 Readout | NMR-223 | NDA/BLA | Small | Psoriasis | |
| 2031-03-28 | 5.0y away | Ph3 Readout | Voxarapivir | NDA/BLA | Mid | CTCL | |
| 2031-03-28 | 5.0y away | Ph2 Data | Datofotisoran | Phase 1/2 | Small | DMD | |
| 2031-04-01 | 5.0y away | Ph2 Data | PAT-6991 | Phase 1/2 | Private | RA | |
| 2031-04-02 | 5.0y away | Ph3 Readout | Zenotinib | Phase 2/3 | Large | MDS | |
| 2031-04-02 | 5.0y away | Ph3 Readout | 208-4501 | Phase 2/3 | Micro | Schizophrenia | |
| 2031-04-03 | 5.0y away | Ph2 Data | VND-7068 | Phase 2 | Small | Gastric Ca | |
| 2031-04-03 | 5.0y away | Ph2 Data | Olpasertib | Phase 2 | Small | RB | |
| 2031-04-03 | 5.0y away | Ph3 Readout | CHI-2221 | Phase 3 | Private | AML | |
| 2031-04-03 | 5.0y away | Ph3 Readout | Pexalucimab | Phase 3 | Private | CKD | |
| 2031-04-04 | 5.1y away | Ph3 Readout | AMO-4131 | NDA/BLA | Private | Dravet | |
| 2031-04-04 | 5.1y away | Ph2 Data | Sotovorutinib | Phase 1/2 | Large | Melanoma | |
| 2031-04-05 | 5.1y away | Interim | Ceviderotide | Preclinical | Large | CRC | |
| 2031-04-05 | 5.1y away | Ph3 Readout | 225-3371 | Approved | Micro | DLBCL | |
| 2031-04-05 | 5.1y away | Interim | Rimanaritide | Phase 1 | Private | PTSD | |
| 2031-04-06 | 5.1y away | Ph3 Readout | BER-3725 | Phase 3 | Private | FSGS | |
| 2031-04-07 | 5.1y away | Ph2 Data | Surafotisoran | Phase 2 | Small | Thymoma | |
| 2031-04-07 | 5.1y away | Ph2 Data | Pemiinavolisib | Phase 1/2 | Private | MG | |
| 2031-04-08 | 5.1y away | Ph3 Readout | Miricapivasertib | Phase 3 | Private | Parkinson's | |
| 2031-04-10 | 5.1y away | Ph3 Readout | IDY-3466 | NDA/BLA | Mid | HCC | |
| 2031-04-10 | 5.1y away | Ph2 Data | Rimaglumide | Phase 2 | Small | SCD | |
| 2031-04-10 | 5.1y away | Interim | Bemafotisoran | Preclinical | Small | NB | |
| 2031-04-11 | 5.1y away | Ph3 Readout | Miriglumide | Phase 3 | Large | Pancreatic Ca | |
| 2031-04-11 | 5.1y away | Ph3 Readout | ILM-2412 | Phase 3 | Large | HS | |
| 2031-04-11 | 5.1y away | Ph3 Readout | Mirinaritide | Phase 2/3 | Private | ALL | |
| 2031-04-11 | 5.1y away | Ph3 Readout | RIK-IIT-658 | Phase 3 | Private | FL | |
| 2031-04-12 | 5.1y away | Ph2 Data | GEN-IIT-381 | Phase 2 | Private | CF | |
| 2031-04-13 | 5.1y away | Ph3 Readout | Lisozanubrutinib | NDA/BLA | Small | Cervical Ca | |
| 2031-04-13 | 5.1y away | Ph3 Readout | Mirimavacamten | Approved | Micro | Angelman | |
| 2031-04-13 | 5.1y away | Ph3 Readout | KIA-7239 | Phase 2/3 | Private | DLBCL | |
| 2031-04-14 | 5.1y away | Interim | DAN-IIT-515 | Preclinical | Private | AML | |
| 2031-04-14 | 5.1y away | Ph3 Readout | Zanufotisoran | Approved | Small | NSCLC | |
| 2031-04-15 | 5.1y away | Ph2 Data | NVO-9630 | Phase 2 | Large | IgAN | |
| 2031-04-16 | 5.1y away | Ph2 Data | Sovarasimod | Phase 1/2 | Large | Celiac | |
| 2031-04-16 | 5.1y away | Ph2 Data | NTR-7700 | Phase 1/2 | Large | FSGS | |
| 2031-04-17 | 5.1y away | Ph3 Readout | CER-4594 | Phase 3 | Private | Celiac | |
| 2031-04-17 | 5.1y away | Ph2 Data | Zoricilimab | Phase 2 | Small | IgAN | |
| 2031-04-18 | 5.1y away | Ph3 Readout | VKT-4052 | Phase 2/3 | Mid | Epilepsy | |
| 2031-04-18 | 5.1y away | Ph2 Data | 618-5050 | Phase 2 | Mid | T2D | |
| 2031-04-18 | 5.1y away | Ph3 Readout | 600-5970 | Approved | Mid | Crohn's | |
| 2031-04-19 | 5.1y away | Ph3 Readout | Datorasimod | Approved | Micro | Huntington's | |
| 2031-04-19 | 5.1y away | Interim | Doxacilimab | Preclinical | Small | FTD | |
| 2031-04-20 | 5.1y away | Interim | GEN-3979 | Phase 1 | Private | IPF | |
| 2031-04-21 | 5.1y away | Ph2 Data | Ribonesiran | Phase 1/2 | Large | Gastric Ca | |
| 2031-04-22 | 5.1y away | Ph3 Readout | FRE-IIT-743 | NDA/BLA | Private | Gastric Ca | |
| 2031-04-23 | 5.1y away | Ph3 Readout | Terazumab | NDA/BLA | Mid | HS | |
| 2031-04-24 | 5.1y away | Ph3 Readout | Lisorapivir | Approved | Mid | UC | |
| 2031-04-24 | 5.1y away | Ph2 Data | Doxarapivir | Phase 2 | Private | OCD | |
| 2031-04-24 | 5.1y away | Ph2 Data | Elrarapivir | Phase 2 | Small | NB | |
| 2031-04-24 | 5.1y away | Ph2 Data | WAT-3378 | Phase 2 | Large | CKD | |
| 2031-04-25 | 5.1y away | Ph3 Readout | Elrafotisoran | Phase 3 | Micro | ADPKD | |
| 2031-04-27 | 5.1y away | Interim | MRK-5413 | Phase 1 | Large | NASH | |
| 2031-04-27 | 5.1y away | Ph2 Data | Tirazasiran | Phase 1/2 | Private | MCL | |
| 2031-04-28 | 5.1y away | Ph3 Readout | ATH-6254 | Approved | Private | PsA | |
| 2031-04-28 | 5.1y away | Ph3 Readout | HOM-3477 | Approved | Private | MCL | |
| 2031-04-28 | 5.1y away | Ph2 Data | 418-6056 | Phase 1/2 | Mid | ADPKD | |
| 2031-04-28 | 5.1y away | Ph3 Readout | Datomavacamten | Phase 2/3 | Mid | Schizophrenia | |
| 2031-04-28 | 5.1y away | Ph2 Data | VAL-183 | Phase 2 | Small | AS | |
| 2031-05-01 | 5.1y away | Ph3 Readout | Lisosotorasib | NDA/BLA | Large | Wilms | |
| 2031-05-02 | 5.1y away | Interim | HIK-6819 | Preclinical | Mid | Wet AMD | |
| 2031-05-02 | 5.1y away | Ph2 Data | AMO-1639 | Phase 2 | Private | Wet AMD | |
| 2031-05-02 | 5.1y away | Ph3 Readout | Kemamavacamten | Phase 3 | Large | NSCLC | |
| 2031-05-03 | 5.1y away | Ph3 Readout | Tixatapinarof | Approved | Mid | Asthma | |
| 2031-05-03 | 5.1y away | Ph3 Readout | ORC-9172 | Phase 3 | Private | OCD | |
| 2031-05-03 | 5.1y away | Ph3 Readout | Mavulemzoparlimab | Phase 3 | Private | FSGS | |
| 2031-05-03 | 5.1y away | Ph3 Readout | SUP-6530 | NDA/BLA | Mid | Alzheimer's | |
| 2031-05-04 | 5.1y away | Ph2 Data | Bemalucimab | Phase 1/2 | Large | PsA | |
| 2031-05-05 | 5.1y away | Ph3 Readout | Olpafutibatinib | Approved | Mid | NMOSD | |
| 2031-05-06 | 5.1y away | Ph3 Readout | AMG-1919 | Phase 2/3 | Large | GBM | |
| 2031-05-07 | 5.1y away | Ph3 Readout | 450-8514 | Phase 3 | Large | PsA | |
| 2031-05-08 | 5.1y away | Ph3 Readout | Sovaderotide | Phase 2/3 | Large | SCLC | |
| 2031-05-08 | 5.1y away | Ph3 Readout | GH-3607 | NDA/BLA | Mid | HCC | |
| 2031-05-09 | 5.1y away | Ph2 Data | GIL-8529 | Phase 1/2 | Large | Ovarian Ca | |
| 2031-05-10 | 5.1y away | Ph2 Data | Pexatenlimab | Phase 1/2 | Large | MDD | |
| 2031-05-11 | 5.2y away | Ph3 Readout | ANG-3408 | Phase 2/3 | Private | PSP | |
| 2031-05-12 | 5.2y away | Interim | ACI-1988 | Phase 1 | Small | PsA | |
| 2031-05-12 | 5.2y away | Interim | 415-7410 | Phase 1 | Large | PAH | |
| 2031-05-13 | 5.2y away | Ph3 Readout | INB-9118 | Phase 3 | Small | Parkinson's | |
| 2031-05-13 | 5.2y away | Interim | Fixabrutinib | Preclinical | Micro | Bladder Ca | |
| 2031-05-17 | 5.2y away | Interim | VRT-6833 | Preclinical | Large | EoE | |
| 2031-05-17 | 5.2y away | Ph3 Readout | NBI-408 | Phase 2/3 | Large | Breast Ca | |
| 2031-05-17 | 5.2y away | Ph2 Data | CRS-184 | Phase 1/2 | Mid | Pompe | |
| 2031-05-17 | 5.2y away | Ph3 Readout | LPC-7933 | Phase 3 | Mid | CSU | |
| 2031-05-17 | 5.2y away | Ph3 Readout | Gelilemzoparlimab | Approved | Private | Obesity | |
| 2031-05-18 | 5.2y away | Ph3 Readout | Tixatuximab | Phase 3 | Private | OCD | |
| 2031-05-18 | 5.2y away | Ph3 Readout | Bemacilimab | NDA/BLA | Micro | Rett | |
| 2031-05-19 | 5.2y away | Interim | SWT-3857 | Phase 1 | Mid | FL | |
| 2031-05-23 | 5.2y away | Interim | Nirazumab | Phase 1 | Micro | Angelman | |
| 2031-05-23 | 5.2y away | Ph3 Readout | NOB-8652 | Approved | Private | Schizophrenia | |
| 2031-05-25 | 5.2y away | Ph3 Readout | ENT-2952 | Phase 3 | Small | CTCL | |
| 2031-05-26 | 5.2y away | Ph3 Readout | GRT-6331 | NDA/BLA | Micro | Migraine | |
| 2031-05-26 | 5.2y away | Ph3 Readout | Polavorutinib | Phase 3 | Private | Thymoma | |
| 2031-05-27 | 5.2y away | Ph3 Readout | VKT-6548 | Phase 2/3 | Mid | Prostate Ca | |
| 2031-05-27 | 5.2y away | Ph3 Readout | Tixasotorasib | Approved | Private | Wet AMD | |
| 2031-05-27 | 5.2y away | Ph3 Readout | RYT-9424 | Phase 2/3 | Mid | Endometrial Ca | |
| 2031-05-27 | 5.2y away | Ph2 Data | MRK-7986 | Phase 1/2 | Large | ADPKD | |
| 2031-05-27 | 5.2y away | Ph2 Data | ZHE-6042 | Phase 2 | Private | AS | |
| 2031-05-28 | 5.2y away | Ph3 Readout | Mavutuximab | Phase 2/3 | Large | Hemophilia A | |
| 2031-05-28 | 5.2y away | Ph2 Data | Rimabrutinib | Phase 1/2 | Mid | Epilepsy | |
| 2031-06-01 | 5.2y away | Ph3 Readout | 300-8538 | NDA/BLA | Mid | ADHD | |
| 2031-06-01 | 5.2y away | Ph3 Readout | Tirainavolisib | Approved | Mid | IPF | |
| 2031-06-02 | 5.2y away | Ph2 Data | MRK-3745 | Phase 2 | Large | CKD | |
| 2031-06-02 | 5.2y away | Ph3 Readout | EOR-IIT-783 | Phase 3 | Private | CKD | |
| 2031-06-02 | 5.2y away | Interim | PET-IIT-168 | Preclinical | Private | SLE | |
| 2031-06-03 | 5.2y away | Interim | QUO-6518 | Preclinical | Private | GIST | |
| 2031-06-03 | 5.2y away | Interim | LUC-2815 | Phase 1 | Micro | Atopic Derm | |
| 2031-06-03 | 5.2y away | Ph3 Readout | GAL-555 | Phase 3 | Private | Psoriasis | |
| 2031-06-05 | 5.2y away | Ph2 Data | COR-8406 | Phase 2 | Private | Parkinson's | |
| 2031-06-05 | 5.2y away | Ph2 Data | Capiosocimab | Phase 1/2 | Private | IPF | |
| 2031-06-06 | 5.2y away | Interim | PFE-1085 | Preclinical | Large | DLBCL | |
| 2031-06-07 | 5.2y away | Ph3 Readout | Lisosotorasib | Phase 3 | Mid | CSU | |
| 2031-06-08 | 5.2y away | Ph3 Readout | DSN-1421 | Phase 3 | Large | ET | |
| 2031-06-08 | 5.2y away | Ph2 Data | 369-4107 | Phase 2 | Large | LGS | |
| 2031-06-08 | 5.2y away | Ph3 Readout | Tixatuximab | Phase 3 | Mid | HNSCC | |
| 2031-06-09 | 5.2y away | Interim | CHI-IIT-962 | Preclinical | Private | Bladder Ca | |
| 2031-06-10 | 5.2y away | Ph3 Readout | DSN-2247 | NDA/BLA | Large | Asthma | |
| 2031-06-10 | 5.2y away | Ph2 Data | Lirazumab | Phase 2 | Micro | AS | |
| 2031-06-10 | 5.2y away | Interim | PRO-2782 | Preclinical | Private | Schizophrenia | |
| 2031-06-11 | 5.2y away | Interim | Pexasertib | Preclinical | Private | NB | |
| 2031-06-13 | 5.2y away | Ph3 Readout | VEC-6874 | Phase 2/3 | Private | FL | |
| 2031-06-13 | 5.2y away | Ph2 Data | Doxabrutinib | Phase 2 | Small | ADHD | |
| 2031-06-14 | 5.2y away | Ph3 Readout | ALM-7482 | Approved | Mid | SCLC | |
| 2031-06-14 | 5.2y away | Interim | YB-3612 | Phase 1 | Private | IPF | |
| 2031-06-15 | 5.2y away | Interim | PRI-IIT-139 | Preclinical | Private | MCC | |
| 2031-06-15 | 5.2y away | Ph3 Readout | ADA-4330 | Approved | Private | LGS | |
| 2031-06-15 | 5.2y away | Ph3 Readout | ANG-3408 | Phase 2/3 | Private | MCL | |
| 2031-06-16 | 5.3y away | Ph3 Readout | LEG-6533 | NDA/BLA | Large | Migraine | |
| 2031-06-16 | 5.3y away | Ph3 Readout | 600-5970 | Approved | Mid | Crohn's | |
| 2031-06-17 | 5.3y away | Ph3 Readout | 488-6595 | Approved | Small | GBM | |
| 2031-06-18 | 5.3y away | Ph3 Readout | EOR-IIT-940 | Phase 3 | Private | FSGS | |
| 2031-06-19 | 5.3y away | Interim | Teranesiran | Phase 1 | Private | Huntington's | |
| 2031-06-19 | 5.3y away | Interim | EVO-5421 | Preclinical | Private | Asthma | |
| 2031-06-19 | 5.3y away | Interim | NAT-IIT-627 | Phase 1 | Private | Heart Failure | |
| 2031-06-20 | 5.3y away | Ph3 Readout | Tirazumab | Phase 2/3 | Private | Ovarian Ca | |
| 2031-06-23 | 5.3y away | Ph3 Readout | CAN-3547 | NDA/BLA | Micro | Prostate Ca | |
| 2031-06-23 | 5.3y away | Ph2 Data | TER-8481 | Phase 1/2 | Private | GBM | |
| 2031-06-23 | 5.3y away | Ph2 Data | 199-761 | Phase 2 | Micro | MG | |
| 2031-06-23 | 5.3y away | Ph3 Readout | PPL-6055 | Phase 2/3 | Small | Migraine | |
| 2031-06-23 | 5.3y away | Ph3 Readout | FER-2526 | NDA/BLA | Private | Epilepsy | |
| 2031-06-23 | 5.3y away | Ph2 Data | CHA-IIT-311 | Phase 2 | Private | CML | |
| 2031-06-24 | 5.3y away | Ph3 Readout | Polasotorasib | NDA/BLA | Micro | RA | |
| 2031-06-24 | 5.3y away | Ph3 Readout | Motaderotide | Phase 2/3 | Private | Pancreatic Ca | |
| 2031-06-24 | 5.3y away | Ph2 Data | Gozecilimab | Phase 2 | Mid | ET | |
| 2031-06-26 | 5.3y away | Ph3 Readout | Tirainavolisib | Approved | Large | PBC | |
| 2031-06-26 | 5.3y away | Ph3 Readout | CLL-8422 | Approved | Small | IPF | |
| 2031-06-26 | 5.3y away | Ph3 Readout | Sovalemzoparlimab | Phase 3 | Small | Migraine | |
| 2031-06-26 | 5.3y away | Ph3 Readout | YB-6541 | Phase 3 | Private | HNSCC | |
| 2031-06-28 | 5.3y away | Ph3 Readout | ILM-4317 | NDA/BLA | Large | SCD | |
| 2031-06-28 | 5.3y away | Interim | Rimanaritide | Phase 1 | Mid | Wilms | |
| 2031-07-02 | 5.3y away | Ph3 Readout | STO-2663 | Approved | Small | PTSD | |
| 2031-07-02 | 5.3y away | Ph3 Readout | BCY-7343 | Phase 2/3 | Small | HNSCC | |
| 2031-07-02 | 5.3y away | Ph2 Data | SHI-2889 | Phase 2 | Private | Fabry | |
| 2031-07-03 | 5.3y away | Ph3 Readout | 450-8514 | Phase 3 | Large | NB | |
| 2031-07-03 | 5.3y away | Interim | ASP-8946 | Phase 1 | Private | MDS | |
| 2031-07-05 | 5.3y away | Ph3 Readout | AER-1540 | Phase 2/3 | Private | Melanoma | |
| 2031-07-05 | 5.3y away | Ph3 Readout | Zoriderotide | Phase 3 | Mid | T2D | |
| 2031-07-05 | 5.3y away | Interim | 600-3422 | Phase 1 | Mid | Hemophilia A | |
| 2031-07-07 | 5.3y away | Interim | Talasotorasib | Preclinical | Mid | TTR Amyloidosis | |
| 2031-07-07 | 5.3y away | Ph3 Readout | GAL-555 | Phase 3 | Private | Psoriasis | |
| 2031-07-07 | 5.3y away | Ph3 Readout | ADA-2164 | Approved | Private | Bladder Ca | |
| 2031-07-08 | 5.3y away | Ph3 Readout | Sovarapivir | Phase 2/3 | Large | Heart Failure | |
| 2031-07-08 | 5.3y away | Ph3 Readout | Teraosocimab | Phase 3 | Private | Migraine | |
| 2031-07-09 | 5.3y away | Ph3 Readout | DSN-2247 | NDA/BLA | Large | MM | |
| 2031-07-09 | 5.3y away | Ph3 Readout | RDY-8710 | Approved | Large | Cervical Ca | |
| 2031-07-10 | 5.3y away | Ph3 Readout | Tezeratamab | Phase 3 | Small | Breast Ca | |
| 2031-07-10 | 5.3y away | Ph3 Readout | QTR-9473 | Approved | Small | Heart Failure | |
| 2031-07-11 | 5.3y away | Interim | 600-6147 | Preclinical | Large | ACC | |
| 2031-07-13 | 5.3y away | Ph2 Data | Mavuvorutinib | Phase 1/2 | Large | RA | |
| 2031-07-13 | 5.3y away | Ph2 Data | Nidatapinarof | Phase 2 | Large | Alzheimer's | |
| 2031-07-13 | 5.3y away | Ph2 Data | MBX-6478 | Phase 1/2 | Small | TTR Amyloidosis | |
| 2031-07-13 | 5.3y away | Interim | Surazumab | Preclinical | Micro | ADPKD | |
| 2031-07-14 | 5.3y away | Ph3 Readout | REC-3246 | Phase 2/3 | Mid | Breast Ca | |
| 2031-07-14 | 5.3y away | Ph3 Readout | Elrazanubrutinib | NDA/BLA | Mid | MCC | |
| 2031-07-15 | 5.3y away | Interim | Capisotorasib | Phase 1 | Private | CKD | |
| 2031-07-16 | 5.3y away | Ph3 Readout | SCI-8054 | Phase 2/3 | Private | Ewing Sarcoma | |
| 2031-07-16 | 5.3y away | Ph3 Readout | Gozemavacamten | Approved | Private | Cervical Ca | |
| 2031-07-16 | 5.3y away | Ph3 Readout | Ivofutibatinib | Phase 3 | Micro | Cervical Ca | |
| 2031-07-16 | 5.3y away | Ph3 Readout | WST-3921 | Phase 2/3 | Large | SLE | |
| 2031-07-16 | 5.3y away | Ph3 Readout | Riluzumab | Approved | Large | PsA | |
| 2031-07-17 | 5.3y away | Ph2 Data | RVM-3746 | Phase 1/2 | Mid | LN | |
| 2031-07-18 | 5.3y away | Interim | Nidacilimab | Preclinical | Private | DMD | |
| 2031-07-19 | 5.3y away | Interim | GR-8075 | Preclinical | Private | HCC | |
| 2031-07-21 | 5.3y away | Ph3 Readout | 269-6259 | Phase 3 | Mid | ACC | |
| 2031-07-22 | 5.3y away | Ph3 Readout | Kemanesiran | Approved | Small | MDD | |
| 2031-07-23 | 5.4y away | Ph3 Readout | Ivosotorasib | Phase 2/3 | Micro | PBC | |
| 2031-07-24 | 5.4y away | Ph3 Readout | PET-IIT-181 | Approved | Private | LGS | |
| 2031-07-25 | 5.4y away | Ph3 Readout | BGN-6990 | Phase 2/3 | Large | CLL | |
| 2031-07-25 | 5.4y away | Ph3 Readout | Rilulucimab | NDA/BLA | Private | Huntington's | |
| 2031-07-25 | 5.4y away | Ph3 Readout | Sovalemzoparlimab | Phase 3 | Small | MS | |
| 2031-07-26 | 5.4y away | Ph3 Readout | Tirainavolisib | Approved | Large | PBC | |
| 2031-07-26 | 5.4y away | Ph3 Readout | SYR-7044 | Phase 3 | Small | NASH | |
| 2031-07-26 | 5.4y away | Ph3 Readout | Voxasotorasib | Phase 3 | Private | Ewing Sarcoma | |
| 2031-07-27 | 5.4y away | Ph2 Data | MEI-6717 | Phase 2 | Micro | Myelofibrosis | |
| 2031-07-27 | 5.4y away | Ph2 Data | Tezecapivasertib | Phase 1/2 | Private | Rett | |
| 2031-07-27 | 5.4y away | Ph2 Data | AII-IIT-540 | Phase 1/2 | Private | NASH | |
| 2031-07-28 | 5.4y away | Ph2 Data | RDY-9256 | Phase 1/2 | Large | FL | |
| 2031-08-01 | 5.4y away | Interim | Motatenlimab | Preclinical | Small | Ovarian Ca | |
| 2031-08-02 | 5.4y away | Interim | CAL-4725 | Preclinical | Micro | Hemophilia A | |
| 2031-08-02 | 5.4y away | Ph3 Readout | CON-544 | NDA/BLA | Private | SLE | |
| 2031-08-02 | 5.4y away | Ph3 Readout | WES-IIT-352 | Phase 3 | Private | DMD | |
| 2031-08-03 | 5.4y away | Interim | NAN-2606 | Phase 1 | Micro | T2D | |
| 2031-08-04 | 5.4y away | Interim | 415-7241 | Phase 1 | Micro | CRC | |
| 2031-08-06 | 5.4y away | Ph3 Readout | RHH-8550 | Approved | Large | RB | |
| 2031-08-06 | 5.4y away | Ph3 Readout | Pexalucimab | Phase 3 | Private | CKD | |
| 2031-08-08 | 5.4y away | Ph3 Readout | Nidasacituzumab | Phase 3 | Mid | OCD | |
| 2031-08-08 | 5.4y away | Ph2 Data | Adagraderotide | Phase 2 | Small | CF | |
| 2031-08-10 | 5.4y away | Ph3 Readout | Mavutenlimab | Phase 3 | Large | SMA | |
| 2031-08-10 | 5.4y away | Interim | PCV-2362 | Phase 1 | Mid | MG | |
| 2031-08-11 | 5.4y away | Ph3 Readout | BSG-8809 | Approved | Micro | EoE | |
| 2031-08-12 | 5.4y away | Interim | GC-6461 | Preclinical | Private | CML | |
| 2031-08-12 | 5.4y away | Ph3 Readout | POL-2929 | Phase 2/3 | Private | Bladder Ca | |
| 2031-08-13 | 5.4y away | Interim | NVO-6275 | Phase 1 | Large | SLE | |
| 2031-08-13 | 5.4y away | Ph2 Data | Talatenlimab | Phase 1/2 | Mid | MCC | |
| 2031-08-13 | 5.4y away | Ph3 Readout | NEO-1781 | NDA/BLA | Mid | Bladder Ca | |
| 2031-08-14 | 5.4y away | Interim | WES-IIT-392 | Phase 1 | Private | T2D | |
| 2031-08-14 | 5.4y away | Ph3 Readout | Rimarelsin | Phase 3 | Private | CRC | |
| 2031-08-16 | 5.4y away | Ph3 Readout | Voxaderotide | Approved | Mid | PsA | |
| 2031-08-16 | 5.4y away | Ph3 Readout | ATH-2491 | Approved | Micro | CSU | |
| 2031-08-17 | 5.4y away | Ph2 Data | Talatuximab | Phase 2 | Mid | NMOSD | |
| 2031-08-18 | 5.4y away | Ph3 Readout | Geliinavolisib | NDA/BLA | Private | CF | |
| 2031-08-18 | 5.4y away | Ph3 Readout | APL-1567 | Approved | Small | ALL | |
| 2031-08-19 | 5.4y away | Ph3 Readout | ADI-7213 | Phase 2/3 | Private | Huntington's | |
| 2031-08-20 | 5.4y away | Ph2 Data | MYG-2072 | Phase 2 | Mid | Meso | |
| 2031-08-22 | 5.4y away | Ph3 Readout | Geliderotide | NDA/BLA | Large | PsA | |
| 2031-08-22 | 5.4y away | Ph2 Data | Sovacagene | Phase 1/2 | Mid | SMA | |
| 2031-08-22 | 5.4y away | Ph3 Readout | Pemizasiran | NDA/BLA | Private | GBM | |
| 2031-08-22 | 5.4y away | Ph3 Readout | Elracagene | NDA/BLA | Large | FSGS | |
| 2031-08-23 | 5.4y away | Ph2 Data | LLY-1956 | Phase 1/2 | Large | MDS | |
| 2031-08-23 | 5.4y away | Interim | Daranesiran | Preclinical | Private | Breast Ca | |
| 2031-08-24 | 5.4y away | Ph2 Data | STA-5151 | Phase 1/2 | Small | Pompe | |
| 2031-08-25 | 5.4y away | Interim | Tiracilimab | Phase 1 | Micro | Crohn's | |
| 2031-08-25 | 5.4y away | Ph3 Readout | KNS-1946 | Phase 3 | Mid | Rett | |
| 2031-08-26 | 5.4y away | Ph2 Data | Bemacapivasertib | Phase 2 | Small | FL | |
| 2031-08-26 | 5.4y away | Interim | CLO-5164 | Phase 1 | Private | LGS | |
| 2031-08-26 | 5.4y away | Ph2 Data | Tezesacituzumab | Phase 2 | Small | GA | |
| 2031-08-26 | 5.4y away | Interim | 600-3422 | Phase 1 | Mid | Hemophilia A | |
| 2031-08-27 | 5.4y away | Ph3 Readout | Olpaosocimab | NDA/BLA | Private | AML | |
| 2031-08-27 | 5.4y away | Ph3 Readout | Motanaritide | Approved | Private | AML | |
| 2031-08-28 | 5.5y away | Interim | TEV-5361 | Preclinical | Large | CTCL | |
| 2031-09-01 | 5.5y away | Ph3 Readout | BIO-6952 | NDA/BLA | Private | FTD | |
| 2031-09-02 | 5.5y away | Interim | RHH-8482 | Phase 1 | Large | Alzheimer's | |
| 2031-09-02 | 5.5y away | Ph2 Data | ZYM-2450 | Phase 2 | Mid | IPF | |
| 2031-09-04 | 5.5y away | Ph3 Readout | TRE-2745 | Phase 2/3 | Private | PAH | |
| 2031-09-04 | 5.5y away | Ph2 Data | SEN-1840 | Phase 2 | Private | Rett | |
| 2031-09-04 | 5.5y away | Interim | Rilunaritide | Phase 1 | Private | PNH | |
| 2031-09-05 | 5.5y away | Ph3 Readout | MNO-1564 | Phase 3 | Micro | Hemophilia A | |
| 2031-09-05 | 5.5y away | Interim | BIG-7200 | Phase 1 | Private | Migraine | |
| 2031-09-06 | 5.5y away | Ph3 Readout | Capirapivir | Approved | Mid | Obesity | |
| 2031-09-06 | 5.5y away | Ph3 Readout | AER-8916 | Approved | Private | GA | |
| 2031-09-06 | 5.5y away | Ph3 Readout | IMM-2816 | Approved | Private | LGS | |
| 2031-09-07 | 5.5y away | Ph3 Readout | MRK-474 | Phase 3 | Large | UC | |
| 2031-09-07 | 5.5y away | Ph3 Readout | DIV-3233 | Phase 2/3 | Large | Cervical Ca | |
| 2031-09-07 | 5.5y away | Interim | Semacapivasertib | Preclinical | Mid | Breast Ca | |
| 2031-09-08 | 5.5y away | Ph2 Data | NAN-6418 | Phase 2 | Micro | OCD | |
| 2031-09-08 | 5.5y away | Interim | REA-6162 | Preclinical | Private | FTD | |
| 2031-09-09 | 5.5y away | Ph3 Readout | Doxasotorasib | Phase 2/3 | Large | ALL | |
| 2031-09-10 | 5.5y away | Ph3 Readout | Voxaderotide | Approved | Mid | PsA | |
| 2031-09-12 | 5.5y away | Ph2 Data | Nirabrutinib | Phase 2 | Large | AS | |
| 2031-09-12 | 5.5y away | Ph2 Data | 006-348 | Phase 1/2 | Mid | Prostate Ca | |
| 2031-09-13 | 5.5y away | Ph3 Readout | GR-6650 | NDA/BLA | Private | Parkinson's | |
| 2031-09-14 | 5.5y away | Interim | Fixarapivir | Preclinical | Large | CKD | |
| 2031-09-14 | 5.5y away | Ph3 Readout | Semaglumide | Approved | Small | Crohn's | |
| 2031-09-15 | 5.5y away | Interim | NOR-5927 | Phase 1 | Private | Epilepsy | |
| 2031-09-16 | 5.5y away | Ph3 Readout | ABB-1817 | Phase 3 | Large | MM | |
| 2031-09-16 | 5.5y away | Ph3 Readout | Sovainavolisib | NDA/BLA | Mid | FSGS | |
| 2031-09-17 | 5.5y away | Ph2 Data | PRI-IIT-560 | Phase 1/2 | Private | TTR Amyloidosis | |
| 2031-09-17 | 5.5y away | Ph2 Data | PAH-7465 | Phase 2 | Small | MS | |
| 2031-09-18 | 5.5y away | Interim | LTR-8109 | Phase 1 | Micro | UC | |
| 2031-09-18 | 5.5y away | Ph3 Readout | FLA-5216 | Approved | Private | CML | |
| 2031-09-18 | 5.5y away | Ph3 Readout | AIP-7637 | NDA/BLA | Small | Obesity | |
| 2031-09-18 | 5.5y away | Ph3 Readout | Tiratapinarof | Phase 3 | Private | PTSD | |
| 2031-09-19 | 5.5y away | Ph3 Readout | CSL-5084 | NDA/BLA | Large | Urothelial Ca | |
| 2031-09-21 | 5.5y away | Ph2 Data | Datofotisoran | Phase 1/2 | Private | MCC | |
| 2031-09-21 | 5.5y away | Interim | RGE-5524 | Phase 1 | Mid | Melanoma | |
| 2031-09-22 | 5.5y away | Ph3 Readout | NVS-6360 | Approved | Large | FTD | |
| 2031-09-22 | 5.5y away | Ph2 Data | CHI-3542 | Phase 2 | Private | MCC | |
| 2031-09-23 | 5.5y away | Interim | Darafutibatinib | Preclinical | Large | OCD | |
| 2031-09-23 | 5.5y away | Ph3 Readout | Kematenlimab | Phase 2/3 | Small | MDS | |
| 2031-09-24 | 5.5y away | Interim | SEV-IIT-334 | Phase 1 | Private | HNSCC | |
| 2031-09-25 | 5.5y away | Ph3 Readout | Gelicilimab | Phase 3 | Mid | Huntington's | |
| 2031-09-26 | 5.5y away | Ph3 Readout | Nidaglumide | Approved | Private | IgAN | |
| 2031-09-27 | 5.5y away | Interim | Gelisacituzumab | Phase 1 | Private | Heart Failure | |
| 2031-09-28 | 5.5y away | Ph2 Data | Tirafotisoran | Phase 2 | Large | GA | |
| 2031-09-28 | 5.5y away | Ph3 Readout | Capifutibatinib | Approved | Large | Migraine | |
| 2031-09-28 | 5.5y away | Ph2 Data | Talatapinarof | Phase 1/2 | Large | FSGS | |
| 2031-09-28 | 5.5y away | Ph2 Data | Lisotenlimab | Phase 1/2 | Private | AS | |
| 2031-09-28 | 5.5y away | Ph3 Readout | MSN-5549 | NDA/BLA | Private | CML | |
| 2031-09-28 | 5.5y away | Ph3 Readout | DEC-4099 | Phase 3 | Private | Cervical Ca | |
| 2031-10-01 | 5.5y away | Ph3 Readout | NAT-IIT-209 | Phase 2/3 | Private | GIST | |
| 2031-10-02 | 5.5y away | Ph3 Readout | DUK-IIT-769 | Approved | Private | ALS | |
| 2031-10-02 | 5.5y away | Ph3 Readout | 028-9914 | NDA/BLA | Small | PBC | |
| 2031-10-02 | 5.5y away | Interim | DIV-5162 | Preclinical | Large | Myelofibrosis | |
| 2031-10-02 | 5.5y away | Ph2 Data | CRD-4273 | Phase 1/2 | Micro | Psoriasis | |
| 2031-10-06 | 5.6y away | Interim | CAM-IIT-125 | Phase 1 | Private | Obesity | |
| 2031-10-06 | 5.6y away | Ph2 Data | KIN-IIT-683 | Phase 2 | Private | MCC | |
| 2031-10-07 | 5.6y away | Ph3 Readout | SCO-5362 | NDA/BLA | Private | PAH | |
| 2031-10-07 | 5.6y away | Ph3 Readout | CLR-3690 | Phase 3 | Micro | Alzheimer's | |
| 2031-10-07 | 5.6y away | Interim | 195-4808 | Preclinical | Small | HCC | |
| 2031-10-07 | 5.6y away | Ph3 Readout | Lirazasiran | Phase 3 | Private | CF | |
| 2031-10-09 | 5.6y away | Ph3 Readout | Daratuximab | Approved | Mid | CML | |
| 2031-10-10 | 5.6y away | Ph2 Data | Pexaderotide | Phase 1/2 | Private | Obesity | |
| 2031-10-10 | 5.6y away | Ph3 Readout | BIO-4284 | Phase 2/3 | Mid | LN | |
| 2031-10-10 | 5.6y away | Ph2 Data | Terarelsin | Phase 1/2 | Mid | NMOSD | |
| 2031-10-10 | 5.6y away | Ph3 Readout | ZTS-9629 | Phase 3 | Large | AS | |
| 2031-10-11 | 5.6y away | Ph3 Readout | Olpafutibatinib | Approved | Mid | Migraine | |
| 2031-10-11 | 5.6y away | Interim | Gozecagene | Phase 1 | Mid | NASH | |
| 2031-10-11 | 5.6y away | Ph3 Readout | CGE-9788 | Phase 3 | Small | T2D | |
| 2031-10-11 | 5.6y away | Interim | Rilusotorasib | Preclinical | Small | Endometrial Ca | |
| 2031-10-12 | 5.6y away | Ph3 Readout | BMY-3371 | Phase 3 | Large | PTSD | |
| 2031-10-12 | 5.6y away | Ph2 Data | 207-2754 | Phase 1/2 | Large | Meso | |
| 2031-10-12 | 5.6y away | Interim | REM-8705 | Preclinical | Private | ALL | |
| 2031-10-13 | 5.6y away | Interim | SIA-643 | Phase 1 | Private | MCC | |
| 2031-10-14 | 5.6y away | Ph3 Readout | Sovafotisoran | NDA/BLA | Large | IPF | |
| 2031-10-14 | 5.6y away | Ph3 Readout | Datocapivasertib | Phase 2/3 | Private | HNSCC | |
| 2031-10-14 | 5.6y away | Ph2 Data | Motaderotide | Phase 2 | Small | MDS | |
| 2031-10-16 | 5.6y away | Ph2 Data | IRC-IIT-265 | Phase 1/2 | Private | Angelman | |
| 2031-10-17 | 5.6y away | Interim | Adagraratamab | Phase 1 | Private | PAH | |
| 2031-10-18 | 5.6y away | Ph3 Readout | DAS-562 | Approved | Private | RCC | |
| 2031-10-19 | 5.6y away | Ph3 Readout | ACR-6734 | Approved | Micro | RCC | |
| 2031-10-19 | 5.6y away | Ph3 Readout | Rilunaritide | Approved | Micro | Rett | |
| 2031-10-19 | 5.6y away | Ph3 Readout | Suracagene | Phase 3 | Large | Atopic Derm | |
| 2031-10-20 | 5.6y away | Ph3 Readout | Fixaratamab | Approved | Mid | Endometrial Ca | |
| 2031-10-21 | 5.6y away | Ph3 Readout | Zanuderotide | Phase 2/3 | Large | Endometrial Ca | |
| 2031-10-21 | 5.6y away | Ph3 Readout | Elrazasiran | NDA/BLA | Small | Dravet | |
| 2031-10-21 | 5.6y away | Interim | GEN-5535 | Phase 1 | Private | AML | |
| 2031-10-22 | 5.6y away | Interim | TOT-3942 | Preclinical | Private | GA | |
| 2031-10-23 | 5.6y away | Ph3 Readout | Mavuzasiran | Phase 3 | Mid | Rett | |
| 2031-10-24 | 5.6y away | Ph3 Readout | Olpaosocimab | NDA/BLA | Private | PNH | |
| 2031-10-24 | 5.6y away | Ph2 Data | ELO-7744 | Phase 2 | Private | CF | |
| 2031-10-24 | 5.6y away | Ph3 Readout | Pexainavolisib | Approved | Private | FTD | |
| 2031-10-25 | 5.6y away | Ph3 Readout | RVM-274 | Phase 3 | Mid | IPF | |
| 2031-10-25 | 5.6y away | Ph3 Readout | Nidanesiran | Approved | Private | RA | |
| 2031-10-27 | 5.6y away | Interim | MRE-2348 | Preclinical | Micro | Heart Failure | |
| 2031-10-27 | 5.6y away | Ph3 Readout | Ivofutibatinib | Phase 3 | Micro | Cervical Ca | |
| 2031-10-27 | 5.6y away | Ph3 Readout | DIV-9629 | Phase 3 | Large | Urothelial Ca | |
| 2031-10-27 | 5.6y away | Ph3 Readout | WST-9696 | Phase 3 | Large | Fabry | |
| 2031-10-28 | 5.6y away | Ph3 Readout | Pexainavolisib | Approved | Private | FTD | |
| 2031-10-28 | 5.6y away | Ph3 Readout | Sovazanubrutinib | Phase 2/3 | Mid | NB | |
| 2031-11-01 | 5.6y away | Ph3 Readout | SEA-4335 | Phase 3 | Private | Pompe | |
| 2031-11-01 | 5.6y away | Interim | GEN-5535 | Phase 1 | Private | AML | |
| 2031-11-02 | 5.6y away | Ph2 Data | KAR-4449 | Phase 2 | Private | Breast Ca | |
| 2031-11-02 | 5.6y away | Ph3 Readout | Zenotuximab | Phase 2/3 | Private | PSP | |
| 2031-11-03 | 5.6y away | Ph3 Readout | Tirasacituzumab | NDA/BLA | Mid | PAH | |
| 2031-11-04 | 5.6y away | Ph2 Data | TAK-2403 | Phase 2 | Large | GBM | |
| 2031-11-04 | 5.6y away | Ph2 Data | Pexaosocimab | Phase 2 | Large | Cervical Ca | |
| 2031-11-04 | 5.6y away | Interim | MAY-IIT-361 | Preclinical | Private | MDS | |
| 2031-11-04 | 5.6y away | Ph3 Readout | Zorivorutinib | NDA/BLA | Mid | CKD | |
| 2031-11-04 | 5.6y away | Ph3 Readout | Motaratamab | Phase 2/3 | Small | FL | |
| 2031-11-05 | 5.6y away | Ph3 Readout | XTA-4333 | Approved | Private | Breast Ca | |
| 2031-11-05 | 5.6y away | Ph2 Data | TRI-2500 | Phase 1/2 | Private | Celiac | |
| 2031-11-06 | 5.6y away | Ph3 Readout | Zorinesiran | Phase 2/3 | Small | Pompe | |
| 2031-11-06 | 5.6y away | Ph3 Readout | Gozemavacamten | Approved | Private | TTR Amyloidosis | |
| 2031-11-07 | 5.6y away | Interim | 452-5607 | Preclinical | Large | NASH | |
| 2031-11-07 | 5.6y away | Ph2 Data | Gelirelsin | Phase 2 | Mid | Rett | |
| 2031-11-07 | 5.6y away | Ph3 Readout | Niralemzoparlimab | Phase 2/3 | Private | HNSCC | |
| 2031-11-07 | 5.6y away | Ph3 Readout | 051-5335 | Phase 3 | Mid | FTD | |
| 2031-11-08 | 5.6y away | Ph3 Readout | UPB-4925 | Phase 2/3 | Small | MM | |
| 2031-11-08 | 5.6y away | Ph3 Readout | GW-7331 | Phase 3 | Private | SMA | |
| 2031-11-08 | 5.6y away | Interim | 417-6972 | Preclinical | Micro | CLL | |
| 2031-11-08 | 5.6y away | Ph2 Data | Gelinaritide | Phase 1/2 | Large | Cervical Ca | |
| 2031-11-09 | 5.7y away | Ph2 Data | INS-860 | Phase 2 | Private | Urothelial Ca | |
| 2031-11-10 | 5.7y away | Ph2 Data | Talabrutinib | Phase 1/2 | Private | FL | |
| 2031-11-11 | 5.7y away | Ph3 Readout | Olpatenlimab | Phase 3 | Small | PBC | |
| 2031-11-11 | 5.7y away | Ph3 Readout | Zorilucimab | Approved | Private | WM | |
| 2031-11-12 | 5.7y away | Ph3 Readout | BIO-5105 | Phase 3 | Mid | NMOSD | |
| 2031-11-14 | 5.7y away | Ph3 Readout | Adagravorutinib | Phase 3 | Private | ET | |
| 2031-11-15 | 5.7y away | Ph3 Readout | ITO-535 | NDA/BLA | Mid | Pompe | |
| 2031-11-15 | 5.7y away | Ph2 Data | ETN-4807 | Phase 1/2 | Small | GA | |
| 2031-11-15 | 5.7y away | Interim | IMM-5415 | Preclinical | Private | Parkinson's | |
| 2031-11-15 | 5.7y away | Ph3 Readout | AMB-7870 | Phase 3 | Private | ADPKD | |
| 2031-11-15 | 5.7y away | Interim | DBV-5518 | Phase 1 | Micro | CRC | |
| 2031-11-16 | 5.7y away | Ph3 Readout | Sematapinarof | NDA/BLA | Large | NSCLC | |
| 2031-11-16 | 5.7y away | Ph3 Readout | Sovasotorasib | NDA/BLA | Private | RSV | |
| 2031-11-16 | 5.7y away | Ph3 Readout | AVE-316 | Phase 3 | Private | Bladder Ca | |
| 2031-11-16 | 5.7y away | Ph3 Readout | ENC-6986 | Approved | Private | MCC | |
| 2031-11-17 | 5.7y away | Ph2 Data | Talafutibatinib | Phase 1/2 | Large | CF | |
| 2031-11-17 | 5.7y away | Interim | ALD-9169 | Preclinical | Small | Fabry | |
| 2031-11-18 | 5.7y away | Ph3 Readout | Fixatuximab | Approved | Large | ALL | |
| 2031-11-19 | 5.7y away | Ph3 Readout | DAS-562 | Approved | Private | RCC | |
| 2031-11-19 | 5.7y away | Ph3 Readout | KIN-IIT-636 | Phase 3 | Private | Endometrial Ca | |
| 2031-11-21 | 5.7y away | Ph3 Readout | Datozasiran | NDA/BLA | Large | Schizophrenia | |
| 2031-11-21 | 5.7y away | Ph3 Readout | CYM-2446 | Phase 2/3 | Private | EoE | |
| 2031-11-21 | 5.7y away | Ph2 Data | Bemasotorasib | Phase 1/2 | Private | PAH | |
| 2031-11-22 | 5.7y away | Ph2 Data | Bemalucimab | Phase 1/2 | Large | PsA | |
| 2031-11-23 | 5.7y away | Interim | Sotolemzoparlimab | Phase 1 | Private | HS | |
| 2031-11-23 | 5.7y away | Ph3 Readout | ASK-6688 | NDA/BLA | Private | Wilms | |
| 2031-11-24 | 5.7y away | Ph2 Data | GMA-729 | Phase 2 | Large | TTR Amyloidosis | |
| 2031-11-26 | 5.7y away | Ph2 Data | NVS-1475 | Phase 2 | Large | MG | |
| 2031-11-26 | 5.7y away | Ph3 Readout | SRP-1135 | Phase 2/3 | Large | Migraine | |
| 2031-11-27 | 5.7y away | Interim | KUM-1252 | Preclinical | Private | Cervical Ca | |
| 2031-12-01 | 5.7y away | Ph3 Readout | Sovacapivasertib | Phase 3 | Large | Schizophrenia | |
| 2031-12-02 | 5.7y away | Ph3 Readout | Sotozumab | Approved | Large | HCC | |
| 2031-12-02 | 5.7y away | Ph3 Readout | Mavuvorutinib | Phase 2/3 | Private | GIST | |
| 2031-12-03 | 5.7y away | Interim | Datozumab | Phase 1 | Large | Schizophrenia | |
| 2031-12-03 | 5.7y away | Ph3 Readout | GEN-IIT-346 | Approved | Private | Bladder Ca | |
| 2031-12-03 | 5.7y away | Ph3 Readout | ZYM-7222 | Approved | Private | Cervical Ca | |
| 2031-12-04 | 5.7y away | Ph3 Readout | Ivotapinarof | Approved | Private | LN | |
| 2031-12-04 | 5.7y away | Ph3 Readout | RNA-7525 | Phase 2/3 | Mid | PV | |
| 2031-12-05 | 5.7y away | Ph3 Readout | Tezeratamab | Phase 3 | Small | Breast Ca | |
| 2031-12-05 | 5.7y away | Ph3 Readout | Tirainavolisib | Phase 3 | Private | Parkinson's | |
| 2031-12-05 | 5.7y away | Ph3 Readout | ORC-2834 | Phase 2/3 | Private | GBM | |
| 2031-12-05 | 5.7y away | Interim | DPH-7069 | Phase 1 | Micro | Urothelial Ca | |
| 2031-12-05 | 5.7y away | Ph3 Readout | TAT-IIT-383 | Phase 3 | Private | PV | |
| 2031-12-06 | 5.7y away | Ph3 Readout | Semalemzoparlimab | Phase 3 | Private | Huntington's | |
| 2031-12-06 | 5.7y away | Interim | BSL-7024 | Phase 1 | Small | SCD | |
| 2031-12-07 | 5.7y away | Ph3 Readout | TAK-8262 | NDA/BLA | Large | Hemophilia A | |
| 2031-12-08 | 5.7y away | Ph2 Data | RAP-8975 | Phase 2 | Micro | FSGS | |
| 2031-12-08 | 5.7y away | Ph3 Readout | Tezecilimab | Approved | Private | NB | |
| 2031-12-09 | 5.7y away | Ph3 Readout | Sovalemzoparlimab | Phase 2/3 | Micro | GIST | |
| 2031-12-09 | 5.7y away | Interim | Polazasiran | Preclinical | Mid | Prostate Ca | |
| 2031-12-09 | 5.7y away | Ph3 Readout | Talarelsin | Phase 3 | Micro | Rett | |
| 2031-12-09 | 5.7y away | Ph3 Readout | VBI-124 | Phase 2/3 | Micro | Melanoma | |
| 2031-12-09 | 5.7y away | Interim | Pemimavacamten | Phase 1 | Private | LGS | |
| 2031-12-09 | 5.7y away | Interim | Polabrutinib | Preclinical | Small | LGS | |
| 2031-12-10 | 5.7y away | Ph3 Readout | MRU-1869 | Approved | Mid | RB | |
| 2031-12-10 | 5.7y away | Ph3 Readout | Fixatuximab | Phase 3 | Private | Psoriasis | |
| 2031-12-10 | 5.7y away | Ph2 Data | Lisoderotide | Phase 2 | Private | Schizophrenia | |
| 2031-12-11 | 5.7y away | Ph3 Readout | ATH-6254 | Approved | Private | PsA | |
| 2031-12-11 | 5.7y away | Ph2 Data | 116-3223 | Phase 2 | Micro | PNH | |
| 2031-12-12 | 5.7y away | Interim | Zorizumab | Phase 1 | Private | SCLC | |
| 2031-12-13 | 5.7y away | Ph3 Readout | Capifutibatinib | Phase 3 | Large | Melanoma | |
| 2031-12-13 | 5.7y away | Ph3 Readout | CAD-8013 | Phase 3 | Micro | Ovarian Ca | |
| 2031-12-14 | 5.7y away | Interim | Tixacagene | Preclinical | Micro | MDS | |
| 2031-12-14 | 5.7y away | Ph3 Readout | Olpacagene | NDA/BLA | Micro | MS | |
| 2031-12-14 | 5.7y away | Interim | Lisosertib | Phase 1 | Private | NSCLC | |
| 2031-12-17 | 5.8y away | Ph3 Readout | VYG-2926 | NDA/BLA | Small | RB | |
| 2031-12-18 | 5.8y away | Ph3 Readout | Pexanaritide | NDA/BLA | Small | Schizophrenia | |
| 2031-12-18 | 5.8y away | Ph3 Readout | Mirivorutinib | Phase 3 | Private | Alzheimer's | |
| 2031-12-19 | 5.8y away | Ph3 Readout | GIL-9227 | Phase 2/3 | Large | PBC | |
| 2031-12-19 | 5.8y away | Ph3 Readout | EYE-3796 | Phase 3 | Micro | Narcolepsy | |
| 2031-12-20 | 5.8y away | Interim | MD-IIT-841 | Phase 1 | Private | CLL | |
| 2031-12-20 | 5.8y away | Ph3 Readout | Taladerotide | Phase 2/3 | Small | NMOSD | |
| 2031-12-20 | 5.8y away | Ph2 Data | Riboosocimab | Phase 2 | Private | Atopic Derm | |
| 2031-12-21 | 5.8y away | Ph3 Readout | BAY-3810 | Phase 2/3 | Large | Angelman | |
| 2031-12-22 | 5.8y away | Ph3 Readout | Rilufutibatinib | NDA/BLA | Private | CRC | |
| 2031-12-23 | 5.8y away | Ph3 Readout | Surainavolisib | NDA/BLA | Small | BCC | |
| 2031-12-23 | 5.8y away | Ph2 Data | Riboinavolisib | Phase 2 | Private | MDD | |
| 2031-12-24 | 5.8y away | Interim | Ivocapivasertib | Phase 1 | Private | Endometrial Ca | |
| 2031-12-24 | 5.8y away | Ph3 Readout | NOR-4666 | Phase 3 | Private | ADPKD | |
| 2031-12-24 | 5.8y away | Ph3 Readout | Lisotinib | Approved | Private | LN | |
| 2031-12-24 | 5.8y away | Ph2 Data | Gozesertib | Phase 1/2 | Private | GA | |
| 2031-12-25 | 5.8y away | Ph3 Readout | RVM-7089 | Phase 3 | Mid | CLL | |
| 2031-12-25 | 5.8y away | Ph3 Readout | Adagracapivasertib | Approved | Private | Dravet | |
| 2031-12-25 | 5.8y away | Ph3 Readout | Teralemzoparlimab | Phase 2/3 | Small | MDS | |
| 2031-12-25 | 5.8y away | Ph3 Readout | STA-6655 | NDA/BLA | Small | FTD | |
| 2031-12-26 | 5.8y away | Ph3 Readout | BEA-2615 | Phase 3 | Mid | Ewing Sarcoma | |
| 2031-12-26 | 5.8y away | Ph3 Readout | Tirazanubrutinib | Approved | Small | CRC | |
| 2031-12-26 | 5.8y away | Ph3 Readout | Datomavacamten | Approved | Small | Wilms | |
| 2031-12-26 | 5.8y away | Interim | LIO-530 | Phase 1 | Private | PNH | |
| 2031-12-26 | 5.8y away | Ph3 Readout | Fixaratamab | Approved | Mid | Endometrial Ca | |
| 2031-12-28 | 5.8y away | Interim | GH-9188 | Phase 1 | Mid | GIST |